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Formulation, Colloidal Characterization, and In Vitro Biological Effect of BMP-2 Loaded PLGA
Nanoparticles for Bone Regeneration
Reprinted from: Pharmaceutics 2019, 11, 388, doi:10.3390/pharmaceutics11080388 . . . . . . . . . 23
Silvia Minardi, Joseph S. Fernandez-Moure, Dongmei Fan, Matthew B. Murphy, 
Iman K. Yazdi, Xuewu Liu, Bradley K. Weiner and Ennio Tasciotti
Biocompatible PLGA-Mesoporous Silicon Microspheres for the Controlled Release of BMP-2 
for Bone Augmentation
Reprinted from: Pharmaceutics 2020, 12, 118, doi:10.3390/pharmaceutics12020118 . . . . . . . . . 41
Patricia Garcı́a-Garcı́a, Ricardo Reyes, Elisabet Segredo-Morales, Edgar Pérez-Herrero,
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Stephanie Hehlgans, Franz Rödel, Thomas J. Vogl and Matthias G. Wacker
Theranostic Sorafenib-Loaded Polymeric Nanocarriers Manufactured by Enhanced
Gadolinium Conjugation Techniques
Reprinted from: Pharmaceutics 2019, 11, 489, doi:10.3390/pharmaceutics11100489 . . . . . . . . . 251
vi
Rana Bakhaidar, Joshua Green, Khaled Alfahad, Shazia Samanani, Nabeehah Moollan,
Sarah O’Neill and Zebunnissa Ramtoola
Effect of Size and Concentration of PLGA-PEG Nanoparticles on Activation and Aggregation
of Washed Human Platelets
Reprinted from: Pharmaceutics 2019, 11, 514, doi:10.3390/pharmaceutics11100514 . . . . . . . . . 267
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Poly(lactic-co-glycolic acid) (PLGA) is one of the most successful polymers that has been used
to produce medicines, such as drug carriers (DC). This is one of the few polymers that the Food and
Drug Administration (FDA) has approved for human administration due to its biocompatibility and
biodegradability [1]. DCs produced with PLGA have gained enormous attention over recent years for
their ability to be versatile vehicles to transport different type of drugs, e.g., hydrophilic or hydrophobic
small molecules or macromolecules, and protect them from degradation and uncontrolled release [2–6].
These drug delivery systems (DDS), including micro and nanoparticles, have the potential to modify
their surface properties and improve interactions with biological materials. Furthermore, they can also
be conjugated with specific target molecules to reach specific tissues or cells [7,8]. They are being used
for different therapeutic applications, such as vaccinations or as treatments for cancer, neurological
disorders, inflammation, and other diseases [9–12].
This Special Issue aims to focus on the recent progress of PLGA as a drug carrier and its new
pharmaceutical applications. It comprises an exciting series of 19 research articles on the recent
advances in the field.
In the first research study presented in this Special Issue, Ho et al. developed polymeric microspheres
which contain micronized triamcinolone acetonide (TA) in order to increase the drug retention time in
joints after intra-articular administration [13]. Poly(lactic-co-glycolic acid)/poly(lactic acid) (PLGA/PLA)
carriers were prepared through spray-drying to incorporate the microcrystals that were previously
prepared by ultra-sonication. In vivo testing in rat models was demonstrated to prolong drug retention
in joints. The TA remained there for over 28 days, which was more 21 days compared with the TA-free
group. Furthermore, these nanocarriers were demonstrated to be stable for one year.
The group of Peula-García used PLGA nanoparticles to carry bone morphogenetic protein
(BMP-2) [14]. The nanocarriers were synthetized by a double-emulsion (water/oil/water, W/O/W)
solvent evaporation technique, using the surfactant Pluronic F68 as a stabilizer. The BMP2-loaded
nanocarriers presented positive results when evaluated using mesenchymal stromal cells from human
alveolar bone regarding their proliferation, migration, and osteogenic differentiation. Another strategy
to encapsulate BMP-2 was conducted by Minardi et al. [15]. PLGA multistage vector composite
microspheres were used as carriers that demonstrated a good capacity for BMP-2 encapsulation and
did not present toxicity for the rat mesenchymal stem cells. García-García et al. applied a combined
strategy to regenerate tissue defects [16]. They used BMP-2- and 17β-estradiol-loaded microspheres,
PLGA-based, in a sandwich-like system produced by a hydrogel core.
In another study, Hwang et al. fabricated PLGA carriers combined also with a hydrogel matrix.
They produced oxaliplatin-loaded PLGA microparticles using a double emulsion technique and
then loaded them into hyaluronic acid and carboxymethyl cellulose sodium-based cross-linked
hydrogels [17]. This drug delivery system was analyzed in rat models and a substantial
improvement was observed in terms of bioavailability and the mean residence time of the
microparticle-loaded hydrogels.
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Kim et al. developed an original system to be used in the topical delivery of trolamine
salicylate (TS), a topical anti-inflammatory analgesic used for the treatment of small joint pain [18].
Here, the optimization process was done using different amounts of PLGA, ethyl 2-cyanoacrylate,
poly (ethylene glycol) (PEG) 400, and TS. The researchers proved that the produced formulations
enhanced the delivery of TS into and across the skin.
Duse et al. used PLGA nanoparticles to encapsulate curcumin, a well know natural compound
that present anticancer benefits [19]. It was shown that the use of PLGA nanoparticles improves the
bioavailability and site-specific drug uptake. The nanoparticles’ efficacy was tested using SK-OV-3
human ovarian adenocarcinoma cells and demonstrated to be very efficient in transporting curcumin.
Furthermore, with the same objective to treat the cancer, our research group used factorial design as a tool
to optimize the co-encapsulation of temozolomide and o6-benzylguanine in PLGA nanoparticles [20].
The produced nanoparticles, rather than demonstrating stability for several days, presented optimal
physicochemical properties for brain delivery, including a size lower than 200 nm and a negative surface
charge. In the same research line, demonstrating the potential of the co-encapsulation, Bazylińska et al.
encapsulated a hydrophobic porphyrin photosensitizing dye—verteporfin—in combination with
low-dose cisplatin, a hydrophilic cytostatic drug [21]. Different coatings were applied to the PLGA
nanoparticles, PEG, or folic acid functionalized. Those nanoparticles proved to have an increased
internalization and efficiency regarding anticancer activity.
Another interesting study proposed by Varga and colleagues, who contributed with an interesting
study of nanoparticle design and optimization where the (±)-α-Tocopherol (TP) with vitamin E activity
was encapsulated in PLA and PLGA nanoparticles [22]. To stabilize the nanoparticles, the non-ionic
stabilizing surfactant Pluronic F127 was used. Several techniques were used to characterize these
novel nanoparticles, such as transmission electron microscopy (TEM), dynamic light scattering (DLS),
and infrared spectroscopy (FT-IR).
Morelli et al. improved paclitaxel delivery in the gastro-intestinal tract by encapsulating the drug
in PLGA nanoparticles coated with PEG [23]. The nanoparticles demonstrated stability in the gastric
tract and simply penetrated inside carcinoma colon 2 (CaCo2) cells.
With the objective to overcome the undesired lag time of the commercially available risperidone,
Janich et al. encapsulated this drug in PLGA–lipid microcapsules and PLGA–lipid microgels [24].
The carriers were evaluated regarding their physio-chemical properties and the first formulation was
demonstrated to achieve a nearly zero order release without a lag time over 2 months.
A research work using PLGA nanoparticles for ocular application was also collected. Ryu et al.
produced rapidly dissolving dry tablets containing alginate and dexamethasone-loaded PLGA
nanoparticles [25]. These nanoparticles presented sustained drug release for 10 h. In vivo experiments
showed their efficiency and make this DDS a promising strategy for aseptic and accurate dose delivery
of ophthalmic drugs.
An interesting approach based on a combination of cell and drug delivery for the treatment of
Huntington’s disease (HD) was proposed by André et al. [26]. The authors used laminin-coated PLGA
nanoparticles to transport brain-derived neurotrophic factor (BDNF). The nanoparticles/cell complexes
were evaluated in an ex vivo model of HD. Promising results were obtained by the researchers,
encouraging them to go further in their research with this system.
Two works lead by Roing and Wacker present new theranostic PLGA-based nanoparticles. In the
first one, biodegradable and photoluminescent polyester (BPLP) with PLGA polymer was used to
fabricate biocompatible photoluminescent nanocapsules [27]. Additionally, superparamagnetic iron
oxide nanoparticles (SPIONs) were incorporated into the polymeric shell to transform the particles
into a magnetic resonance/photoluminescence dual-model imaging theranostic platform. The particles
demonstrated good uptake and biocompatibility with hCMEC/D3 endothelial cells. In the second study,
three different technologies for the encapsulation of sorafenib into PLGA and PLGA–PEG copolymers
were adopted [28]. Those nanoparticles presented size ranges between 220 and 240 nm. In order
to transform those nanoparticles in a theranostic medicine, gadolinium complexes were covalently
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attached to the nanoparticles’ surface. That way, the nanoparticles could be located using magnetic
resonance imaging.
PLGA toxicity was investigated by Bakhaidar et al. [29]. Here, the researchers studied the
impact of size-selected PLGA–PEG nanoparticles on platelet activation and aggregation. The results
demonstrated that nanoparticles of all sizes are associated with the surface of platelets leading to
possible internalization. Furthermore, the NP–platelet interaction proved to not conduct platelet
aggregation, making these PLGA nanoparticles promising delivery systems for targeted drug delivery
to platelets.
Another relevant study was performed by Operti et al., who used microfluidics technology
as a tool to manufacture particles in a highly controllable way [30]. In their study, they produced
PLGA particles at diameters ranging from sub-micron to micron using a single microfluidics device.
Through modification of flow and formulation parameters, the nanoparticle size changed substantially.
Furthermore, in this study, the researchers proved how the particle size influences the release
characteristics, cellular uptake, and in vivo clearance of these particles.
Finally, a research study regarding the importance of new techniques to characterize PLGA
nanoparticles was included in this special edition. Shmool et al. investigated the dynamics of
PLGA microspheres prepared by freeze-drying [31]. The water-oil-water (w/o/w) double-emulsion
technique was selected for the production of the microspheres. Their molecular mobility at lower
temperatures, leading to the glass transition temperature, using temperature-variable terahertz
time-domain spectroscopy (THz-TDS), was evaluated. THz-TDS records show distinct transition
processes, one in the range of 167–219 K, associated with local motions, and the other in the range of
313–330 K, associated with large-scale motions.
The papers presented in this Special Issue represent a small part of the research that is ongoing in
the field of PLGA nanocarriers all over the world. The huge potential of PLGA nanoparticles make
them a promising drug delivery system with outstanding properties and with much more potential for
exploring in the coming years. With this Special Issue, the editors expect that the readers from the field
find it stimulating and contributing more ideas or methodologies for their future work.
Conflicts of Interest: The authors declare no conflict of interest.
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Abstract: A novel polymeric microsphere (MS) containing micronized triamcinolone acetonide (TA)
in a crystalline state was structured to provide extended drug retention in joints after intra-articular
(IA) injection. Microcrystals with a median diameter of 1.7 μm were prepared by ultra-sonication
method, and incorporated into poly(lactic-co-glycolic acid)/poly(lactic acid) (PLGA/PLA) MSs using
spray-drying technique. Cross-sectional observation and X-ray diffraction analysis showed that drug
microcrystals were evenly embedded in the MSs, with a distinctive crystalline nature of TA. In vitro
drug release from the novel MSs was markedly decelerated compared to those from the marketed
crystalline suspension (Triam inj.®), or even 7.2 μm-sized TA crystals-loaded MSs. The novel system
offered prolonged drug retention in rat joints, providing quantifiable TA remains over 28 days.
Whereas, over 95% of IA TA was removed from joints within seven days, after injection of the
marketed product. Systemic exposure of the steroidal compound was drastically decreased with the
MSs, with <50% systemic exposure compared to that with the marketed product. The novel MS was
physicochemically stable, with no changes in drug crystallinity and release profile over 12 months.
Therefore, the TA microcrystals-loaded MS is expected to be beneficial in patients especially with
osteoarthritis, with reduced IA dosing frequency.
Keywords: triamcinolone acetonide; microcrystal; PLGA microsphere; local delivery; spray-drying
technique; intra-articular injection; joint retention; systemic exposure
1. Introduction
Intra-articular (IA) injection of corticosteroids, such as triamcinolone acetonide (TA) crystalline
suspension, is commonly recommended to alleviate pain and inflammation in knee joints [1,2].
Marketed injectable TA suspensions are intended to be slowly dissolved in the synovial fluid, and the
glucocorticoid molecules steadily bind to and activate the glucocorticoid receptors, obstructing the
production of inflammation mediators, including prostaglandins, leukotrienes, and pro-inflammatory
cytokines [3]. Nevertheless, the analgesic and/or anti-inflammatory effect of the TA crystalline
suspension are reported to be weakened within two weeks following IA injection because of a rapid
efflux of the drug from the arthritic joint [4–6]. As the synovial lining is ultra-structured with permeable
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intercellular gaps measuring 0.1–5.5 μm, therapeutic agents injected via the IA route tend to easily
escape from the joint [7,8]. Moreover, the steroidal compound is quite soluble in aqueous media
(21 μg/mL in phosphate buffered saline at 25 ◦C) [9], and TA crystals that have decreased to a few
microns in size might be readily translocated into systemic circulation. In vitro release experiments
showed that the marketed TA crystalline suspension was completely dissolved within 2 h [10].
Several pharmaceutical approaches, including hydrogels, liposomes, nanoparticles, and
microparticles (MPs), have been explored to prolong the retention time of steroidal compounds in the
synovial tissues, minimizing systemic exposure following IA injection [2,10–15]. When considering
the leaky structure of the synovium, one of the sound strategies for localized delivery to the synovial
tissues is administering the therapeutic agents to IA after entrapping in a micro-sized carrier system.
Biocompatible and biodegradable polymeric MPs generally larger than 10 μm have been reported
to be effective for remaining in the synovial cavity and providing a sustained-release profile in the
joint [2,9,16]. Actually, a single IA injection of the PLGA MPs was clinically demonstrated to be
effective in providing an extended retention time of the corticosteroid in joints while reducing the drug
distribution in the bloodstream [17].
We previously formulated a PLGA MS system containing TA as in a stable crystalline form,
to achieve the sustained-release profile in joints after IA injection [18]. Compared to the polymeric MS
containing TA in an amorphous state, the TA crystals-loaded MSs prepared by layering the suspended
drug crystals with PLGA polymer exhibited excellent physicochemical stability under storage condition
(25 ◦C/60% R.H.) in terms of drug crystallinity and drug content in MSs. However, the MS system
containing TA crystals with a median diameter of 7 μm could not effectively retard drug release, as the
coating layer on the irregular TA crystals was unfair, with insufficient coating thickness; the extent of
drug released from the MSs reached 75% for 12 h under sink condition. Thus, we assumed that the
additional micronization process of the TA crystals might be beneficial, prior to encapsulation process,
to obtain satisfactory coating thickness on the TA crystals, providing sustained-release profile in joints.
Herein, the goals of this study were to construct uniform TA microcrystals and embed the
microcrystals in the polymeric MS, providing a prolonged retention profile in the joint following IA
injection. The uniform drug microcrystals were prepared by an ultra-sonication method and then
encapsulated into the polymeric MS by a spray-drying technique. The physicochemical characteristics
of the microcrystals-loaded MSs were evaluated in terms of outer and inner structures, particle size,
the drug loading amount, and loading efficiency. In vitro drug release patterns from the MSs were
regulated by adjusting the ratio of PLGA to PLA polymers and the ratio of drug to the polymer.
The in vivo concentration profile of TA in the plasma and joint tissue following IA injection of the
microcrystals-loaded MSs were comparatively evaluated with those of the marketed TA crystalline
suspension in rats.
2. Materials and Methods
2.1. Materials
TA powder and Triam inj.® were kindly provided by Shinpoong Pharmaceutical Co. (Seoul,
Korea). PLGA polymer with a lactide/glycolide ratio of 50:50 (5050DLG 4A, molecular weight
38,000–54,000 kDa) and PLA polymer (R203H, 18,000–24,000 kDa) were purchased from Lakeshore
Biomaterials (Birmingham, AL, USA). Polysorbate 20, polysorbate 80, Sorbian monolaurate (Span
20), poly(ethyleneglycol) 4000 (PEG 4000), polyethylene-polypropylene glycol 188 (Poloxamer 188),
cholesterol, benzalkonium chloride (BKC), sodium lauryl sulfate (SLS), and phosphate buffered
saline tablets were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Lecithin
(l-α-phosphatidylcholine) was obtained from Avanti Polar Lipids, Inc. (Alabaster, AL, USA). Gelatin
and glycerol were provided from TCI Chemicals, Co. (Tokyo, Japan). Acetonitrile (ACN), ethyl alcohol,
and methanol of HPLC grade were obtained from J.T. Baker (Phillipsburg, NJ, USA). All other reagents
were analytical grade.
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2.2. Preparation of TA Microcrystals Using an Ultra-Sonication Method
Drug microcrystal suspension was fabricated using an ultra-sonication method previously reported
with slight modifications [19]. Different kinds of stabilizers (polysorbate 20, polysorbate 80, span 20,
PEG 4000, poloxamer 188, cholesterol, and BKC) were dissolved in ACN in the concentration ranges
from 0.05 to 0.5 w/v % as shown is Table 1. TA powder (100 mg) was then added to the solution and
vigorously vortexed for 5 min to disperse the drug powder homogeneously. The ultra-sonicator (Model
Vibracell VC-505, Sonics and Materials Inc., Newtown, NC, USA) equipped with a 1/2-inch (13 mm)
probe was placed into the TA suspension and it was sonicated for 3 min at 40% amplitude with 3 s
pulses (on/off alteration). To prevent temperature elevation, the samples were located inside an ice
bath during the sonication procedure. Prepared TA microcrystal suspensions were then stored at room
temperature for further experiments.
2.3. Preparation of TA Microcrystals-Loaded MSs Using a Spray-Drying Technique
TA microcrystals-loaded MSs were fabricated by a spray-drying technique with a Buchi mini-spray
dryer (Model B-290, Buchi Labortechnik AG, Flawil, Switzerland). The feeding solution was
prepared by subsequently dissolving PLGA/PLA polymers and lecithin into the BKC-stabilized
TA microcrystal suspension. The composition of each microcrystals-embedded MSs is represented
in Table 2. The feeding solution was then pumped into the spray dryer nozzle at a feeding rate
of 3 mL/min and a stirring rate of 250 rpm. The inlet and outlet temperatures were set to 70 ◦C
and 45 ◦C, respectively, to evaporate the organic solvent. The atomizing air flow was 246 L/h and
the aspirator capacity was 100%. Prepared microcrystals-loaded MS powders were collected and
stored in a desiccator (Model OH-3S, As-one, Seoul, Korea) at 25 ◦C for 24 h to remove the residual
organic solvent.
2.4. Morphological Features of TA Microcrystals and Microcrystals-Loaded MSs
2.4.1. Appearance f TA Microcrystals and Microcrystals-Loaded MSs
Morphological features of raw material, TA microcrystals, and polymeric MSs were observed by
SEM (Model Sigma 500, Carl Zeiss, Oberkochen, Germany). Drug powder and MSs samples were
placed on a carbon tape and fixed onto an aluminum stub. The TA microcrystal suspension was
dropwise loaded on the carbon tape and then dried for 6 h at room temperature to remove the aqueous
vehicle. The platinum coating procedure was then conducted using an automatic sputter coater (Model
108Auto, Cressington, UK) at 15 mA. Appearance of samples was scrutinized by an electron microscope
at an accelerated voltage of 15 kV.
2.4.2. Cross-Sectional Image of TA Microcrystals-Loaded MSs
The internal structure of the microcrystals-loaded MSs was scrutinized by SEM after fixing the
MSs in the gelatin blocks. At first, the gelatin medium was prepared by dissolving gelatin (20 w/v %)
and glycerin (5 w/v %) in distilled water [20]. Approximately 40 mg of the MSs powder was dispersed in
the 3 mL of gelatin medium inside the polystyrene disposable base mold (Tissue-Tek®, 15 × 15 × 5 mm)
at 37 ◦C. The mold was then placed in a deep freezer maintained at −70 ◦C for 12 h. The frozen gelatin
block was mounted to the cryostat stub (Model CM3050S, Leica Microsystems, Wetzlar, Germany)
using an optimum cutting temperature compound (Sakura Finetechnical Co., Ltd., Tokyo, Japan).
The MS-loaded block was then sectioned at a thickness of 20 μm at −20 ◦C and was immediately placed
on the double-sided carbon tape. Samples were defrosted for 1 h at room temperature and coating and
observation procedures were conducted using the same method as described above.
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2.4.3. Hyperspectral Mapping Images of TA Microcrystals-Loaded MSs
A hyperspectral microscopy imaging system (Model CytoViva®, Cytoviva Inc., Auburn, AL,
USA) was employed to visualize TA microcrystals inside the MSs. The Cytoviva® system included
a BX-41 microscope (Olympus Corporation, Tokyo, Japan), a visible-near infrared hyperspectral
imaging system, dual fluorescence module, and high-resolution adaptor. Approximately 10 μL of TA
microcrystal suspension, blank MSs, and TA microcrystals-loaded MSs suspended in 1 mL of 0.5 w/v %
polysorbate 80 solution was dropped onto a cover glass and the hyperspectral spectra were analyzed.
The mapping process was performed on the TA microcrystals-loaded MS image, with acquired spectra
of TA microcrystals and blank MSs (HyperVisual Software ENVI 4.8, ITT Visual Information Solutions,
Boulder, CO, USA). The spectra corresponding to TA microcrystals and the blank MSs were expressed
as red and yellow, respectively, in the hyperspectral image of TA microcrystals-loaded MSs.
2.5. Physicochemical Characterization TA Microcrystals and Microcrystals-Loaded MSs
2.5.1. Crystallinity Analysis
The crystalline state of TA powder, TA microcrystals, blank MSs, and microcrystals-loaded MSs
was analyzed using an X-ray diffractometer (XRD, Model Ultima IV, Rigaku, Tokyo, Japan) at 25 ◦C.
For the TA microcrystal suspension, the aqueous vehicle was removed by centrifuging the suspension
at 3500 g for 10 min, and subsequently, oven drying at 40 ◦C for 12 h. Each sample was put on the
glass sample plate and the diffraction pattern over a 2θ range of 5–35◦ was determined using a step
size of 0.02◦. Voltage, current, and scan speed were set to 40 kV, 30 mA, and 1 s/step, respectively.
2.5.2. Particle Size Analysis
Size distributions of TA microcrystals and MSs were determined by Mastersizer MS 2000 (Malvern
Instruments Ltd., Worcestershire, UK) equipped with a Hydro 2000 S automatic dispersion unit. Prior
to analysis, MSs powder was suspended in the aqueous medium consisting of 1 w/v % PEG 4000
and 0.5 w/v % polysorbate 20. The suspended samples were then dropwise added to an automatic
dispersion unit to obtain a 10–15% range of obscuration. Sample and background measurement
times were set to 5 s and 10 s, respectively, and 5 runs were conducted for each measurement. Mie
theory was applied to calculate the size distribution by volume with the refractive index value of 1.52.
The resultant particle sizes of the three batches were averaged and presented as mean ± standard
deviation (SD) (n = 3). The d0.5, d0.9, and d0.1 indicated the median value defined as the diameter
where 50%, 90%, and 10% of the population were below this value, respectively. SPAN value was
an indicator representing the homogeneity of the particle size and was calculated by dividing the
difference of d0.9 and d0.1 by d0.5 [21].
2.5.3. Determination of Loading Amount and Efficiency of TA Microcrystals in MSs
To dissolve TA microcrystals-loaded MSs, 10 mg of MSs were added to 1 mL of dimethyl sulfoxide
and then sonicated with a bath-type sonicator (Model 5510E-DTH, Bransonic, USA) for 10 min.
The opaque solution was diluted with ACN and distilled water mixture (3:2 v/v) and was subsequently
centrifuged at 16,000 g for 10 min to remove the precipitates. The concentration of TA in the supernatant
was determined by a Waters HPLC system (Waters Corporation, Milford MA, USA) comprised of
a pump (Model 515), auto sampler (Model 717 plus), UV detector (Model 486), and equipped with
a Capcell Pak C18 column (150 mm × 2.0 mm, 3 μm, Shiseido, Tokyo, Japan). The mobile phase
consisted of ACN and distilled water at a volume ratio of 3:2 and was eluted with a flow rate of
1.0 mL/min. The detection wavelength was set to 254 nm. The calibration curve of TA was linear in the
concentration range of 1–100 μg/mL, with r2 values of 0.999. The drug loading amount and loading
efficiency were calculated as follows [22]:
Drug loading amount =WL/WT, (1)
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Drug loading efficiency (%) = (WL/WF) × 100, (2)
where WL, WT and WF represent the weight of TA in microcrystals-loaded MSs (mg), total weight of
microcrystals-loaded MSs (mg) and feeding weight of TA (mg).
2.6. In Vitro Drug Release Profiles and Morphological Changes of Microcrystals-Loaded MSs
In vitro release profiles of TA from the novel MSs were comparatively evaluated with that of
a marketed product under accelerated test conditions (45 ± 0.5 ◦C). To guarantee sink condition during
the experiment, 0.5 w/v % of SLS and 0.05 w/v % of poloxamer 188, were added to 10 mM phosphate
buffered saline (pH 7.4). MSs or the marketed product (Triam inj.®, TA 40 mg/mL) containing 20 mg of
TA were immersed into 200 mL dissolution medium maintained at 45 ± 0.5 ◦C and then shaken with an
agitation speed of 100 rpm. At predetermined intervals, 1 mL of the release medium was withdrawn
and centrifuged at 16,000 g for 10 min. The supernatant was diluted two-fold with the mobile phase and
TA concentration in the aliquot was determined by HPLC as described above. The equivalent volume
of fresh pre-warmed dissolution medium was replenished to maintain a constant medium volume.
The morphological changes of the novel MSs during the in vitro release test were scrutinized by
SEM. At predetermined intervals, MSs prepared with the PLGA:PLA ratio of 4:0 (F1), 1:3 (F4), and 0:4
(F5) were withdrawn and centrifuged at 900 g. The pelletized MSs were stored at −70 ◦C for 24 h and
lyophilized for 24 h. The appearance of the lyophilized MS samples was observed by SEM with the
same procedure described earlier.
2.7. In Vivo Systemic Exposure and Joint Retention of TA after IA Injection in Rats
2.7.1. Animals and Experimental Protocols
In Vivo pharmacokinetic studies were performed after approval from the Institutional Animal
Care and Use Committee (IACUC) of Seoul National University Bundang Hospital (approval number:
BA1608-206/050-01, date of approval: August 9, 2016). Six-week-old male Sprague-Dawley rats (250 ±
20 g) were acquired from Samtako (Kyungki-do, Korea). Four or five rats were housed in each cage
and kept in a temperature- and relative humidity-controlled room (23 ± 1 ◦C and 50 ± 5%, respectively)
with a 12-h light-dark cycle. During the acclimatization period, rats were allowed free access to tap
water and standardized chow.
After at least three days of the acclimatization period, rats were divided into three groups (n = 9
per group) by a stratified randomization scheme for similar body weights groups. The hair on both
hind knee joints was removed using hair removal cream. Prior to IA injection, spray-dried MS (F4
and F8) were re-dispersed in the sterile diluent composed of 0.66 w/v % sodium chloride, 0.63 w/v %
carboxymethylcellulose sodium, and 0.04 w/v % polysorbate 80 at the same drug concentration
(2.5 mg/mL as TA). Each group received 50 μL of the marketed product, F4, and F8, respectively, using
an insulin syringe (31 G) in both knee joints, to administer 125 μg of TA per knee. At the predetermined
time, blood samples (approximately 0.2 mL) were collected from the submandibular vein using a 26 G
heparinized syringe. Blood samples were centrifuged at 16,000 g for 10 min. The obtained plasma
samples were then stored at −70 ◦C until being analyzed by LC-MS/MS assay.
Apart from the systemic exposure evaluation, knee samples were collected to estimate the level of
TA in joint tissues. After 3, 7, 21, 28, and 42 days of the IA injection in both knees, two animals from
each group were sacrificed, and both knees were removed using bone cutters. After removing any
residual substances and adhered tissues, knees were accurately weighed and stored at −70 ◦C until
LC-MS/MS analysis.
2.7.2. LC-MS/MS Analysis of TA Concentration in Plasma and Knee Tissues
The TA concentrations in rat plasma or joint tissue were determined using the LC–MS/MS assay
previously reported [23]. In brief, thawed plasma (100 μL) was mixed with 900 μL of methanol and
vigorously vortexed for 10 min, to precipitate protein. After centrifuging at 16,000 g, a supernatant
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(10 μL) was analyzed through an LC-MS/MS system (Model LC-20 Prominence HPLC, Shimadzu and
Model API 2000, AB/SCIEX, Foster City, CA, USA). In the case of articular samples, the frozen knee
tissues were thawed and immersed in 2 mL of ACN and shaken overnight to extract TA from the tissue.
The extracted solution was centrifuged at 16,000 g for 5 min and the supernatant was injected into the
LC-MS/MS system. The transitions of 435.1/415.0/15 precursor ion (m/z)/product ion (m/z)/collision
energy (V) were then monitored for TA. Data acquisition/analyses were conducted using Analyst®
version 1.5.2 software (ABSciex, Concord, ON, Canada). The assay was validated thoroughly and
showed acceptable precision and accuracy, with a lower limit of quantification of 0.2 ng/mL in both rat
plasma and knee tissue extract.
2.7.3. Pharmacokinetic Parameters from TA Concentration Profile in Plasma
Pharmacokinetic parameters such as area under the plasma concentration versus time curve
(AUC0–7days), maximum plasma concentration (Cmax), time needed to reach the maximum plasma
concentration (Tmax), and terminal half-life (T1/2) in plasma were calculated using the linear trapezoidal
rule in the BA Calc 2007 pharmacokinetic analysis program (Korea Food & Drug Administration,
Seoul, Korea).
2.8. Physicochemical Stability of TA Microcrystals-Loaded MSs
The long-term storage stability of the novel MSs was evaluated in terms of drug crystallinity,
drug content, and in vitro release profile. TA microcrystals-loaded MS (F4) power was placed into the
scintillation vial and was stored in the chamber maintained at 25 ◦C and 60% R.H. After 12 months of
storage, the drug crystallinity, drug content, and in vitro release profile were evaluated with the same
method as previously described.
2.9. Statistical Analysis
Each experiment was performed at least thrice and the data are presented as the mean ± SD.
Statistical significance was determined using a one-way analysis of variance (ANOVA) test and was
considered to be significant at p < 0.05 unless otherwise indicated.
3. Results and Discussion
3.1. Formulation and Physical Characteristics of TA Microcrystals
Various stabilizers were screened to micronize TA powder in the organic solvent using a probe
type ultra-sonicator (Table 1). ACN was employed as the vehicle as it exhibited low solubility for
the steroidal compound (<1 mg/mL), and high solvation capacity for PLGA and PLA polymers [18].
When the surface stabilizer was not included in the vehicle, TA powder was not uniformly dispersed
in the medium after the homogenization process, rather forming large precipitates. The addition of
steric stabilizers, such as polysorbate 20, polysorbate 80, PEG 4000, poloxamer 188, and cholesterol
could not provide a uniform dispersion of the split TA microcrystals, forming drug aggregates within
24 h. On the other hand, when BKC was included in the organic vehicle at a concentration of 0.1 to
0.5 w/v %, TA microcrystals with a median size below 2.1 μm were shaped with re-dispersibility in the
organic solvent (Table 1 and Figure 1A). When the concentration of the cationic surfactant was less than
0.05 w/v %, it could not afford the re-dispersibility of TA microcrystals. Thus, BKC at the concentration
of 0.1 w/v % was employed for further preparation of TA microcrystal suspension in ACN.
The morphological feature of the TA microcrystals stabilized by 0.1 w/v % BKC was observed by
FE-SEM. TA raw material showed characteristic crystal forms, such as hexahedron, octahedron, and
dodecahedrons, with different sizes in the range from 2 to 20 μm (Figure 1C). Whereas, the crystal size
was markedly decreased to 1–3 μm by the ultra-sonication process (Figure 1D), coinciding with the
crystal size as determined by Mastersizer (d0.5, 1.7 μm). In spite of crystal size reduction, no noticeable
change to the shape was observed in the TA microcrystals. The crystalline state of TA microcrystals
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was further evaluated by comparing the X-ray diffraction spectrum of TA microcrystals with that of
the raw material (Figure 1B). The spectrum of TA microcrystals was identical to that of drug powder,
exhibiting distinctive diffraction peaks at 2θ equal to 9.9◦, 14.5◦, 17.6◦, and 24.7◦. On the other hand,
the cationic surfactant showed no distinctive diffraction peaks over the 2θ range of 5–35◦. Taken
together, we concluded that TA powder was effectively micronized to 1–3 μm, with no crystalline
changes during the ultra-sonication process.
Table 1. Effects of kinds of stabilizers on size, homogeneity, and dispersibility of TA microcrystals
in ACN.
Stabilizer (w/v %) 1 Crystal Size (d0.5, μm) 2,3 Homogeneity (SPAN) 2,4 Dispersibility 5
- 6 7.21 ± 1.02 2.14 ± 0.13 Aggregated
Polysorbate 20 0.5% 6.63 ± 0.82 2.11 ± 0.07 Aggregated
Polysorbate 80 0.5% 7.35 ± 0.91 1.99 ± 0.04 Aggregated
Span 20 0.5% 17.7 ± 6.27 1.81 ± 0.11 Aggregated
PEG 4000 0.5% 7.15 ± 3.07 2.10 ± 0.88 Aggregated
Poloxamer 188 0.5% 5.44 ± 1.84 2.00 ± 0.52 Aggregated
Cholesterol 0.5% 8.72 ± 3.49 1.81 ± 0.60 Aggregated
BKC 0.5% 2.11 ± 0.05 1.32 ± 0.03 Re-dispersible
BKC 0.2% 1.94 ± 0.06 1.20 ± 0.03 Re-dispersible
BKC 0.1% 1.73 ± 0.02 1.21 ± 0.01 Re-dispersible
BKC 0.05% 4.75 ± 0.23 1.99 ± 0.02 Aggregated
1 Weight per volume concentration in ACN. 2 Expressed as mean ± SD (n = 3). 3 Indicates the volume weighted
diameter below which 50% of the total particle. 4 Calculated by dividing the difference between d0.9 and d0.1 by d0.5.
d0.9 and d0.1 indicate the volume weighted diameters below which 90% and 10% of the total particle, respectively.
5 Visually evaluated after 24 h storage at room temperature. 6 Indicates without stabilizer.
 
Figure 1. Morphological and physical characteristics of TA microcrystals. (A) Size distribution of the
drug microcrystals stabilized by BKC, (B) XRD patterns of (a) TA raw material, (b) BKC powder, and
(c) TA microcrystals, SEM images of (C) TA raw material, and (D) TA microcrystals stabilized by BKC
at the concentration of 0.1 w/v %.
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3.2. Formulation and Physical Characteristics of TA Microcrystals-Loaded MSs
Various TA microcrystals (1.7 μm median size) or intact TA powder (7.2 μm)-embedded MSs
were fabricated using the spray-drying technique, and these particle size, homogeneity, drug loading
amount, and loading efficiency are represented in Table 2. The median particle size of MSs prepared
ranged from 15.8 to 18.8 μm, with a narrow size distribution possessing a SPAN value below 2.1.
The formulation variables, such as TA crystal size, the ratio of PLGA and PLA polymers, and the
ratio of drug to polymer, did not cause marked differences in size and homogeneity of TA-loaded
MSs (Table 2). The particle size of the novel MS was considered to be suitable for IA prolonged
delivery, preventing the trans-synovial efflux of injected TA microcrystals [17,24,25]. There was also
no remarkable difference in the drug loading efficiency in the polymeric MSs between the formulas,
exhibiting more than 90% drug loading efficiency in all formulations. The absence of the external
phase during the spray-drying process might prevent distribution and/or diffusion of TA microcrystals
during the external phase, and thus promote TA crystals to be located in the polymeric matrix after
solvent evaporation, irrespective of composition variables. On the other hand, the loading amount of
TA in MS was adjusted from 0.09 to 0.31 w/w, by controlling the drug to polymer weight ratio from 1:2
to 1:10.
Table 2. Compositions and physicochemical characteristics of TA microcrystals-loaded MSs.
Compositions Characteristics
TA crystal











Efficiency (%) 4, 5
F0 7.21 ± 1.02 1:3 1:5 15.9 ± 0.95 2.03 ± 0.04 0.16 ± 0.02 97.2 ± 2.35
F1 1.73 ± 0.02 4:0 1:5 16.2 ± 1.35 1.89 ± 0.05 0.15 ± 0.01 93.5 ± 0.87
F2 1.73 ± 0.02 3:1 1:5 17.2 ± 0.43 1.89 ± 0.02 0.15 ± 0.04 92.7 ± 5.76
F3 1.73 ± 0.02 2:2 1:5 16.1 ± 0.56 2.06 ± 0.02 0.14 ± 0.01 90.9 ± 1.01
F4 1.73 ± 0.02 1:3 1:5 16.9 ± 0.35 1.80 ± 0.01 0.16 ± 0.01 98.1 ± 1.84
F5 1.73 ± 0.02 0:4 1:5 15.9 ± 0.06 2.11 ± 0.01 0.15 ± 0.02 96.3 ± 2.48
F6 1.73 ± 0.02 1:3 1:2 18.9 ± 0.25 1.70 ± 0.01 0.31 ± 0.00 96.0 ± 0.18
F7 1.73 ± 0.02 1:3 1:3 15.8 ± 1.11 2.04 ± 0.07 0.22 ± 0.01 93.7 ± 1.33
F8 1.73 ± 0.02 1:3 1:10 16.9 ± 0.42 1.20 ± 0.01 0.09 ± 0.02 99.5 ± 2.55
1 Presented as d0.5 value; the volume weighted diameter below 50% of the total particle. 2 Calculated by dividing the
difference between d0.9 and d0.1 by d0.5: d0.9 and d0.1 by d0.5: d0.9 and d0.1 are the volume weighted diameters below
90% and 10% of the total particle, respectively. 3 Calculated by dividing the weight of TA in microcrystals-loaded
MSs by total weight of microcrystals-loaded MSs (mg). 4 Expressed as the percentage (%) after dividing the weight
of TA loaded in MSs by total fed weight of TA (mg). 5 Expressed as mean ± SD (n = 3); Note: Lecithin was included
in all formulations at the weight ratio of 5 w/w % to the total amount of polymers.
The novel TAs-loaded MSs were further characterized in terms of outer and internal structures
and drug crystallinity in MS (Figure 2). The MSs (F4) prepared by the spray-drying technique was
highly spherical, with a smooth and homogeneous surface (Figure 2A). In the cross-sectional image,
the microcrystals showed different textures from the polymeric matrix and were found to be uniformly
embedded in the polymeric matrix (Figure 2B). The number of microcrystals loaded per MS was
elucidated by translating the loading amount into the number of MS and TA microcrystals. In the
process of converting the weight to a number, the volume of single MS and TA microcrystal was
calculated with the assumption that the shape of the MS and microcrystal were spherical and cubic,
respectively, with both having a density of 1.0. In the MS formulations prepared with the drug to
polymer ratio of 1:2 (F6), 1:3 (F7), 1:5 (F4), and 1:10 (F8), the number of microcrystals embedded in
each MS was calculated as 215, 94, 82, and 50, respectively. In the hyperspectral image (Figure 2C),
TA microcrystals (red color) were observed to be principally located inside the PLGA/PLA MS (yellow
color). However, individual microcrystals were not separately spotted in the image, probably because
of the low resolution of Cytoviva®. The characteristic peak of TA microcrystals was identically detected
in the microcrystals-load MS (Figure 2D), denoting that TA microcrystals stabilized by BKC were
successfully incorporated in the MSs, with no crystalline changes during the fabrication process.
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Figure 2. Morphological and physical characteristics of the microcrystals-loaded MSs. Representative
micrograph of (A) intact and (B) cross-sectioned microcrystals-loaded MS (F4), (C) hyperspectral image
of microcrystals-loaded MSs, and (D) XRD patterns of (a) TA microcrystals, (b) blank MS, (c) F4 MS
(drug:polymer = 1:5), and (d) F8 MS (1:10); Notes: Inset in (B) is ×5000 magnified images and the
arrow points to the TA crystal surrounded by the polymeric matrices. In the hyperspectral image (C),
PLGA/PLA polymers and TA microcrystals are colored as yellow and red, respectively.
3.3. In Vitro Drug Release and Degradation Profiles of TA Microcrystals-Loaded MSs
In Vitro drug release profiles from the marketed product, the drug powder- or micronized TA
crystals-loaded MSs were evaluated under accelerated dissolution conditions. Although the synovial
fluid does not assure the sink condition for the drug dissolution, the in vitro release test under sink
conditions was favored for quicker comparison between the formulations. Moreover, as the drug release
profiles from PLGA/PLA MSs could be retarded from days to months at body temperature (37 ◦C),
the liberation pattern of the steroidal compound from the MSs was further facilitated by elevating
the temperature of the dissolution media (45 ◦C), promoting the degradation and/or hydrolysis of the
biodegradable polymers [26–28]. Actually, the accelerated test at high temperature was reported to be
beneficial for faster comparison of release behavior between MS formulas, with high correlation with
that obtained at 37 ◦C [27]. Shen and Burgess (2012) revealed that the time required to reach 100%
drug release from the MSs prepared with PLGA polymer with the glass transition temperature (Tg)
of 44–48 ◦C was determined to be 10, 5, 3, and 1.3 days, respectively, at temperatures of 45, 50, 53,
and 60 ◦C. Herein, the temperature of the dissolution medium was set to 45 ◦C, which did not exceed
the Tg values of both polymers (46–52 ◦C). When the polymeric MSs were exposed to the medium at
temperatures above the Tg of the polymer, the drug diffusion coefficient was drastically increased [29],
diminishing the difference between the release profiles between the polymeric particulates.
Under the accelerated condition, the marketed product containing 13 μm-sized TA crystals
stabilized by polysorbate 20 and sodium carboxymethyl cellulose was rapidly liquefied in the aqueous
medium, showing complete drug release within 90 min (Figure 3A). It coincided with a previous report
that showed that the TA crystal suspension was readily dissolved in phosphate buffered saline within
2 h [10]. The drug release from the MS with 7.2-μm-sized TA crystals (F0) was not markedly retarded
compared to the intact drug crystal, releasing over 95% of TA within 3 h. The incomplete and/or erratic
coating thickness of the polymeric layer on the TA crystals probably could not effectively restrain
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the dissolution and diffusion procedures of the TA crystals into the aqueous media. On the other
hand, drug release from the MSs containing smaller TA crystals (median size of 1.7 μm) was markedly
impeded compared to the marketed product or 7.2-μm-sized TA crystal-loaded MS, especially as the
ratio of PLA increased in the MS (Figure 3A).
 
Figure 3. In Vitro release profile of TA from the novel MSs under accelerated conditions (45 ◦C).
(A) Drug release profile from the marketed product (×), 7.2 μm-sized TA crystals-loaded MS (F0, –), and
1.7 μm-sized TA crystals-loaded MS prepared with different PLGA:PLA ratios; 4:0 (F1, ), 3:1 (F2, ),
2:2 (F3, ), 1:3 (F4, ), and 0:4 (F5, ) and (B) drug release profile from MSs prepared with different
drug:polymer ratios; 1:2 (F6, ), 1:3 (F7, ), 1:5 (F4, ), and 1:10 (F8, ); Notes: The inset graph (A) is
the magnified release profile from the marketed product and 7.2 μm-sized TA crystals-loaded MS. Data
are expressed as the mean value (n = 3) and error bars are SDs.
As the glycolic acid has faster hydration/swelling behavior compared to lactic acid [30], MSs
prepared with over 50% of PLGA polymers (F1, F2, and F3) showed higher burst release, with over
60% of drug released within 2 days. After the initial burst release, the extent of TA liberated from
the F1, F2, and F3 polymers continuously rose, exhibiting over 90% release after 7 days under sink
condition. On the other hand, the F4 formula with a PLGA:PLA ratio of 1:3, exhibited a more protracted
release profile compared to that of F1, F2, and F3, exhibiting a linear release pattern for 21 days after
a 53% initial release in the first 2 days. F5 (PLGA:PLA ratio of 0:4) showed the slowest release profile,
displaying only 52% of the accumulated drug release after 21 days. Although there was marked
difference in release profile depending on the ratio of PLGA and PLA polymer, the drug release pattern
from novel drug microcrystals-loaded MSs were characterized by initial burst release and subsequent
slow release profile, which is consistent with the typical release pattern of PLGA/PLA based MPs
previous reported [31,32]. In the early phase, TA microcrystals located on or inner compartment near
the surface of the MS might be rapidly dissolved by surrounding and/or penetrated aqueous media,
and released from polymeric matrix mainly by diffusion mechanism. After initial burst release, the
drug release rate tended to be retarded, due to the increased diffusion distance. Afterward, and the
remaining steroidal compound in the MSs might be liberated by polymeric degradation and erosion
and/or collapse of polymeric MSs.
Different drug release patterns depended on the PLGA:PLA ratio were highly consistent by the
morphological changes of TA microcrystals-loaded MSs. As shown in Figure 4, because of the rapid
swelling and hydrolysis nature of PLGA polymer, the PLGA MSs (F1) began to collapse and was
excavated within three days. Thus, the drug microcrystals embedded in the PLGA MS might be readily
exposed to aqueous media, and immediately dissolved under sink condition. On the contrary, because
of the greater hydrophobicity of the PLA polymer compared to the PLGA polymer, the hydrolytic
degradation of PLA MS (F5, PLGA:PLA = 0:4) progressed slowly. When the MSs were scrutinized at 3
and 7 days, fine pores were formed on the roughed surface and the pore size was gradually enlarged
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as time elapsed. Nevertheless, the overall globular shape and dimension of MS were retained even at
21 days, supporting the slow and incomplete release profile of TA from the MS (F7). The degradation
pattern of F4 prepared with the PLGA:PLA ratio of 1:3 was intermediate between those of MSs prepared
with PLGA or PLA polymer F1 and F5, respectively. After surface erosion and pore formation at three
days, the MS was then gradually collapsed over 21 days. The drug release rate from F4 was markedly
delayed compared to that from F1 but was much faster and higher than that from F5, releasing over
80% of the drug loaded for 21 days. The ratio of PLGA to PLA polymers was fixed to 1:3, expecting the
prolonged release pattern for further investigation.
 
Figure 4. Morphological changes of TA microcrystals-loaded MSs prepared with different PLGA:PLA
ratios, 0:4 (F1), 1:3 (F4), 0:4 (F5) under the accelerated release conditions (45 ◦C); Note: Scale bars in
each image indicate 2.0 μm.
The in vitro release profile of TA from the PLGA/PLA MSs prepared with different drug to polymer
ratios was further evaluated. As shown in Figure 3B, the initial drug release from the novel MSs were
gradually decreased, as the drug to polymer ratio was increased. When the ratio of drug to polymer
was 1:2 (F6) or 1:3 (F7), the percentage of drug released for 24 h had reached approximately 86% and
78%, respectively. On the other hand, in the formulations of the drugs:polymer ratio of 1:5 (F4) and 1:10
(F8), the release of the steroidal compound from the MSs were markedly retarded, exhibiting less than
60% of drug release over 5 days. Drug release from the F4 or F8 was steeped after 7 days, probably
because of erosion and/or collapse of the MSs, but prolonged for 21 days. Formulas F4 and F8 were
further exploited for in vivo pharmacokinetic study in rats, expecting an extended release profile over
one month in the knee joint.
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3.4. In Vivo Systemic Exposure and Ioint Retention of TA after IA Injection in Rats
The systemic exposure and local bioavailability of TA following a single IA injection of the
marketed product or the novel MSs (F4 and F8) were evaluated in normal rats. The IA dose of TA
treated in all groups was same to 0.25 mg per knee, which was well tolerated in rats [10]. The plasma
levels of TA as a function of time following IA injection of the marketed product, F4, and F8 are
represented in Figure 5 and the relevant PK parameters are summarized in Table 3. It is recommended
that the exposure of the steroidal compound in blood be minimized, as the exogenous corticosteroid can
cause Cushing syndrome, incurred impaired wound healing, infection, and muscle weakness [10,33,34].
However, unfortunately, the plasma level of TA was drastically elevated after administration of the
marketed product, reaching Cmax value of 218.7 ng/mL after 3.7 h. This rapid redistribution of TA into
the bloodstream is in agreement with earlier reports that intra-articularly injected TA crystals were
rapidly absorbed, with a Tmax value of 4 h in patients with osteoarthritis [6,35,36]. This rapid drug
efflux from the knee joint is also correlated with in vitro release profiles, denoting that TA crystalline
suspension injected in the joint might be rapidly dissolved and passed out the gap in the synovial
membrane. After reaching a Cmax of 3.7 h, the plasma level of TA sharply decreased below 30 ng/mL
after 12 h post-administration of the marketed product.
 
Figure 5. Plasma concentration–time profiles of TA following IA administration of the marketed
product, F4 (drug:polymer = 1:5) and F8 (drug:polymer = 1:10) in rats at a dose of 0.5 mg/kg; Note:
Each point represents mean ± SD (n = 5).
Table 3. Pharmacokinetic parameters of TA in plasma following IA administration of the marketed
product, F4, and F8 in rats.
Parameters Marketed Product F4 F8
AUC0–7day (ng·h/mL) 2787.4 ± 187.4 1500.4 ± 218.9 * 1022.2 ± 161.9 *,**
Cmax (ng/mL) 218.7 ± 26.6 75.6 ± 17.2 * 32.2 ± 12.0 *,**
Tmax (h) 3.7 ± 0.8 1.8 ± 0.4 * 1.4 ± 0.5 *
T1/2 (h) 1 5.3 ± 0.1 9.0 ± 0.5 * 13.3 ± 2.7 *,**
1 Calculated from the plasma concentration–time curve from Tmax to 24 h after IA injection; Notes: Data are
expressed as mean ± SD (n = 5). Statistical analysis was performed using the one-way ANOVA test; * significantly
different from the marketed product (p < 0.05), ** significantly different from F4 (p < 0.05); Abbreviations: AUC0–7days,
area under the plasma concentration–time curve until day 7; Cmax, maximum plasma concentration; Tmax, time to
reach maximum plasma concentration; T1/2, elimination half-life of the drug.
In contrast, the systemic exposure of the exogenous corticosteroid was markedly decreased
following IA injection of the TA microcrystals-loaded MSs (F4 and F8). The Cmax values of TA following
IA injection of F4 and F8 were determined to 75.6 ng/mL and 32.2 ng/mL, respectively, which were only
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34% (p < 0.05) and 15% (p < 0.05) that of the marketed product. Correspondingly, AUC0–7days values in
the F4- and F8-treated groups were drastically decreased to less than 54% (p < 0.05) and 37% (p < 0.05)
of that obtained from the marketed product, respectively. These pharmacokinetic data indicated that
the novel MSs remarkably lessened the redistribution of dissolved and/or micronized compound into
the bloodstream, prolonging the retention time of TA in the knee. Between the two groups treated
with MSs prepared with loading amount of 0.16 (F4) and 0.09 (F8), respectively, the drug exposure to
blood was much lowered in the F8-treated group, showing 68% and 42% decreased AUC0-7days and
Cmax values compared to those obtained from the F4-treated group. This pharmacokinetic tendency is
explainable with the in vitro release test results, which revealed that the extent of drug released from
the polymeric matrix declined as the drug to polymer ratio increased.
The drug remaining in the joint tissue following IA single injection of each formula was further
assessed in normal rats (Figure 6). After the IA injection of the marketed product, the drug concentration
in the joint at three days post-dosing was only 5.6 μg/g because TA crystals were quickly effluxed from
the joint tissue. The percentages of the drug remaining in the joint tissue at 3 and 7 days were calculated
to be only 4.5% and 2.4%, respectively. After 21 days, the drug concentration in the joint tissue was
below the limit of detection. This result is in line with a previous report that only two of eight patients
with osteoarthritis had quantifiable synovial TA concentration at week 6, following IA injection of the
marketed product [37]. On the other hand, the novel MS formulations exhibited a markedly profound
and prolonged concentration profile in joint tissue compared to the marketed product, exhibiting
quantifiable TA concentration over 28 days. Three days after the single administration of F4 or F8,
the drug concentration in joints was determined to be 45 μg/g and 67 μg/g, respectively, which is
one-third and one-half of the initial dose. In both MSs-treated groups, the TA concentration in the
tissue gradually decreased as time elapsed, but approximately 5% of the initial dose was still detected
at 28 days. These findings suggested that the retention time of TA in the joint tissue was extended with
the sustained-release pattern of the novel MSs.
 
Figure 6. TA remains in rat joint tissue following IA administration of the marketed product, F4, and
F8 at a dose of 125 μg of TA per knee; Notes: Vertical bars represent mean ± SD (n = 6). Statistical
analysis was performed using the one-way ANOVA test; * significantly different from the marketed
product (p < 0.05), ** significantly different from F4 (p < 0.05). BLOQ value of LC-MS/MS analysis was
determined to 0.2 ng/mL.
3.5. Long-Term Stability of TA Microcrystals-Loaded MS
The physicochemical stability of the novel MS was evaluated after 12 weeks of storage under
ambient conditions (25 ◦C, 60% RH). The storage condition of the MSs was set to ambient condition,
as there was morphological change above 40 ◦C, due to softening of the polymer over Tg. At first,
the drug crystallinity in the MS was assessed using XRD because a change in drug crystalline nature
may occur during storage, affecting the drug chemical stability and release pattern from the MS. Under
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ambient conditions, the crystallinity of TA microcrystals embedded in the MS was stably maintained
over 12 months, with no changes in diffraction pattern (Figure A1). There was also no change in drug
content in F8 MS, displaying over 97% drug content after 12 months of storage. The in vitro dissolution
pattern was also comparable with that of MSs immediately prepared, exhibiting a sustained-release
profile of over 21 days (Figure A1). From these findings, we concluded that the novel MS system was
physicochemically stable at least for one year under ambient conditions.
4. Conclusions
A novel parenteral sustained-release system of TA was successfully prepared by micronizing TA
powder into 1.7 μm-sized microcrystals, and subsequently embedding into PLGA/PGA polymeric
MSs using a spray-drying technique. TA microcrystals were efficiently entrapped into the polymeric
MSs, preserving their distinctive crystalline nature. In vitro drug release from the novel MSs was
markedly retarded compared to the marketed product and even 7.2 μm-sized TA crystal-loaded
MSs, exhibiting a prolonged release profile over 21 days under accelerated conditions (45 ◦C). In an
in vivo pharmacokinetic study in normal rats, the duration that the TA remained in the joint tissue
was markedly extended, providing profound drug remains at 28 days following IA single injection.
Moreover, TA microcrystals-loaded MSs drastically decreased the systemic exposure of the steroidal
compound compared to the marketed product. Thus, the novel IA long-acting system could be
a valuable tool, providing both increased drug retention in the knee and diminished systemic exposure
of TA following a single administration.
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Appendix A
 
Figure A1. Physicochemical stability of TA microcrystals-loaded MS (F4) after 12 months of storage
under ambient conditions. (A) XRD patterns of F4 MS (a) after preparation and (b) after 12 months of
storage, (B) in vitro release profile of F4 after preparation and after 12 months storage under accelerated
conditions; Notes: XRD pattern and release profile of F4 MS after preparation are identical to those
depicted in Figures 2D and 3B, respectively. Each point in (B) in vitro release profile represents mean ±
SD (n = 3).
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Abstract: Nanoparticles (NPs) based on the polymer poly (lactide-co-glycolide) acid (PLGA) have
been widely studied in developing delivery systems for drugs and therapeutic biomolecules, due to
the biocompatible and biodegradable properties of the PLGA. In this work, a synthesis method for
bone morphogenetic protein (BMP-2)-loaded PLGA NPs was developed and optimized, in order to
carry out and control the release of BMP-2, based on the double-emulsion (water/oil/water, W/O/W)
solvent evaporation technique. The polymeric surfactant Pluronic F68 was used in the synthesis
procedure, as it is known to have an effect on the reduction of the size of the NPs, the enhancement of
their stability, and the protection of the encapsulated biomolecule. Spherical solid polymeric NPs
were synthesized, showing a reproducible multimodal size distribution, with diameters between
100 and 500 nm. This size range appears to allow the protein to act on the cell surface and at the
cytoplasm level. The effect of carrying BMP-2 co-adsorbed with bovine serum albumin on the NP
surface was analyzed. The colloidal properties of these systems (morphology by SEM, hydrodynamic
size, electrophoretic mobility, temporal stability, protein encapsulation, and short-term release profile)
were studied. The effect of both BMP2-loaded NPs on the proliferation, migration, and osteogenic
differentiation of mesenchymal stromal cells from human alveolar bone (ABSC) was also analyzed
in vitro.
Keywords: BMP-2; PLGA nanoparticles; Pluronic F68
1. Introduction
In the context of nanomedicine, tissue regeneration using colloidal micro- and nano-structures
having unique size and surface activity has received increasing attention over recent years. Many efforts
have been made to improve the engineering of these nano-systems in order to reach a “smart” delivery
of bioactive molecules in order to optimize their therapeutic advantages and minimize harmful side
effects [1]. With this aim, a broad spectrum of biocompatible nanocarriers has been described, showing
properties suitable for different biological and therapeutic applications [2]. Among these varied
proposals, polymeric nanosystems represent a major group in which poly lactic-co-glycolic acid (PLGA)
is one of the most widely used due to its biocompatibility, biodegradability, and low cytotoxicity,
gaining the approval from different drug agencies for human use [3,4].
Pharmaceutics 2019, 11, 388 23 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2019, 11, 388
PLGA-based structures are described as micro- and nanocarriers to deliver a wide variety of active
molecules and drugs, synthetic or natural molecules with hydrophilic or hydrophobic properties, and
biomolecules from proteins to nucleic acids [5–7]. PLGA micro- and nanosystems can be set up using
different formulation techniques, with the possibility of a systemic or local distribution. These systems
can be applied not only in tissue regeneration but also in very diverse therapies: Anticancer drug
delivery, infections, inflammatory diseases, or gene therapy [3]. Despite this great potential, certain
applications, especially in protein encapsulation, are hindered by problems, such as an uncontrolled
release profile and protein denaturation [8–11].
The water-in oil-in water (W/O/W) double emulsion method is an “emulsion solvent evaporation”
technique frequently used to encapsulate hydrophilic molecules as proteins in PLGA NPs [6,12].
The appropriate choice of organic solvents, the use of polymer-surfactant blends, and the addition of
stabilizer-protective agents have proved to be key aspects for optimizing the resulting systems [9,11].
Additionally, a surface specific functionalization can be used to improve their versatility, allowing
the chemical surface immobilization of different molecules in order to confer targeting or adhesive
properties to these nanocarriers [13].
Within tissue engineering, bone regeneration has a broad range of applications, mostly in the field
of dentistry, where PLGA is suggested as a reference polymer to formulate NPs with bone-healing
uses [14]. The literature describes the delivery of bioactive molecules, normally growth factors, using
polymeric microparticles (MPs) and NPs with PLGA as the main component [13]. Among the bone
morphogenetic growth factors, BMP-2 (bone morphogenetic protein 2) has been the most frequently
cited, with many examples in which encapsulation or surface adsorption enables adequate entrapment
efficiency and diverse release patterns [15–19]. For proteins with a very short half-life, such as BMPs,
biodegradable PLGA nanosystems provide protection and optimal dosage for an adequate stimulation
of cell differentiation [20,21].
Thus, within this scenario, in the present work, we seek to optimize a nano-particulate system in
order to carry out and control the release of BMP-2 using as a starting point the synthesis procedure of
a lysozyme-loaded NP system, previously described for the encapsulation of that model protein [11].
Also, to encapsulate BMP-2, we prepared a second system in which this protein was co-adsorbed
with bovine serum albumin onto the surface of empty NPs. The size and morphology, the protein
encapsulation efficiency, the surface characteristics, and the colloidal and temporal stability were
studied to complete the physico-chemical characterization of both NP systems.
The release profile of BMP-2 indicates the potential of a PLGA nanocarrier for bone regeneration
and depends heavily on the polymer degradation by hydrolysis [22]. However, over the short
term, during which the release does not depend on this chemical degradation, proper control of
release is necessary in order to modulate other physical processes. Thus, we focused our release
experiments on the short-term using different techniques to compare the two NP samples and establish
the corresponding BMP-2 release profiles. Finally, the biological activity (cell migration, proliferation,
and osteogenic differentiation) was tested in vitro using mesenchymal stromal cells (MSCs) derived
from alveolar bone [23].
2. Materials and Methods
2.1. Nanoparticle Synthesis
2.1.1. Formulation
Poly(lactide-co-glycolide) acid (PLGA 50:50) ([C2H2O2]x[C3H4O2]y), x = 50, y = 50 (Resomer®
503H, (Evonik, Essen, Germany), 32–44 kDa was used as the polymer, and polymeric surfactant
Pluronic F68 (Poloxamer 188) (Sigma-Aldrich, St. Louis, MO, USA) as the emulsifier. Their structure,
based on a poly(ethylene oxide)-block-poly(propylene oxide)-block-poly(ethylene oxide), is expressed
as PEOa-PPOb-PEOa with a = 75 and b = 30. Human recombinant bone morphogenetic protein,
rhBMP-2 (Sigma-H4791), was used as therapeutic biomolecule. Water was purified in a Milli-Q
24
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Academic Millipore system. A double-emulsion synthesis method was used following a procedure
previously described with slight modifications [11]. In this method, 100 mg of PLGA and 3 mg of
deoxycholic acid (DC) were dissolved in a tube containing 1 mL of ethyl acetate (EA) and vortexed.
In total, 40 μL of a buffered solution at pH 12.8, with or without rhBMP-2 (200 μg/mL), were added
and immediately sonicated (Branson Ultrasonics 450 Analog Sonifier) for 1 min (Duty cycle dial: 20%,
Output control dial: 4) with the tube surrounded by ice. This primary W/O emulsion was poured into
a plastic tube containing 2 mL of a buffered solution (pH 12) of F68 at 1 mg/mL, and vortexing for
30 s. Then, the tube surrounded by ice was sonicated at the maximum amplitude for the micro tip for
1 min (Output control: 7). This second W/O/W emulsion was poured into a glass containing 10 mL of
the buffered F68 solution and kept under magnetic stirring for 2 min. The organic solvent was then
rapidly extracted by evaporation under vacuum to a final volume of 8 mL. The resulting empty and
BMP-2 encapsulated NP systems were named NP and NP-BMP2, respectively. A detailed scheme of
the synthesis procedure, with a yield based on the PLGA component always higher than 85%, is shown
in Figure S1 of the Supplementary Materials.
2.1.2. Cleaning and Storage
After the organic solvent evaporation, the sample was centrifuged for 10 min at 20 ◦C at 12,000 rpm.
The supernatant was filtered using Millipore nanofilters, 0.1μm for measuring the free non-encapsulated
protein. The pellet was then resuspended in phosphate buffer (1.15 mM NaH2PO4), PB, to a final
volume of 4 mL and kept refrigerated at 4 ◦C. Under these conditions, the systems kept colloidal
stability at least for one month.
2.1.3. Protein Loading and Encapsulation Efficiency
The initial protein loading was optimized for the nanoparticle formulation, preserving the final
colloidal stability after the evaporation step and taking into account the amounts shown in the literature
for this growth factor when encapsulated inside PLGA NPs [24,25]. Thus, we chose 2 μg as the initial
total mass of rhBMP-2, which means a relation of 2 × 10−5% w/w (rhBMP-2/PLGA). The amount of
encapsulated rhBMP-2 was calculated by measuring the difference between the initial added amount,
and the free non-encapsulated protein present in the supernatant after the cleaning step, which was
tested by a specific enzyme-linked immuno-sorbent assay following the instructions of the manufacturer
(ELISA, kit RAB0028 from Sigma-Aldrich, St. Louis, MO, USA). Then, protein-encapsulation efficiency





where MI is the initial total mass of rhBMP-2, and MF is the total mass of rhBMP-2 in the
aqueous supernatant.
2.1.4. Physical Protein Adsorption
Bovine serum albumin (BSA) and rhBMP-2 were coupled on the empty nanoparticle surface by
a physical adsorption method. The appropriate volume of an aqueous protein solution containing
0.5 mg of BSA and 2 μg of rhBMP-2 was mixed with 5 mL of acetate buffer (pH 5) containing empty
NPs with 12.5 mg of PLGA. This provided a starting amount of proteins corresponding to 0.04% w/w
(protein/PLGA), while the mass relation between proteins was 0.4 w/w (rhBMP-2/BSA). This solution
was incubated at room temperature for 2 h under mechanical stirring. The nanoparticles were separated
from the buffer solution by centrifugation, and after the supernatants were filtered (Millipore nanofilters,
0.1 μm), they were qualitatively analyzed by gel electrophoresis while the protein quantification was
made by a bicinchoninic acid protein assay (BCA) (Sigma-Aldrich, St. Louis, MO, USA) for BSA and
the specific ELISA for rhBMP-2. The nanoparticle pellet was resuspended in phosphate buffer (pH 7.4)
and stored at 4 ◦C. This system was named NP-BSA-BMP2.
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2.1.5. Protein Separation by Gel Electrophoresis, SDS-PAGE
The protein-loaded NPs and different supernatants were treated at 90 ◦C for 10 min in the
following buffer: 62.5 mM Tris-HCl (pH 6.8 at 25 ◦C), 2% (w/v) sodium dodecyl sulfate (SDS), 10%
glycerol, 0.01% (w/v) bromophenol blue, 40 mM dithiothreitol (DTT). Samples were then separated by
size in porous 12% polyacrylamide gel (1D SDS polyacrylamide gel electrophoresis), under the effect
of an electric field. The electrophoresis was run under constant voltage (130 V, 45 min) and the gels
were stained using a Coomassie Blue solution (0.1% Coomassie Brilliant Blue R-250, 50% methanol and
10% glacial acetic acid) and destained with the same solution lacking the dye.
2.2. Nanoparticle Characterization: Morphology, Size, Concentration, and Electrokinetic Mobility
NPs were imaged by scanning electron microscopy (SEM) with a Zeiss SUPRA 40VP field-emission
scanning electron microscope from the Scientific Instrumentation Center of the University of Granada
(CIC, UGR).
The hydrodynamic size distribution of the NPs was evaluated by nanoparticle tracking analysis
(NTA) with a NanoSight LM10-HS (GB) FT14 (NanoSight, Amesbury, UK) and an sCMOS camera.
The particle concentration according to the diameter (size distribution) was calculated as an average
of at least three independent size distributions. The total concentration of NPs of each system was
determined in order to control the number of particles used in cell experiments. The measurement
conditions for all samples were 25 ◦C, a viscosity of 0.89 cP, a measurement time of 60 s, and a camera
gain of 250. The camera shutter was 11 and 15 ms for the empty and BMP-loaded NPs, respectively.
The detection threshold was fixed at 5.
The electrophoretic mobility of the NPs was determined using a Zetasizer® NanoZeta ZS device
(Malvern Instrument Ltd., Malvern, UK) working at 25 ◦C with an He-Ne laser of 633 nm, and a 173◦
scattering angle. Each data point was taken as an average over three independent sample measurements.
For each sample, the electrophoretic mobility distribution and the average electrophoretic mobility
(μ-average) were determined by the technique of laser Doppler electrophoresis.
2.3. Colloidal and Temporal Stability in Biological Media
The average hydrodynamic diameter and the polydispersity index (PDI) by dynamic light
scattering (DLS) of each NP system were measured in different media (phosphate buffer (PB) saline
phosphate buffer (PBS), and cell culture medium: Dulbecco’s modified Eagle’s medium, DMEM
(Sigma)). Also, data on temporal stability were gathered by repeating these analyses at different times
after synthesis (0, 1, and 5 days) and after 1 month under storage conditions.
In vitro release experiments were conducted as follows: 1 mL of each sample for each incubation
time was suspended in PBS at 37 ◦C. After the corresponding time (24, 48, 96, 168 h), NPs were
separated from the supernatant of released proteins by centrifugation for 10 min at 14,000 rpm (10 ◦C).
The NP pellet was suspended in 1 mL of 0.05 M NaOH and stirred for 2 h for a complete polymer
degradation. The alkaline protein solution was assayed by BCA and ELISA to quantify the unreleased
amount. The protein released was calculated taking into account the total encapsulated amount. All
experiments were made in triplicate.
2.4. Cell Interactions
For all biological in vitro studies, a cell population cultured from the maxillary alveolar bone
was used. This population was previously characterized and confirmed to present all characteristics
of a mesenchymal stromal cell population (MSC) [23]. Cells were taken from healthy human
donors after the approval from the Ethics Committee for Human Research from the University of
Granada (424/CEIH/2018). Regular Dulbecco’s modified Eagle’s medium (DMEM) with 1 g/L glucose
(DMEM-LG) (Gibco), 10% fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, MO, USA), 1:100 of
non-essential amino acid solution (NEAA) (Gibco), 0.01 μg/mL of basic fibroblast growth factor (bFGF)
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(PeproTech, London, UK), 100 U/mL of penicillin/streptomycin, and 0.25 μg/mL of amphotericin B
was used as culture medium for all experiments. Cultures were maintained at 37 ◦C in a 5% CO2
atmosphere (2000 cells/well). All biological experiments were repeated in triplicate at least 3 times
per condition.
2.4.1. Cell Migration
A cell-migration assay was conducted as previously described [26,27]. Briefly, MSCs were
distributed on to three wells for each condition and allowed to grow to a cell confluency close to
99%, in 24-wells/plate at 3000 cells/cm2, and in each well three different scratches were made. Then,
cells were starved for 24 h by adding culture medium without serum. A scratch was made using
a pipette tip along the diameter of the well. A wash step with PBS was performed to remove the
scratched cells. Fresh complete culture media was added and supplemented depending on the assigned
group (BMP-2, NP- BMP2, and NP-BSA-BMP2 at 1.25, 2.5, and 5 ng/mL of BMP-2). Afterwards,
nine images were taken from the same area in each condition until 48 h later. On these images, the
scraped area was measured by ImageJ software (National Institute of Health, Bethesda, MD, USA;
http://rsbweb.nih.gov/ij/). The reduction in the scratched area over time was measured considering
the area at time 0 as 100% open.
2.4.2. Cell Proliferation
Proliferation was evaluated by a sulphorhodamine (SRB) assay [28]. The assay was conducted by
seeding the cells at 1500 cells/cm2 in a 96-well plate at a confluence not higher than 50%. After cell
attachment, the different supplements were added (BMP-2, NP- BMP2, and NP-BSA-BMP2 at 1.25,
2.5, and 5 ng/mL of BMP-2) and the cells were maintained in culture for up to 7 days. At each time
point, the cells were washed with 1X PBS and fixed by adding ice-cold 10% trichloroacetic acid for
20 min at 4 ◦C. Then, the cells were washed 3 times with dH2O and dried until all time points were
collected. Each well received 0.4% SRB in 1% acetic acid for 20 min at room temperature with gentle
shaking. The staining was finished by washing each well 3 times with 1% acetic acid and drying it at
room temperature for 24 h. The dye was retrieved from the cells by adding 10 mM Tris Base at pH 10.5
and gently shaking for 10 min. The solution recovered was then distributed in a 96-well plate and the
optical absorbance was read at 492 nm.
2.4.3. Osteogenic Differentiation
Osteogenic differentiation was evaluated by adding osteogenic media to the cell culture in
combination with free BMP-2, NP-BMP2, and NP-BSA-BMP2 at the highest dosages used in
previous experiments. Cells were seeded at 3000 cells/cm2 and cultured to reach an 85% to
90% confluency. This was followed by the addition of induction media containing 10 mM of
β-glycerophosphate (Fluka, 50020), 0.1 μM of dexamethasone (Sigma-Aldrich, D2915) and 0.05 mM
of L-ascorbic acid (Sigma-Aldrich, A8960). Cell cultures were maintained for 7 days to analyze
early activity. At day 7, cells were collected in 1 mL of TRIzol®. Then, RNA was extracted and
converted to cDNA. Alkaline phosphatase (ALP) was then evaluated, expression being calculated
relative to glyceraldehyde-3-phosphate dehydrogenase protein (GAPDH) by the 2−ΔΔCt method.
These procedures were conducted as described elsewhere [23]. Forward and reverse primer sequences
were AGCTCATTTCCTGGTATGACAAC and TTACTCCTTGGAGGCCATGTG for GAPDH, and
TCCAGGGATAAAGCAGGTCTTG and CTTTCTCTTTCTCTGGCACTAAGG for ALP.
2.4.4. Statistical Evaluation
Cell migration and proliferation were evaluated by ANOVA followed by Tukey multiple
comparisons test for pairwise analysis. Comparison between the levels of ALP at 4 vs. 7 days
were analyzed by paired Student’s t test. In all cases, a p value lower than 0.05 was established as
statistical significance.
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3. Results and Discussion
3.1. Nanoparticle Formulation
Double emulsion-solvent evaporation has been described as a robust and frequently used method
to produce biomolecule-loaded PLGA NPs [6,12,13,29]. A formulation previously optimized by
our group enabled the preservation of the biological activity of encapsulated biomolecules using a
slightly aggressive organic solvent. Moreover, deoxycholic acid has been used in the first step of the
formulation in order to improve the colloidal stability of NPs and, simultaneously, to obtain NP surfaces
enriched with carboxylic groups, improving their versatility and allowing a subsequent chemical
immobilization of different specific ligands [30]. By means of this improved formulation, in the present
work, we developed empty nanoparticles (NPs) or nanoparticles encapsulating rhBMP-2 (NP-BMP2).
A schematic description of the synthesis procedure is shown in Figure S1 of the Supplementary Data.
For NP-BMP2, we achieved a protein-encapsulation efficiency (EE) of 97 ± 2%. This result is consistent
with the literature in which several authors have reported similarly high values encapsulating this
protein inside PLGA nano- and microparticles [31,32]. Our formulation has several factors leading to
this very high EE value: The low protein/polymer relation in mass [33], the affinity of rhBMP-2 to an
unspecific interaction with hydrophobic surfaces [31], or the addition of stabilizers (poloxamer) in
the second step of the double-emulsion procedure [13]. The absence of rhBMP-2 in the supernatant
resulting from the centrifugation step in the cleaning process was verified by ELISA and SDS-PAGE, in
which a clear band corresponding to 14 kD of rhBMP-2 polypeptidic chains is shown for lane A in
Figure 1, corresponding to NP-BMP2. The mass of protein encapsulated, around 2 μg, is similar to that
of different PLGA micro- and nanosystems described in the literature [18,34,35]. Taking into account
the storage conditions for our samples, this corresponds to 500 ng/mL, which represents a sufficient
concentration for practical applications since this growth factor shows in vitro biological activities at
very low dosages (5–20 ng/mL) [13].
Figure 1. SDS polyacrylamide gel electrophoresis (SDS-PAGE) analysis under reducing conditions of
solid PLGA Nanoparticles (PLGA NPs) and liquid (supernatant) fractions of different NP systems. Lane
P: Protein standards; lane A: NP-BMP2 (bone morphogenetic protein); lane B: supernatant of NP-BMP2
after synthesis and encapsulation of rhBMP-2; lane C: NP after physical adsorption of BSA/rhBMP-2;
lane D: supernatant after physical adsorption of BSA(bovine serum albumin)/rhBMP-2 on NP system.
On the other hand, a second nanosystem resulted, modifying the way in which rhBMP-2 is
incorporated in the nanocarrier. There are several examples of surface adsorption of different growth
factors in micro- and nanoparticles [35–37], and surface immobilization over the encapsulation has
28
Pharmaceutics 2019, 11, 388
recently been proposed as a way to modulate the later release of biomolecules. This process, which
depends on the slow diffusion of biomolecules through the polymeric matrix, is consequently highly
influenced by the protein–polymer interaction [38,39] and polymer degradation [3,6]. Thus, this new
focus on the use of PLGA NPs for biomolecule delivery was explored by immobilizing the protein
rhBMP-2 on the surface of empty NPs by means of simple physical adsorption. This process is known
to be governed by electrostatic and hydrophobic interactions between protein molecules and NP
surfaces [40].
For this, the surface-charged groups, the hydrophilicity, the net charge of the protein molecules,
and the characteristics of the adsorption medium are the reference parameters. Thus, we designed a
co-adsorption experiment in which a mixture of rhBMP-2 and BSA (0.4% w/w, rhBMP-2/BSA) interact
simultaneously with the PLGA NP surface. Albumins are routinely used as protective proteins when
growth factors are incorporated in PLGA NPs [13,19]. Moreover, a surface distribution of BSA molecules
can improve the colloidal stability of NPs at physiological pH due to their net negative charge under
these conditions [41]. Figure S2 from Supplementary Materials shows a scheme of the co-adsorption
process. The adsorption efficiency is higher than 95% and in SDS-PAGE from Figure 1, two bands
characteristic of both proteins can be seen in lane C, corresponding to the NP-BSA-BMP2 nanosystem.
However, lane D, corresponding to the run of the supernatant from the centrifugation of the nanosystem
after adsorption processes, shows the absence of any protein. This result is fully explained by taking
into account the pH of the medium (pH 5.0), near the isoelectric point of BSA, where the adsorption of
this protein onto negatively charged nanoparticles presents a maximum [40,42]. The immobilization
of rhBMP-2 on the negatively charged surface of NPs proves they are electrostatically favored due to
the positive net charge of this protein at acid and neutral pH.
3.2. Nanoparticle Characterization
3.2.1. Nanoparticle Size
SEM and STEM micrographs (Figure 2) show that the samples consist of spherical particles of
different diameters (between 150 and 450 nm), a range similar to that found in a previous work in
which NPs were loaded with lysozyme following a similar synthesis protocol [11]. In that work,
the DLS technique failed to provide a reliable size distribution. Therefore, the NTA technique was
directly used to determine the hydrodynamic size of the BMP2-loaded NPs (see NTA video in the
Supplementary Material).
The size distributions for empty (NP) and BMP-loaded NPs (NP-BMP2) from NTA (Figure 3 and
videos S1, S2) were consistent with the SEM images. Particles with diameters between 100 and 500 nm
were found to have the highest particle concentration at around 200 nm. The loading with BMP had
an effect on the size distribution, leading to more defined peaks. These measurements enabled us
to determine the concentration of particles in the measured sample: 6.88 ± 0.09 × 108 pp/mL and
5.19 ± 0.12 × 108 pp/mL for NP and NP-BMP2 nanosystems, respectively. These values were used
(by taking into account the corresponding dilution) to control the number of particles added in the
cell experiments.
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Figure 2. Scanning electron microscopy (SEM) micrograph of rhBMP-2-loaded nanoparticles
(NP-BMP2).
Figure 3. Hydrodynamic diameter distribution of NP (circles) and NP-BMP2 (thick black line) measured
at pH 7.0 (phosphate buffer) by nanoparticle tracking analysis (NTA).
3.2.2. Electrokinetic Mobility and Colloidal Stability
The surface charge of nanoparticles can be analyzed using an electrokinetic study by measuring
the electrophoretic mobility (μe) under different conditions. Figure 4 shows the μe and zeta potential
values for the three nanosystems: NP, NP-BMP2, and NP-BSA-BMP2, at low ionic strength and
different pH values. The electric surface charge of NPs resides in the carboxylic groups of the uncapped
PLGA and deoxycholic acid molecules. These functionalized groups are additionally useful due to the
possibility of a chemical surface vectorization in order to develop directed delivery nanocarriers [43].
It was previously confirmed that protonation of these acidic surface groups at pH values under
their pKa value was tightly correlated with a loss of surface charge and consequently a reduction (in
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absolute value) of the electrophoretic mobility of the colloidal system [44,45]. Usually, when colloidal
particles are coated by protein molecules, the μe values change markedly compared with the same
bare surfaces and are influenced by the electrical charge of the adsorbed protein molecules [46,47].
The electrokinetic behavior of the NP-BMP2 system remains similar to that of NP, and encapsulation
of rhBMP-2 does not affect the surface charge distribution. A similar result was reported by d’Angelo
et al. on encapsulating different growth factors in PLGA-poloxamer blend nanoparticles in the same
proportion w/w of protein/polymer [24]. This may be due to the low amount of encapsulated protein
and its distribution in the inner part of the NPs (far from the surface). In our system, this internal
distribution may be favored by the encapsulating conditions where the basic pH (pH 12.0) of the water
phase containing rhBMP-2 allows a negative charge of these protein molecules, thereby preventing
their electrostatic specific interaction with acidic groups of the NPs.
Figure 4. Electrophoretic mobility and zeta potential vs. pH in buffered media of low salinity (ionic
strength equal to 0.002 M) for the different nanosystems: (black square) NP; (blue triangle) NP-BMP2;
(red circle) NP-BSA-BMP2.
The electrokinetic distribution for the NP-BSA-BMP2 system radically changes. As previously
shown, the very high adsorption efficiency leads to NPs with both proteins adsorbed around their
surface. This situation is closely correlated with the μe values from Figure 4. Taking into account the
w/w relation between adsorbed proteins (250 times higher for BSA), albumin molecules modulate the
behavior at pH values below their isoelectric point (pI 4.7), where the positive net charge of BSA masks
the original surface charge of NPs and even changes their original values to positive ones. This is a
typical result found for this protein-covering colloidal particles [42,48]. At neutral and basic pH values,
BSA molecules have a negative net charge, and the slight decrease in the absolute μe values could be
due to the reduction of the negative net surface charge of NPs, which may be shielded, at least in a
small part, by the positive charge of rhBMP-2 molecules under their basic isoelectric point (pI 9.0).
The colloidal stability for the different nanosystems (NP, NP-BMP2, and NP-BSA-BMP2) was
determined by analyzing the size distributions in various media (PB, PBS, and DMEM) at different
times after synthesis (0, 1, and 5 days). Size distributions similar to the original ones were found for
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the two formulations, NP and NP-BMP2, in all the media analyzed. This result was similar to that
previously found for these types of NPs encapsulating lysozyme [11], in which the combination of
electrostatic and steric interactions generated by surface chemical groups of NPs confer the stability
mechanism that prevents colloidal aggregation [33]. The decrease of the absolute value of the zeta
potential for the NP-BSA-BMP2 system as a consequence of surface protein distribution does not affect
its colloidal stability. This system also maintains the same size distribution in the different media. It is
commonly accepted that a zeta potential higher than +30 or −30 mV will give rise to a stable colloidal
system [49] and the zeta potential value for NP-BSA-BMP2 is above −30 mV. Colloidal stability in PBS
and DMEM, typically used media for the development of scaffold or cell interactions, respectively,
assures the potential use of these nanosystems for in vitro or in vivo living environments. Additionally,
these systems maintained their size under storage in PB, at 4 ◦C for at least 1 month (data not shown),
showing this to be an adequate medium for sample storage.
3.2.3. Protein Release
One of the main problems for micro- or nanosystems of PLGA drug delivery is to find the
appropriate release pattern for encapsulated/attached protein molecules. A wide spectrum of
formulations modulates this property by the use of different types of synthesis processes, PLGA
polymers, co-polymers, and stabilizers [3,13]. An adequate limitation and control in the burst release
is critical for BMPs in order to ensure long-term continuous release that, favored by the polymer
degradation, provides better in vivo action in driving bone and cartilage regeneration [20]. Therefore,
we previously developed a dual PLGA nanosystem for controlled short-term release, where protein
diffusion and protein–polymer interaction are the main factors governing this process [11].
In the present work, NP-BMP2 and NP-BSA-BMP2 nanosystems represent two different ways in
which rhBMP-2 was incorporated into the nanocarrier. Figure 5A shows the cumulative release of both
proteins, rhBMP-2 and BSA, for different systems as a function of time in a short-term period (7 days).
The encapsulated rhBMP-2 protein reaches an amount released of around 30% of the initial encapsulated
one while adsorbed rhBMP-2, despite its surface distribution, is three times lower. However, BSA
shows released amounts up to 80% of the initial adsorbed ones. In all cases, error bars correspond to
the standard deviations from three independent experiments. Under these conditions, the growth
factor encapsulated in NP-BMP2 presents a release pattern similar to that previously found with the
same formulation but using lysozyme as the protein [11]. Poloxamer in the water phase of the synthesis
process can be key in modulating both specific and unspecific interfacial protein interactions [50].
Thus, the relation between protein–polymer interaction and protein diffusion appears to be well
balanced, preventing an excessive initial burst and simultaneously maintaining the needed protein
flux to release around a third of the encapsulated rhBMP-2 in 7 days. Although an excessive initial
burst has been widely reported for PLGA NPs related with protein molecules close to the surface [6],
this situation did not appear for the NP-BMP2 system, this being consistent with the electrokinetic
behavior that did not show the presence of protein near surface. The literature offers some examples
with reduced short-term release of BMP-2 using more hydrophilic PLGA-PEG co-polymers [16] or a
different synthesis process [25].
The release performance for the NP-BSA-BMP2 system, also shown in Figure 5A, presents notable
differences. The electrokinetic profile has previously justified the surface location of BSA and rhBMP-2
on the surface, which could lead to a fast release of both proteins. However, results from Figure 5A,B
show this trend only for the BSA protein that is released from NPs, with about 20% of the initial amount
remaining after seven days. However, up to 90% of the initial load of rhBMP-2 protein, unlike BSA,
remains attached to the surface. The NP surface with hydrophilic groups form poloxamer molecules
and a negative charge due to the abundant presence of carboxylic groups (end-groups of PLGA and
deoxycholic acid molecules) favor a desorption process for BSA, whose molecules have a negative
charge under release conditions (physiological pH). This agrees with the results of other authors who,
even after encapsulating BSA in PLGA-poloxamer blend NPs, achieved a fast burst release of above
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40% to 50% of the initial protein amount [33]. Moreover, the co-encapsulation of albumins with growth
factors could strongly affect its release profile, causing an initial burst [21,24]. Otherwise, the specific
electrostatic attraction between positive rhBMP-2 molecules and negative surface groups slows down
the short time release of this protein. This result is in agreement with the low release of adsorbed
BMP previously found using PLGA micro- and nanoparticles with uncapped acid end groups [38,51].
Thus, the combination of different methods for trapping BMP-2 into and around NPs shows up the
possibility of attaining a properly controlled release, balancing the interactions between polymers,
stabilizers, and protein.
(A) (B) 
Figure 5. (A) Cumulative release of rhBMP-2 for NP-BMP2 (black square) and NP-BSA-BMP2 (red
circle) systems; and cumulative release of BSA for NP-BSA-BMP2 (blue triangle) system, incubated for
different times at 37 ◦C in saline phosphate buffer (pH 7.4). (B) SDS-PAGE analysis under reducing
conditions of solid fraction of NP-BSA-BMP2 after release at different times where the number of each
lane corresponds to the time in hours.
3.3. Biological Activity and Interactions
3.3.1. Cell Migration
Cell migration is the first and necessary step in tissue regeneration [52]. Thus, a regenerative
agent must accelerate cell migration or, at least, not interfere with it. In the present study, we found no
differences between the groups, doses, and control in terms of closure of a scratched area (ANOVA
with Tukey multiple comparisons test) (Figure 6). In contrast to our findings, previously published
data suggests a positive effect of BMP-2 on cell migration [53,54]. However, in those studies, the doses
applied, and the cell types were different than in the current experiments. We used lower doses of
BMP-2 in order to test whether, even at low dosages, BMP-2 could still provide benefits if protected
in a nanoparticle system. As mentioned, we demonstrated no negative effect of the system on cell
migration. Our results nonetheless support the idea that BMP-2 activity is mediated by the activation of
the phosphoinositide 3-kinase (PI3K) pathway, a common group of signaling molecules that participate
in several process with BMP-2 and other molecules [26,54]. It should also be mentioned that the
timeframe of a migration assay is short. Thus, the potential advantages of a controlled-release system
as the one under study might be limited. That is, the release of BMP-2 from the nanoparticles, as
demonstrated in Figure 5, is limited to the first 48 h. Thus, a sustained positive effect on migration
activity over time could be hypothesized.
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Figure 6. Migration assay. Percentage of scratched area closure at 24 and 48 h on different groups
and doses.
3.3.2. Cell Proliferation
Proliferation is another of the cell activities required for tissue regeneration. However, this property
must be balanced with both migration and differentiation, and not all three characteristics increase
at the same time and with the same ratios [55]. In fact, reportedly, when a dose of BMP-2 induces
higher proliferation, it decreases differentiation [56]. This property has been extensively analyzed but
discrepancies can still be detected in the literature. Therefore, Kim et al. analyzed different doses of
BMP-2 and its effect on cell proliferation and apoptosis. It was confirmed in vitro that high doses, but
still lower than those used clinically, reduce cell proliferation and increase apoptosis [57]. This should
be avoided. We have found that although free BMP-2 does not induce higher proliferation than the
control at any of the doses applied nor time points (ANOVA with Tukey multiple comparisons test),
the same amount of BMP-2 encapsulated or adsorbed onto PLGA nanoparticles boosts proliferation,
this being statistically significant when using a dose of 2.5 ng/mL or higher (ANOVA with Tukey
multiple comparisons test) (Figure 7). These dosages are still lower than those suggested in previous
studies. Apart from that difference, a positive effect on proliferation was still achieved. Moreover,
following the release pattern from Figure 5, more BMP-2 is expected to be released over time beyond
the 7-day time frame. Thus, a sustained induction effect could be expected as well until full confluency
of the cell culture.
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Figure 7. Proliferation of human mesenchymal stromal cells (MSCs) as measured by sulphorhodamine
(SRB) absorbance. Results were normalized to T0 in each group.
3.3.3. Osteogenic Differentiation
It has been confirmed that cell differentiation induced by BMP-2 needs the presence of permissive
osteoinductive components. Particularly, β-glycerophosphate has been shown to exert a synergistic
effect with BMP-2 in inducing cell differentiation [56]. Thus, to test for osteogenic differentiation, we
analyzed the expression of ALP mRNA. Maximum ALP activity was found to occur 10 days after
stimulation with PLGA-based microparticles containing BMP-2 in co-encapsulation with human serum
albumin [16]. Although other tests could have been used to reinforce our findings, ALP is known to
modulate the deposition of mineralized nodules, thus indicating osteoblastic activity. For all of this, we
supplemented the differentiation media with β-glycerophosphate and either free BMP-2, NP-BMP2, or
NP-BSA-BMP2 for 4 and 7 days so that we could capture the early dynamics of the expression of the
gene. In our study, we identified an increase in the expression of ALP in all groups from day 4 to day 7
(Figure 8). Although ALP at day 7 in the BMP-2 group appears to be higher than for the other two
groups, the change did not prove significant. In fact, differences between groups were not statistically
significant within any time period. Noteworthy though, the increase was not significant within the
BMP-2 group (p = 0.141, Student’s t test), but it was significant within the other two groups (p = 0.025
and p = 0.003; NP-BMP2 and NP-BSA-BMP2 groups, respectively). This, again, could be taken as a
confirmation of the sustained release of the protein from the nanoparticle system beyond the earlier
time points.
This and both the migration and proliferation studies described below lead us to confirm that the
system proposed can maintain a proper release of BMP-2 over time, sustaining a positive effect on cell
migration and proliferation with initial reduced doses of BMP-2. The fact that the excessive initial
burst is prevented is important for the application of this nanotechnology in bone regeneration, as
in dentistry. In this way, the negative effects of initial high doses of BMP-2 are avoided at the same
time as the molecule is protected from denaturalization inside the NP. Thus, the regenerator effects are
maintained over time.
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Figure 8. Relative fold change in the expression of ALP mRNA (control group: BMP2 at 4 days). * =
Statistical significance of the comparison over time (p = 0.025 and p = 0.003, Student’s t test; NP-BMP2
and NP-BSA-BMP2 groups).
4. Conclusions
In this work, a delivery PLGA-nanosystem previously developed for model proteins was chosen
as the reference system to carry and deliver the growth factor BMP-2. This NP system, with a dual
size distribution, was developed following a double-emulsion formulation in which the process
and the components used were optimized to reach the appropriate colloidal and biological behavior.
Encapsulation and adsorption are two different processes to load BMP-2 in PLGA NPs. Both were tested
to elucidate the factors controlling them and their influence in the physico-chemical and biological
properties of nanosystems. We verified that protein–polymer specific interactions have a major role in
the way that protein molecules are carried and delivered from NPs. In vitro experiments showed that
BMP-2-loaded PLGA NPs are the nanocarriers with the best release profile over the short-term without
an initial burst and with moderate and sustained release of active protein before the onset of polymer
degradation. Therefore, the biological activity is positive with no negative interaction with migration
or proliferation but rather the induction of cell differentiation through the expression of ALP.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/8/388/s1,
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Abstract: Bone morphogenetic protein-2 (BMP-2) has been demonstrated to be one of the most
vital osteogenic factors for bone augmentation. However, its uncontrolled administration has been
associated with catastrophic side effects, which compromised its clinical use. To overcome these
limitations, we aimed at developing a safer controlled and sustained release of BMP-2, utilizing
poly(lactic-co-glycolic acid)-multistage vector composite microspheres (PLGA-MSV). The loading and
release of BMP-2 from PLGA-MSV and its osteogenic potential in vitro and in vivo was evaluated.
BMP-2 in vitro release kinetics was assessed by ELISA assay. It was found that PLGA-MSV achieved
a longer and sustained release of BMP-2. Cell cytotoxicity and differentiation were evaluated in vitro
by MTT and alkaline phosphatase (ALP) activity assays, respectively, with rat mesenchymal stem
cells. The MTT results confirmed that PLGA-MSVs were not toxic to cells. ALP test demonstrated that
the bioactivity of BMP-2 released from the PLGA-MSV was preserved, as it allowed for the osteogenic
differentiation of rat mesenchymal stem cells, in vitro. The biocompatible, biodegradable, and
osteogenic PLGA-MSVs system could be an ideal candidate for the safe use of BMP-2 in orthopedic
tissue engineering applications.
Keywords: BMP-2; silicon; microsphere; PLGA; bone regeneration; controlled release
1. Introduction
Autologous bone grafting remains the gold standard for spinal fusion, traumatic non-union and
total hip arthroplasty complicated by osteolysis [1–3], yet it comes with morbidity (separate incision,
graft site pain, potential infection, etc.) and might provide insufficient volumes of bone for complex or
multilevel reconstruction [4]. Bone morphogenetic protein-2 (BMP-2) is a transforming growth factor
known to play a key role in the development and repair of bone and cartilage [5]. Initially, it appeared
to provide an ideal solution [6–8] to enhance bone growth but as its clinical use has expanded, multiple
complications associated with BMP-2 use have come to light including local wound problems, chemical
radiculitis, bony overgrowth into the canal or foramen, osteoclast activation with associated bony
resorption and device displacement, and, possibly, cancer when used at very high doses in an off-label
Pharmaceutics 2020, 12, 118 41 www.mdpi.com/journal/pharmaceutics
Pharmaceutics 2020, 12, 118
manner [1,9–11]. It is thought these complications were associated with the uncontrolled release and
systemic distribution of supraphysiologic doses of this potent growth factor [1,12]. One promising
way to avoid these complications is via the controlled local delivery of very small but effective doses
using the combination of growth factors with controlled drug delivery vehicles [13–17].
To date, however, systems designed to provide this controlled release have been limited by:
(a) a burst release phenomena which leads to similar supraphysiologic dosing, inefficiently sustained
dosing, and uncontrolled delivery as that seen with delivery systems currently used clinically; (b) the
inability to preserve the quaternary structure of drugs following release from the delivery system; and
(c) delivery system (polymer) degradation byproducts that have a secondary negative impact on the
structure of the drugs released [16,18]. Therefore, a new carrier system capable of sustained, regulated,
local release of small but effective doses that do not impact BMP-2 functionality are needed to allow
the avoidance of the biological complications associated with burst supraphysiologic dosing [16].
With the development of nanomaterials, several types of particles, both nano and micro, have been
used as growth factor delivery carriers [19]. Of these, nanoporous silicon has emerged as a material
uniquely capable of the preservation of protein stability and function with predictable degradation
properties in physiologic fluids and systems [16,17,19–22]. The breakdown product, orthosilic acid,
has also been shown to stimulate mineralization by osteogenic cells while retaining the ability to buffer
the breakdown products of coating polymer (poly(lactic-co-glycolic acid), PLGA) [19,23].
Recently, by integrating the drug preserving and encapsulating capabilities of nanoporous silicon
with the further controlled release capabilities achieved by polymer encapsulation (using PLGA), we
optimized a double controlled delivery system for the controlled and sustained temporospatial release of
growth factors [17]. The platforms consisted of the mesoporous silicon-based multistage vector (MSV),
encapsulated within a PLGA microparticle (PLGA-MSV). In our previous study, we demonstrated
that PLGA-MSV is able to efficiently load a growth factor (i.e., PDGF-BB) and release it in a controlled
fashion in vivo, with a significant reduction of the initial burst release, while preserving its functionality
(i.e., inducing vascularization) [17].
The aim of the current study was to optimize the release of BMP-2 through the PLGA-MSV
delivery system and assess its effectiveness in inducing osteogenesis in vitro.
2. Materials and Methods
2.1. Preparation of PLGA-MSV Microspheres
The PLGA-MSV microspheres were fabricated by a modified S/O/W emulsion method as in our
previously published studies [7]. Briefly, PLGA (Sigma Aldrich, St. Louis, MO, USA was dissolved
in dichloromethane (DCM; Fisher Scientific, Loughborough, UK) to form PLGA/DCM organic phase
solution (10% and 20% w/v). BMP-2 loaded particles (8 × 107) were suspended into 1 mL of PLGA/DCM
solutions (10% and 20% w/v respectively) by vortex mixing and sonication for 2 min. The organic phase
containing the MSV particles was transferred into 3 mL of PVA (2.5% w/v) solution and emulsified
for 1 min by vortex mixing. The primary emulsion was then gradually dispersed into 50 mL of PVA
solution (0.5% w/v). The resulting suspension was stirred continually for 2 h under a biochemical hood,
and the DCM evaporated rapidly during the stirring process. PLGA-MSV microspheres were washed
with deionized water 3 times and lyophilized overnight. The freeze-dried BMP-2 loaded PLGA-MSV
microspheres were then stored at −80 ◦C.
2.2. Characterization of PLGA-MSV Microspheres
The morphology of the microspheres was characterized by scanning electron microscope (SEM;
Nova NanoSEM 230, FEI, Lincoln, NE, USA) and confocal microscope (Nikon A1 laser confocal
microscope). The samples were sputter coated with 8 nm of platinum (Pt; Cressington sputter coater
208 HR System, Ted Pella, Inc., Watford, UK) and examined by SEM under a voltage of 3 kV, spot size
3.0, and a working distance of 5 mm.
42
Pharmaceutics 2020, 12, 118
2.3. Loading of BMP-2 into Nanoporous Silicon Particles (MSV)
Two hundred microliters of BMP-2 growth factor solution (Peprotech) was added into 8 × 107
oxidized nanoporous silicon particles in an Eppendorf tube. The suspension was mixed throughout
by vortex mixing and sonication. The tube was gently rotated on a rotator at room temperature for 2
h to allow the adsorption of BMP-2 into the MSV particles. The BMP-2 loaded particles were then
spun down by centrifugation (Sorvall Legend X1R Centrifuge, Thermo Scientific, Waltham, MA, USA)
(4500 rpm for 5 min), lyophilized overnight, and stored at −80 ◦C for future use. The concentrations
of the BMP-2 loading solution and the supernatant were measured by Elisa assay to determine the
amount of BMP-2 loaded into the MSV particles.
2.4. Evaluation of Growth Factor (BMP-2) In Vitro Release
The BMP-2 loaded PLGA-MSV microspheres (10% and 20% w/v) containing 8 × 107 of MSV
particles were dispersed into 0.5 mL of 1% BSA solution at 37 ◦C. The BMP-2 loaded PLGA microspheres
(10% and 20% w/v) were used as a control. At predetermined time intervals, the suspension was
spun down at 4500 rpm for 5 min and 0.5 mL of each supernatant was collected, and replaced with
0.5 mL of fresh 1% BSA solution. The amount of BMP-2 released from BMP-2 loaded PLGA-MSV
microspheres was detected using an enzyme-linked immunosorbent assay kit (BMP-2 ELISA, R&D
Systems, Minneapolis, MN, USA).
2.5. Cell Isolation and Culture
The study protocol and all operations were reviewed and approved by the Houston Methodist
Research Institute’s Institutional Animal Care and Use Committee (IACUC, protocol IS00003525,
18 August 2010). All investigators complied with the National Research Council’s Guide for the Care
and Use of Laboratory Animals. Male Sprague Dawley rats (N = 10) with an average weight of 310 g
were used in the study. The rodents underwent a mandatory 48 h acclimation time prior to any surgical
procedures and were housed in pairs with ad libitum water and chow until the study period began.
Bone marrow stromal cells (BM-MSCs) were isolated from male Sprague Dawley rats as previously
described. Briefly, femora and tibiae bones were removed from male Sprague Dawley rats (100–125 g)
sacrificed by CO2 overdose under isoflurane anesthesia. Bones were cleaned of connective tissues,
ligaments, and muscle by scalpel, washed thoroughly in phosphate-buffered saline (PBS, Invitrogen,
Carlsbad, CA) containing 2% penicillin and streptomycin (P/S, Invitrogen). The proximal and distal
ends of each bone were removed and the marrow was gently flushed out with PBS containing 1% fetal
bovine serum (FBS, HyClone, ThermoFisher 124 Scientific, Logan, UT, USA) and 1% P/S. The diaphysis
regions were crushed using a mortar 125 and pestle while submerged in PBS washes until the PBS
appeared clear, indicating complete removal of the remaining marrow and perivascular cells. The total
BM fraction was kept on ice for up to 1 h prior to further purification. The total BM cell fractions
was counted by hemocytometer and then purified to mononuclear cells by centrifugation on Ficoll
(150× g for 30 min without brake). The mononuclear BM populations were counted, resuspended in
standard media (alpha-MEM (αMEM, Invitrogen) with 20% FBS, 1% P/S, 1% sodium pyruvate and 1%
GlutaMAX (Invitrogen)). Cells were seeded in T75 flasks at a density of approximately 105 cells/cm2
and cultured in hypoxic conditions (5% O2, 5% CO2) to maintain their multipotency. Upon reaching
80% confluency, cells were passaged and split 1:4 in new flasks.
Cells were cultured in α-minimum essential medium (αMEM; Invitrogen) supplemented with
20% (v/v) defined fetal calf serum (Invitrogen), 1%, l-glutamine (Invitrogen), 1% sodium pyruvate
(Invitrogen), 100 U/mL penicillin, and 100 μg/mL streptomycin (Invitrogen) as the standard growth
media. Osteogenic growth media included 10 mM β-glycerophosphate, 0.1 mM ascorbate-2-phosphate,
and 100 nM dexamethasone. Cells were maintained at 37 ◦C in a humidified 5% CO2 atmosphere. Cell
culture media was changed every 3 days.
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2.6. Cell Metabolic Activity—MTT Assay
MTT assay of BM-MSC treated with PLGA-MSV microspheres was performed to quantify
metabolic activity [8]. Two thousand and five hundred BM-MSCs were seeded and cultured in a 24-cell
culture well plate in the presence of the PLGA and PLGA-MSV microspheres (BM-MSCs:Particles,
1:5). Cells only were used as a control. MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay was performed on day 1, 4, and 7. Cell culture media was removed from cell culture
wells and 500 μL of MTT working solution (0.5 mg/mL) were added into the wells. The cells were
incubated in the MTT working solution at 37 ◦C for 4 h. The solution was removed from the cell
culture wells and replaced with 500 μL of dimethyl sulfoxide (DMSO; Sigma Aldrich). The cells were
incubated with DMSO at room temperature for 30 min. The solutions were transferred to a 96 well
plate and the absorbance of the colored solutions was quantified by a spectrophotometer (Synergy
H4 Hybrid Reader, BioTek, Winooski, VT, USA) at 570 nm. DMSO was used as blank. Cells only and
PLGA particle wells were used as controls.
2.7. Alkaline Phosphatase (ALP) Activity Assay
Osteogenic differentiation was measured by ALP activity, a biomarker of osteoblastic differentiation.
The assay was carried out according to manufacturer guidelines for the spectrophotometric procedure
using ALP reagent (Vector Laboratories, Inc. Burlingame, CA, USA). The BM-MSCs were plated into a
24 well cell culture plate at a density of 2500 cells per well with the PLGA-MSV microspheres (20%
w/v) loaded with BMP-2 was used as the experiential group. Cells alone, cells cultured with BMP-2,
and empty PLGA-MSV microspheres without BMP-2 (20% w/v) were used as controls. Cell culture
media was changed every 3 days. Cells were cultured in α-minimum essential medium (αMEM;
Invitrogen) supplemented with 10% (v/v) fetal calf serum (Invitrogen), 100 U/mL penicillin, and
100 μg/mL streptomycin (Invitrogen) as the standard growth media. Culture conditions were 37 ◦C in
a humidified 5% CO2 atmosphere. The osteogenic growth media included 10 mM β-glycerophosphate,
0.1 mM ascorbate-2-phosphate, and 100 nM dexamethasone. Cell culture media was replenished twice
weekly. Cells were cultured in standard media until 60% confluence and then switched to osteogenic
media. ALP assays were performed at week 1, 2, and 3. The medium was aspirated and 1 mL of PBS
was added into each well to wash the cells. Cells were washed 3 times with PBS, and fixed in 10%
buffered formalin for 15 min. Cells were then washed twice in deionized (DI) water and covered in ALP
stain made fresh. ALP staining stock solution was made from ALP substrate kit III (Vector Laboratories.
Inc., Burlingame, CA, USA) into 5 mL of 100 mM tris-HCl (pH = 8.2) solution. Absorbance of cells
after staining was used to quantify ALP activity. The experiments were performed in triplicate.
2.8. Von Kossa Co-Staining
Cell cultures were co-stained for calcium-triphosphate mineral deposition by Von Kossa staining.
Co-staining of the cell culture was performed to simultaneous both quantify ALP activity and provide
a qualitative assessment of mineral deposition. Following ALP staining, cells were washed twice in DI
water and soaked in in 1% aqueous silver nitrate (AgNO3) and placed under ultraviolet (UV) light
for 60 min and then rinsed with DI water. To remove unreacted silver, 5% sodium thiosulfate was
added for 5 min, removed and cells rinsed in DI water. Following this cell nuclei were counterstained




The PLGA-MSVs were characterized by SEM-energy-dispersive X-ray (EDX) and confocal
microscopy. SEM images show that the spherical-shaped PLGA-MSVs with smooth surfaces had a
wide distribution from a few microns to approximately 50 μm, with an average diameter of 23 ± 3
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(n = 50; Figure 1A). EDX spectrum showed the presence of a Si peak (Figure 1B), which indicates the
presence of MSV particles inside of the PLGA microspheres. The full encapsulation of MSV was further
confirmed by optical microscopy, where hemispherical MSVs appeared yellow in color (Figure 1C).
MSVs were also loaded with a reporter protein (FITC-BSA) and imaged by confocal microscopy.
Imaging clearly demonstrated that the FITC-BSA loaded MSVs (in green) were fully encapsulated
(Figure 1D–F).
 
Figure 1. SEM and confocal images of PLGA-multistage vector (MSV). Representative SEM image of
PLGA-MSV (A). EDX spectrum of PLGA-MSV microspheres showing the presence of the silicon peak
corresponding to MSV (B). Confocal laser microscopy Z-stack of PLGA-MSVs loaded with FITC-BSA
(in green), showing that MSVs were fully encapsulated into the PLGA microsphere (D,E). Close up of a
PLGA-MSV (C,F).
3.2. PLGA-MSV Loading with BMP-2 and In Vitro Release
Recombinant human BMP-2 was used in this study. BMP-2 is a 29 kDa protein with an isoelectric
point of 8.21 (Peprotech). The BMP-2 loaded PLGA-MSV microspheres (with a PLGA coating of 10%
and 20% w/v) were used for in vitro sustained release studies. The loading efficiency of BMP-2 into MSV
particles is shown in Figure 2A. Consistent with mass transport theory, the greater number of particles
added to the solution of BMP-2, the greater amount of loading achieved and thus a higher loading
efficiency. The in vitro release profiles of BMP-2 from different types of microspheres were monitored
for 40 days. A delayed burst release over three days was demonstrated by 10% w/v PLGA-MSV
microspheres (Figure 2B). When monitored to 40 days 90% of release was achieved within 10 days
and sustained release equilibrium near 24 days (Figure 2C). In contrast, BMP-2 release from 20% w/v
PLGA-MSV microspheres showed a more linear-like release with a more linear early release profile
(Figure 2B). This slower rate of BMP-2 release continued until equilibrium was reached at 41 days
(Figure 2C).
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(A) (B) (C) 
Figure 2. The in vitro loading and release profiles of BMP-2 using PLGA-MSV microspheres (10%, 20%
w/v; n = 3). (A) The loading profiles of BMP-2 into MSV particles with fixed BMP-2 concentrations and
mass, and varied MSV microparticle number. Cumulative release profile of BMP-2 from different 10%
and 20% PLGA-MSV in the first three days (B) and over 41 days, (C). Values are reported as mean ±
standard deviation. A value of p < 0.05 was considered statistically significant: ** p < 0.01 (calculated
by t test analysis).
3.3. Cell Metabolic Activity—MTT Assay
Cell metabolic activity in the presence of the PLGA and PLGA-MSV microspheres was analyzed
using MTT assay. Figure 3 shows the results of MTT assay for BM-MSCs cultured with PLGA-MSV
microspheres at 1, 4, and 7 days. Metabolic activity among cells alone (control) and cells with the
PLGA-MSV microspheres shared the similar trend and there was no significant difference among of
the three groups at 1, 4, or 7 days. Cells in each group achieved a comparable metabolic activity and
reached equilibrium at each time point.
Figure 3. MTT assay for rat bone marrow stromal cells (BM-MSCs) cultured with 10% PLGA-MSV
and 20% PLGA-MSV microspheres over 7 days (n = 3). Cell viability is reported as absorbance at
490 nm. The cell metabolic activity of BM-MSCs in the presence of both formulations of PLGA-MSV
was comparable to that of untreated cells (CTRL). Values are reported as mean ± standard deviation.
No statistical significance was found among selected experimental conditions.
3.4. PLGA-MSV-BMP2 Enhances Alkaline Phosphatase Activity (ALP)
ALP is synthesized by osteoblasts and is a biomarker of presumed ECM production during
BM-MSC differentiation [24]. As shown in Figure 4, at weeks 1 and 2, BMP-2 loaded 20%
PLGA-MSV(PLGA-MSV-BMP2) microspheres showed higher ALP activities compared to cells alone
and cells treated with BMP-2 (BMP2). At week 2, cells treated with PLGA-MSV-BMP2 showed the
highest ALP activity during the duration of the investigation. The ALP activities decreased to a fairly
low level for all controls and experimental groups after 3 weeks. Although, interestingly, the ALP
activity of the control remained elevated at this time point.
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Figure 4. ALP activity of untreated BM-MSCs (CTRL), BM-MSCs treated with soluble BMP-2 or 20%
PLGA-MSV loaded or non-loaded with BMP-2 over 3 weeks (mean ± SD, n = 3). Values are reported as
mean ± standard deviation. Data was analyzed through 2-way ANOVA. A value of * p < 0.05 was
considered statistically significant (**** p < 0.0001).
3.5. ALP Staining and Von Kossa Staining
All groups were co-stained for ALP and calcium using standard ALP staining and Von Kossa
stain. ALP staining data of BM-MSC treated with BMP2 and PLGA-MSV-BMP2 correlated with ALP
quantitative activity data. BMP2 and PLGA-MSV-BMP2 showed qualitatively increased staining at 1
and 2 weeks while untreated cells showed increased ALP staining at 3 weeks (Figure 5).
Figure 5. ALP and Von Kossa co-staining of BM-MSCs and BM-MSCs with experimental groups.
ALP activities increased from week 1 to week 2 and then decreased from week 2 to week 3 in BMP2
and BMP2-PLGA-MSV. The cells in the presence of the PLGA-MSV-BMP-2 microspheres at week 2
showed the strongest ALP activity (red circles) among all of the control and experimental groups over
the 3-week culture period. Von Kossa staining progressively increased in all groups with BMP2 and
BMP2-PLGA-MSV showing the most staining at week 3 (Scale bar: 60 μm).
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Von Kossa staining was performed to assess functional activity of BM-MSC osteoinduction.
Calcium deposition was delayed compared to ALP staining. Calcium (black stain) is seen in the
PLGA-MSV-BMP2 group as early as one week and continues to increase throughout the 3 weeks
having the most deposition of all groups. In the control and BMP2 group calcium begins to be seen at
2 weeks yet the deposition of calcium only continues to increase in the BMP2 group. PLGA-MSV did
not demonstrate appreciable deposition until week 3 (Figure 5).
4. Discussion
This study reports the development and investigation of a PLGA based protein delivery system,
PLGA-MSV microspheres, for controlled protein release to stimulate cell differentiation. Herein, we
studied the loading and release of BMP-2 from MSV, the relationship of PLGA:BMP concentration
on BMP-2 release, and the effect of long-term constant BMP-2 stimulation on BM-MSCs. BMP-2 was
successfully encapsulated into the microsphere system and the performance was tested in vitro. The
experiments show that: (1) BMP/PLGA-MSV microspheres had the ability to release small but effective
doses of BMP-2 for 40 days in a controlled, linear fashion; (2) the release profile of the BMP/PLGA-MSV
microspheres was dependent on the PLGA coating of 10% or 20%; (3) the PLGA-MSV system did not
impact cell metabolic activity; and (4) BMP-2 released from PLGA-MSV microspheres was capable of
osteoinduction of BM-MSCs.
Previously, published reports with the clinical and pre-clinical use of BMP-2 have demonstrated
bone augmentation, but the growth occurred in an uncontrolled and non-physiologic fashion. Partly due
to the short half-life and need for supraphysiologic dosing, this resulted in heterotopic bone formation.
Clinically this has translated in to the development of multiple complications [1,10]. Currently
formulated BMP devices must be used at high concentrations resulting in problems with protein
release timing stability, and need for accessory factors [11,12]. Additionally, the bone regenerative
process under these conditions is very different from the normal physiologic processes in normal
bone healing in which multiple BMPs and other growth factors are present in overlapping temporal
patterns [13,14]. Here we reported a biomolecular release vehicle capable of controlling release kinetics
of an encapsulated molecule for localized protein delivery, in this case BMP2. This phenomenon is
affected by the percentage of PLGA used indicating an added level of spatiotemporal control of the
system. Increasing PLGA percentage slowed release kinetics from a burst release to a more constant
release and could theoretically lead to more prolonged and slowed release kinetics [25,26]. The slower
release kinetics may be more biologically accurate and induce a more sustained response in contrast to
the massive burst release kinetics often seen from PLGA alone [27]. Here we demonstrated this system
is capable of long-term delivery as well as in vitro osteoinduction.
As many of the issues attributed to the use of growth factors in regenerative medicine have been
centered on the lack of controlled release, this model presents a system for localized delivery within a
clinically relevant scenario such as a healing fracture. MSCs are the major regenerative cell involved in
the fracture healing process [28]. Their stimulation is paramount for the successful regeneration of
tissue and organized bone formation. Without their coordinated efforts through properly induced
pathways, dysregulated and disorganized growth occurs leading to weakened fracture callus formation
and recurrent injuries [15,16]. Previously, investigators have demonstrated the efficacy of BMP2 release
on the activity of MSCs [17]. Here we show that normal cellular function is not inhibited by the
PLGA-MSV system and that sustained BMP-2 release results in MSC osteoinduction and increased ALP
activity compared to BMP-2 alone. Cells can proliferate normally in the presence of the PLGA-MSV
microspheres, which, indicates that these materials were nontoxic to cells and compatible with normal
cell function. When loaded with BMP, the PLGA-MSV system was used to stimulate BM-MSC in vitro.
ALP enzyme activity was increased in the PLGA-MSV-BMP-2 group and this correlated with ALP
staining. These findings translated to a persistent and increasing deposition of calcium seen in the
Von Kossa co-stain. The delayed deposition of calcium is consistent with normal biological function
and an expected outcome [29]. The PLGA-MSV-BMP system induced early and robust ALP activity
48
Pharmaceutics 2020, 12, 118
at one week compared to BMP2 alone. At this same time point calcium is already detected in the
Von Kossa stain of the PLGA-MSV-BMP2 group. This suggests that the slowed release may in fact
have greater biological activity compared to high dose free BMP. This localized effect may provide
insights into the further concomitant use of MSCs and PLGA-MSV vectors for regenerative purposes
in other applications.
There are several limitations with the current study. First the lack of free PLGA-BMP2 makes
direct comparison difficult. There have been several studies looking at the use of PLGA as a protein
carrier and more specifically a BMP2 carrier. These studies reported the release kinetics of BMP2 from
PLGA and its impact in vitro on osteoinduction. Given the historical findings with PLGA alone as the
carrier we chose to focus on the use of MSV encapsulated in PLGA. Second, while ALP activity, staining
and calcium deposition all form part of the evaluation of BM-MSC osteoinduction further studies
in the transcriptional changes and more quantitative histological assessments could be performed.
This was out of the scope of this initial work and is the focus of subsequent works in progress. Third,
an additional comparison group looking into the effects of PLGA-MSV ratio on bioactivity toward
BM-MSC is needed. While there were significant differences between the release profiles between
10% and 20% PLGA-MSV-BMP2 no biologic data was obtained. This is currently a subject of current
investigation. Lastly, this is only an in vitro study with one cell line. The biologic milieu of the in vivo
micro-environment is composed of a complex interplay of signaling and cell types. While our in vitro
findings are promising they warrant analysis in an in vivo fracture model to assess the efficacy of
localized controlled release.
5. Conclusions
In conclusion, this biocompatible, biodegradable, and osteogenic PLGA-MSV microsphere system
holds promise as a candidate for the delivery of safe, local, small but effective doses of bioactive proteins
for pharmaceutical induction of osteoregeneration. The local and long-term delivery of proteins and
other bioactive molecules for orthopedic applications may avoid the complications associated with
burst release and supraphysiologic dosing of BMP-2 currently afforded by available delivery systems.
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Abstract: The controlled release of active substances—bone morphogenetic protein 2 (BMP-2) and
17β-estradiol—is one of the main aspects to be taken into account to successfully regenerate a
tissue defect. In this study, BMP-2- and 17β-estradiol-loaded microspheres were combined in a
sandwich-like system formed by a hydrogel core composed of chitosan (CHT) collagen, 2-hidroxipropil
γ-ciclodextrin (HP-γ-CD), nanoparticles of hydroxyapatite (nano-HAP), and an electrospun mesh
shell prepared with two external electrospinning films for the regeneration of a critical bone defect in
osteoporotic rats. Microspheres were made with poly-lactide-co-glycolide (PLGA) to encapsulate
BMP-2, whereas the different formulations of 17β-estradiol were prepared with poly-lactic acid
(PLA) and PLGA. The in vitro and in vivo BMP-2 delivered from the system fitted a biphasic profile.
Although the in vivo burst effect was higher than in vitro the second phases (lasted up to 6 weeks)
were parallel, the release rate ranged between 55 and 70 ng/day. The in vitro release kinetics of
the 17β-estradiol dissolved in the polymeric matrix of the microspheres depended on the partition
coefficient. The 17β-estradiol was slowly released from the core system using an aqueous release
medium (Deff = 5.58·10−16 ± 9.81·10−17m2s−1) and very fast in MeOH-water (50:50). The hydrogel core
system was injectable, and approximately 83% of the loaded dose is uniformly discharged through
a 20G needle. The system placed in the defect was easily adapted to the defect shape and after 12
weeks approximately 50% of the defect was refilled by new tissue. None differences were observed
between the osteoporotic and non-osteoporotic groups. Despite the role of 17β-estradiol on the bone
remodeling process, the obtained results in this study suggest that the observed regeneration was
only due to the controlled rate released of BMP-2 from the PLGA microspheres.
Keywords: BMP-2-microspheres; hydrogel system; 17-βestradiol release; bone regeneration;
osteoporosis; poly-lactide-co-glycolide; polylactic acid
1. Introduction
Regeneration of bone critical defects is still a challenge in the orthopedic field. Local treatment with
bone morphogenetic protein (BMP-2) incorporated in different biomaterial scaffolds has demonstrated
to be efficient to induce new bone formation for critical bone defect in several animal models. Nowadays,
collagen sponges loaded with recombinant BMP-2 are clinically available as bone graft substitutes
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for the treatment of nonunion and critical-sized bone defects. Although BMP-2 is a potent osteogenic
agent, a controlled release profile is required for safety and efficacy. Thus, the scaffold to fill the bone
defect should not only be designed to act as support and guide for tissue growth, but also to control
the release rate of active substances. Although many materials and structures have been proposed to
construct these scaffolds, the control of the release rate has not always been taken into account. In fact,
in some cases the protein is incorporated in the material by incubation and, unless a material-protein
interaction occurs, a burst release at an early period would be expected. Consequently, a high dose
of BMP-2 would be in blood circulation, leading to a high risk of side effects and, at the same time,
a significant loss of the protein in the site of action. In addition, some authors showed that BMPs in these
cases might also stimulate bone resorption due to the high dose of BMP-2 associated to uncontrolled
release [1]. To minimize the osteoclastic effect of BMPs, some authors proposed the addition of an
anti-catabolic agent. The most frequently studied combination has been BMP-2 with bisphosphonates
as anti-resorption agents such as alendronate [2,3] and zolendronate [4]. The results indicated good
bone regeneration with improved bone quality and mineralization in different localizations compared
to BMP-2 alone [5,6].
Among the several natural polymeric scaffolds prepared for bone regeneration, chitosan is a
biomaterial frequently used for this purpose. In a recent extensive review [7] based on chitosan (CHT)
applied in bone tissue regeneration, different advantageous aspects were showed and discussed such as
biocompatibility, capacity for BMPs sustained release, improvement of cell proliferation, and increase
of in vitro and in vivo differentiation and mineralization. However, bone graft materials to simulate
bone structure, e.g., collagen, the major ECM of bone tissue, and hydroxyapatite (HAP), a mineral
component of the bone, have also been widely studied [6,8–14].
Although the aforementioned studies indicated positive results, the mentioned strategies applied
in osteoporosis (OP) conditions have not always been effective [15]. According to recent reports,
the prolonged subcutaneous administration of alendronate and the low level of estrogen in OP alters
the evolution of calvarial bone repair due to estrogen, Transforming Growth Factor beta 1 (TGF-β1),
and α-estrogen receptor (α-ER) interaction [16]. Menopausal women are the population most affected
by this disease due to estrogen deficiency. Previous reports revealed that local implantation of scaffolds
loaded with combinations of BMP-2 and 17β-estradiol formulated in microspheres of polylactic acid
(PLA) or PLGA, in rat calvaria critical defects increased the bone repair in OP rats, but the new bone
that refilled the defect was less mineralized compared to non-OP groups [17,18].
As some biomaterials may promote bone regeneration, controlled release of the active substances
is required for efficient and safe bone regeneration [19,20]. In this study, we propose a loaded BMP-2
and 17β-estradiol sandwich-like system, comprising two polymeric external films and a core of a
biocomposite hydrogel containing microspheres, to provide sustained release of active substances.
The core system composed of CHT, collagen, HAP nanoparticles (nano-HAP), polyethylene glycol
(PEG-400) and 2-Hidroxipropil γ-Ciclodextrin HP-γ-CD was previously characterized in terms of
composition, rheological behavior and mass-transfer using RITC-dextran as macromolecule model and
17β-estradiol in microspheres [21]. In the present study, we aim to study the influence of the release
rate of 17β-estradiol on the osteogenic effect induced by BMP-2 released from PLGA microspheres
within core system after sandwich-like system implantation in a OP rats critical size defect. Therefore,
17β-estradiol was incorporated into the system in 3 forms: free and dispersed in the core, encapsulated
in microspheres prepared with a mixture of PLA and PLGA dispersed within the hydrogel and lastly
encapsulated in the PLGA films shell prepared by electrospinning technique.
2. Materials and Method
2.1. Materials
PLGA 75:25 (Resomer® RG755-S), PLGA 50:50 (Resomer® RG504), PLGA 85:15 (Resomer® RG858-S),
and PLA (Resomer® RG203-S) were supplied by Evonic Industries (Darmstadt, Germany). Chitosan
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(Protasan® UP-CL-213) was purchased from NovaMatrix (Sandvika, Norway). 2-Hidroxipropil
γ-Ciclodextrin (CAVASOL® W8 HP), was supplied by Wacker Chemical (Burghausen, Germany).
The bovine collagen type I was purchased from CellSystems Biotechnologie (Vertrieb GmbH,
Germany). Riboflavin (RB), Poly(ethylene glycol) 400, Poly(vinyl alcohol) (PVA, Mw 33–70 kDa;
87–90% hydrolyzed), 17β-estradiol, and all the other reagents were purchased from Sigma-Aldrich,
(St. Louis, MO, USA). The recombinant human bone morphogenetic protein 2 (BMP-2) was bought from
Biomedal Life Sciences (Sevilla, Spain). Citrate-coated carbonated apatite nanoparticles (nano-HAP)
were kindly donated (Jaime Gómez-Morales, PhD, Laboratory of Crystallographic Studies, CSIC,
Granada, Spain).
2.2. Microspheres Preparation and Characterization
The BMP-2 microspheres were prepared by the double emulsion method (w/o/w) previously
described [22]. Briefly, 200 μL of an aqueous solution (0.2% PVA) of BMP-2 (260 μg) was emulsified
with 1 mL of a PLGA mixture (150 mg) of RG504 and RG858 [4:1] in methylene chloride (DCM) by
vortexing 1 min (position 10, Genie® Industries 2, Sciencies Industries Inc. USA). Then, this emulsion
was poured into 10 mL of 0.2% PVA solution vortexed 15 s, then poured into 100 mL of 0.1% PVA and
kept under magnetic stirring for 1 h for solvent evaporation.
The 17β-estradiol microspheres were prepared by a modified solvent evaporation method
previously described [17]. Briefly a mixture of 17β-estradiol (4 mg), PLA-S RG203-S (160 mg) and
PLGA RG858 (40 mg) dissolved in 0.6 mL of DCM:Methanol (DCM:MeOH) (80:20) was emulsified
with 4 mL of 1% PVA aqueous solution by vortexing 1 min (position 10), and then added to 100 mL of
0.16% PVA solution, under magnetic stirring for organic solvent evaporation (1 h).
Both type of microspheres were collected by filtration (Pall Corporation, pore size 45 μm,
Sigma-Aldrich, USA), lyophilized, and stored at 4 ◦C until use.
Microspheres were characterized in terms of size (Mastersizer 2000, Malver Instruments, Malvern,
UK) and morphology (SEM, Jeol JSM-6300, Tokyo, Japan). To determine the BMP-2 encapsulation
efficiency and to carry out the BMP-2 release assays, some batches were prepared with 125IBMP-2.
The BMP-2 was labeled with 125INa (Perkin-Elmer) by the iodogen method [23]. The content of
17β-estradiol in the microspheres was determined spectrophotometrically at λ = 280 nm previous
dissolution in a mix of DCM:MeOH (80:20).
To determine the solubility of 17β-estradiol in the polymer matrix of the microspheres, differential
scanning calorimetry (DSC 025, TA Instruments, New Castle, DE, USA) was performed. 17β-estradiol
and lyophilized microspheres were analyzed after drying in an oven at 37 ◦C overnight. In addition,
samples of polymer blends (RG 203-S and RG 858, 4:1) and samples of the polymer blend with excess
17β-estradiol (8.5%) were dissolved in DCM:MeOH (80:20) and maintained in a hood for 24 h. Then,
samples were placed 48 h more in a vacuum desiccator to complete the evaporation of the organic
solvent. The analysis of all samples was performed with the same thermal program in two thermal
cycles under a nitrogen atmosphere (50 mL/min). In the first cycle, temperature was increased to
40 ◦C (10 ◦C/min) and then cooled to −20 ◦C (5 ◦C/min) to avoid possible water interference. Once the
samples were stabilized, they underwent a final heating cycle from −20 ◦C to 270 ◦C (10 ◦C/min).
2.3. Fabrication and Characterization of the Film
The film was fabricated by a previously described electrospinning method [24]. Briefly, 7 mg of
17β-estradiol and 300 mg of a mixture of PLGAs, RG755-S and RG858 [4:1] were dissolved in 2 mL
of hexafluoroisopropanol (Sigma-Aldrich, Steinheim, Germany) and electrospun at 7kV; flow rate of
3.0 mL/h and 10 cm of distance from the collector.
The film quality was checked in terms of porosity, thickness and fiber diameter using helium
pycnometer (AccuPyc 1330, Micromeritics, Norcross, GA, USA), stereo microscopy (Leica M205C,
Leica Las, v3 sofware), and SEM (Jeol, JSM-6300, Tokyo, Japan), respectively.
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2.4. Core System Preparation and Characterization
To prepare the core system, approximately 20 mg of microspheres were dispersed in 50 μL of the
hydrogel composed by a mixture of collagen type I (5 mg/mL), HP-γ-CD (34 mg/mL), RB (0.4 mg/mL),
CHT (5 mg/mL), PEG-400 (150 mg/mL), and 5 mg of nano-HAP. Then, the hydrogel was cross-linked
with 5% w/w TPP sterile aqueous solution (0.5 μL/μL of hydrogel) and visible light blue at 468 nm
(Dental device) for 3 min [21]. The dose of BMP-2 was 6 μg in microspheres and the total 17β-estradiol
dose was 200 μg in three different forms: electrospun films, microspheres, or dispersed into the gel.
The quality of the core system was checked according to its rheological characteristics and
porosity previously described [21]. In addition, water uptake and mass loss assays were carried out by
incubation of aliquots of 300 μL of the core system in 5 mL of sterile MilliQ water (37 ◦C) under orbital
agitation (25 rpm). At specific times, six samples were withdrawn, we then removed excess water,
weighed, and freeze-dried the samples. Then, three samples were visualized by SEM (Jeol JSM-6300) to
see the evolution of the internal structure after incubation. The other three samples were used to record
the dried weight and calculate the percentage of mass loss and water uptake, applying Equations (1)
and (2), respectively, where W0 is the initial weight of the sample and Ww and Wd are the weights of









To test the syringeability of the core system two syringes of 1 mL were loaded with a suspension
of microspheres of 17β-estradiol in the hydrogel, up to 0.5 mL. Then, 4 doses of 50 μL each were
unloaded from both syringes assayed for fluidity through a 20G needle and dose uniformity. For this,
the discharged samples were lyophilized, and the 17β-estradiol content evaluated by spectrophotometry
at 280 nm, after dissolution in DCM: MeOH (80:20).
2.5. In Vitro Release Assays
BMP-2 in vitro release assays were carried out by incubating an amount of 125I-BMP-2 microspheres
and an amount of core system with the same amount of 125I-BMP-2 microspheres in sterile MilliQ water
at 37 ◦C and 25 rpm. The amount of BMP-2 released was calculated by measuring the radioactivity of
supernatant samples with a gamma counter (Cobra® II, Packard).
The in vitro release of 17β-estradiol from the different formulations (dispersed in the core system,
microspheres, microspheres incorporated to the core system, and electrospun films) was carried out at
37 ◦C and 25 rpm using two release media: an aqueous solution of sodium lauryl sulfate (SLS) 1% [25]
and MeOH:water (50:50) [26,27]. The released 17β-estradiol was measured in the supernatant using the
spectrophotometric method. The effective diffusion coefficient, Deff in the matrix of the microspheres
and the mass transfer coefficient of the drug in the boundary layer h, were calculated according to the
non-steady-state Fick law, as previously described in detail [21]. Whether or not the released fraction
of 17β-estradiol from the microspheres dispersed in the core system was analyzed, and Equations
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where Mt and M∞ are the total mass of drug released to the media at time t and at the end of the
experiment, respectively. The βns are the infinite roots (eigenvalues) of the Equation (4):
βn cot βn + L− 1 = 0 (4)
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For large values of L, the roots of Equation (4) are multiples of the number pi and Equation (3) can
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As stated previously, to minimize the residual sum of squares, “genetic algorithms” already
implanted in R software (R Foundation for Statistical Computing, version 3.6.1., 2019, Vienna, Austria)
were used [21].
2.6. Animal Experiments
All animal experiments were carried out in conformity with the European Directive (2010/63UE)
on Care and Use in Experimental Procedures. Furthermore, the animal protocols were approved on 5
November 2014 by the Ethics Committee for Animal Cares of the University of La Laguna (CEIBA)
with identification code CEIBA2014-0128. All surgical procedures were made under aseptic conditions.
2.6.1. Animal Models
Forty female adult Sprague-Dawley rats approximately 12 weeks old, weighing 200–250 g,
were divided in 4 groups of 10 each. The experimental osteoporosis was induced in 3 groups by
three different protocols, OVX, chronic administration of DEX and OD. The forth group was the
sham, non-osteoporotic control group (non-OP). The bilateral ovariectomy was carried out under
isoflurane anesthesia, via dorsal approach to the animals of OVX and OD groups. Analgesia
consisted in buprenorphine administered subcutaneously (0.05 mg/kg) before surgery and paracetamol
(70 mg/100 mL) in the water, for 3 days post-surgery. The DEX group received 0.3 mg/kg body weight
of dexamethasone-21-isonicotinate (Deyanil retard, Fatro Ibérica, Barcelona, Spain) administered
subcutaneously once ievery two weeks [28] up to the time of euthanasia. Then, two weeks after the
ovariectomy, the rats of group OD were chronically treated with DEX as the DEX group. The 40 rats
were sacrificed after 12 weeks and the calvaria and femurs were extracted to be histologically analyzed.
The results of these analyzes were used to evaluate the 3 protocols tested to induce OP.
2.6.2. Animals Groups
Fifty female Sprague-Dawley rats (12 weeks old), weighing 200–250 g, were divided into 2 groups
of 25 each: OP and non-OP. The rats of the OP group were ovariectomized and the rats of the non-OP
group underwent similar surgery but the ovaries were not resected. Twelve weeks post-surgery, 8 mm
critical size cranial defects were created surgically with a trephine burr in the rats under isoflurane and
the systems were placed into the defects [20]. Analgesia treatment was administrated.
Female rats were divided into 5 groups of 10 rats each—5 OP and 5 non-OP—and the applied
regenerative treatment is reflected in Table 1. The implantation of the systems was carried out following
a two steps procedure. First, a layer of film (bottom film), previously soaked in the blood produced
during the surgery, was placed in the defect then 50 μL of the hydrogel mixed with the microspheres
and partially cross-linked with UV light, was discharged. Second, the hydrogel was completely
cross-linked by dripping 25 μL of sodium tripolyphosphate (TPP) forming the core system, after 5 min,
a second layer of film (soaked in blood) was placed on the top, like a sandwich, and the wound was
then closed.
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Table 1. Experimental groups to evaluate regenerative efficiency.
Group Designations Treatment
Blank I (B) System loaded with blank microspheres and blank films
Blank II (B-HAP) System loaded with blank microspheres and 5 mg of nano-HAP andblank films
BMP+EF System loaded with 6 μg of BMP-2 in microspheres and 200 μg of17β-estradiol in the 2 films
BMP+EMs System loaded with 6 μg of BMP-2 in microspheres and 200 μg of17β-estradiol in microspheres, blank films
BMP+ED System loaded with 6 μg of BMP-2 and 200 μg of 17β-estradioldispersed, blank films
2.6.3. 125I-BMP-2 in Vivo Release Assay
The BMP-2 release kinetics was monitored periodically by measuring the remaining 125I-BMP-2 at
the rat calvarial defect site (n = 5) using an external probe-type gamma counter (Captus ®, Capintec
Inc., Ramsey, NJ, USA), as previously described and validated [29].
2.7. Rat Mesenchymal Stem Cells (rMSCs) Osteogenic Differentiation
The rMSCs were obtained by centrifugal isolation as previously described [30] from the bone
marrow of the femur of OVX female Sprague-Dawley rats. Briefly, the cells were resuspended in
high glucose DMEM (HyClone® Utah) supplemented with 10% fetal bovine serum (Biowest, South
America Origin), 1% penicillin–streptomycin (PAA, Pasching, Austria), and 2 mM l-Glutamine stable
(Biowest, France) (Complete Culture Medium, CCM). Then, cells were cultured in flasks of 75 cm2 and
subcultured by incubating at 37◦C and 5% CO2. The culture medium was changed every 2–3 days.
To test the osteogenic differentiation, 50,000 cells (passage 2) in 20 μL of CCM were added over
aliquots of 300 μL of the core system (hydrogel with microspheres) with and without nano-HAP
and incubated at 37 ◦C and 5% CO2 for 1.5 h for cell adhesion. The homogeneous cell distribution
was checked by light microscopy. Afterwards, 500 μL of CCM were added to each well, after 3 days
incubation the medium was changed to CCM supplemented with 10 mM β-glycerol phosphate, 10–7 M
dexamethasone and 50 μM ascorbate-2-phosphate. At 7, 14, and 21 days of culture, three wells of each
time point were washed (2 times) with Hank’s balanced salt solution (HBSS 1x) and cooled at 4 ◦C. Then,
500 μL of 0.1 M buffer Tris-HCl, 0.1M NaCl, and 0.05 M MgCl2 (pH = 9.2–9.5) containing Nitro blue
tetrazolium chloride (NBT, Roche Diagnostics, Mannheim, Germany) and 5-Bromo-4-chloro-3-indolyl
phosphate (BCIP, Roche Diagnostics, Mannheim, Germany) were added and incubated at 37 ◦C
and 5% CO2 under soft agitation for 1.5 h. Then, the NBT/BCIP was removed and the cells were
fixed with a solution of 3.7–4% p-formaldehyde buffered to pH = 7.0 (Panreac®, Barcelona, Spain)
during 30 min. After this, the formaldehyde was removed, and the wells were washed 3 times with
HBBS 1x. Immediately after this, cells were visualized by stereo microscopy (Leica M205C, Leica
Las, v3 software). In addition, samples were dehydrated in a graded series of ethanol before being
embedded in Paraplast® and microtome (Shandon Finesse 325, Thermo Fisher Scientific, Madrid,
Spain) sections were observed by light microscopy (LEICA DM 4000B, Barcelona, Spain).
2.8. Histology, Immunohistochemical, and Histomorphometrically Evaluation
First, to check the osteoporotic-like condition, 12 weeks after the 12 rats undergone the different
protocols were sacrificed and the femurs and calvaria were analyzed. The femurs and calvaria were
fixed (4% paraformaldehyde solution), decalcified in Histofix® Decalcifier (Panreac, Barcelona, Spain)
and prepared for histological analysis as previously described [20,22].
Bone morphology was analyzed by hematoxylin–erythrosin staining. The histomorphometric
analyze was carried out in femurs by measuring the following parameters; thickness of the cortical
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bone (Ct.Wi) and number (Tb.N), width (Tb.Wi) and separation (Tb.Sp) of the trabeculae in cancellous
bone. In the calvaria bone, the histomorphometric analysis was carried out by measuring the following
parameters, cortical bone thickness (CBT) and intercortical space thickness (IST) occupied by trabecular
bone in transversal sections of calvaria.
To determine the capacity of the bone active substances, so as to regenerate the critical size defect
practiced in the calvaria of the rats, samples of the 10 groups of 5 rats each were examined.
Samples were processed as previously described [22]. New bone formation was identified by
hematoxylin–erythrosin staining. Bone mineralization was assessed with VOF trichrome stain, in which
red and brown staining indicates advanced mineralization, whereas less mineralized, newly formed
bone stains blue [31]. Sections were analyzed by light microscopy (LEICA DM 4000B, Barcelona, Spain).
Computer-based image analysis software (Leica Q-win V3 Pro-Image Analysis System, Barcelona,
Spain) was used to evaluate all sections. A region of interest (ROI) within the defect (50 mm2) for
quantitative evaluation of new bone formation was defined. New bone formation was expressed as a
percentage of repair with respect to the original defect area within the ROI. From the total bone repair,
the areas of mature bone (MB) and immature bone (IB) were determined, and the MB/IB ratio for each
experimental group as well as between non-osteoporotic and osteoporotic-like animals was calculated.
For immunohistochemical analysis, sections were deparaffined and rehydrated in Tris-buffered
saline (TBS) (pH 7.4, 0.01 M Trizma base, 0.04 M Tris hydrochloride, 0.15 M NaCl), which was
used for all further incubations and rinse steps. Sections were incubated in citrate buffer (pH 6)
at 90 ◦C for antigen retrieval, followed by incubation in 0.3% hydrogen peroxide in TBS buffer for
20 min. After a rinse step, sections were blocked with 2% FBS in TBS–0.2% Triton X-100 (blocking
buffer). The indirect immunohistochemical procedure was carried out by incubating the sections
with osteocalcin (OCN) polyclonal antiserum (1/100) (Millipore, Barcelona, Spain) in blocking buffer
overnight at 4 ◦C. Sections were rinsed three times, then incubated with biotin-SP-conjugated donkey
anti-rabbit F(ab) fragment (1/200) (Millipore, Barcelona, Spain) in blocking buffer for 1 h followed, after
another rinse step, by incubation in peroxidase-conjugated streptavidin (1/300) (Millipore, Barcelona,
Spain) for 1 h. Peroxidase activity was revealed in Tris–HCl buffer (0.05 M, pH 7.6) containing 0.05% of
3,3′-diaminobenzidine tetrahydrochloride (Sigma, Poole, UK) and 0.004% hydrogen peroxide. Reaction
specificity was confirmed by replacing the specific antiserum with normal serum or by pre-adsorption
of the specific antiserum with the corresponding antigen.
OCN staining was evaluated using computer-based image analysis software (ImageJ, NIH,
Bethesda, MD, USA). OCN staining was measured by applying a fixed threshold to select for positive
staining within the ROI. Positive pixel areas were divided by the total surface size (mm2) of the
ROI. Values were normalized to those measured from blank scaffolds and are reported as relative
staining intensities.
Statistical analysis was performed with SPSS.25 software. We compared the distinct treatments
by means of a one-way analysis of variance (ANOVA) with a Tukey multiple comparison post-test.
Significance was set at p < 0.05. Results are expressed as means ± SD.
3. Results
3.1. Sandwich-Like System Characterization
The characteristics of the microspheres, electrospun film, and core system are shown in Table 2.
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Table 2. Characteristics of the component of the sandwich-like system. Microspheres: size and
encapsulation efficiency. Electrospun film: thickness and porosity of the film and average diameter of
the fibers). Core system: porosity freshly prepared and lyophilized and water uptake and mass loss
after incubation in MilliQ water, 37 ◦C, and 25 rpm.
Microspheres Size (μm) E.E. (%)
17β-estradiol 101.4 (10% < 29.73, 90% < 198.31) 83.5 ± 1.84
BMP-2 112.1 (105 < 60.3, 905 < 174.8) 71 ± 7
Film
Thickness (μm) Fiber diameter (μm) Porosity (%)




Porosity (%) Incubation time Water uptake (%) Mass loss (%)
72
7 days 135.9 ± 2.6 18.85 ± 7
28 days 138.9 ± 11.0 29.19 ± 4.88
SEM image of the microspheres is shown in Figure 1A and the differential scanning calorimetry
thermograms of the 17β-estradiol microspheres components are plotted in Figure 2. The glass transition
temperature (Tg) of the mixture of polymers RG 203-S and RG 858 [4:1] was located at 52–58 ◦C, in the
temperature range of the PLA (RG203-S) and PLGA (RG858). The DSC analysis of pure 17β-estradiol
showed three endothermic peaks (Figure 2A), the first two at 118.1 ◦C and 174.4 ◦C, previously
attributed to the partial and complete loss of hydrogen-bound water and reticular water, respectively.
The third at 179.4 ◦C corresponds to the melting point [32]. This last peak, characteristic of the crystalline
structure of 17β-estradiol, was not detected in the spectrum of the polymers and 17β-estradiol blend
or in the thermogram of the microspheres (Figure 2B). These results indicated that 17β-estradiol was
dissolved in the polymer by at least 8.5%.
 
Figure 1. SEM images (A) microspheres, (B) hydrogel, (C) hydrogel high magnification detail, (D) core
system freshly prepared, (E) internal structure of the core system after 4 weeks incubation in water at
37 ◦C and 25 rpm, and (F) high magnification detail of Figure 1E. Scale bars: (A–E) 100 μm, (C) 1 μm,
(F) 20 μm.
The integrity of the system was assayed throughout the 4-week test duration. The SEM images
of the internal structure of the hydrogel (Figure 1B,C), the freshly prepared core system (Figure 1D),
and after 4 weeks incubation showed that the microspheres were homogeneously dispersed in the
hydrogel and are trapped in the core system during incubation (Figure 1E,F). The core system absorbed
a significant amount of water during the first days of incubation which was maintained over time.
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Contrarily, the system lost little mass: less than 20% during the first week and approximately 35% after
4 weeks (Table 2). In addition, the core system flew well through the 20 G needle and the average dose
discharged was 83.5 ± 6% of the loaded dose.
 
Figure 2. Differential scanning calorimetry thermograms. (A) Curve of pure 17β-estradiol. (B) Curves
of PLA (RG203-S); PLGA (RG858), polymer blend (RG203-S:RG858, [4:1]), and polymer blend with
8.5% of 17β-estradiol, previously dissolved in DCM:MeOH (80:20) and the curve of the microspheres
of 17β-estradiol (B).
3.2. Osteogenic Differentiation
The alkaline phosphatase positive (ALP+) cell count, in the hydrogels pre-seeded with rMSCs
and cultured in the osteogenic differentiation culture medium, showed a discrete and progressive
increase in the number of cells between 7 and 21 days of culture in the hydrogels without and with
nano-HAP; the number being significantly higher in those containing nano-HAP (Figure 3). Likewise,
qualitatively, the cells presented, in the scaffolds with nano-HAP, greater intensity of color, suggesting
greater ALP activity (Figure 3) than without nano-HAP.
 
Figure 3. Alkaline phosphatase (ALP) activity in rMSCs cultures. (a) Representative images from
hydrogels 20 days after cultured showing the AP-positive (ALP+) cells’ morphology (arrowheads) in
hydrogel without (non-HAP) and with nanohydroxyapatite (HAP). (b) Graphic showing the number
of APL+ cells/microscopic field at different time points of analyses (7, 14, and 21 days) after culture in
each system. Scale bar = 20 μm. The identical symbol on different bars indicates significant differences.
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3.3. Release Profiles of 125I-BMP-2 and 17β-Estradiol.
Although the hydrogel provoked a strong reduction of the burst effect, the in vitro release of
BMP-2 from the microspheres and from the core system showed a biphasic profile. During the first 24 h,
approximately 7% of the protein was release from the core system versus 27% from the microspheres
directly dispersed in the medium. Afterward, the release rate was kept in the range of 60 to 55 ng/day
(Figure 4). The in vivo release profile was also biphasic, with a first phase that lasted up to 7 days
whereas approximately 50% of the protein released. Then, the release rate was reduced to 70 ng/day,
which is slightly higher than the in vitro rate.
Figure 4. BMP-2 release assays. In vivo release profile of 125I-BMP-2 from PLGA-microspheres in the
system after implantation in the rat calvaria defect (n = 5). In vitro release of 125I-BMP-2 (incubation in
water at 37 ◦C and 25 rpm) from PLGA-microspheres and from the PLGA microspheres dispersed in
the system.
The in vitro release rate of 17β-estradiol in the aqueous medium depended on the formulation
(Figure 5B); 100% and 70% of the 17β-estradiol dispersed in the hydrogel and in the electrospun
film were detected in the medium after 4 weeks incubation, respectively. The release profile was
characterized by a high burst effect; approximately half of the dose was released during the first day.
By contrast, the 17β-estradiol release rate was extremely slow from the microspheres alone and from
the microspheres included in the hydrogel (core system). Both release profiles were similar: less
than 20% was delivered in 4 weeks. However, in the MeOH: water (50:50) medium there were not
differences in the transfer profiles. The presence of MeOH modifies the solubility of 17β-estradiol,
showing a strong burst effect that varied in a range between 70 and 85% in the first 24 h (Figure 5A).
 
Figure 5. In vitro 17-β-estradiol release profiles in different release media at 37 ◦C and 25 rpm. (A) In
MeOH:water (50:50). (B) In aqueous solution of SLS 1%. (ED) 17β-estradiol dispersed in the core
system; (EF) 17β-estradiol in the electrospinned film; (microspheres) 17β-estradiol pre-encapsulated in
microspheres and (core system) 17β-estradiol microspheres in the hydrogel.
62
Pharmaceutics 2019, 11, 648
The estimated values of Deff and h for 17β-estradiol release in the different media are showed in
Table 3. Although the value of Deff of 17β-estradiol in SLS was significantly lower compared to the
MeOH:water (50:50), there were not differences for h regardless of the release media used. h is the
contribution of hydrogel, as part of the boundary layer, to the whole mass transfer process, and the
value of this coefficient should not change by varying the release media. The values of R2 (Table 3),
together with the comparison of experimental and predicted values of the released fractions shows a
good fit of the data to the proposed model for both release media.
Table 3. Estimated values of effective diffusion coefficient (Deff) and mass transfer coefficient (h) for
17β-estradiol release in different media applying Equations (3)–(6).
Release Media Deff (m2/s) h (m/s) R2 (%) Value
MeOH:water (50:50) 2.28·10−15 ± 5.00·10−17 7.56·10−10 ± 2.89·10−10 95.47 ± 0.07
SLS 1% 5.58·10−16 ± 9.81·10−17 4.01·10−10 ± 4.94·10−10 92.49 ± 2.71
3.4. Histology, Immunohistochemical, and Histomorphometrically Evaluation
3.4.1. Osteoporotic Model
The osteoporotic model was assessed in both long bone (femur) and flat bone (calvaria).
The histological analysis of calvaria showed evident changes in the structure and microarchitecture of
the bone among the different experimental groups. Although the non-OP animals showed a normal
bone structure in cortical bone (CB) and trabecular bone (TB), in the intercortical space (ICS), for the
different OP models (DEX, OVX, and OD (Figure 6a), it was observed a progressive decrease in cortical
bone thickness (CBT) and an increase in the intercortical space thickness (IST), being the group OD the
one that presented greater alteration of the tissue bone structure (Figure 6b).
 
Figure 6. Validation of the OP model in calvarial bone. (a) Representative images in transversal section
of calvaria in non-osteoporotic animals (non-OP) and in each of the different experimental models of
osteoporosis tested showing the bone structure in each one. (b) Histomorphometric analysis of the
cortical bone thickness and intercortical space thickness evaluated in calvaria in the different models of
osteoporosis. CB: cortical bone; BMa: bone marrow; ICS: intercortical space; TB: trabecular bone. Scale
bar = 100 μm. The identical symbol on different bars indicates significant differences.
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The histological analysis of the femurs showed evident changes in the structure and
microarchitecture of the bone among the different experimental groups. Although the non-OP
animals showed a normal bone structure, in the different OP models (DEX, OVX and OD), structural
changes were observed, both at the level of cortical and cancellous bone, showing a less compact bone
and with a more porous structure (Figure 7a). The histomorphometric analysis revealed differences in
the parameters measured in cancellous bone (Tb.N, Tb.Wi., and Tb.Sp.), with a significant reduction in
all of them, in OVX and OD compared to the non-OP and DEX animals (Figure 7b–d). The cortical bone
thickness (Ct.Wi.), although it showed a slight reduction in the groups (OVX and OD) with respect to
the non-OP and DEX groups, was not significant (Figure 7e).
 
Figure 7. Validation of the OP model in long bone (femur). (a) The left column shows representative
panoramic images in longitudinal section of rat femur in non-osteoporotic animals (non-OP) and
in each of the different experimental models of osteoporosis tested. The right column shows high
magnification images of the distal portion of the femur, showing differences in the microarchitecture of
the bone in the different models. The column on the left shows detail of the boxed areas in which the
structural characteristics of the compact and trabecular bone can be observed in each of the models.
Histomorphometric analysis of the different parameters evaluated in femur in the different models of
osteoporosis (b), Tb. N (mm), (c) Tb. Wi (μm), (d) Tb. Sp. (μm), and (e) Ct. Wi (μm). CB: cortical bone;
TB: Trabecular bone; BMa: bone marrow. Scale bars: Left column 250 μm. Right column 50 μm. The
identical symbol on different bars indicates significant differences.
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3.4.2. Calvarial Critical Size Defect
The histological analysis at the level of the calvarial defect showed a few new bone formations
in the blank groups (B and B HAP), being limited to the margins of the defect in both, non-OP, and
OP groups (Figure 8a). The groups implanted with BMP-2 + 17β-estradiol in the three different
formulations showed a greater area of newly formed bone in the defect area, not only in the margins, but
also in inner zone of the defect (Figure 8a). The newly formed bone in the different experimental groups
of non-OP and OP animals showed a normal morphology and VOF staining, revealing significant
areas of mineralization, slightly higher in the groups of non-OP animals (Figure 8a).
Figure 8. Repair process in calvarial defect. (a) Representative images in horizontal section of calvarial
critical size defects in non-OP and OP rats showing the repair response at the defect level in the different
experimental groups 12 weeks post-implantation. (b) Histomorphometrical analysis comparing of
the degrees of repair (%) among the different experimental groups in non-OP and OP rats 12 weeks
post-implantation. (c) Histomorphometric analysis showing the ratio between mature bone and
immature bone (MB/IB) among the different experimental groups (d) and between non-OP and OP rats,
estimated using VOF staining. Bars represent means ± SD (n = 4). The identical letter on different bars
indicates significant differences. BMa: bone marrow; CT: connective tissue; NB: newly formed bone; DS:
defect site. Scale bar = 1 mm. The identical symbol on different bars indicates significant differences.
The histomorphometric analysis showed little repair response in the blanks groups (B and B HAP)
of non-OP and OP animals, with repair percent between 6 and 8%. The groups implanted with BMP-2
+ 17β-estradiol in the three different formulations, on the contrary, showed a significantly higher repair
response of 38–45%, with no differences being observed between non- OP and OP animals (Figure 8b).
The histomorphometric analysis of mature and immature bone showed a higher quantity of
mature bone, and therefore with a greater degree of mineralization, in the experimental groups of
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non-OP with respect to OP animals. The ratio between mature and immature bone (MB/IB) showed
individually higher values in all non-OP with respect to OP groups as well as on the whole, with
values of 1.47 in non-OP animals and 0.99 in OP (Figure 8c,d).
The immunohistochemical analysis of osteocalcin (OCN), a marker of late osteogenesis and
mineralization, showed a low immunoreaction in the blank groups (B and B HAP) in both non-OP and
OP animals, with no differences between them (Figure 9a). In the groups implanted with BMP-2 +
17β-estradiol in the three different formulations, the immunoreaction was higher and more intense
with respect to the blank groups, in this case being slightly higher in the non-OP animals (Figure 9a).
 
Figure 9. OCN relative expression. (a) Representative images in horizontal section of calvarial critical
size defects in non-OP and OP rats showing OCN immunoreactivity in the different experimental
groups 12 weeks post-implantation. (b) Histomorphometric analysis showing the relative staining
values for OCN-ir. Bars represent means ± SD (n = 4). The identical letter on different bars indicates
significant differences. CT: connective tissue; NB: newly formed bone. Scale bar = 100 μm. The identical
symbol on different bars indicates significant differences.
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The histomorphometric analysis confirmed the histological data, showing slightly higher relative
staining values in the BMP-2 +17β-estradiol groups in non-OP animals (Figure 9b).
4. Discussion
In the present study, a BMP-2-17β-estradiol hydrogel system, with porosity of approximately 72%,
was evaluated for regeneration of a critical size defect in rat calvaria. Although the system had already
been characterized in terms of rheological behavior, porosity, interactions between components, mass
transfer parameters, and cell viability, here the good injectability of the system was showed, and its
characterization has been completed by testing the water uptake and mass loss as well as differentiation
studies in cultures of osteoporotic rMSCs. In vitro release profiles of 17β-estradiol in two media and
the in vitro and in vivo release profile of BMP-2 were also analyzed.
The osteogenic differentiation of osteoporotic rMSCs seeded on the system was assessed in order
to test the effect of the incorporation of the nano-HAP on the cell behavior. The results showed greater
ALP activity and a greater number of differentiated cells in the systems with nano-HAP. Therefore,
nano-HAP systems were subsequently used in the in vivo experiments.
First, a histological evaluation of the femur and calvaria of rats suffering the three treatments for
osteoporosis induction was carried out. OP is a systemic bone disease characterized by the increase
of bone porosity, loss of bone mass and changes in the microstructure of the skeletal. Consequently,
the OP population has an increased risk of fracture.
Despite the high number of OP studies and the several publications dedicated to tissue repair in
non-OP specimens, very few reports devoted to bone defect regeneration in OP have been published.
As OP might be primary post-menopausal or secondary, due to corticoid chronic administration,
three animal models were used for OP induction: OVX, chronic glucocorticoid treatment, and the
combination of both. In previous reports, a combination OD rat model was used. However, the high
deterioration observed in the animals, the risk of induced additional disorders on the skeletal and the
fact that bone loss reverses after corticoid stop [33] justify the bone histological study of the different
treatment, in order to simplify the model and improve animal welfare. In general, OP condition is
established through the analysis of long bones and lumbar spine but few data of the effect on the calvaria
of the animals used as OP models are available [34]. Most of the publications on the regeneration of
calvaria critical size defect in OP animals do not report the effects of OP in the calvaria [35,36]. In the
present study, the data comparing the response of the femurs and calvarias to the three treatments
revealed that the effect of OVX was similar to OD combination, consequently the fabricated system
was tested in OVX rats.
As some authors have observed a delay in bone consolidation of OVX rats [37] and as this
combination of BMP-2 and 17β-estradiol, formulated in microspheres, when applied to a critical
calvaria defect, improved bone healing in OP rats, but the new bone was less mineralized [17,18],
we tried to prolong the release of active substances to cover this delay. The drugs were incorporated to
the hydrogel system pre-encapsulated in microspheres for prolonged controlled release. To reduce
the release rate of the active substances the microspheres were prepared with a mixture of polymers,
25% of the RG 858 was incorporated to the RG 504 for BMP-2 microspheres as well as to the RG203-S
for 17β-estradiol microspheres. RG 858 is a PLGA 85:15, of high molecular weight with a degradation
rate lower than that of RG 504 and RG203-S. The BMP-2 release profiles showed a two-phase behavior
with a weak burst effect that coincides with the period in which the system loses mass and uptakes a
high amount of water. However, the burst effect of BMP-2 that can be seen from the microspheres
was damped by the hydrogel, probably due to the interaction of the protein with the chemical groups
of the HAP [6,13]. Afterwards, the second phases were practically parallel, which indicated a mass
transfer process controlled by the access of water inside the microspheres, dissolution and diffusion of
the protein throughout the porous of the polymeric matrix.
The release profile of 17β-estradiol as liposoluble drug in a MeOH:water (60:40) release medium
was previously characterized [21]. By contrast, here two release media were used, MeOH:water (50:50)
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and an aqueous solution of SLS, because we suspected that the solvent affected the release rate of
the lipophilic substance. In fact, the release of 17β-estradiol in MeOH:water was fast regardless of
the formulations. However, the in vitro release of 17β-estradiol was formulation-dependent when
an aqueous medium was used; a high decrease of the release rate of the drug from the microspheres
was observed. As DSC results indicated, 17β-estradiol formed a solid solution in the microspheres,
which indicates that the release process takes place by molecular diffusion of 17β-estradiol within the
microspheres, governed by the partition coefficient, and consequently the aqueous medium dissolved
it very slowly. In addition, the higher estimated values of Deff in the MeOH:water compared with
the aqueous medium, confirmed the dependency on the release media. The calorimetric analysis of
the electrospun sheet was not carried out because the amount of 17β-estradiol would have had to be
increased to be detected and its characteristics would have been modified. Although 17β-estradiol is
expected to also be dissolved in the polymer of the film, the large specific surface area that microfibers
expose to the medium causes the drug to release rapidly. Similarly, 17β-estradiol dispersed in the
hydrogel was very little retained. Obviously, neither media are physiological, but it seems more correct
to use an aqueous medium to predict release in vivo. Although, with reservations, one would also
expect a slightly faster release rate in vivo as the biological components present in the tissue could
accelerate the drug release from the system.
Despite the beneficial role of the nano-HAP controlling the BMP-2 burst effect as well as its
positive effect on the proliferation and osteogenic differentiation of rMSC, which justifies the use of
nano-HAP in the system, the reparative effect of the blank scaffolds with and without nano-HAP was
not enough to be considered useful. Unlike that observed in this study, other authors showed better
bone repair in different bone defects practiced in osteoporotic goats implanted with a system of type
I collagen containing nano-HAP than without [38]. By contrast, another study [6] found, as in the
present study, that the use of nano-HAP and calcium sulfate bone substitute scaffolds in rat critical
calvaria defect showed no effect on repair and mineralization at 8 and 12 weeks with respect to the
empty defect. In both studies, the systems were loaded with BMP-2 combined with 17β-estradiol or
zolendronic acid [6] that might abolish the effect of the HAP observed in vitro.
Although previously our group reported [17,18] a better result in bone regeneration of OP animals
combining BMP-2 and 17β-estradiol, in this study, the repair effect observed has been similar to that
observed in non-OP groups. The three combinations of BMP-2 with 17β-estradiol in each of the three
formulations used showed the same effect at 12 weeks. However, the ratios of mature and immature
bone in normal and osteoporotic animals showed significant differences, indicating that the quality of
the repaired bone, at least after 12 weeks, was better in normal animals.
Although these results coincide with previous work, in the present study it seems that the
mineralization of the bone formed slightly improved in the OP animals. The difference in the relative
osteocalcin expression was not statistically significant. These results might suggest that a longer
release of BMP-2 together with the composition of the system, presence of collagen and nanoHAP
favor the mineralization process. In any case, it would be necessary in future to conduct studies aimed
at discerning the role of each of these components in the process. However, we have not been able
to reproduce the positive effect of 17β-estradiol combined with BMP-2 in a hydrogel composed of
Pluronic, Tetronic and, cyclodextrin, with other scaffolds of different composition [18]. In addition,
according to the present study, the fact that the different release profiles of 17β-estradiol had no effect
on the repair of the defect indicates that 17β-estradiol, when applied locally, and regardless of the
release rate (available dose) and of the obvious role that it plays on bone remodeling, does not justify its
inclusion as active substance in the repair of bone defects neither in normal animals nor in osteoporotic
ones. Therefore, new strategies and alternative drugs are currently being designed trying to accelerate
mineralization of new bone in OP groups.
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5. Conclusions
The prepared hydrogel system resulted to be easily injectable and solidified fast due to crosslinking
of collagen and chitosan chains. The system helps control the burst effect of BMP-2 pre-encapsulated
in PLGA microspheres, probably due to the nano-HAP. Release of 17β-estradiol from PLA-PLGA
microspheres was more complex and is governed by the partition coefficient of the drug which is
in solid dissolution in the microspheres. The system was biocompatible both in vivo and in vitro.
However, the regenerative effect detected in the critical bone defect of both OP and non -OP rats was
mainly due to the osteogenic effect of BMP-2 released in a controlled rate for 6 weeks. A delay in
the mineralization of the new bone which fills the defect in OP animals was observed. 17β-estradiol
released from different formulations and included in the system does not improve bone repair.
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Abstract: Colorectal cancer (CRC) is one of the most malignant and fatal cancers worldwide.
Although cytoreductive surgery combined with chemotherapy is considered a promising therapy,
peritoneal adhesion causes further complications after surgery. In this study, oxaliplatin-loaded
Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles were prepared using a double emulsion method
and loaded into hyaluronic acid (HA)- and carboxymethyl cellulose sodium (CMCNa)-based
cross-linked (HC) hydrogels. From characterization and evaluation study PLGA microparticles
showed smaller particle size with higher entrapment efficiency, approximately 1100.4 ± 257.7 nm and
77.9 ± 2.8%, respectively. In addition, microparticle-loaded hydrogels showed more sustained drug
release compared to the unloaded microparticles. Moreover, in an in vivo pharmacokinetic study after
intraperitoneal administration in rats, a significant improvement in the bioavailability and the mean
residence time of the microparticle-loaded hydrogels was observed. In HC21 hydrogels, AUC0–48h,
Cmax, and Tmax were 16012.12 ± 188.75 ng·h/mL, 528.75 ± 144.50 ng/mL, and 1.5 h, respectively.
Furthermore, experimental observation revealed that the hydrogel samples effectively protected
injured tissues from peritoneal adhesion. Therefore, the results of the current pharmacokinetic study
together with our previous report of the in vivo anti-adhesion efficacy of HC hydrogels demonstrated
that the PLGA microparticle-loaded hydrogels offer novel therapeutic strategy for CRC treatment.
Keywords: oxaliplatin; PLGA; hydrogel; intra-abdominal anti-adhesion barrier; colorectal cancer
1. Introduction
Colorectal cancer (CRC) is one of the most malignant cancers worldwide. Although the incidence
of CRC is low, the number of new cases that are malignant and fatal is still the highest among both
men and women. In addition, peritoneal carcinomatosis is one of the numerous manifestations of
CRC identified at the first diagnosis in more than 10% of CRC patients, and it is extremely fatal,
with median survival of approximately 6 months [1,2]. The treatment strategies for both CRC and
peritoneal carcinomatosis patients depend on the type and stage, and optimal therapy comprises
cytoreductive surgery combined with chemotherapy [3].
Peritoneal adhesion is one of the most common postoperative complications associated with
cytoreductive surgery. Previous studies indicated their occurrence in more than 50% cases, and they have
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even higher recurrence rates (85–93%) [4,5]. As cytoreductive surgery and intraperitoneal chemotherapy
are closely related to the completeness of cytoreduction, problems associated with cytoreductive surgery
are still a big challenge in medical science. Therefore, hydrogel-based anti-adhesion barriers came into
the spotlight to reduce adhesion by mechanical separation of injured tissue surfaces during peritoneal
repair after surgery [6].
Oxaliplatin (Figure 1) is a third-generation, platinum-based, systemic chemotherapeutic agent for
CRC [7], and it is expected to be similarly effective in peritoneal carcinomatosis. Therefore, it is currently
being used as a part of the standard chemotherapy regimen, FOLFOX (oxaliplatin with 5-fluorouracil
and leucovorin) [8], for the clinical treatment of metastatic CRC [9]. However, a recent study conducted
in a murine model confirmed that intraperitoneally administered oxaliplatin enhanced peritoneal
tissue concentration while reducing its systemic absorption, suggesting a possible decrease in toxicity
associated with systemic chemotherapy [10]. Therefore, the new approach comprising cytoreductive
surgery followed by intraperitoneal oxaliplatin delivery has resulted in significant improvement in the
disease states of CRC and peritoneal carcinomatosis [11].
Biodegradable microparticles have been widely investigated for the controlled delivery of
chemotherapeutic agents [12,13]. In addition, neither an initial burst release, nor the presence of
a lag phase are desirable for the chemotherapeutic agents as it can be associated with adverse effects.
Poly-(d,l-lactide-co-glycolide) (PLGA) is an unique copolymer approved by the regulatory agencies for
the manufacturing of bioresorbable surgical sutures. Owing to its biodegradability and biocompatibility,
PLGA become the first line materials for the production of injectable microparticle based controlled
release system [14]. A recent report of metformin/irinotecan-loaded nanoparticles have shown an initial
2 h burst release, however, increase the drug retention time in tumor and increase drug circulation [15].
Moreover, alternative reports of paclitaxel-loaded PLGA microparticles have been evaluated for cancer
therapy. These models revealed protection of the therapeutic payload from premature burst release,
and enable the sustained release of paclitaxel [16,17].
Figure 1. Chemical structures of Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles and hyaluronic
acid (HA) and carboxymethyl cellulose sodium (CMCNa)-based cross-linked (HC) hydrogel components
(A) HA; (B) CMCNa; (C) HC hydrogel; (D) Oxaliplatin; and (E) PLGA.
Recently we succeeded in synthesizing novel hyaluronic acid (HA) and carboxymethyl cellulose
sodium (CMCNa)-based cross-linked (HC) hydrogels loaded with oxaliplatin [18]. These novel HC
hydrogels significantly prevented intraperitoneal adhesion and offered the highest anti-adhesion barrier
in an in vivo rat model. However, pharmacokinetic evaluation of oxaliplatin-loaded HC hydrogels
was not carried out. Several reports of microparticles-loaded hydrogels in various drug delivery
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system showed controlled drug release for over a prolonged period [19,20]. Therefore, to provide
an adequate anti-adhesion barrier effect after cytoreductive surgery and deliver intraperitoneal
chemotherapy, oxaliplatin-loaded PLGA microparticles were prepared, characterized, and loaded
into HC hydrogels. In addition, an in vitro oxaliplatin release study of PLGA microparticle-loaded
HC hydrogels in comparison with that of commercially available Guardix-Sol® hydrogel was carried
out. Furthermore, in vivo pharmacokinetic analysis was carried out to demonstrate the efficacy of
intraperitoneal chemotherapy with oxaliplatin-PLGA microparticles loaded into HC hydrogels.
2. Materials and Methods
2.1. Materials and Animals
Oxaliplatin was a gift from Boryung Pharm (Ansan, Korea). Resomer® RG 502 H (Poly-(d,l-lactide-
co-glycolide)) PLGA, molecular weight (MW) approximately 7000–17,000, was purchased from Evonic
Ind., (Darmstadt, Germany). Hyaluronic acid (HA, MW 1000 kDa) was a gift from Huons (Seongnam,
Korea). Poly-(vinyl alcohol) (PVA, MW approximately 89,000–98,000), carboxymethyl cellulose sodium
(CMCNa, MW approximately 700 kDa), and adipic acid dihydrazide (ADH) were obtained from Sigma
Aldrich (St. Louis, MO, USA). 1-Ethyl-3-(3-(dimethylaminopropyl) carbodiimide (EDC) was purchased
from Tokyo Chemical (Tokyo, Japan). All other chemicals were of reagent grade, and Milli-Q® water
(Millipore1, Molsheim, France) was used throughout the study.
Male Sprague-Dawley (SD) rats were purchased from YoungBio (Seongnam, Republic of Korea).
The animals were housed in a semi-specific pathogen free facility using standard cages at 19 ± 1 ◦C and
50 ± 5% relative humidity, with a 12-h light-dark cycle. The rats were fed a standard diet, provided
with purified water, and allowed to move freely. All experiments were approved by the Institutional
Animal Care and Use Committee (IACUC-201809-788-01) at Yonsei University, Seoul, Korea, and were
performed according to IACUC guidelines.
2.2. Preparation of Oxaliplatin-PLGA Microparticles
Oxaliplatin-PLGA microparticles were prepared using a double emulsion method [21]. Briefly,
oxaliplatin (20 mg) was dissolved in 5 mL of deionized water (first aqueous solution, W1) containing
0.5% (w/v) PVA. The resulting oxaliplatin containing W1 was added dropwise to 12.5 mL DCM,
containing 1 g of PLGA 502 H, using a homogenizer ULTRA-TURRAX® (IKA-WERKE GMBH &
Co. KG, Staufen, Germany) at 12,000 rpm for 2 min. This primary emulsion (W1/O) was slowly
added to 100 mL of 1% (w/v) PVA solution (second aqueous solution, W2) and emulsified at 400 rpm
using magnetic stirrer for 3 h while the DCM was allowed to evaporate completely under vacuum.
The resultant microparticles were collected, washed using distilled water, centrifuged, and freeze-dried
using an ilShinBioBase (Seoul, Korea) freeze-drier under vacuum (5 mTorr). Samples were pre-frozen
for 2 h at −60 ± 1.0 ◦C prior to final drying at −88 ± 1.0 ◦C for 2 days. The collected freeze-dried
microparticles were stored at 4 ◦C and further evaluated by scanning electronic microscopy (SEM) to
characterize the morphological features.
2.3. Synthesis of HA-CMCNa Cross-Linked Hydrogels
Hydrogels were synthesized using variable ratios of HA and CMCNa (Figure 1) by chemical
cross-linking, as described by our previous study [18]. Briefly, HA and CMCNa at ratios of 1:2 and
2:1 (w/w) were dissolved in deionized water with continuous stirring. After complete dissolution,
2 mM/L of ADH was added to the mixture, and the pH was adjusted to 4.75 ± 0.05 using 0.1 M
HCl. After vortex mixing for 1 min, 2 mM/L EDC was added, and the resulting mixture was stirred
thoroughly at room temperature (25 ± 1.0 ◦C) for at least 12 h to allow for complete cross-linking.
The reaction was maintained at pH 4.75 ± 0.05 by the addition of 0.1 M HCl. Finally, the cross-linking
reaction was terminated by elevating the pH of the mixture to 7.0 ± 0.05 via the slow addition of
0.1 M NaOH. The hydrogel samples were purified as previously described by Luo et al. [22]. Briefly,
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the hydrogel samples were dispensed into a dialysis bag (Mw cut-off 18,000 Da) previously treated
with a 70% ethanol (EtOH) solution and dried. The bag was submerged and dialyzed for 12 h in 0.1 M
NaCl followed by alternating solutions of 25% EtOH for 6 h and DW for 6 h. The remaining hydrogels
in the dialysis bag were rinsed using EtOH, and then centrifuged at 2000 rpm for 10 min to remove the
remaining ADH. Finally, the precipitated hydrogels (HC12 and HC21) were collected and stored until
further experiments.
2.4. Preparation of Oxaliplatin-PLGA Microparticle-Loaded Hydrogel
Guardix-Sol® is a commercial anti-adhesive hydrogel used for the prevention of post-operative
adhesion. Above, we synthesized HC12 and HC21 hydrogel composites with variable weight ratios
of HA and CMCNa. Next, oxaliplatin-PLGA microparticles were dispersed gently in the hydrogel
(HC12, HC21, and Guardix-Sol®). Briefly, precisely weighed oxaliplatin-PLGA microparticles were
mixed with 10 mL of hydrogels at room temperature (25 ± 1.0 ◦C) with continuous stirring for 30 min.
The final concentration of oxaliplatin was 2 mg/ mL of hydrogel. After complete dissolution was
visually observed, samples were evaluated for in vitro and in vivo release of oxaliplatin.
2.5. Characterization of Oxaliplatin-PLGA Microparticles
2.5.1. Morphology
The morphology of oxaliplatin-PLGA microparticles was evaluated using SEM (JSM-6700F, JEOL,
Tokyo, Japan). Briefly, a small amount of powder was sprinkled onto double-sided adhesive tape
attached to an aluminum stub and was sputter-coated with gold under vacuum. Photographs were
taken at 5×magnification with an accelerating voltage of 1–5 kV to reveal the surface characteristics of
the particles.
2.5.2. Particle Size Analysis
The mean particle size and distribution of oxaliplatin-PLGA microparticles were analyzed by
dynamic light scattering (DLS) using an electrophoretic light scattering spectrophotometer (ELS-Z,
Otsuka Electronics, Hirakata, Japan).
2.5.3. Rheological Measurements
The rheological measurements for HC12, HC21, and Guardix-Sol® hydrogels were performed
using a Brookfield rheometer (Brookfield Digital Rheometer Model DV-III, DV3T™ Rheometer,
Middleboro, MA, USA) equipped with a Peltier system for temperature control. Precisely, about 0.5 g
of sample was applied to the plate and allowed to equilibrate. Measurements were performed at
37 ± 0.5 ◦C with shear rates ranging from 200–500 s−1. Before each measurement, the samples were
allowed to rest for 5 min at 37 ± 0.5 ◦C. Results were analyzed with Brookfield software (Firmware
version 1.2.2-9).
2.5.4. Encapsulation Efficiency
Freeze-dried oxaliplatin-PLGA microparticles (eq. 2 mg of oxaliplatin) were dissolved in 5 mL of
DCM. After 5 min of vortexing, particles were allowed to dissolve properly, and the tube was gently
swung in incubator at 37 ± 0.5 ◦C for 1 h. Then, 5 mL of DW was added to the tube and vortexed
vigorously for 1 h. The suspension was centrifuged at 12,000 rpm for 5 min to precipitate PLGA.
The upper aqueous phase was collected, and the concentration of oxaliplatin was determined by HPLC.
Encapsulation efficiency (EE %) was calculated using the following Equation (1):
EE % =Mactual oxaliplatin/Mtheoretical oxaliplatin × 100 (1)
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2.6. In Vitro Oxaliplatin Release from PLGA Microparticles Loaded into Hydrogels
To evaluate the in vitro oxaliplatin release rate from oxaliplatin-PLGA microparticles, an amount
equivalent to 2 mg of oxaliplatin was weighed and suspended in 1 mL of HPLC grade water.
The suspension was transferred into dialysis bags (MWCO 14,000) and then submerged in 20 mL
of double distilled water in capped 50 mL Falcon® tube. Samples were shaken at 30 rpm at the
predetermined time points (1, 2, 3, 4, 6, 8, and 12 h); 1 mL of sample was collected from the medium
and 1 mL of pre-warmed medium was immediately added to the tubes. Experiments were performed
in triplicate (n = 3), and the collected samples were analyzed with HPLC after necessary dilution.
The release profile was expressed as the ratio of cumulative oxaliplatin release to initial oxaliplatin
loading versus time, using the following Equation (2):
Percent of oxaliplatin release =Mt/M0 × 100 (2)
For the in vitro oxaliplatin release from the PLGA microparticle-loaded hydrogels (from
Section 2.4.), a similar method was used. Briefly, 1 mL PLGA microparticle-loaded hydrogel (HC12,
HC21, or Guardix-Sol®) was transferred to one end-closed dialysis bags (MWCO 14,000). The other
end of the bag was closed properly, and the samples were submerged in 20 mL of double distilled
water in capped 50 mL Falcon® tube. Samples were shaken at 30 rpm at similar time points (1, 2, 3, 4,
6, 8, and 12 h). Subsequently, 1 mL of sample was collected from the medium and 1 mL of pre-warmed
medium was immediately added to the tubes. Experiments were performed in triplicate (n = 3),
and the collected samples were analyzed with HPLC after necessary dilution with the mobile phase.
The release profile was expressed as cumulative oxaliplatin release calculated using Equation (2).
2.7. In Vivo Oxaliplatin Release in SD Rat’s Intraperitoneal Cavity
In vivo oxaliplatin release from the prepared hydrogels was evaluated in the intraperitoneal
cavity of SD rats, and oxaliplatin solution was also evaluated for comparison. Briefly, a total of fifteen
male SD rats, aged 4–6 weeks, were randomly divided into three groups (n = 5, per group) and were
anesthetized with isoflurane. Intra-abdominal adhesions were induced to mimic the postoperative
surgical conditions, as described previously [23]. The peritoneum was exposed by a 5-cm ventral
midline incision. The left abdominal sidewall was scraped with a 1 cm2 piece of 100-grit sandpaper
200 times. In group 1, oxaliplatin solution was introduced, whereas, group 2 and 3 were exposed to
oxaliplatin powder and oxaliplatin-PLGA microparticles, loaded into HC21 hydrogel, respectively.
All the rats from each group were administered oxaliplatin in the form of a solution or loaded into
hydrogel at a dose level of 5 mg/kg body weight [24]. The abdominal layers and skin incision were then
completely closed, and each rat was kept separately in single cases. All surgeries were performed by the
same individual. At predetermined time interval (0.5, 1, 1.5, 2, 3, 5, 8, 14, 24, and 48 h), approximately
1-mL blood samples were collected from the conjunctiva using a capillary tube and kept in an ice bath.
Blood samples collected from the rat’s conjunctiva were centrifuged at 10,000 rpm (9425× g) for
10 min at 4 ◦C. The supernatant plasma was obtained and stored at −80 ◦C until analyzed. The frozen
plasma samples were thawed, and approximately 200 ± 5 mg was weighed. The samples were
oxidized into metals and organic materials by treating with 6 mL nitric acid using a microwave
sample pre-treatment machine equipped with platinum (Pt) sensor (Microwave Reaction System,
Multi-wave PRO, Anton Paar, Graz, Austria). Samples were heated at predefined temperature and
pressure (200 ± 0.5 ◦C and 4.0 MPa) for 1 h and diluted up to 30 mL with deionized water, and the
concentrations of Pt were analyzed using ICP-MS (NexION 300 D, PerkinElmer, Waltham, MA, USA).
Pharmacokinetic parameters AUC0–48h (area under curve), Cmax (peak concentration), and Tmax (time to
peak concentration) were calculated using noncompartmental analysis.
After the last blood sample collection at 48 h, rats were housed individually in standard case with
a 12-h light-dark cycle. The rats were fed a standard diet, provided with purified water, and were
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allowed to move freely. After 10 days, they were sacrificed, and the peritoneum was opened. For all
rats, adhesion type and extent were assessed, and photographs were taken.
2.8. High-Performance Liquid Chromatography (HPLC) Analysis
In vitro oxaliplatin release and % EE were determined by using HPLC Agilent 1200 Infinity Series
HPLC system (Agilent Technologies, Waldbronn, Germany). Briefly, XTerra™ RPC18 column (particle
size 5 μm, inside diameter 4.6 mm, and length 250 mm; Waters Corporation, Milford, MA, USA) at 210
nm using an HPLC-UV spectrometer (Agilent 1290 infinity). The mobile phase was a 20:80 mixture
of ACN and deionized water and was set to a flow rate of 0.8 mL/min (Model 1260 Quat Pump VL).
The samples were diluted as necessary, and 20 μL of each sample was injected using an autosampler
(Model 1260 ALS).2.9. Statistical Analysis
In vitro percent (%) cumulative oxaliplatin release and in vivo pharmacokinetic study data are
expressed as the means ± standard deviations. The t-test or two-sided RM ANOVA and Bonferroni test
were applied to the analyses of the differences between the groups. A p value < 0.05 was considered as
a statistically significant difference.
3. Results and Discussion
3.1. Characterization of PLGA Microparticles
PLGA-based microparticles were prepared using the double emulsion method. The microparticles
were characterized for size, morphology, and encapsulation efficiency. As shown in Table 1,
oxaliplatin-loaded PLGA microparticles had a particle size of more than 1 μm diameter, with a small
standard deviation. Encapsulation efficiency was 77.9 ± 2.8%, which is excellent for a hydrophilic
drug like oxaliplatin. Although the encapsulation of hydrophilic drugs in PLGA microparticles is
challenging due to the partitioning of weakly associated drugs from the oil phases to the external
water phase, the double emulsion technique is the most commonly used method for encapsulating
hydrophilic drugs. In addition, the SEM image shown in Figure 2A reveals the morphology of the
microparticles. Uniform size and spherical particles were observed, which is in agreement with the
particle size results. To fulfill the aims of this study, PLGA microparticles were further loaded into HC
hydrogels and the in vitro release and in vivo pharmacokinetic studies were conducted.
Table 1. Compositions and characterizations of Poly-(d,l-lactide-co-glycolide) (PLGA) microparticles












Emulsion 1 50 - - 1100.4 ± 257.7 77.9 ± 2.8
HC12 Hydrogel Synthesis by
cross-linking
reaction
- - 1 2 - -
HC21 Hydrogel - - 2 1 - -
3.2. Preparation and Characterization of HC Hydrogels
Cross-linked HC hydrogels were prepared using variable weight ratios of HA and CMCNa.
HC hydrogel synthesis was carried out based on our previous description [18]. In the presence of
ADH (as a nucleophile), EDC (a water-soluble carbodiimide) linked both HA and CMCNa molecules
with its amine group. EDC is not incorporated into the final product, but converts into a non-toxic
water-soluble urea derivative, which is removed by dialysis. Moreover, CH2COO−anions provided
by CMCNa react with H+ ions, leading to carboxyl group formation and facilitation of cross-linking.
Therefore, the reaction in the presence of EDC is pH-dependent and was performed at pH 4.75 ± 0.05.
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To evaluate the rheology of the HC hydrogel along with the commercial product Guardix-Sol®,
a Brookfield Digital Rheometer was used. All measurements were performed at 37 ± 0.5 ◦C, with shear
rates ranging from 200 to 500 s−1. All hydrogels followed non-Newtonian shear thinning (pseudo)
plastic flow behavior (Figure 2B). Decreasing viscosity with increasing shear rates was observed, which
demonstrated viscosity-dependent shear rates [25].
In addition, variable ratios of the composition (HA and CMCNa) alter the viscosity of the HC
hydrogels. The order could be written as follows: HC21 > HC12, as markedly increased viscosity was
observed with HA. The highest viscosity was observed with the HC21 formulation, whereas the lowest
viscosity was observed with HC12. The viscosity of Guardix-Sol® was measured for comparison
with those of the synthesized HC hydrogels, and it showed moderate viscosity. The rheology results
correlated with the mechanical characteristics of the polymer, in which viscosity scaled linearly
with molecular weight. The mechanical properties (entanglement phenomenon) of the polymers
increased with increasing molecular weight. Finally, the hydrogels were loaded with oxaliplatin-PLGA
microparticles and their in vitro and in vivo characteristics were evaluated.
 
(A) (B) 
Figure 2. (A) SEM image of oxaliplatin-PLGA microparticles (at X5.000 magnification); (B) rheology
properties of hydrogel samples () HC21, () Guardix-Sol®, and () HC12 (measurements were
performed at 37 ± 0.5 ◦C).
3.3. In Vitro Oxaliplatin Release Study
An in vitro oxaliplatin release study was conducted on oxaliplatin-PLGA microparticles generated
using the double emulsion method. In addition, oxaliplatin-PLGA microparticles and oxaliplatin
powder were dispersed into hydrogels (HC12, HC21, and Guardix-Sol®), and an in vitro oxaliplatin
release study was conducted. Plots of cumulative oxaliplatin release (%) versus time (h) are shown in
Figure 3A–C. In vitro release profile for oxaliplatin-PLGA microparticles (red closed circle; () showed
immediate release. With an initial burst release, about 63.2% oxaliplatin was released at 4 h. Oxaliplatin
release from PLGA microparticles is a combination of diffusion and bioerosion mechanism [26]. During
the diffusion stage, oxaliplatin release occurs by diffusion through aqueous channels. The release could
also be triggered by the external pores on the surface or through leaching of the oxaliplatin at or near
the surface, leading to an initial burst release. Besides, the standard deviation values of the results of
the in vitro release study for the hydrogels were low, which indicate excellent reproducibility of the
release behavior. However, when oxaliplatin-PLGA microparticles were loaded into three different
hydrogel systems, HC12, HC21, and Guardix-Sol®, slight initial burst release was observed. Although
the rate of burst release was almost the same for the three systems, HC12, with the lowest viscosity,
showed the maximum release. In contrast, the higher the viscosity of the hydrogel system, the lower
the burst and sustained release observed. This may be due to low leaching of the drugs and high
protection of the microparticles by the hydrogels.
Table 2 demonstrated the kinetic models adopted for evaluation. Where Mt was the cumulative
drug released at time t and M was the initial drug present in the PLGA microparticles-loaded hydrogels.
k1, kH, and kKP are the first order, Higuchi, and Korsmeyer-Peppas release constant, respectively.
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Mt/M∞ was the fraction of drug released at time t, and n was the diffusional release exponent
symbolic of the release mechanism. The rate of oxaliplatin release from the HC12, Guardix-Sol®
and HC21-loaded PLGA microparticles were slower and constant compared with the oxaliplatin
powder-loaded hydrogels, as indicated by the KH values of 18.9686, 17.5626, and 20.6559% h1/2,
respectively. Release constants were determined using the slope of the appropriate plots, and the
regression coefficient (R2) was obtained through linear regression analysis (Table 2). The coefficient
of determination (R2) was used as an indicator of curve fit for each of the considered models [27].
The regression coefficients R2, from the Korsmeyer-Peppas plots were 0.9342, 0.9554, and 0.9366 for
HC12, Guardix-Sol® and HC21, respectively, thus the log of cumulative drug release was proportional
to the log of time. The best linear fits were observed for the PLGA microparticles-loaded hydrogels
using both the Higuchi and Korsmeyer-Peppas models, suggesting that oxaliplatin release from the
PLGA microparticles-loaded hydrogels were diffusive process. Oxaliplatin gradually dissolved into
the fluid within the swelled hydrogels, then slowly diffused from polymeric networks of the hydrogels.
Table 2. Release rate constants and regression coefficient R2 obtained from drug release profile based
on kinetic equations.
Equations
Loaded in HC12 Hydrogel
Loaded in Guardix-Sol®
Hydrogel















a Higuchi model: kH
(% h1/2) 28.5970 18.9686 22.1635 17.5626 24.3401 20.6559 20.0882
R2 0.6738 0.9611 0.7431 0.9783 0.7746 0.9485 0.8026
b First—Order model:
k1 (h−1)
0.0302 0.0421 0.0263 0.0469 0.0379 0.0522 0.0219
R2 0.1639 0.6646 0.2327 0.7224 0.2640 0.6451 0.4145
c Korsmeyer—Peppas
model: kKP
0.4517 0.5033 0.3750 0.5475 0.5352 0.6308 0.2884
R2 0.5495 0.9342 0.6099 0.9554 0.6512 0.9366 0.7767
a Higuchi model: (Mt = kH × t1/2); b First—Order model: (ln Mt = lnM + k1 × t); c Korsmeyer—Peppas model:
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Figure 3. In vitro oxaliplatin release from PLGA microparticles (red, ). Oxaliplatin release profile
from oxaliplatin powder and oxaliplatin-PLGA microparticles-loaded in (A) HC12; (B) Guardix-Sol®;
and (C) HC21 hydrogel. Mean ± S.D. (n = 3).
Although hydrogels are swellable materials with high water content, which readily allow the
release or leaching of hydrophilic drugs through the channels, high viscosity might hinder this process.
Therefore, release may be completed through bioerosion. In this study, three different hydrogel
systems—HC12, HC21, and Guardix-Sol®, were loaded with oxaliplatin powder and oxaliplatin-PLGA
microparticles. The HC12 hydrogel system (low viscosity) was loaded with oxaliplatin powder and
more than 90% oxaliplatin release occurred within 3 h, followed by saturated release behavior up to
12 h. However, oxaliplatin-PLGA microparticles loaded into the HC12 hydrogel showed a slower
release pattern than that of the oxaliplatin powder. Approximately 50% oxaliplatin was released after
4 h, followed by 64.2% release up to the end of the experiment (p < 0.05). Due to the less hydrophilicity
of the PLGA copolymers, they absorb less water, and subsequently degrade more slowly. Therefore,
drug release from the PLGA microparticles was delayed. In the case of Guardix-Sol®, with moderate
viscosity, a sustained release profile was observed for the oxaliplatin-PLGA microparticles. During the
first 2 h of the release study, less than 30% of oxaliplatin was released; however, 59.25% of oxaliplatin
was released after the same amount of time when loaded with oxaliplatin powder (p < 0.05).
In addition, the HC21 hydrogel system (high viscosity) showed a similar sustained release profile
when loaded with oxaliplatin-PLGA microparticles. In all three systems, more rapid oxaliplatin
release was observed when oxaliplatin was loaded as a powder compared to that when loaded
as microparticles. The release rate was faster than those of both oxaliplatin-PLGA microparticles
and oxaliplatin-PLGA microparticles-loaded hydrogels. Additionally, both Guardix-Sol® and HC21
showed similar sustained release patterns up to 12 h. Although PLGA microparticles were generated
using the well-known double emulsion method, further studies are necessary to establish process
parameters and extensive characterization of the particles.
3.4. Pharmacokinetics in Rats
The bioavailability of oxaliplatin-PLGA microparticles loaded into the HC21 hydrogel was
evaluated in rats. Figure 4 shows the mean concentration–time profiles of oxaliplatin in rats after
a single dose (5 mg/kg) of oxaliplatin solution, oxaliplatin-PLGA microparticles, and oxaliplatin
powder loaded into the HC21 hydrogel. The samples were introduced through a midline incision to
open the peritoneum immediately after introducing intra-abdominal adhesions by multiple scraping
to mimic postoperative surgical conditions. Intraperitoneal absorption of oxaliplatin solution was
obviously higher than that of the hydrogel loaded samples (oxaliplatin-PLGA microparticles and
oxaliplatin powder). For oxaliplatin solution AUC0–48h, Cmax, and Tmax were 8181.51 ± 176.89 ng·h/mL,
2265.28 ± 192.51 ng/mL, and 1.0 h, respectively. In the case of oxaliplatin powder loaded into the
HC21 hydrogel, AUC0–48h, Cmax, and Tmax were 16,571.37 ± 139.13 ng·h/mL, 690.63 ± 140.54 ng/mL,
and 1.5 h, respectively. Intraperitoneal bioavailability of oxaliplatin was significantly increased
by up to 2-fold in the HC21 hydrogel (Table 3). In particular, 1.9-fold higher bioavailability was
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observed in the case of oxaliplatin-PLGA microparticles loaded into the HC21 hydrogel compared
to that of the oxaliplatin solution. AUC0–48h, Cmax, and Tmax were 16,012.12 ± 188.75 ng·h/mL,
528.75 ± 144.50 ng/mL, and 1.5 h, respectively. Moreover, mean residence time (MRT) was increased
by 2.7-fold for oxaliplatin-PLGA microparticles when loaded into the HC21 hydrogels (p < 0.05).
When the oxaliplatin-PLGA microparticles were loaded into the HC21 hydrogel, oxaliplatin release
rate decreased due to the multi-layered encapsulation, which was observed from the in vitro release
study. Therefore, in the high, moderate, and low viscous hydrogels (HC21, Guardix-Sol®, and HC12,
respectively), oxaliplatin release from the PLGA microparticles, followed by release from the hydrogels,
was observed in a sustained manner (Figure 3). Furthermore, using sustained-release hydrogels allows
a longer residence time of the component at the application site (intraperitoneal after cytoreductive
surgery), which offers additional benefits through the prevention of intra-abdominal adhesion and
improvement in the delivery of intraperitoneal oxaliplatin from the PLGA microparticles.
Figure 4. Plasma concentration-time profile of Pt in rats after intra-peritoneal administration of
oxaliplatin powder and oxaliplatin-PLGA microparticles-loaded in HC21 hydrogel, and oxaliplatin
solution. Data are expressed as the Mean ± standard deviation (n = 5). *, p < 0.05 represents a significant
difference, two-sided RM ANOVA and Bonferroni test.
Table 3. In vivo pharmacokinetic parameters after intra-peritoneal administration to rats (n = 5).
Formulations
Pharmacokinetic Parameters
Cmax (ng/mL) Tmax (h) AUC0–48h (ng·h/mL) MRT (h)
Oxaliplatin solution 2265.28 ± 192.51 1 8181.51 ± 176.89 4.36 ± 0.65
Oxaliplatin powder loaded HC21 690.63 ± 140.54 1.5 16571.37 ± 139.13 10.29 ± 0.33
Oxaliplatin-PLGA microparticle loaded HC21 528.75 ± 144.50 1.5 16012.12 ± 188.75 12.02 ± 0.41
3.5. Intraperitoneal Anti-Adhesion Effect
An extensive investigation of the intraperitoneal anti-adhesion efficacy of HC hydrogels was
conducted in our previous study, after introducing peritoneal injury to generate peritoneal adhesion [18].
HC hydrogel groups (treated) showed the highest anti-adhesion barrier compared to the control group
(non-treated). In the present study, the pharmacokinetic parameters of the PLGA microparticles loaded
into the HC21 hydrogel were evaluated and compared with those of oxaliplatin powder loaded into
hydrogels. Artificial injury on the left abdominal sidewall was introduced to mimic surgical conditions
and observe the anti-adhesion barrier effect of hydrogel samples followed by the intraperitoneal
delivery of oxaliplatin. The method was adopted from experienced surgeons certainly feasible in
human administration after cytoreductive surgery in colorectal cancer treatment. Intraperitoneal
anti-adhesion effect was observed and recorded photographically. Figure 5 shows a photographical
representation of adhesion characteristics of the study groups.
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Figure 5. Photographical expression of in vivo anti-adhesion efficacy observed in rats after introducing
intra-peritoneal injury. (A) oxaliplatin solution; (B) oxaliplatin powder-loaded HC21 hydrogel; and (C)
oxaliplatin-PLGA microparticles-loaded HC21 hydrogel.
HC21 hydrogel samples exhibited an efficient anti-adhesion barrier effect towards the injury.
Although hydrogels were not intended to cure the injury, long resident time hydrogels significantly
prevented adhesion along with rapid recovery of the injury, possibly due to mechanical separation
from the injury site [28]. As reported previously, the washing away or displacement of the oxaliplatin
solution from the application site allows less barrier or protection to the injury site [29]. Therefore,
dense adhesion on the abdominal wall was observed, and, although current study was not intended to be
carried out extensively, adhesion scoring and extent (as disclosed in a previous report) and photographic
representation demonstrated the superiority of the hydrogels in terms of the anti-adhesion barrier. In the
hydrogel-loaded samples, no or minor adhesion was observed in the treated rat abdomen (Figure 5B,C).
Although two different samples were evaluated after loaded in HC21 hydrogel both oxaliplatin
powder and oxaliplatin-PLGA microparticles loaded hydrogels showed significant improvement as
anti-adhesion barrier. Subsequently, both hydrogel systems showed rapid wound recovery effect may
be due to mechanical separation- could be seen from the blood spot in Figure 5C. Instead, oxaliplatin
solution presents no barrier to the injure site and dense abdominal adhesion was observed. The HC21
hydrogel-loaded sample showed enhanced anti-adhesion protection to the injury site, suggesting
its potential therapeutic application in CRC patients who have undergone cytoreductive surgery.
Although the current study evaluated the pharmacokinetic profile of PLGA microparticle-loaded HC
hydrogels, a further pharmacodynamics study on a CRC model is required to evaluate the composition
of the hydrogels.
4. Conclusions
Oxaliplatin-PLGA microparticles were loaded into hydrogels to improve intraperitoneal
chemotherapy with an anti-adhesion barrier effect. In an in vitro release study, we observed sustained
oxaliplatin release from PLGA microparticles loaded into hydrogels in comparison with the unloaded
sample. Moreover, in the in vivo pharmacokinetics study on rats, PLGA microparticle-loaded hydrogels
showed higher bioavailability compared to oxaliplatin solution. Furthermore, visual observations
revealed that the HC hydrogels were effective as an intra-abdominal anti-adhesion barrier.
Therefore, intraperitoneal delivery of PLGA microparticle-loaded hydrogels, which have an effective
intra-abdominal anti-adhesion barrier, is expected to provide an optimized alternative therapy for
CRC. Earlier reports of cytotoxicity study for PLGA (RG502H) microparticles exhibited non-cytotoxic
at increasing concentration [30]. Additionally, both HA and CMCNa are considered as inert and
non-cytotoxic. However, cytotoxicity profile for the novel oxaliplatin-PLGA microparticles-loaded HC
hydrogels were yet to revealed. As the investigation undertaken in current study was preliminary,
pharmacokinetic and anti-adhesion efficacy of this multi-complex drug delivery system, further studies
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are required to address cytotoxicity, cell viability, toxicity in liver function, and efficacy in CRC model
in vivo.
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Abstract: Trolamine salicylate (TS) is a topical anti-inflammatory analgesic used to treat small joint
pain. The topical route is preferred over the oral one owing to gastrointestinal side effects. In this study,
a poly(lactide-co-glycolide) (PLGA)-based in situ bio-adhesive film-forming system for the transdermal
delivery of TS was designed and evaluated. Therefore, varying amounts (0%, 5%, 10%, 20%, and
25% (w/w)) of PLGA (EXPANSORB® DLG 50-2A, 50-5A, 50-8A, and 75-5A), ethyl 2-cyanoacrylate,
poly (ethylene glycol) 400, and 1% of TS were dissolved together in acetone to form the bio-adhesive
polymeric solution. In vitro drug permeation studies were performed on a vertical Franz diffusion cell
and dermatomed porcine ear skin to evaluate the distinct formulations. The bio-adhesive polymeric
solutions were prepared successfully and formed a thin film upon application in situ. A significantly
higher amount of TS was delivered from a formulation containing 20% PLGA (45 ± 4 μg/cm2) and
compared to PLGA-free counterpart (0.6 ± 0.2 μg/cm2). Furthermore, the addition of PLGA to the
polymer film facilitated an early onset of TS delivery across dermatomed porcine skin. The optimized
formulation also enhanced the delivery of TS into and across the skin.
Keywords: NSAIDs; PLGA; polymeric film; topical drug delivery; trolamine salicylate
1. Introduction
Topical drug delivery has many advantages over systemic drug administration, such as minimizing
side effects, bypassing first-pass metabolism, and ensuring better patient compliance [1]. However,
dermal drug delivery is usually limited to certain drug molecules, owing to the well-known barrier
function of the skin. The outermost layer of the skin, the stratum corneum, generally only allows
permeation of molecules with a molecular weight <500 Da, a logP between 1 and 3, and a melting
point of <250 ◦C [2].
Among the available topical formulations, non-steroidal anti-inflammatory drugs (NSAIDs)
constitute approximately 18 world-wide marketed molecules (some examples include diclofenac,
methyl salicylate, salicylic acid, and ketoprofen) [3]. As an example, topical salicylates are known to
be absorbed by the dermal tissue and have been reported to be effective in relieving local pain [4].
Trolamine salicylate (TS), a derivative of salicylic acid offers many benefits over other topical analgesics,
including a lack of distinct odor, low systemic absorption upon dermal or topical administration,
and low skin irritation [5]. Although topical salicylates are widely used, compliance is often an issue,
owing to the frequent dosing regimen (three to four times per day).
The development of topical formulations has made an important contribution to medical practice.
To deliver active pharmaceutical ingredients into or through the skin, various types of formulations
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are known, such as gels and emulsions. The type of vehicle chosen depends on the properties of the
drug and the intended target area. In addition, the hydrophilicity and lipophilicity of the drug must be
compatible with the vehicle. “Conventional” vehicles are inelegant and have the drawback of poor
control of both the amount of drug applied and the area of skin exposed [6]. As a result, the use of
topical formulations to deliver molecules to systemic circulation is less than ideal, thus resulting in
substantial variability in the extent and duration of drug effects [7]. To overcome the shortcomings
of skin drug delivery, the former Alza Corporation pioneered a transdermal patch in which system
design and explicit control of the surface area led to improved passive drug delivery to the systemic
circulation at a predetermined rate. Transdermal patches are recommended to be applied to a flat
surface area to ensure adhesion to skin over a prolonged period of time. However, in the case of
arthritis and other joint pain, the use of a patch is not suitable because of the uneven surface at the
application sites. Pain associated with arthritis requires drug application at the pain region, which is
usually difficult to cover with conventional patches [8]. In addition, clinical trials have shown that the
topical application of NSAIDs delivers drugs at a higher local concentration to the tissue, resulting in
better pain management [9].
Bioadhesive in situ film-forming systems provide many advantages such as higher dosing
flexibility, extended release properties, higher patient compliance, improved cosmetic appearance, and
less chance for loss of formulation by rubbing [10].
Poly(lactide-co-glycolide) (PLGA) is one of the most promising polymers used for the fabrication
of drug delivery devices and tissue engineering applications [11]. PLGA is biocompatible and
biodegradable, and its properties such as the erosion profile and mechanical strength can be controlled
as needed. Furthermore, PLGA can be engineered to control the drug release behavior by changing the
polymer molecular weight and the molar ratio of lactide to glycolide [12–14]. However, a detailed
characterization of such systems is required to prevent potential dose dumping, and an inconsistent
drug release profile [15].
In this study, a PLGA-based in situ bioadhesive film-forming system for the transdermal delivery
of TS was designed and evaluated for drug permeation across dermatomed porcine ear skin. Different
types of plasticizer and solvents were screened to optimize the film forming behavior. The effects
of different ingredients were studied on the permeation profile of TS. The optimized formulations
were developed by finding a proper ratio between polymer, adhesive, and plasticizer and showed
enhancement of TS delivery into and across the skin.
2. Materials and Methods
2.1. Materials
All polymers (Table 1) were kindly donated by Merck KGaA (Darmstadt, Germany). Trolamine
salicylate and ethyl-2-cyanoacrylate were purchased from Sigma (St. Louis, MO, USA). Glycerol and
Poly(ethylene glycol) 400 was purchased from VWR (Richmond, BC, Canada) and Acros organics
(Morris Plains, NJ, USA), respectively. Propylene glycol was obtained from EKI Industries (Joliet, IL,
USA). Porcine ear skin was procured from a local slaughterhouse. Phosphate-buffered saline (PBS;
10 mM, pH 7.4), acetonitrile, ethyl acetate, and acetone were purchased from Fisher Scientific (Waltham,
MA, USA).







EXPANSORB® DLG 50-2A 1:1 –COOH 5–20
EXPANSORB® DLG 50-5A 1:1 –COOH 42–65
EXPANSORB® DLG 50-8A 1:1 –COOH 80–130
EXPANSORB® DLG 75-5A 3:1 –COOH 37–84
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2.2. Development of Film-Forming Polymeric Solutions
2.2.1. Screening of Components
To choose a compatible solvent for PLGA, 1 g of PLGA and 0.25 g of cyanoacrylate (CA) were
dissolved together in 1 g of four different solvents (ethanol, ethyl acetate, propylene glycols, and acetone)
and left overnight mixing. To select a proper plasticizer, we added a few drops (0.25 g) of one of the
three different plasticizers namely glycerol, poly(ethylene glycol) 400 (PEG 400), and propylene glycol
to the polymeric mixture to increase the flexibility of the film. Each formulation (6.4 μL) was then
applied on the dermatomed porcine ear skin, and the film forming behavior was investigated.
2.2.2. Optimization of Formulations
Optimized film-forming solutions were prepared by the addition of the PLGA and CA to the
solvent. After obtaining a clear solution, the plasticizer and the drug were added. The solutions were
left overnight mixing in glass vials to allow the drug to dissolve completely at room temperature.
A detailed composition of each formulation can be found in Table 2.
Table 2. Composition of the distinct formulations (% (w/w)).
Different Types of PLGA Different Amounts of PEG 400 Different Concentrations of PLGA
F1 F2 F3 F4 F1′ F5 F6 F7 F1” F8 F9 F10 F11
Code 50-2A 50-5A 50-8A 75-5A 4:1:1 4:1:0 4:1:2 4:1:3 20% 0% 5% 10% 25%
Polymer 50-2A 50-5A 50-8A 75-5A 50-2A 50-2A 50-2A 50-2A 50-2A 50-2A 50-2A 50-2A 50-2A
PLGA 20 20 20 20 20 24 17 15 20 0 5 10 25
Cyanoacrylate 5 5 5 5 5 6 4.25 3.75 5 15 12.5 10 2.5
Plasticizer
PEG 400 5 5 5 5 5 0 8.75 11.25 5 15 12.5 10 2.5
Solvent
Acetone 69 69 69 69 69 69 69 69 69 69 69 69 69
Drug
Trolamine
Salicylate 1 1 1 1 1 1 1 1 1 1 1 1 1
2.2.3. Effect of Plasticizer PEG 400, Types of PLGA, and Various Concentration of PLGA for Topical
Delivery of TS
PLGA, 50-2A, was used to test the effects of plasticizer on the permeation profiles of TS. The ratio
of PLGA to CA was kept at four to one. Then, the proportion of the plasticizer was increased from 0 to
3. The highest amount PEG 400 was added to F7, at 11.25 g (11.25% (w/w)), then reduced to 8.75 g
(F6; 8.75% (w/w)), 5 g (F’1; 5% (w/w)), and finally to no PEG 400 in F5 (Table 2).
For the comparison of different types of PLGA, the ratio of each component was kept at 4:1:1
(PLGA:cyanoacrylate:PEG 400). To investigate the effects of different amounts of PLGA in TS permeation
profiles, we incorporated different amounts of PLGA into formulations. PLGA 50-2A was used in all
formulations, and the ratio of PEG 400 and cyanoacrylate was kept at 1:1. To increase the amount of
PLGA, the amount of cyanoacrylate was decreased from 25 to 0 in increments of 5.
2.3. Evaluation of the Formulations
2.3.1. Crystallization Study and Solvent Evaporation Study
To observe the crystallization of the drug in the films, we placed 6.4 μL of formulations on a
microscopic slide and evaluated the samples under a microscope after the evaporation of acetone.
To study the extent and time of solvent evaporation, 6.4 μL of F1 formulation was placed on a
microscopic slide using a positive displacement pipette. The slides were left in a convection oven
(32 ◦C) for a pre-determined time and weighed at 2 min, 1 h and 24 h to calculate the percentage
evaporation of the solvent over time.
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2.3.2. In Vitro TS Release Study
The release profiles of TS from the formulations F1, F2, F3, and F4 (different PLGA types) were
determined to study the impact of the polymer properties on the drug release kinetics. Polymer films
containing 64 μg of TS (equal to a surface area of 0.64 cm2) was added to the bottom of a glass vial.
Then, 5 mL of PBS were added and left under constant shaking at 150 rpm and 30 ◦C. Samples (300 μL)
were withdrawn from the vials at predetermined time points, and the same amount of fresh receptor
solution was replaced. The samples were analyzed by high-performance liquid chromatography
(HPLC) as outlined below.
2.3.3. In Vitro Permeation Study
Skin Preparation
The outer region of full-thickness ear skin was removed carefully with a scalpel. The skin was
then washed with PBS, dried, wrapped with Parafilm, and stored at −80 ◦C until use. The porcine ear
skin was dermatomed with a Dermatome 75 mm (Nouvag AG, Goldach, Switzerland) prior to use.
The average thickness of the dermatomed skin pieces was 0.50 ± 0.02 mm.
Evaluation of Skin Integrity
Before conducting a permeation study, we evaluated the integrity of the skin membrane by
measuring the skin resistance value. The skin was mounted on a vertical Franz diffusion cell with the
stratum corneum side facing up, and then 300 μL of PBS was added to the donor compartment. A silver
electrode and silver chloride electrode were placed in the receptor and the donor chambers, respectively,
without touching the skin membrane. Two electrodes were connected to a digital multimeter (34410A
6 12 digit multimeter; Agilent Technologies, Santa Clara, CA, USA) and waveform generator (Agilent
33220A, 20 MHz function/arbitrary waveform generator) [16]. The resistance of the employed skin (Rs)
was calculated according to the following formula:
Rs = VsRL/(V0 − Vs) (1)
where RL and V0 were 100 kΩ and 100 mV, respectively. Skin pieces with a resistance lower than 10
KΩ were discarded.
Next, permeation studies were performed on a jacketed Franz diffusion cell with a diffusion area
of 0.64 cm2 (PermeGear, Bethlehem, PA, USA) on dermatomed porcine ear skin. PBS was used as
the receptor solution (5 mL). The skin was clamped between the donor and receptor chambers of a
vertical diffusion cell with the stratum corneum side in contact with the donor solution. The distinct
formulations (64 μg of TS per 0.64 cm2) was added in the donor compartment. The temperature of
the receptor medium was maintained at 37 ◦C, and the skin surface temperature was about 32 ◦C.
The amount of drug diffused over the dermatomed porcine ear skin was determined by removal of
aliquots of 300 μL at pre-determined time points over 72 h from the receptor compartment. The volume
was immediately replaced with the same amount of fresh buffer. The samples were analyzed by HPLC
as outlined below. A skin extraction study was carried out to determine the drug amount that had
penetrated into the skin. After 72 h, the skin samples were removed from Franz diffusion cell and the
residual polymer film was removed with D-squame tape. The skin surface was wiped offwith two
cotton buds dipped in receptor solution. Then, the skin was dried with two cotton buds. The utilized
tape and the four cotton buds were pooled and extracted with 30 mL of receptor solution. After the
cleaning procedure, the epidermis and dermis were separated. The tissue was minced manually and
added to 1 mL of receptor solution. Samples were shaken for 4 h followed by filtration using a 0.45 μm
membrane filter and analyzed by HPLC.
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2.4. Quantitative Analysis
TS was quantified by HPLC analysis. A Waters Alliance HPLC system (2795 Separating Module;
Waters Co., Milford, MA, USA) equipped with a Photodiode detector (Waters 2475) and a Kinetex EVO
C18 column (5 μm, 100 Å, 150 × 4.6 mm; Phenomenex, Torrance, CA, USA) was used. The mobile
phase consisted of a 70/30 (v/v) mixture of acetonitrile and 0.1% of trifluoroacetic acid in distilled
water. The injection volume and the flow rate were set to 20 μL and 1.0 mL/min, respectively, and the
detection wavelength of TS was 304 nm. The reversed-phase HPLC method provided a linear range of
0.1–100 μg/mL (R2 = 0.999).
2.5. Statistical Analyses
All results are reported as the mean with the standard error of the mean (SE) from at least
three replicates. Statistical calculations were performed with GraphPad Prism Version 8.0 (GraphPad
Software, Inc., San Diego, CA, USA). One-Way ANOVA followed by Tukey HSD post hoc test was
applied to compare the results of different groups. Statistically significant differences were denoted
by p < 0.05.
3. Results
3.1. In Situ Film-Forming Behavior
PLGA and CA did not dissolve completely in propylene glycol and ethanol. Complete dissolution
was achieved in ethyl acetate and acetone. However, ethyl acetate did not evaporate upon application
and the obtained polymer films were difficult to handle. Therefore, acetone was chosen as the solvent
for the system. A successful film formation behavior on the dermatomed porcine ear skin was observed
with the plasticizer PEG 400. Upon administration, the solvent evaporated instantaneously and left a
thin and transparent film layer behind.
3.2. Crystallization Study and Solvent Evaporation Study
Formulation (F1–F11) was observed under the light microscope after complete evaporation of the
solvent. No drug crystals were observed in the polymer films during the slide crystallization study,
indicating the solubility of TS in the film matrix after evaporation of the organic solvent (Figure 1).
After 2 min in the convection oven, the result demonstrated 75.3 ± 4.1% (n = 3) solvent evaporation,
and it did not further evaporate for 24 h.
 
Figure 1. Microscopic images of the 20% PLGA formulation (F1) on glass sides (a) without and (b) with
added drug (10× magnification) did not show drug crystallization after complete evaporation of
the solvent.
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3.3. In Vitro Release Study for Different Types of PLGA
In the first hour, F3 and F4 released 34% and 38%, respectively. In contrast, a smaller amount was
released after 1 h with F1 and F2 (20% and 13%, respectively). After 72 h, the drug release from F1, F2,
and F3 was completed (>90%), whereas only 68% of TS was released from F4 (Figure 2).
Figure 2. In vitro drug release profile from different types of PLGA (n = 6).
3.4. Effects of Each Ingredient and Permeation Study
3.4.1. Effects of Plasticizer
Four formulations with different amounts of PEG 400 were prepared, and a thin film was formed
upon application on the skin. The amount of TS delivered in the receptor solution after 72 h was found
to be 16 ± 3 μg/cm2 and 24 ± 3 μg/cm2 in F5 and F7, respectively. A significantly higher amount of TS
was delivered to the receptor with F1′ (47 ± 8 μg/cm2) and F6 (47 ± 5 μg/cm2). Moreover, formulation
without any plasticizer (F5) delivered only 2.7 ± 0.3 μg/cm2, the least amount of drug into the skin
(Figure 3). The highest amount of PEG 400 facilitated the largest amount of TS delivery into the skin
(individual values in Table 3). Because there was no significant difference between the F1′ and F6
groups in the amount of drug in the receptor, the F1′ ratio was chosen to carry out permeation studies
to investigate the effects of different types of PLGA.
Figure 3. Permeation profiles of TS through porcine ear skin to study the effects of plasticizer. The group
is representative of the ratio between PLGA:CA:PEG 400. (a) Cumulative amount (b) Average amount
in the epidermis, dermis, and total skin.
92
Pharmaceutics 2019, 11, 409
Table 3. Amounts of TS extracted after 72 h in the epidermis and dermis and the total amount of TS for
all groups.
Groups Epidermis (μg/cm2) Dermis (μg/cm2) Total (μg/cm2)
Different types of
PLGA
50-2A (F1) 10.4 ± 1.4 1.5 ± 0.4 11.9 ± 1.7
50-5A (F2) 12.6 ± 2.5 1.3 ± 0.4 13.9 ± 2.4
50-8A (F3) 8.6 ± 1.3 1.1 ± 0.4 9.8 ± 1.5
75-5A (F4) 8.7 ± 0.5 1.0 ± 0.2 9.7 ± 0.7
Effect of plasticizer
4:1:1 (F1’) 8.6 ± 0.6 1.6 ± 0.3 10.1 ± 0.6
4:1:0 (F5) 2.5 ± 0.2 0.3 ± 0.1 2.7 ± 0.3
4:1:2 (F6) 14.3 ± 2.5 1.9 ± 0.5 16.2 ± 2.8
4:1:3 (F7) 14.2 ± 0.7 3.7 ± 0.6 17.9 ± 1.0
Different amount
of PLGA
20% (F1”) 9.1 ± 2.0 18.2 ± 4.0 27.4 ± 6.0
0% (F8) 6.3 ± 0.6 0.40 ± 0.1 6.7 ± 0.5
5% (F9) 9.9 ± 1.0 0.62 ± 0.2 10.5 ± 1.2
10% (F10) 11.5 ± 1.5 22.9 ± 3.0 34.4 ± 4.5
25% (F11) 9.5 ± 0.8 1.9 ± 0.4 11.4 ± 1.1
3.4.2. Effects of Different Types of PLGA
All formulations were able to form a polymeric solution, and then a thin layer of film was formed
upon application on the skin. After 72 h, all three formulations with the one to one ratio (G/L) delivered
17 ± 3, 17 ± 3, and 19 ± 3 μg/cm2, respectively, and no significant difference was observed in the
cumulative amount of TS in the receptor. In contrast, F4 delivered 11 ± 1 μg/cm2, a significantly lower
amount than was observed for the other three groups. There was no significant difference in the drug
amount delivered into the skin (Figure 4).
3.4.3. Effects of Concentration of PLGA
All formulations were able to form a polymeric solution and formed a thin layer of film after
complete evaporation of the solvent. The highest amount of TS (45 ± 4 μg/cm2) was delivered
with 20% PLGA (F1”), followed by the formulation with 25% of PLGA (F11) (21 ± 4 μg/cm2). The
formulations with 0%, 5%, and 10% PLGA delivered a significantly lower amount of TS, at 0.6 ± 0.2,
1.6 ± 0.3, and 5.6 ± 0.7 μg/cm2, respectively (Figure 5). The formulation with 10% (F10) and 20% (F1”)
PLGA delivered significantly higher amounts into the skin. However, the 0%, 5%, and 25% PLGA
formulations delivered a lower amount of TS into the skin (values in Table 3).
Figure 4. Permeation profiles of TS through porcine ear skin for the different types of PLGA. The
group is representative of different types of PLGA: (a) Cumulative amount (b) Average amount in the
epidermis, dermis, and total skin.
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Figure 5. Permeation profiles of TS through porcine ear skin for different concentrations of PLGA.
The group is representative of different concentrations of PLGA: (a) Cumulative amount (b) Average
amount in the epidermis, dermis, and total skin.
4. Discussion
4.1. Parameters for the Development of Film-Forming Polymeric Solutions
Limitations of conventional formulations for topical drug delivery include poor adherence to the
skin, poor permeability, and a low compliance rate [17]. Bioadhesive film, because it is an intermediate
between transdermal patches and semisolid dosage forms, has the advantages of both systems, such as
transparency, no stickiness, convenience, less frequent dosing, sustained drug release, and resistance
to wiping off. In addition, incorporating cosmetic or therapeutic agents is more convenient with
this system than conventional topical drug delivery systems, owing to lower potential loss of the
formulation by rubbing.
First, the most important parameters for polymeric solutions are the polymers. Suitable polymers
for successful film forming systems may possess transparency, flexibility, and drug encapsulation ability
at moderate temperature. To develop a suitable formulation to decrease the frequency of application of
topical analgesics, common film-forming polymers, such as hydroxypropyl, methylcellulose, polyvinyl
pyrrolidine, and acrylate copolymer, were searched in the literature. However, many of the polymers
were hydrophilic and might not provide water resistance in daily life. PLGA was chosen to be
incorporated in the polymeric solution because of its many benefits, such as its water resistance,
nonirritating and nonallergic qualities, and capability for drug incorporation [15]. To provide an
efficient local drug delivery system, Eskandari et al. have investigated the use of butyl-2-cyanoacrylate.
To ensure good adhesion of the film to the skin, CA, which is compatible with PLGA, was chosen.
CA gets stiffened by polymerization process in the presence of moisture [18–20]. When the polymeric
film is applied on the skin, the film is formed upon polymerization of PLGA and CA due to the
moisture of the skin. Polymerized CA is an excellent polymer candidate for drug delivery because it is
a biodegradable, hemostatic, nonallergenic tissue adhesive with local antibacterial properties, and it is
inexpensive and widely available [18,19,21]. In addition, it is commonly used and is acceptable to the
public, owing to its use in liquid bandage formulations [22]. Currently, CA is used in surgical and
clinical adhesives in various surgical procedures such as the treatment of arteriovenous malformation,
retinal ruptures, and skin graft placements [23,24]. Eskandari et al. have shown that CA can successfully
incorporate drugs for slow release of antibiotics to specific areas without causing an inflammatory
response [25].
Solvents play an important role in film formation. The solvent used in the film forming system is
responsible for drug-polymer solubility and also affects drug permeation. Some common solvents used
in polymeric solutions are ethanol, ethyl acetate, propylene glycols, and acetone [26]. The combination
of the PLGA and the adhesive was tested for dissolution in different solvents such as acetone, ethyl
acetate, and ethanol. All the ingredients were dissolved readily in acetone and formed a film upon
application to the skin. Acetone is approved in use of topical formulation per the inactive ingredient
list of FDA [27]. Also, a toxicology report by US. Department of Health and Human Services reported
that dermal exposure to acetone did not affect the human health negatively [28].
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Apart from the polymer and solvent, other excipients such as plasticizers must be added into
the formulation. Plasticizers are low molecular weight resins that may interact with polymer chains
and affect polymer-polymer bonding [29]. These interactions may affect film flexibility as well as the
permeability toward drug substances. The commonly used plasticizers in polymeric solutions include
fatty acid esters, glycol derivatives, phthalate esters, and phosphate esters [30]. The plasticizer used
should be compatible with the polymers and should have low skin permeability. Hence, choosing a
proper plasticizer is important for the polymeric matrix. In addition, determining the right amount of
plasticizer is critical for film-forming polymeric solutions. After the selection of two polymers to form
the polymeric solution, proper plasticizers were screened for tolerance to mechanical stress, which
may be exerted on the formed film by the movement of the skin. In selecting an appropriate plasticizer,
compatibility with the polymers and plasticization efficiency were considered. After application on
dermatomed porcine skin, the acetone evaporated, and a thin transparent film was formed in situ.
Based on the results, PEG 400 was incorporated as a plasticizer to enhance the mechanical properties
and flexibility of the film.
4.2. Characterization Methods for Film-Forming Polymeric Solutions
In a transdermal delivery system, drug solubility in the polymer matrix system is a critical factor
that may affect the rate and extent of drug permeation [31]. If a drug is not soluble in a polymer matrix,
it will become supersaturated and hence unstable. Moreover, when a drug is successfully incorporated
in a polymeric matrix, many studies have reported that the stability of the drug improves [32,33].
PLGA formulations are widely used in transdermal and dermal delivery and have a safety profile
showing a lack of skin irritation and uniform drug dosing [15,34].
The drug was successfully dissolved in the polymeric matrix, and the absence of crystallization,
which might hinder drug permeation into the skin, was verified. In patch development, to improve the
permeation and release profiles of drugs, the investigation of the supersaturated state is an important
step. A possible strategy to study the solubility of a drug is to disperse it uniformly into a polymeric
matrix to prevent drug crystallization [35]. Different techniques have been described to determine the
solubility of drugs in polymer matrixes [31,36,37]. Such solubility testing can be time consuming and
difficult. Among different techniques, Jain et al. have compared two different methods to predict drug
solubility in the polymeric matrix: differential scanning calorimetry and slide crystallization study [31].
In that study, the author found that the experimental solubility potential and the theoretical values
from a solubility calculator were similar. In addition, low drug solubility in the drug-polymer matrix
was shown to negatively affect drug release. The author concluded that simple slide crystallization
was able to predict the saturation solubility of a drug in the polymer. In the present study, after
complete evaporation of solvents from our drug-polymeric matrix, crystallization of the drug was
not observed under a light microscope, and we confirmed the drug solubility and stability in the
system. The complete TS solubility in the polymer matrix system after evaporation of acetone was
studied to ascertain that the stability and solubility of TS was not a factor affecting the rate and extent
of drug permeation.
The amount of residual solvent was also measured and calculated. Instant solvent evaporation
and complete dryness of the formulation was observed after 2 min. As a result, approximately 25% of
the residual solvent was left on the application site. Per the International Conference on Harmonisation
residual solvent guideline, solvents are classified in the three categories which set limits depending
on the toxicity data for each solvent. Acetone is categorized as a Class III solvent, which has a low
toxic potential and is safe to use in human [38]. Furthermore, Baino et al. reported that the drug
concentration increases upon evaporation of the solvent, which may result in a greater driving force
to deliver the drug into the system [39]. However, this variable was eliminated by keeping the solid
content of all the formulations constant. Thus, residual solvent was not a factor that led to differences
in the permeation profile of TS from the formulations tested.
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4.3. In Vitro Release Study for Different Types of PLGA
In this study, the release profiles of TS from different PLGA polymers were determined to study
the effects of the PLGA parameters on the drug release kinetics. In terms of developing a polymeric
system, knowing the release mechanisms and the physicochemical properties is important. The two
main release mechanisms related to drug release from a PLGA-based system are degradation and
diffusion. Often, the release rate is initially determined by diffusion followed by degradation controlled
at the final stage [40]. PLGA systems commonly release the drug in a bi-phasic or a tri-phasic pattern.
In this study, for higher molecular weight PLGA polymers, we observed a bi-phasic profile of drug
release, with a burst release followed by relatively slow diffusion. Lower molecular weight PLGA
groups showed a monophasic release profile, which is preferable for drug delivery systems because it
follows a zero-order release profile [41]. The formulation with higher molecular weight compounds
50-8A and 75-5A released almost 40% after 1 h, thus indicating dose dumping, whereas the release
profiles for 50-2A and 50-5A showed a gradual release until 72 h. In this study, the film was submerged
in the receptor solution, which was more hydrophilic than the polymeric solution. Because the drug
was hydrophilic, it may be preferentially located in the receptor solution over the PLGA system. Thus,
the higher molecular weight, and hence more lipophilic PLGA, resulted in a more rapid release of the
drug than was observed in the groups with lower molecular weight. Based on the result of the release
study, 50-2A was chosen for the final formulation to avoid dose dumping effect as well as provide a
gradual release of TS until 72 h.
4.4. In Vitro Permeation Study
In vitro permeation studies, using the vertical Franz diffusion cell model, have been commonly
used to evaluate drug delivery into and across the skin, and is well established as a reliable tool [42,43].
In addition, FDA recommends and endorses the use of an in vitro permeation test to evaluate topical
products. FDA guidelines have included the merits of this approach and have established a strong
correlation between the in vitro permeation test (IVPT) and in vivo bioavailability data with narrow
inter- and intra-variability between data [44–46].
4.4.1. Effects of Plasticizers
Plasticizers are important components of film forming systems because they improve the
appearance of the film, prevent film cracking, increase film flexibility, and confer desired mechanical
properties [47]. By selecting an appropriate plasticizer and optimizing its concentration in the
formulation, the release rate of a therapeutic compound can be controlled. To observe the effects of the
plasticizer, we kept the formulation ratio between the polymer and the adhesive at 4 to 1 (PLGA:CA),
and the same amounts of other components were included, i.e., solvents and drug concentrations.
The ratio of plasticizer was increased from 0 to 4 (0%, 5%, 8.75%, and 11.25% w/w). The polymeric
films without any plasticizer and 11.25% w/w plasticizer delivered a significantly lower amount of TS
after 72 h, than did those with 5 and 8.75% w/w PEG 400. The films with a plasticizer concentration of
8.75% w/w did not significantly improve the diffusion of the drug in the receptor (as compared with
the results with 5% w/w plasticizer concentration). However, the amount of PEG 400 showed a linear
relationship up to 8.75% w/w with regarding TS delivery into the skin. The formulation with 11.25%
w/w did not show a significant increase over 8.75% w/w regarding TS delivery into the skin. Hence,
5% w/w was considered the optimum concentration for the plasticizer. These results may have been
due to a polymer-plasticizer interaction that affected the release of the drug from the system. Barhate
et al. have studied the carvedilol permeation profile with and without PEG 400 as a plasticizer and
have found that the incorporation of PEG 400 increases the film flexibility and permeation rate [48].
The results suggested that too little or too much plasticizer in the polymeric solution can negatively
affect the permeation profile of TS. In formulating a polymeric solution, minor variations might be
acceptable; however, major changes in the composition should be carefully considered, because they
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might unfavorably affect the properties of the film forming system and consequently the mechanical or
cosmetic performance in drug delivery into the skin.
4.4.2. Effects of Different Types of PLGA
PLGA is one of the most commonly used biodegradable polymers in the field of biomedical
devices because of its favorable degradation characteristics and the possibility for sustained drug
delivery. It can be engineered to control drug release by changing the polymer molecular weight and
ratio of lactide to glycolide. Commercially available PLGA combinations are 50:50, 65:35, 75:25, and
85:15 (LA:GA) in different molecular weights [49]. These physical properties affect the solubility, glass
transition temperature, and inherent viscosity, thus resulting in tensile strength and polymer chain
flexibility. These parameters help delivery systems or medical devices achieve the desired dosage and
release interval. However, evaluation of the system is required to minimize the potential toxicity from
dose dumping, inconsistent release, and drug-polymer interactions [50]. In this study, four different
types of PLGA were chosen and incorporated in the polymeric solution. Three formulations were 50:50
(LA:GA) with different molecular weights. One of the formulations was 75:25 (LA:GA). There was no
significant difference among formulation groups with the same ratio of LA:GA, but the group with
a higher proportion of lactide delivered less TS after 72 h. Moreover, the amount of drug delivered
into the skin did not show significant differences across all four groups. PGA is a hydrophilic and
highly crystalline polymer with a relatively fast degradation rate. Although PGA and PLA are similar
structurally, they exhibit different physicochemical properties because of the presence of a methyl
group on the alpha carbon. Delayed release of the drug from the higher ratio of LA delivered fewer
drugs to the receptor at the end of the study. However, the same ratio with different molecular weights
did not show a difference in drug delivery to the receptor and skin. Farahani has investigated the
degradation mechanism of PLGA (50:50) and has reported that up to eight weeks are required for
complete degradation [51]. In this study, drug diffusion was found to be important factor affecting
in vitro release of the drug from the formulation; hence the rate of diffusion influenced drug delivery
into and across the skin. Three formulations with 50:50 (LA:GA, different molecular weights) did not
result in a difference in permeation profile of TS into and across skin; however, the formulation with
75:25 (LA:GA) delivered a significantly lower amount of TS due to its slower diffusion rate.
4.4.3. Effects of Different Amounts of PLGA
To test the effects of the amounts of PLGA in TS permeation profiles, we varied the amount of
PLGA without changing the ratio between CA and plasticizer. The amount of PLGA was increased
from 0% to 25% w/w. Formulations with 20% and 25% PLGA delivered significantly higher amounts
than the other groups. Formulations with lower amounts of PLGA required more CA. CA has been
used as a synthetic adhesive for tissue adhesive application since the 1980s. CA polymerizes rapidly in
the presence of weak basic conditions, such as in water. The interaction between skin and the polymer
results in the impressive adhesive strength of CA. Moreover, CA is superior to rival polymers in terms
of its strong wet adhesion, drug incorporation, and rapid curing [52–55]. The trend in permeation
profile was observed because the drug’s affinity toward CA was greater than that toward PLGA.
Although CA has good adhesion to skin, the rapid polymerization of CA is associated with heat
dissipation at the application site, and the brittleness can be problematic [56]. PLGA content was
increased while the amount of CA was reduced proportionally to maintain a similar solid content of all
formulation. The cumulative drug amount linearly increased with an increase in the amount of PLGA
in the formulation. In the optimized formulation, 20% w/w PLGA was added, resulting in the highest
delivery after 72 h without compromising its adhesive property. In this study, an in-situ film forming
system was developed by minimizing the CA component and maximizing the amount of PLGA in
solution, thus enhancing the delivery of TS into and across the skin.
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5. Conclusions
Film forming solutions were successfully formulated with polymers from different chemical
groups such as PLGA and polymerized CA. These formulations contained a combination of polymers,
a volatile solvent, and other optional excipients such as plasticizers, and fixed concentrations were
used for all excipients involved. The optimized formulation also enhanced the delivery of TS into and
across the skin.
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Abstract: Accumulation of photosensitisers in photodynamic therapy in healthy tissues is often the
cause of unwanted side effects. Using nanoparticles, improved bioavailability and site-specific drug
uptake can be achieved. In this study, curcumin, a natural product with anticancer properties, albeit
with poor aqueous solubility, was encapsulated in biodegradable polymeric poly(lactic-co-glycolic
acid) (PLGA) nanoparticles (CUR-NP). Dynamic light scattering, laser Doppler anemometry and
atomic force microscopy were used to characterise the formulations. Using haemolysis, serum stability
and activated partial thromboplastin time tests, the biocompatibility of CUR-NP was assessed. Particle
uptake and accumulation were determined by confocal laser scanning microscopy. Therapeutic
efficacy of the formulation was tested in SK-OV-3 human ovarian adenocarcinoma cells post low
level LED irradiation by determining the generation of reactive oxygen species and cytotoxicity.
Pharmacologic inhibitors of cellular uptake pathways were used to identify the particle uptake
mechanism. CUR-NP exhibited better physicochemical properties such as stability in the presence of
light and improved serum stability compared to free curcumin. In addition, the novel nanoformulation
facilitated the use of higher amounts of curcumin and showed strong apoptotic effects on tumour cells.
Keywords: PLGA; nanoscaled drug delivery; LED; cancer; serum stability; reactive oxygen species;
cellular uptake
1. Introduction
Light has long been used in the treatment of diseases as different as psoriasis, rickets or cancer [1].
With an alarming mortality rate, cancer is one of the most prevalent causes of death worldwide [2].
Hence, tremendous efforts have been made to develop novel safe, selective and effective cancer
therapies. One such treatment, photodynamic therapy, exemplifies a novel minimally invasive tumour
targeting therapy, in which tumour tissues can be selectively destroyed by three main mechanisms [3,4].
In the first case there is a combination of three individually inert entities viz. a photoactive drug
molecule (photosensitiser; PS), oxygen and a light source of a specific wavelength, which upon
combining, activate the photosensitiser and exhibit toxicity towards cancer cells and tissues [5,6].
This process of photosensitisation hugely relies upon the presence of molecular oxygen and forms
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the basis for a successful photodynamic therapy (PDT) [7]. After absorbing energy from the light
source, the PS interacts with molecular oxygen via energy transfer process or electron transfer process
and generates reactive oxygen species (ROS), which oxidise cellular and subcellular organelles to
induce either apoptosis or necrosis leading to cell death [8,9]. Since cytotoxic ROS occurs only after
irradiation of the PS, tumour tissues can be targeted with high precision. Due to its high reactivity and
short half-life, ROS generation only targets cells lying in close proximity of the site of irradiation [1].
The half-life of singlet oxygen in biological systems is ~0.01–0.04 μs, with a restricted site of action
of a radius spanning 0.01–0.02 μm [5,10]. PDT can also damage the tumour-associated vasculature,
leading to tumour infarction. Finally, PDT can activate the immune response against tumour cells. All
three mentioned mechanisms can also influence each other and act synergistically. PDT has an added
advantage of almost no or minimal effect towards healthy tissues, making this therapy site specific [11].
It could also be combined with other therapies or immune-stimulatory agents like microbial adjuvants
or cytokine for T-cell therapy and adoptive cellular therapy, respectively [1]. Another advantage of PDT
is its effectiveness against otherwise chemoresistant cell types [12]. Furthermore, the photosensitiser
can be administered by various means, such as systemically, locally or topically [1].
For the success of any PDT, it is important to choose an optimal PS. Despite many studies performed
using different PS, only a few have reached the stage of advanced human clinical trials or even U.S.
Food and Drug Administration (FDA) approval for clinical use [13]. A very promising photosensitiser
for photodynamic treatment of tumours is curcumin. Curcumin (diferuloylmethane), is a naturally
occurring yellowish polyphenol extract from the rhizomes of turmeric (Curcuma longa), which is
cultivated widely in south and southeast tropical Asia [14]. Curcumin is the most active component of
turmeric, making up approx. 0.5–3.14% of the dry weight of turmeric powder. Curcumin is used for a
variety of therapeutic activities against many different diseases and conditions such as skin diseases,
pulmonary and gastrointestinal systems, aches, pains, wounds, sprains, and liver disorders [15].
Offering a variety of potential applications, curcumin has been commonly used as a food-colouring
agent (E100) as well as in pharmaceutical research due to its anti-inflammatory, anti-oxidative,
anti-carcinogenic and anti-microbial effects [16,17]. It is a proven anticancer agent and therefore a
perfect choice for a photosensitiser [18]. However, curcumin exhibits a very low level of bioavailability,
since it is a highly lipophilic substance (solubility 11 ng/mL in phosphate buffer saline, PBS; pH 5) [19].
Systemically absorbed curcumin is prone to an extensive first-pass metabolism and undergoes a fast
metabolic reduction with biliary excretion [20]. In 1978, Wahlstrom and Blennow observed the uptake
of curcumin using Sprague–Dawley rats. After oral administration of 1 g/kg curcumin only negligible
amounts of curcumin could be found in blood plasma [21].
These limitations can be overcome by the use of polymeric nanoparticles such as carrier systems,
wherein the active substance is protected from degradation in the physiological environment and the
bio-membrane permeability and cellular uptake of highly hydrophobic molecules are facilitated [17].
Several studies have revealed a remarkable enhancement of curcumin’s phototoxicity through
nanoparticle encapsulation [22–26]. One such polymer is PLGA, which is an FDA and European
Medicines Agency (EMA) approved biocompatible and biodegradable polymer [27,28]. In the body,
PLGA undergoes hydrolysis wherein the endogenous metabolite monomers lactic acid and glycolic
acid are and easily metabolised by the body (to water and carbon dioxide) via Krebs cycle [27,29,30].
The degradation time of PLGA and the release of drug from the nanoparticles mainly depends on
the nature of copolymer composition [31]. In this study, PLGA 50:50 was chosen due to its ability to
hydrolyse much faster than other types of PLGA with a half-life (50% loss of molecular weight) of 15
days for microspheres [32,33].
Another important aspect in PDT is the choice of the irradiation device. There is an array of
radiation devices available for PDT such as lasers or lamps [13]. In the current study, with an aim to
make PDT more cost effective, efficient and safe, we have utilised a custom manufactured prototype
low level light emitting diode (LED) array for the irradiation of PS [34]. LEDs are energy efficient,
generate less thermal energy in the form of heat and are versatile in terms of structural form. They
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have the ability to emit light over a wide area with a relatively homogenous output, which enables
treatment of larger lesions in fewer therapy sessions. Using a combination of curcumin loaded PLGA
nanoparticles and LED-based PDT, superficial tumours (melanomas and lymphomas) and accessible
adenocarcinomas (such as ovarian and cervical) could be treated effectively. The PLGA nanoparticles
can be administered intratumourally or could be surface modified to enable systemic application.
In the present study, we have exploited the combination of biodegradable PLGA nanoparticles
and LED-based PDT using curcumin as a photosensitiser. The nanoparticles have been characterised
for their size and surface charge using Dynamic light scattering (DLS) and laser Doppler anemometry
(LDA), respectively. Structural morphology was analysed using atomic force microscopy (AFM) and
transmission electron microscopy (TEM). The photo-destructive effects have been evaluated in vitro by
cytotoxicity assays and confocal laser scanning microscopy (CLSM). The cellular uptake in SK-OV-3
cells was also analysed using three different uptake inhibitors. Irradiation experiments were carried
out in SK-OV-3 tumour cells and the oxidative stress induced during the irradiation was analysed
by determining the inhibition of ROS. Furthermore, haemolysis assays using fresh blood, serum
stability using serum and activated partial thromboplastin time tests (aPTT) using plasma were used
to demonstrate the biocompatibility of the curcumin-loaded polymeric nanoparticles.
2. Materials and Methods
2.1. Materials
Curcumin (95% purity) was obtained from Alfa Aesar (Ward Hill, MA, USA); PLGA
(Resomer RG 503 H) was supplied by Evonik (Essen, Germany); poly(vinyl alcohol) (PVA,
Mowiol 4-88) was purchased from Kuraray (Hattersheim, Germany); polysorbate 80 (Tween
80), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 2’,7’-dichlorofluorescin
diacetate (DCFDA) and tert-butyl hydroperoxide (TBHP) were obtained from Sigma-Aldrich Chemie
(Taufkirchen, Germany). Inhibitors of cellular uptake, viz. Filipin III, chlorpromazine and dynasore
were also obtained from Sigma Aldrich. Ultrapure water, generated by a PURELAB flex 4 device
(ELGA LabWater, High Wycombe, UK) was used for all experiments. For cell culture studies, ultrapure
water was additionally autoclaved and filter-sterilised using 0.2 μm polyethersulphone membrane
filters (Sarstedt, Nümbrecht, Germany) prior to use. HPLC-grade ethyl acetate (VWR, Darmstadt,
Germany) was used to prepare the organic phases. All other chemicals used were of analytical grade.
All buffers used in this study were prepared in the laboratory, unless stated otherwise.
2.2. Light Source
The LED device used in this study was custom made by Lumundus (Eisenach, Germany) to be
usable with microtiter plates. The device is equipped with an array of two different LEDs, capable of
emitting light at wavelengths of 457 nm and 620 nm, respectively. Irradiation time, current (i.e., 20, 40,
60, 80, and 100 mA) and wavelength settings are adjustable as per the energy requirement. Radiation
intensity was calculated based on the current and irradiation time.
2.3. Cell culture
The human ovarian adenocarcinoma cell line SK-OV-3 was procured from American Type Culture
Collection (ATCC, Manassas, VA, USA). SK-OV-3 cells were cultivated in Iscove’s modified Dulbecco’s
medium (Capricorn Scientific, Ebsdorfergrund, Germany) supplemented with 10% foetal bovine serum
(Sigma-Aldrich, Taufkirchen, Germany) at 37 ◦C and 7% CO2 in humidified atmosphere. The medium
was replaced every other day and the cells were sub-cultured upon reaching 80% confluency.
2.4. Formulation of Nanoparticles
Curcumin-loaded nanoparticles (CUR-NP) and unloaded PLGA nanoparticles (NP) were prepared
from PLGA by the emulsion–diffusion–evaporation technique as previously described by Kumar
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et al. [35]. In a pilot study, the method was optimised by varying formulation parameters (e.g.,
concentration of PLGA, PVA and curcumin; homogenisation speed and time). Briefly, 200 mg of PLGA
were dissolved in 5 mL ethyl acetate at room temperature. Curcumin stock solution was prepared by
dissolving curcumin in ethyl acetate (2 mg/mL). Equal volumes of PLGA and curcumin stock solutions
were mixed and filtered through a 0.45 μm nylon syringe filter (Pall Corporation, New York, NY, USA).
The organic solution was added dropwise to an aqueous solution of 2% PVA (w/w) and the resulting
emulsion was stirred in a sealed tube for about 3 h, before homogenising for 10 min at 13,400 rpm using
an Ultra-Turrax T25 homogeniser (IKA-Werke, Staufen, Germany). Nanoprecipitation was induced by
adding water at a constant rate of 120 mL/h using a syringe pump (Perfusor, B. Braun, Melsungen,
Germany). Finally, the organic solvent was evaporated by stirring overnight at room temperature in a
dark environment. The nanosuspension was adjusted to a final volume of 50 mL and a concentration
of 0.1 mg/mL curcumin. Unloaded nanoparticles were prepared by the same protocol, except that
pure ethyl acetate was used instead of the curcumin stock solution. To remove agglomerates, the
nanoformulations were centrifuged at 2000× g for 45 s using an Eppendorf Centrifuge 5418 (Eppendorf,
Hamburg, Germany). The resulting pellet was discarded, and the supernatant was washed three times
with water to separate the nanospheres from non-encapsulated curcumin. Between each washing
step, centrifugation at 16,000× g for 45 min was performed. For prolonged storage, the CUR-NP were
freeze-dried using an Alpha 1-4LSC lyophiliser (Martin Christ Gefriertrocknungsanlagen, Osterode am
Harz, Germany) using 0.5% PVA as a cryoprotectant. Afterwards the nanoformulations were stored at
4 ◦C protected from light.
2.5. Dynamic Light Scattering and Laser Doppler Anemometry
To determine particle size distribution and zeta (ζ)-potential of the particles, DLS and LDA were
used, respectively (Zetasizer Nano ZS, Malvern Instruments, Malvern, UK). A viscosity of 0.88 mPa ×
s and a refractive index of 1.33 of water at 25 ◦C were assumed for data interpretation. Measurement
position and laser attenuation were automatically adjusted by the instrument. The instrument performs
15 size runs per measurement with each lasting 10 s. For ζ-potential measurements, the instrument
automatically performs 15–100 runs per measurement, depending upon the sample. All samples were
diluted with filtered PBS buffer (1:100) [36]. Data from at least three independent experiments were
measured for both DLS and LDA analysis.
2.6. Morphological Characterisation
To investigate the morphology of CUR-NP and to confirm size data obtained by DLS measurements,
AFM was performed using a Nanowizard 3®(JPK Instruments, Berlin, Germany) and a Digital
Nanoscope IV Bioscope (Veeco Instruments, Santa Barbara, CA, USA), respectively. Formulations
were diluted 1:100 with water and 20 μL of the diluted sample were placed onto a silica wafer or an
untreated microscopic glass slide. The samples were left to settle onto the surface for a few minutes
and the remaining fluid was absorbed by a lint-free wipe (Kimtech Precision Wipes, Kimberly-Clark,
Fullerton, CA, USA). Measurements were performed in tapping mode, in which the cantilever
oscillated with determined amplitude close to its resonance frequency, with scan rates from 0.5 to 1 Hz.
A HQ:NSC16/AL_BS (Anfatec Instruments, Oelsnitz, Germany) cantilever was used [37]. Data were
processed using JPKSPM data processing software (v. 5.1.8, JPK instruments).
For the TEM analysis, the nanoparticle suspension was applied onto 300-mesh copper grids.
Samples were then negative stained thrice with 2% uranyl acetate (pH 4.2), which was alternated by
washing steps with water. The samples were then allowed to dry overnight before being examined
under the TEM (LEO 912 AB, Carl Zeiss, Jena, Germany) [22].
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2.7. Yield, Encapsulation Efficiency and Loading Capacity
The freeze-dried nanoparticles were weighted, and the percentage yield was calculated using the
following equation
%Yield =
Dry weight of nanoparticles
Weight of drug and polymer used for NP preparation
× 100 (1)
The encapsulation efficiency (%EE) was determined by extracting curcumin from nanospheres that
were previously washed and separated from free curcumin, as previously described in Section 2.4. The
nanosuspension was mixed with an equal volume of acetonitrile (a solvent for PLGA and curcumin)
and sonicated for 20 min. The absorbance of this solution was measured spectrophotometrically at
425 nm using a Multiskan GO micro plate reader (Thermo Fischer Scientific, Waltham, MA, USA), and
the amount of drug quantified using a calibration curve recorded with known curcumin concentrations.
For determination of the total drug content, nanoparticles without any washing procedure were





In addition, the loading capacity (LC) was calculated using the equation:
%LC =
Drugencapsulated
Dry weight of nanoparticles
× 100 (3)
2.8. In Vitro Drug Release
For determination of drug release, 10 mg lyophilised nanoparticles were redispersed in 30 mL
PBS buffer (pH 5.5 and pH 7.4) containing 1% polysorbate 80 (v/v) to assure sink conditions. This
dispersion was stored under absence of light in a shaking incubator (TH 15/KS 15, Edmund Bühler,
Bodelshausen, Germany) at 37 ◦C under slight agitation (50 rpm). For the following seven days, 500 μL
samples were drawn and replaced with fresh medium. The samples were centrifuged for 10 min at
16,000× g (Centrifuge 5418, Eppendorf AG) and the amount of curcumin present in the supernatant
was determined spectrophotometrically at 425 nm, using Multiskan GO micro plate reader (Thermo
Fischer Scientific).
2.9. Serum Stability
To study the stability of the formulations in physiologically relevant conditions, 2 mL serum
was diluted with 20 mM HEPES (pH 7.4) to make a 60% serum solution. Curcumin-loaded PLGA
nanoparticles were added in a ratio of 1:5 (v/v). The mixture was incubated at 37 ◦C in a shaking
incubator at 100 rpm for 24 h. Samples were further diluted to a ratio of 1:20 (v/v) with 20 mM HEPES
(pH 7.4) prior to DLS and LDA analyses at different time points. All measurements were carried out in
triplicates [38].
2.10. In Vitro Irradiation Experiments
Cells were seeded onto in 96-well plates (10,000 cells/0.35 cm2 (per well); Nunclon Delta, Thermo
Fisher Scientific, Waltham, MA, USA) and were allowed to adhere overnight. Various concentrations
of CUR-NP and free curcumin (dissolved in DMSO) were added to the wells and incubated for 4 h.
Irradiation was performed at a wavelength of 457 nm with a radiation fluence of 8.6 J/cm2 and the
plates were incubated overnight. Dark (un-irradiated) plates were used as control [39]. Subsequently,
the medium was replaced with fresh medium containing MTT dye and cells were incubated for 4 h.
Absorbance of the resulting formazan crystals dissolved in DMSO was measured using a plate reader
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(FLUOstar Optima; BMG Labtech, Offenburg, Germany) at 570 nm. Viability of untreated cells was
considered as 100%.
2.11. Cellular Uptake Studies
To determine the cellular uptake mechanism, SK-OV-3 cells were seeded at a density of
10,000 cells/0.35 cm2 (per well) in 96-well plates (Nunclon Delta, Nunc/Thermo Fischer Scientific,
Waltham, MA, USA) and incubated overnight. The next day, cells were washed with PBS containing
Ca2+ and Mg2+ (pH 7.4) and were incubated for 30 min with pharmacological inhibitors of different
endocytic mechanisms viz. dynasore (80 μM), chlorpromazine (14 μM) and Filipin III (8 mM) [40].
After incubation with the uptake inhibitors, cells were washed again with PBS and exposed to 50 μM
CUR-NP or free curcumin (dissolved in DMSO) for 4 h. After irradiation at 457 nm with a radiation
fluence of 8.6 J/cm2, cells were incubated with MTT and the absorbance from resulting formazan
crystals (dissolved in DMSO) was determined at 570 nm as described above.
2.12. Reactive Oxygen Species
ROS were determined using 2’,7’-dichlorofluorescin diacetate (DCFDA, Abcam, Cambridge, UK)
according to the supplier’s protocol with slight modifications [34]. Briefly, SK-OV-3 cells were seeded in
96-well plates as mentioned above. The next day, cells were incubated with CUR-NP for 4 h. Tert-butyl
hydroperoxide (TBHP, 50 μM) was used as positive control. Cells were subsequently washed using PBS
containing Ca2+ and Mg2+ (pH 7.4) and supplemented with fresh medium. Irradiation was carried out
at 457 nm with a radiation fluence of 8.6 J/cm2. The cells were washed again with PBS and incubated
with culture medium (IMDM without phenol red) containing 25 μM DCFDA for 1 h. Cell culture
lysis reagent (Promega, Mannheim, Germany) was used to lyse the cell and fluorescence was recorded
using a FLUOstar Optima plate reader (λex 480 nm/λem 520 nm).
2.13. Intracellular Visualisation of PDT
Cells were seeded onto 12-well plates (90,000 cells/3.5 cm2 (per well); Nunclon Delta) containing
cover slips (15 mm in diameter). The plates were incubated for 24 h, before being used for the
experiments. CUR-NP suspension was added dropwise to each well. After 4 h, the supernatant
was removed and cells were washed twice with PBS containing Ca2+ and Mg2+ (pH 7.4). Cell were
treated with a 4% formaldehyde solution for 20 min to fix them. The nucleus was counterstained with
0.1 μg/mL 4’,6-diamidino-2-phenylindole (DAPI) for 20 min. Finally, the cells were washed again with
PBS (pH 7.4) and the cover slips were mounted onto slides. Samples were examined under a LSM700
confocal laser-scanning microscope (Carl Zeiss Microscopy, Jena, Germany).
2.14. Activated Partial Thromboplastin Time Test
An aPTT test was performed as previously described, using a Coatron M1 coagulation analyser
(Teco, Neufahrn, Germany) to determine the effect of the formulations on blood coagulation [41].
Briefly, 25 μL of plasma was mixed with 25 μL each of sample and of aPTT reagent followed by
addition of an equal volume of pre-warmed 0.025 M calcium chloride solution to activate coagulation.
Coagulation was determined spectrophotometrically.
2.15. Haemolysis Assay
To determine the effect of the formulations on blood, human erythrocytes were isolated from fresh
blood as described previously [42]. Briefly, following prior consent from the donor, whole blood was
collected into EDTA tubes as centrifuged to separate the red blood cell (RBC) pellet. The RBC pellet
was washed thrice with PBS buffer (pH 7.4) and diluted to a ratio of 1:50 with PBS. The erythrocytes
were incubated together with the formulations in V-bottom microtiter plates placed in an orbital
shaker KS4000 IC (IKA Werke) for 1 h at 37 ◦C. Supernatants were collected from the plates following
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centrifugation and the absorbance was determined at 540 nm using a plate reader (FLUOstar Optima).
PBS (pH 7.4) and 1% Triton X-100 were used as controls.
2.16. Statistical Analysis
All experiments were performed in triplicates and data are presented as mean ± standard




Preliminary experiments were performed to determine an ideal stabiliser concentration,
homogenisation speed and curcumin content. In emulsion–diffusion–evaporation technique, PVA acts
as a stabiliser of the nanodroplets and is one of the widely used emulsifier for polymeric nanoparticle
preparations. Both, particle size and size distribution are affected by the concentration of PVA in the
aqueous phase during particle preparation [35]. After testing different PVA concentrations, we narrowed
down to 2% PVA considering the physicochemical properties of the resultant nanoformulations. The
Z-average data from DLS as well as LDA results are summarised in Table 1. CUR-NP and NP showed
a narrow size distribution indicating a high reproducibility. No extensive change in particle size was
noticeable after curcumin loading. This was also the case for lyophilised samples, thereby showing
that lyophilisation has no deleterious effects on the physicochemical characteristics. Furthermore, LDA
revealed a slightly negative ζ-potential at pH 7.4, regardless of curcumin loading for both formulations.
Table 1. Hydrodynamic diameter, polydispersity index (PDI) and ζ-potential of curcumin-loaded
poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CUR-NP) and unloaded PLGA nanoparticles (NP).
Lyophilised samples represent samples resuspended after lyophilisation. Hydrodynamic diameters
are expressed as a measure of particle size distribution by intensity. All samples were measured in
triplicates (n = 9, independent formulations) and results are expressed as means ± SD.
Sample Diameter [nm] PDI ζ-potential [mV]
NP 194.7 ± 8.7 0.09 ± 0.05 −5.33 ± 0.88
CUR-NP 203.6 ± 7.8 0.08 ± 0.04 −5.24 ± 0.86
Lyophilised NP 195.0 ± 6.9 0.09 ± 0.05 −5.09 ± 0.73
Lyophilised CUR-NP 201.8 ± 6.0 0.09 ± 0.03 −5.43 ± 0.67
PLGA in an aqueous environment undergoes hydrolysis spanning over several weeks, depending
on the ratio of lactic acid to glycolic acid. The PLGA 50:50 used in this study therefore exhibits the
fastest degradation [43]. To increase the storage stability the nanoparticles were lyophilised, using
PVA as cryoprotectant. Freeze-dried and resuspended nanoparticles showed no extensive change in
particle size (CUR-NP +0.3 nm, NP −1.8 nm) or polydispersity index (data not shown).
For the determination of encapsulation efficiency, a direct method of dissolving the purified
particles and measuring the actual amount of curcumin available in the nanoparticle formulation was
used. Since curcumin is near to insoluble in water, un-encapsulated free curcumin should exist in
crystalline form. In this case the crystals would sediment during ultracentrifugation and be present in
the pellet. Hence discarding the supernatant would not lead to sufficient separation of nanoparticles
from crystalline curcumin. Therefore (in contrast to NP), a first separation step of centrifugation with a
relatively low force of 2000× g is necessary to sediment the larger crystals. The optimised formulation
of CUR-NP showed a relatively high encapsulation efficiency (EE) with an actual loading capacity
of 2% (Table 2). The good EE results can be explained by the fact that PLGA and curcumin are both
soluble in ethyl acetate, which was employed for the nanoparticle preparation process. Moreover,
PLGA’s ability to effectively encapsulate curcumin has been demonstrated in previous studies [44–46].
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Table 2. Theoretical load, percentage of yield, encapsulation efficiency and loading capacity of
curcumin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CUR-NP) and unloaded PLGA
nanoparticles (NP). All samples were measured in triplicates (n = 9, independent formulations) and
results are expressed as means ± SD.
Sample Theoretical Load [%] a %Yield %EE %LC
NP - 80.5 ± 2.3 - -
CUR-NP 2.5 87.5 ± 0.7 80.4 ± 10.6 2.0 ± 0.3
a % w/w loading of curcumin to polymer; EE, encapsulation efficiency; LC, loading capacity.
3.2. Morphological Characterisation
In all images (Figure 1), round-shaped CUR-NP with a monomodal size distribution are clearly
visible. Due to dilution of pure nanoparticle samples, even single CUR-NPs with a smooth surface
indicating that the curcumin is completely incorporated could be visualised. The AFM size analysis
was in agreement with the DLS measurements. It should however be noted that the differences in size
arising from the DLS and AFM measurements is because the hydrodynamic diameter is obtained in
aqueous conditions whereas the latter is measured under atmospheric conditions [47]. Furthermore,
a PVA corona was noticeable in TEM micrographs (Figure 1C). While free PVA was removed through
centrifugation and washing of the redispersed nanoparticles prior to each experiment, it is a known
fact, that small quantities of PVA still remain on the surface of PLGA nanoparticles, which cannot be
removed even by extensive washing. This strong adsorption of PVA may be caused by hydrophobic
bonding of PVA’s hydroxyl groups to the acetyl groups of PLGA [48].
 
Figure 1. Morphology of representative curcumin-loaded poly(lactic-co-glycolic acid) (PLGA)
nanoparticles (CUR-NP) shown by atomic force microscopy (AFM) (A,B) and transmission electron
microscopy (TEM) (C). (A) Freshly prepared nanoparticles, (B,C) nanoparticles post lyophilisation. All
AFM micrographs are presented in height mode. Samples were negatively stained with 2% uranyl
acetate prior to TEM measurement. Scale bars in TEM micrographs represent 200 nm.
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3.3. In Vitro Drug Release
Different mechanisms were reported for the drug release from PLGA nanoparticles: (i) desorption
of drug absorbed on the particles surface, (ii) diffusion through the polymer matrix, (iii) erosion of the
polymer matrix, and (iv) a combination of erosion and diffusion processes [29,49].
The cumulative drug release of curcumin from CUR-NP at pH 5.5 and 7.4 is shown in Figure 2.
Due to curcumin’s low water solubility (~0.01 μg/mL at pH 5 and ~0.4 μg/mL at pH 7.3) and low
stability at neutral to basic pH, the addition of a solubility-enhancing component was necessary to
assure sink conditions and to achieve UV/VIS detectable concentrations [50]. We chose polysorbate 80
for this purpose, since it is reported, that it is capable of increasing the solubility of hydrophobic drugs
and protecting them against degradation through the formation of micelles [51].
 
Figure 2. Cumulative in vitro drug release of curcumin from CUR-NP in phosphate buffer (pH 5.5 and
7.4) containing 1% polysorbate 80 to assure sink conditions. The inset represents the first 12 h of the
release study in a different scale (hours instead of days).
CUR-NP showed a typical biphasic release pattern of PLGA nanoparticles with a burst release of
around 20% loading within the initial 4 h, followed by controlled release of 90% drug loading over
the following 7 days. Burst release is most likely attributed to the drug absorbed to the particle’s
surface, while controlled release might be induced through a combination of erosion and diffusion
processes [52,53]. Furthermore, drug release was much faster in acidic medium compared to pH 7.4
which could be caused by a faster degradation rate of PLGA under acidic conditions [33].
Tumour cells often exhibit an extracellular pH of around 6.5, which would lead to a faster release
of curcumin in this acidic environment and therefore an increased cytotoxicity compared to healthy
tissue [54,55]. Since the pH of endosomes is even lower (pH ~5.5), drug release of internalised
nanoparticles would proceed even faster, leading to higher intracellular curcumin concentration and
enhanced tumour damage [56]. Both mechanisms could be used for passive tumour-targeting strategy.
3.4. Serum Stability
Serum stability assay was performed to evaluate the susceptibility of the formulations. For this
purpose, DLS and LDA analyses were performed after incubating the nanoparticles in serum. The
experiments were carried at 37 ◦C in a shaking incubator to simulate physiological conditions. The
results show shrinkage in the nanoparticle size after 24 h incubation time in serum (Table 3). This could
be related to a release of curcumin bound to the particle surface, which leads to particle erosion [57].
Furthermore, the decrease in particle size could be caused by osmotic forces, as reported previously [58].
109
Pharmaceutics 2019, 11, 282
The increase in the PDI of the nanoparticles could be attributed to the decrease in homogeneity in the
presence of serum. After an initial increase (as compared to DLS measurements from native particles),
the ζ-potential decreased to more negative values. The initial increase could be due to the accumulation
of plasma proteins on the surface of the NP and the subsequent decrease could be attributed to the
drug release (curcumin) onto the surface of the NP [59].
Table 3. Physicochemical changes of poly(lactic-co-glycolic acid) (PLGA) nanoparticles containing 0.1
mg/mL curcumin. Particles were incubated for 24 h in serum at a volume ratio of 5:1. The hydrodynamic
diameter is expressed as a measure of particle size distribution by intensity. All samples were measured
in triplicates (n = 9, independent formulations) and data are expressed as means ± SD.
Time [h] Diameter [nm] PDI ζ-potential [mV]
0 183.50 ± 2.11 0.19 ± 0.01 2.19 ± 0.49
1 180.80 ± 3.70 0.19 ± 0.01 −8.30 ± 0.21
4 180.45 ± 3.32 0.22 ± 0.01 −12.65 ± 0.35
24 173.57 ± 2.21 0.22 ± 0.01 −13.30 ± 0.10
3.5. Irradiation Experiments
For the photo destructive effect of PDT, SK-OV-3 ovarian carcinoma cells were incubated with
different concentrations of CUR-NP und free curcumin for 4 h and were irradiated with different
radiation fluence. The efficacy of the irradiation was determined by MTT assay. As shown in Figure 3A,
after treatment of cells, curcumin-loaded biodegradable nanoparticles and free curcumin dissolved
in DMSO show a high photocytotoxic effect. There is a remarkable difference between the dark
(non-irradiated) and irradiated plates. An incubation time of 4 h was found to be ideal among all the
formulations, since burst release of around 20% curcumin loading from CUR-NP was found within 4 h
of drug release studies (Figure 2). In the initial studies, a radiation fluence of 1.4, 4.3, 8.6 and 13.2 J/cm2
were tested using CUR-NP and for the subsequent studies, the fluence was narrowed down to 8.6
J/cm2 for the LED induced PDT (data not shown). Beyond a curcumin concentration of 50 μM, there
was no further difference in the effect of PDT. It can also be seen that free curcumin dissolved in DMSO,
induced a higher photocytotoxicity effect, which could be attributed to controlled release properties
of PLGA nanoparticles, as this might be a rate limiting step for the drug being available for light
activation. Nevertheless, since DMSO-dissolved curcumin is not suitable for therapeutic applications
and due to its hydrophobic nature, we have used a biodegradable polymeric PLGA nanoformulation
to increase the bioavailability of curcumin and to make it suitable for therapeutic applications [60].
The internalisation and subsequent localisation of the photosensitiser within the tumour determine the
outcome of the therapy.
3.6. Subcellular Localisation of Curcumin
To visualise the effect of PDT on tumour cells, qualitative fluorescence microscopic analysis was
performed after irradiation (457 nm; 8.6 J/cm2) of the cells with 50 μM CUR-NP and free curcumin
dissolved in DMSO. The cells were fixed with 4% formaldehyde solution and the cell nucleus was
counterstained with 300 nM DAPI. Substantial intracellular localisation of curcumin near the cell’s
nucleus could be seen in both dark and irradiated samples, as shown in Figure 3B. Upon irradiation,
photo-destruction induced by PDT could be clearly observed in the micrographs, which is evident from
the nuclear perforation. This might be due to the chromatin condensation and DNA fragmentation
caused by the curcumin induced PDT [8]. Comparing free curcumin dissolved in DMSO with
curcumin-loaded nanoparticles reveals that CUR-NPs indeed damage the nucleus while only free
curcumin alone is not as damaging although the micrographs show a cellular uptake of curcumin by
both the samples. This confirms the hypothesis that curcumin particles are internalised by uptake
mechanisms such as endocytosis and free curcumin penetrates the cells by diffusion and loses its effect
(Section 3.6). It could also be seen that upon irradiation, the fluorescence of free curcumin increased
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and was more distributed than the CUR-NP. Furthermore, the irradiated blank/untreated cells show
no photo-destruction.
 
Figure 3. Phototoxic effect of curcumin-loaded poly(lactic-co-glycolic acid) PLGA nanoparticles
(CUR-NP) and free curcumin dissolved in DMSO (CUR) on SK-OV-3 ovarian carcinoma cells: (A) for
the MTT-assay, either the nanoformulation or free curcumin was incubated for 4 h at 37 ◦C and were
irradiated at 457 nm with a radiation fluence of 8.6 J/cm2. Dark was used as negative control and
represents cells without irradiation. All samples contain 0.1 mg/mL curcumin and were measured
in triplicates (n = 9, independent formulations). Results are expressed as means ± SD. (B) CLSM
micrographs of SK-OV-3 cells incubated with CUR-NP or free curcumin for 4 h at 37 ◦C and subsequent
irradiation (457 nm, 8.6 J/cm2). The cell nucleus was counterstained with 0.1 μg/mL DAPI and was
fixed with 4% formaldehyde solution. The curcumin concentration in CUR-NP was 50 μM. Nuclear
damage is clearly witnessed in the irradiated samples whereas in the dark, the nucleus is intact. Dark
was used as negative control and represents cells without irradiation. Scale bars denote 20 μm.
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3.7. Cellular Uptake
Different cells use different endocytic pathways for the internalisation of nanoparticles. To study
cellular uptake, several different inhibitors of endocytic pathways were utilised. For this purpose,
the dynamin-, clathrin- and clathrin-independent endocytosis pathways were considered. Dynasore,
a GTPase inhibitor rapidly and reversibly inhibits dynamin activity, which is essential for membrane
fission during clathrin-mediated endocytosis (CME). Chlorpromazine also causes a block in CME
by inducing the assembly of adaptor proteins and clathrin, leading to the formation of endosomes
which then fuse with lysosomes [61]. Chlorpromazine also interferes with the intracellular clathrin
processing [62]. Filipin III derived from Streptomyces filipensis is a polyene macrolide antibiotic, which
inhibits the raft/caveolae endocytosis pathway. It interacts with cholesterol whose presence and state
influence endocytic functions [63]. Figure 4 shows a substantial inhibition of CUR-NP by Filipin III and
chlorpromazine. The uptake mechanism is dependent on the cell line and hence the data should be
regarded cautiously. In our case, chlorpromazine exhibited an 80–90% inhibition of clathrin-dependent
endocytosis of CUR-NP and Filipin III a marked 100% inhibition of caveolae-mediated and lipid-raft
mediated endocytosis but both could not inhibit free curcumin. Free curcumin dissolved in DMSO does
not seem to be internalised by any of these endocytic pathways suggesting a different internalisation
mechanism such as diffusion [64]. The inhibition by dynamin dependant endocytosis by Dynasore
showed no effect on the CUR-NP.
 
Figure 4. Cellular uptake of curcumin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(CUR-NP) and free curcumin (dissolved in DMSO) in SK-OV-3 cells in presence of three specific
inhibitors. After 30 min incubation time with different inhibitors (i.e., 8 μM Filipin III, 80 μM Dynasore
and 14 μM chlorpromazine), cells were incubated with 50 μM of either CUR-NP or free curcumin
dissolved in DMSO for 4 h at 37 ◦C and were irradiated at 457 nm with a radiation fluence of 8.6 J/cm2
(IR). The MTT assay was performed at the end of the experiment to determine the effect of the pathway
inhibits on internalisation. Viability of untreated cells was considered as 100%. Dark was used as
negative control and represents unirradiated samples. Blank represents cells without any inhibitor. All
samples were measured in triplicates (n = 9, independent formulations) and results are expressed as
means ± SD.
3.8. Reactive Oxygen Species
ROS generation is the backbone of PDT and is a determining factor in the efficacy of the therapy.
As shown in Figure 5, curcumin induced the production of cytotoxic reactive oxygen species after
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cells were irradiated (50 μM curcumin; 8.6 J/cm2 radiation fluence). ROS was determined by the
measurement of the fluorescence from the lysed cells. Upon incubation with cells, a deacetylated form
of DCFDA is oxidised by the resulting ROS to form fluorescent DCF [65]. As expected, curcumin-loaded
biodegradable PLGA polymeric nanoparticles exhibited the highest ROS generation followed by free
curcumin dissolved in DMSO thereby corresponding to the results of the PDT. The fact that CUR-NP
caused the maximum damage to the tumour cells can be explained by the ROS generation, which in
this case was intracellular and could be only detected from the cells, which have internalised. Since
free curcumin was not internalised by the endocytic pathways, mentioned in Figure 4, the uptake from
CUR-NP seems to be higher. As expected, blank (negative control) did not show any ROS generation.
 
Figure 5. Production of cellular reactive oxygen species (ROS) in response to curcumin-loaded
poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CUR-NP) or free curcumin (0.1 mg/mL). ROS was
measured in SK-OV-3 cells after exposure (for 45 min) to 2’,7’-dichlorofluorescin diacetate (25 μM)
and incubation with CUR-NP or free curcumin for 4 h at 37 ◦C with subsequent irradiation (457 nm,
8.6 J/cm2). Tert-butyl hydroperoxide (TBHP) was used as positive control and non-irradiated cells
served as negative control (Dark), whereas Blank represents untreated cells. Values are represented
in relative fluorescence units (RFU). All samples were measured in triplicates (n = 9, independent
formulations) and results are expressed as means ± SD.
3.9. Haemocompatibility
To study the effect of the nanoformulation on human erythrocytes, haemolysis assay, which
determines the amount of haemoglobin released from the erythrocytes upon exposure to NPs (Figure 6A)
was performed. To determine the change in coagulation time upon addition of NPs, aPTT was
determined (Figure 6B). Upon its release from erythrocytes, haemoglobin reacts with the atmospheric
oxygen to form oxyhaemoglobin [66]. The CUR-NP used in the study showed a minimal haemolytic
potential. An increase in the aPTT time was also found to be minimal in the case of CUR-NP. The
aPTT analysis revealed that the encapsulated curcumin increased the coagulation time by only 4.01 s,
whereas upon addition of free curcumin alone, the coagulation time increased to 120.13 s suggesting an
interaction of curcumin with the intrinsic proteins or coagulation factors. The normal coagulation time
for the plasma was tested to be 32.2 ± 0.1 s and was found to be in the normal range [67]. Coagulation
time between 30 and 40 s is considered within acceptable range and coagulation time above 70 s denotes
spontaneous and continuous bleeding leaving the patients with the risk of haemorrhage [67–69].
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Figure 6. Blood compatibility of curcumin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles
(CUR-NP), unloaded PLGA nanoparticles (NP) or free curcumin: (A) haemolysis assay and (B) aPTT
test were performed. Where applicable, curcumin was used at a concentration of 0.1 mg/mL. Blank
represents erythrocytes in the haemolysis assay and blood plasma in the aPTT test, respectively. Triton
X-100 was used as positive control in (A) and is considered as 100% haemolysis. All samples were
measured in triplicates (n = 9, independent formulations) and results are expressed as means ± SD.
Dotted lines indicate the tolerance/threshold limits.
4. Conclusions
In this study, curcumin-loaded biodegradable PLGA nanoparticles (CUR-NP) were formulated
for photodynamic therapy using a custom manufactured prototype low power LED device.
CUR-NP exhibited better physicochemical properties compared to free curcumin, such as improved
serum stability. Furthermore, haemocompatibility of curcumin was improved through polymeric
encapsulation, minimising the risk of haemorrhages in patients. Successful cellular uptake of CUR-NP
was demonstrated with the aid of confocal laser scanning microscopy, which showed photo-destruction
and nuclear perforation. Nanoformulation facilitated the use of higher amounts of curcumin, which
would otherwise be impossible due to its poor solubility and stability in aqueous media. Curcumin,
which elsewise is safe for normal cells, showed cytotoxic effects on tumour cells upon irradiation at a
low intensity therefore selectively inhibiting tumour growth. Since production of ROS occurs only
upon irradiation of the intracellular photosensitiser, tumour tissues can be targeted with precision.
Using LED as an irradiation source offers a number of advantages such as portability, durability and
economical compared to lasers. Moreover, LED’s have the ability to irradiate a relatively larger area,
which could be beneficial for the treatment of large tumours or even skin cancer. The use of visible
light of low-energy makes this therapy safer for both the patient and the operator. Finally, the good
biocompatibility of this well-documented and highly reproducible formulation process of polymeric
nanoparticles are significant advantages of this anti-tumour therapy. Transforming this novel strategy
into a safe and effective therapy by combining PDT with other therapies would be our prime research
interest in the future.
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Abstract: Poly(d,l-lactic-co-glycolic) (PLGA) nanoparticles (NPs) have been widely studied for several
applications due to their advantageous properties, such as biocompatibility and biodegradability.
Therefore, these nanocarriers could be a suitable approach for glioblastoma multiforme (GBM) therapy.
The treatment of this type of tumours remains a challenge due to intrinsic resistance mechanisms.
Thus, new approaches must be envisaged to target GBM tumour cells potentially providing an
efficient treatment. Co-delivery of temozolomide (TMZ) and O6-benzylguanine (O6BG), an inhibitor
of DNA repair, could provide good therapeutic outcomes. In this work, a fractional factorial design
(FFD) was employed to produce an optimal PLGA-based nanoformulation for the co-loading of
both molecules, using a reduced number of observations. The developed NPs exhibited optimal
physicochemical properties for brain delivery (dimensions below 200 nm and negative zeta potential),
high encapsulation efficiencies (EE) for both drugs, and showed a sustained drug release for several
days. Therefore, the use of an FFD allowed for the development of a nanoformulation with optimal
properties for the co-delivery of TMZ and O6BG to the brain.
Keywords: drug delivery; experimental design; fractional factorial design; O6-methylguanine DNA
methyltransferase (MGMT) protein; glioblastoma multiforme
1. Introduction
Nanomedicine has been arousing increasing interest, since it allows the early diagnosis and
monitoring of several diseases and also can increase the efficacy of conventional pharmacological
treatments by enabling their controlled delivery [1–4]. Several materials have been widely studied for
nanoparticles (NPs) development. Among polymeric materials, poly(d,l-lactic-co-glycolic) (PLGA) is
perhaps the most used, due to being FDA-approved, biocompatible, biodegradable, and having tunable
physicochemical properties [5]. Since these polymeric NPs allow the release of drugs in a controlled
and sustained manner for long periods, the required drug doses and administration frequency can be
minimized, decreasing the toxicity of the encapsulated drug [6]. Additionally, PLGA NPs are up-taken
by endocytic mechanism, circumventing the p-glycoprotein-mediated cellular efflux, enabling drug
accumulation in the target cells. Also, since this polymer can be easily functionalized with different
materials, the design of NPs with diverse targeting moieties can be achieved [7].
Therefore, several efforts have been conducted in seeking the development of PLGA NPs for
novel therapies with several therapeutic drugs without reducing their bioavailability or activity.
The entrapment of therapeutic drugs in PLGA NPs also allow a reduction in their toxicity, and therefore
these NPs have been extensively studied for cancer treatment. Most particularly, several attempts to
encapsulate temozolomide (TMZ) in PLGA NPs for brain delivery have been conducted [8]. TMZ,
the gold standard treatment for glioblastoma multiforme (GBM), presents several limitations, as it
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has low bioavailability and high toxicity, reducing its pharmacological activity [9]. Therefore, TMZ
encapsulation in a nanocarrier emerges as a suitable approach to increase its chemotherapeutic efficacy,
since it will avoid drug elimination after administration and increase its accumulation in the target
tissues. GBM is the brain cancer with a high mortality rate, since its classical therapy fails to effectively
cure the disease [10]. Thus, it is urgent to find new approaches for its treatment.
In fact, different PLGA delivery nanosystems were developed for TMZ in the last decade. Jain et
al., 2014 developed PLGA NPs for TMZ entrapment. Although exhibiting promising results, modifying
the NPs’ surface with a targeting moiety to improve the specificity of the nanocarriers could be a
suitable strategy to enhance its efficiency [11]. Later, Ananta et al., 2016 prepared PLGA NPs that
were not able to maintain a favorable sustained release of TMZ [12]. Also, some authors used active
targeting strategies to increase the NPs specificity to GBM cells. In fact, Jain et al., 2011 modified
the surface of PLGA NPs with transferrin molecules to promote transport across the blood–brain
barrier (BBB). The developed nanocarriers enhanced the accumulation and cytotoxic effect of TMZ in
mice’s brains [13]. Lee et al., 2016 also functionalized PLGA NPs with folate molecules to increase the
NPs accumulation in target cells, but the prepared nanosystems did not exhibit good encapsulation
efficiency (EE) values [14]. Our group (2018) also developed anti-transferrin receptor monoclonal
antibody modified PLGA NPs for the delivery of TMZ. The obtained results showed that PLGA NPs
are a promising approach for GBM treatment with TMZ [15].
However, GBM patients usually exhibit low sensitivity to therapy due to intrinsic resistance
mechanisms. The O6-methylguanine DNA methyltransferase (MGMT) protein is highlighted as one of
the main causes of therapeutic failure of TMZ [16]. Therefore, new strategies to decrease resistance to
therapy are necessary. A promising approach is the use of molecules that are able to revert or inhibit
these intrinsic resistance mechanisms. Most recently, co-treatment with O6-benzylguanine (O6BG) has
been explored to decrease the resistance to TMZ’s therapy by binding to the MGMT protein, leading to
its inhibition, and consequently hindering the repair of the damaged DNA [17,18]. Nanoencapsulation
of O6BG may reduce its toxicity in healthy tissues by targeted delivery. Accumulation of O6BG
in healthy tissues is undesirable to avoid inactivation of the MGMT protein in these tissues, and
consequently exacerbates the toxicity of alkylating agents, such as TMZ [19].
Also, systemic administration of two free drugs usually leads to infective pharmacological activity
and, consequently, treatment failure, due to differences in the biodistribution profile of each drug [20].
Therefore, the entrapment of both drugs in NPs should address this problem. In fact, to increase
therapeutic efficiency, the co-loading of TMZ with other molecules in PLGA NPs has also already been
studied for glioblastoma therapy. Xu et al., 2016 proposed the co-delivery of TMZ with paclitaxel using
PLGA NPs [21]. Until this moment, to the best of our knowledge, the co-encapsulation of TMZ and
O6BG in a nanosystem was not reported. Thus, the aim of this work was to prepare a nanocarrier for
the co-loading of both drugs.
However, the use of PLGA NPs faces a few limitations because of their poor loading capacity and
the typical initial burst release. Additionally, the production of PLGA NPs requires different stages
that can present high costs and be difficult to scale-up, such as centrifugation and dialysis. Also, it can
be challenging to entrap hydrophilic drugs, since those exhibit a high partition into the aqueous phase
during NPs preparation [6]. Therefore, is necessary to optimize the preparation methods. As well,
usually the entrapment of two distinct molecules, with different physicochemical properties such as
hydrophilicity and molecular weight, can be a challenging task. Though, high encapsulation of both
drugs is desirable to increase the nanosystem efficiency and to reduce the amount of administered
polymer. Also, it is essential to control the physicochemical properties of the developed NPs, such
as size and surface charge, since these parameters control their biological fate, biodistribution, and
toxicity, therefore affecting their therapeutic potential [22,23].
Therefore, experimental design could be a suitable approach to optimize the nanoformulation.
In fact, in the last years, experimental design has been used for the optimization of drug-loaded
NPs [24,25]. This is because a nanoformulation design requires full knowledge of the correlation between
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the experimental factors and the obtained NPs properties. To obtain an optimized nanoformulation
using a conventional screening method (evaluating the effect of one experimental variable at a time) is
expensive and time-consuming. Experimental design is therefore a validated and useful tool for the
development and optimization of experimental procedures with a lower number of observations while
still providing the desired information on the correlation between the experimental and the response
variables. The obtained model can then be used for predicting future observations within the original
design range [26]. Different types of experimental designs can be used, and in this work, a fractional
factorial design (FFD) is proposed. When several experimental variables are being studied, FFD is a
rapid and reliable tool, allowing the exploration of a maximum number of variables, while requiring
less experimental observations, and still obtaining the desired information. However, since it uses only
a partial combination of factors, some information about possible interactions can be lost [27].
Thus, the effect of five experimental variables on the physicochemical properties of the developed
PLGA NPs and encapsulation efficiency (EE) of both drugs was studied in this work. The studied
experimental factors were the amounts of TMZ, O6BG, surfactant, organic solvent, and polymer.
2. Materials and Methods
2.1. Materials
TMZ (MW 194.15, purity ≥99%) was purchased from Selleck Chemicals (Munich, Germany).
O6BG (MW 241.25, purity ≥98%) was obtained from Abcam (Cambridge, UK). PLGA Resomer®
RG503H (50:50; MW 24,000–38,000), poly(vinyl alcohol) (PVA) Mowiol® 4-88 (MW 31,000), phosphate
buffer saline (PBS) and dichloromethane were acquired from Sigma–Aldrich (St. Louis, MO, USA).
Uranyl acetate was provided by electron microscopy sciences (Hatfield, UK).
2.2. Preparation of TMZ+O6BG-Loaded PLGA NPs
For the synthesis of PLGA NPs loading, both TMZ and O6BG, a variation of the single
emulsion–solvent evaporation method, were used [28]. Known amounts of PLGA, TMZ, and O6BG
were dissolved in a dichloromethane solution. A 2% (w/v) PVA solution was added drop-by-drop to
the prepared organic solution. Then, the solution was vortexed (Genius 3, ika®vortex, Germany) and
placed in an ultrasonic bath at an ultrasonic frequency of 45 kHz (Ultrasonic cleaner, VWRTM, Kuala
Lumpur, Malaysia) to yield an oil-in-water (o-in-w) emulsion.
The emulsion was then poured into a 0.2% (w/v) PVA solution and maintained in unremitting
agitation in a magnetic stirrer (800 rpm, Colorsquid, ika®, Staufen, Germany) until complete organic
solvent evaporation (6 h). The suspension was then filtered using a membrane with a pore size
of 200 nm, (polyethersulfone membrane syringe filter, VWR, Radnor, PA, USA) and stored at 4 ◦C
overnight to increase the NPs’ stability, avoiding their aggregation. After, the samples were centrifuged
for 30 min at 14100× g (MiniSpin®plus, Eppendorf, Hamburg, Germany), to separate NPs from the
non-encapsulated drug. The supernatant containing the non-encapsulated drug was saved for analysis.
2.3. Experimental Design and Data Analysis
High and comparable EE values for each drug are a prerequisite for the co-loading in the same
NPs. In preliminary studies, it was verified that the co-encapsulation of TMZ and O6BG reduced
the encapsulation of each drug alone. Thus, it was necessary to optimize the entrapment of both
drugs. Also, it was important to control the physicochemical properties of the developed NPs, since
these parameters influence the therapeutic efficacy and toxicity of the NPs. To obtain an optimized
formulation, it is useful to study how the several experimental parameters influence the entire
production process.
Therefore, a 25-2 FFD was implemented using the Minitab Statistical Software (Minitab Inc., State
college, PA, USA) to determine the effect of different experimental factors on the PLGA NPs features.
The studied independent variables were the amount of both used drugs, the quantity of surfactant and
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organic solvent, and the amount of polymer. A variation of a full factorial design, in which only a
subset of the total runs was performed, took place. The chosen factors of interest were varied on two
levels (determined in preliminary studies) according to the experimental plan presented in Table 1. Two
replicates were conducted for each combination and for center levels, and the order of the experiments
was randomly sorted to avoid any bias.
Table 1. Process and formulation parameters of the used FFD.
Parameter Component Units Applied Level
Low Level (−1) Centre Level (0) High Level (+1)
X1 mTMZ mg 0.250 0.625 1
X2 mO6BG mg 0.250 0.625 1
X3 %PVA % (w/v) 2 3 4
X4 VDCM mL 0.50 0.75 1
X5 mPLGA mg 10 15 20
Note: mTMZ—Mass of TMZ; mO6BG—Mass of O6BG; %PVA—percent weight per volume of PVA; VDCM—Volume of
dichloromethane; mPLGA—mass of PLGA.
The observed response dependent variables were the NPs size, PdI, zeta potential values, and EE
of both TMZ and O6BG. For the experimental design, 18 formulations were prepared, and an outline
of the experimental plan and its results is shown in Table 2.
Table 2. Outline of the experimental design and results. The experimental levels (low, centre, and high)
are represented by the coded values of −1, 0, and +1, respectively.
Run
Order
Coded Independent Variables Measured Dependent Variables








1 +1 +1 −1 +1 −1 183 0.148 −26.2 55.1 78.5
2 −1 +1 +1 −1 −1 202 0.110 −26.7 38.7 74.1
3 0 0 0 0 0 173 0.115 −23.4 45.1 71.6
4 +1 +1 −1 +1 −1 179 0.165 −24.1 56.7 80.8
5 −1 −1 −1 +1 +1 178 0.132 −24.4 53.5 94.0
6 −1 +1 −1 −1 +1 193 0.158 −22.4 52.3 91.6
7 +1 −1 −1 −1 −1 162 0.158 −27.5 31.8 99.0
8 0 0 0 0 0 178 0.127 − 22.1 44.7 77.3
9 −1 −1 +1 +1 −1 192 0.190 −27.0 42.6 79.7
10 +1 +1 +1 +1 +1 171 0.142 −20.3 27.2 78.5
11 +1 −1 +1 −1 +1 200 0.137 −22.7 40.3 99.8
12 +1 −1 +1 −1 +1 205 0.109 −22.5 46.3 99.6
13 +1 +1 +1 +1 +1 180 0.118 −22.3 28.9 82.6
14 +1 −1 −1 −1 −1 176 0.125 −28.0 36.6 99.5
15 −1 +1 −1 −1 +1 189 0.130 −21.7 50.9 95.5
16 −1 −1 −1 +1 +1 172 0.158 −23.4 54.5 98.0
17 −1 −1 +1 +1 −1 184 0.146 −26.2 46.7 78.1
18 −1 +1 +1 −1 −1 205 0.141 −27.5 36.5 76.9
The applied experimental design accounts for main terms and two-factor interactions terms.
The latter refers to two different variables that interact with each other, creating a combined effect
on the response that independently would not occur. Therefore, the main effects and the two-factor
interactions are accounted for in the used regression model. Thus, regression equations were obtained
for each studied dependent variable to quantify the relationship between these and all the experimental
independent variables. The experimental data was then fitted to the following polynomial regression
Equation (1) [29]:
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in which Y is the predicted response; β0 is the intercept term and the remaining term; Xi,j is the studied
levels of the independent variables; and βj,i is the fitted coefficients for Xi,j.
The statistical regression models for the different dependent variables were fitted independently.
Additionally, the polynomial equations were statistically validated using ANOVA (Analysis of Variance)
by statistical significance of coefficients, R2 values, and normal distribution of the residues. Minitab
Statistical Software was also used for the statistical analysis of the data.
2.4. TMZ+O6BG-Loaded PLGA NPs Physicochemical Characterization
2.4.1. Dynamic Light Scattering for Size Determination
The mean diameter and size distribution of the prepared NPs were evaluated by dynamic light
scattering (DLS). The measurements were performed in a ZetaSizer Nano ZS (Malvern Instruments,
Worcestershire, UK). The attained data is given in intensity distribution. The intensity-weighted mean
diameter (Z-average) is given. For the optimized formulation, at least three independent measurements
were performed, and obtained results are expressed as the mean and standard deviation (SD). Statistical
analysis was performed using the t-student test, and p-values ≤ 0.05 were considered significant.
2.4.2. Laser Doppler Velocimetry Method for Zeta Potential Determination
The zeta potential values of the prepared NPs were determined by laser doppler velocimetry
method. The measurements were also performed in a ZetaSizer Nano ZS (Malvern Instruments,
Worcestershire, UK). The analysis was performed using the dielectric constant of water. For the
optimized formulation, at least three independent measurements were performed, and obtained results
are expressed as the mean and SD. Statistical analysis was performed using the t-student test.
2.4.3. Transmission Electron Microscopy for Morphological Analysis
The morphological analysis of the NPs was obtained by transmission electron microscopy (TEM).
The NPs were prepared on copper grids (Formvar/Carbon-400 mesh Copper, Agar Scientific, Essex,
UK) and negatively stained. For that, 10 μL of samples were stained with 2% (v/v) uranyl acetate for
45 s, and air-dried. This is a heavy metal salt able to scatter electrons, enhancing the contrast to better
visualize the samples [30]. Then, the NPs were visualized using a JEM 1400 electron microscope (Jeol,
Tokyo, Japan) at an accelerating voltage of 80 kV.
2.5. TMZ+O6BG-Loaded PLGA NPs Stability Studies
The stability of the prepared PLGA NPs was analysed through size and zeta potential variations.
PLGA NPs’ dispersions in ultrapure water were stored at 4 ◦C and DLS measurements were performed
at different timepoints to evaluate variations in PLGA NPs size and zeta potential values. These
measurements were performed weekly, for 6 weeks. For optimized nanoformulation, three independent
samples were used.
2.6. Drug Encapsulation Efficiency of TMZ+O6BG-PLGA NPs
The TMZ and O6BG EE values of the prepared PLGA NPs were assessed by UV–Vis
spectrophotometry, using the following Equation (2):
EE =
total amount o f drug− amount o f f ree drug
total amount o f drug
× 100 (2)
Non-encapsulated TMZ and O6BG molecules were separated from the NPs colloidal suspension
by centrifugation (30 min, 14100× g, MiniSpin®plus, Eppendorf, Germany) and quantified (UV-1700
PharmaSpec UV-Vis spectrophotometer, Shimadzu, Kyoto, Japan) at 240 nm and 329 nm for O6BG and
TMZ, respectively. The results were correlated to control samples corresponding to total amount of
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drug. For the optimized formulation, three independent experiments were conducted, and obtained
results are expressed as the mean and SD. Statistical analysis was performed using the t-student test.
2.7. In Vitro Release of TMZ and O6BG from PLGA NPs
To assess the drug release profile of the developed NPs, in vitro dialysis studies were performed for
20 days at 37 ◦C. For that, a cellulose dialysis membrane (Float-A-Lyzer G2, CE, 10KDa, SpectrumLabs,
Los Angles, CA, USA) was rinsed in ultrapure water for 24 h before the beginning of the experiments
and equilibrated with release medium 1 h before the dialysis.
A known amount of TMZ+O6BG-PLGA NPs diluted in 2 mL of release medium was placed
into the inner space of the dialysis membrane. The outside space was filled with a known volume of
release medium to ensure sink conditions. PBS (pH 7.4, 0.01 M) was used as the release buffer to mimic
the physiological salt concentrations and pH of blood plasma. The dialysis membrane was kept in
continuous stirring at 200 rpm at 37 ◦C, simulating the physiological temperature. The amount of drug
release at predetermined timepoints (0, 6, and 24 h; and day 3, 6, 8, 9, 11, 13, 16, and 20) was quantified
by UV-Vis spectrophotometry (UV-1700 PharmaSpec UV-Vis spectrophotometer, Shimadzu, Kyoto,
Japan). A solution of TMZ and O6BG in PBS was used as control. For the optimized formulation, three
independent experiments were conducted, and obtained results are expressed as the mean and SD.
Statistical analysis was performed using the t-student test.
The TMZ and O6BG release curves, representing the percentage of drug released in function of
time, were then plotted by the following Equation (3):
% drug released =
amount o f drug released at time t
amount o f encapsulated drug
× 100 (3)
3. Results and Discussion
3.1. Statistical Analysis of Experimental Data
The applied experimental design allowed the identification of the experimental factors influencing
the physicochemical properties of the NPs, astheir size and the encapsulation efficiency of both drugs
on the polymeric matrix. Since zeta potential (≤−20 mV) and PdI values (<0.2) were always inside the
desired range, they were not considered for this model.
Previous nanoformulation studies were conducted to identify the five major experimental variables
that affect the PLGA NPs properties, such as size and EE of both drugs. The amount of TMZ, O6BG,
surfactant, organic solvent, and polymer were chosen and varied in two levels. The levels choice
was based on the knowledge acquired in the preliminary experiments. All other parameters, such as
type of surfactant and organic solvent, aqueous to organic phase ratio, time of sonication, ultrasonic
frequency of sonication, process temperature, and emulsification and evaporation processes, were
maintained constantly.
The mathematical model (Equation (1)) was fitted to the data and statistical analysis was
performed using ANOVA (Table 3). As Table 3 shows, the model is statistically significant (p < 0.05)
with insignificant lack of fit (p > 0.05) for all the chosen responses. Hence, the linear model was
acceptable for response prediction within the range of experimental variables.
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Figure 1 also shows a satisfactory agreement between experimental observations and predicted
response, proving that the applied regression model is suitable for the determination of the optimal
experimental settings for the preparation of NPs.
Figure 1. Graphical plots of the experimental values versus the model predicted values for (A)
mean size, (B) EE for TMZ, and (C) EE for O6BG. Red dots indicate high values and blue dots low
values, respectively.
The statistical analysis of the obtained results also allowed the determination of the regression
coefficient (RC) values that describes the direction of the relationship between an experimental variable
and the variable response. A negative sign before a factor indicates that the response decreases, whereas
a positive sign shows that the response increases with the experimental factor. With the RC values, it
was possible to obtain the polynomial regression equation for each studied response, quantifying the
relationship between each of the studied experimental variables and the response. The non-significant
factors (p > 0.05) were excluded from the mathematical model, allowing the reduction in complexity of
the attained equations.
Response surface analysis and contour graphs were plotted based on the determined model
polynomial function in a three and a two-dimensional model, respectively, illustrating the effect of the
chosen significant independent factors on each observed response. The effect of all the independent
variables on each dependent variable was studied and the effects of the most significant variables are
discussed in detail below.
3.1.1. Effect on NPs’ Size
The size of the NPs is a critical property, influencing its half-life, biodistribution, and cellular
internalization. The size of the NPs ranged from 162 nm (sample 7) to 205 nm (sample 12). Almost all
the studied variables significantly affected the size of the NPs (p < 0.05), as shown in Table 3.
The polynomial Equation (4) describes the relationship between the significant studied
experimental variables (p < 0.05) and the size of the NPs:
Size = 134.9− 9.67 amount TMZ (mg) + 83.9 amount O6BG (mg)
+ 15.05 amount PVA (%) + 1.644 amount PLGA (mg)
−13.41 amount O6BG (mg) × amount PVA (%)
− 2.541 amount O6BG (mg) × amount PLGA (mg)
(4)
The experimental factor that most significantly affected NPs size was the amount of surfactant,
which exhibited a positive effect on the size of the NPs. Thus, an increase in PVA concentration led
to an increase in NP size. Although using a high quantity of surfactant can induce the creation and
stabilization of smaller NPs due to a reduction of the interfacial tension between the polymer and the
external aqueous phase [31], the opposite effect was verified. This may be explained by the increased
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viscosity of the aqueous phase when increasing the PVA concentration. A higher viscosity decreases
the shear stress, originating emulsion droplets with larger sizes. Also, higher amounts of surfactant
can promote the coalescence of the NPs, yielding NPs with larger diameters [32]. Also, some studies
report that residual PVA remains at the surface, contributing to the size increase [33].
Additionally, the amount of PLGA also exhibited a significantly positive effect on the size of
the NPs (p < 0.05). Increasing the polymer amount increases the viscosity of the organic phase,
decreasing the shear stress, as mentioned above. Also, the augmented viscosity hampers the diffusion
of the organic solvent into the aqueous phase, leading to the formation of larger emulsion droplets,
originating larger NPs after solvent evaporation [34].
Higher initial loading of O6BG positively affected the NPs size (p < 0.05), since it will result in
higher drug loading, as will be discussed later. The contrary was observed for TMZ amount (p < 0.05),
since higher amounts of TMZ will decrease its entrapment, as will also be discussed later.
Response surface analysis and contour graphs were plotted (Figure 2) based on this model
polynomial function. Contour and surface response plots allowed visual identification of the optimal
levels of each factor, to choose the most suitable values for the development of an optimal formulation.
Both response surface and contour plots (Figure 2A,B) showed that the lower the amount of PVA and
PLGA, the lower the NPs size, as already predicted by the calculated positive RC values (Equation (4)).
Thus, optimal nanoformulation with small dimensions would fall into the low and central levels of
both factors.
Figure 2. (A) Response surface plot and (B) contour plot showing the effect of two factors (amount of
PVA and PLGA) on the resulting NPs size. (C) Response surface plot and (D) contour plot showing the
effect of two factors (amount of TMZ and O6BG) on the resulting NPs size.
In addition to all the five factors significantly affecting the NPs size, some significant two-factor
interactions were observed (Table 3). Interaction plots on Figure 3 show high interaction between
two factors. Each point in the interaction plot shows the mean size values at different combinations
of factor levels. As the lines are not parallel, with different slopes, the plot indicates that there is an
interaction between the two factors [35]. The same is verified in all the attained interaction plots.
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Figure 3. Interaction plots for size data means showing significant two-way interaction terms for the
independent variables. Solid blue lines display factor at low level, whereas dashed green lines are the
high level of the factors. (A) interaction term X2X3: amount of O6BG/amount of surfactant, (B) X2X5:
amount of O6BG/amount of PLGA.
The main effects can be confused with the two-factor interactions, which explains the results
obtained in Figure 2. Although Equation (4) predicts that the lower the amount of TMZ and the higher
the amount of O6BG, the higher the NPs size, optimal values fall into high levels of both TMZ and
O6BG. As shown in Figure 3A,B, at low levels of both PLGA and PVA amounts, O6BG positively
affects the size of the NPs. On the other hand, at high levels of PLGA and PVA, increasing the O6BG
amount decreases the size of the NPs.
3.1.2. Effect on the Encapsulation Efficiency of TMZ
High encapsulation of the drug is desirable to increase the nanosystem efficiency and to reduce
the amount of administered polymer. The EE values for TMZ in the prepared NPs ranged from 27.2
(sample 10) to 56.7% (sample 4).
The polynomial Equation (5) describes the relationship between the significant studied
experimental variables (p < 0.05) and the EE of TMZ:
EE% TMZ = 11.84− 8.80 amount TMZ (mg) − 3.40 amount PVA (%)
+ 7.95 amount DCM (mL) + 1.461 amount PLGA (mg)
−13.87 amount O6BG(mg) × amount PVA (%)
− 2.153 amount O6BG (mg) × amount PLGA (mg)
(5)
EE values were significantly influenced by almost all the studied independent variables, as shown
by the calculated p-values on Table 3. All the experimental variables show a positive effect on the EE
of TMZ, except PVA concentration and TMZ amount. PLGA had a positive effect on the EE of TMZ.
As already mentioned, a higher amount of PLGA polymer results in larger NPs and, consequently,
higher encapsulation of the drug. Also, the increased viscosity caused by higher PLGA concentration
mentioned above could complicate the diffusion of TMZ molecules into the aqueous phase, enhancing
the drug’s entrapment into the NPs’ polymeric matrix [36]. On the other hand, increased volumes of
organic solvent increased drug solubility, therefore increasing drug entrapment.
Also, the encapsulation of TMZ decreased with PVA concentration due to a higher partition
of TMZ molecules into the aqueous phase during emulsification, decreasing the EE values. It is
reported that drug molecules can diffuse out from the oil nanodroplets and solubilize in PVA micelles
at the aqueous phase [37]. Increasing the TMZ amount may cause saturation of the organic phase,
leading to the partition of the drug molecules to the aqueous phase, lowering its entrapment in the
polymeric matrix.
Response surface analysis and contour graphs (Figure 4) show that the optimal formulation would
be prepared with low amounts of PVA and TMZ, and high amounts of PLGA and organic solvent.
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Figure 4. (A) Response surface plot and (B) contour plot showing the effect of two factors (amount
of PVA and PLGA, respectively) on the resulting EE TMZ values. (C) Response surface plot and (D)
contour plot showing the effect of two factors (amount of TMZ and DCM, respectively) on the resulting
EE TMZ values.
All five studied variables were part of an extensive interaction system. A significant two-factor
interaction of O6BG amount with both PLGA and PVA amounts (Table 3) was verified (p < 0.05), as
shown in Figure 5.
Figure 5. Interaction plots for EE of TMZ data means showing significant two-way interaction terms
for the dependent variables. Solid blue lines display factors at a low level, whereas green dashed lines
are the high level of the factors. (A) interaction term X2X3: amount of O6BG/amount of surfactant, (B)
X2X5: amount of O6BG/amount of PLGA.
The described two-factor interaction between the PVA and O6BG amounts shows a significant
PVA concentration effect and interaction term (Figure 5A). There is a difference among the means of
the two PVA levels, but not a difference in the means among O6BG amount. This proves that although
the amount of O6BG did not show a significant direct effect on the EE values, the interaction term
exists. The amount of O6BG affected the nanoformulation at both low and high PVA amounts. At low
PVA levels, the O6BG amount showed a positive effect in the TMZ encapsulation. The opposite was
observed at high PVA amounts.
The same is verified in the two-factor interaction between the PLGA and O6BG amounts (Figure 5B).
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3.1.3. Effect on the Encapsulation Efficiency of O6BG
The EE values of O6BG in the prepared NPs ranged from 70.9 (sample 3) to 99.8% (sample 11).
The polynomial Equation (6) describes the relationship between the significant studied
experimental variables (p < 0.05) and the EE of O6BG:
E% O6BG = 104.4− 4.12 amount PVA (%) + 0.854 amount PLGA (mg) (6)
PVA and PLGA amounts were the only studied independent variables that significantly influenced
the EE values, as shown by the calculated p-values on Table 3. While PLGA concentration showed a
positive effect on the EE of O6BG, PVA concentration exhibited a negative influence. In fact, increasing
PVA concentration hampered the encapsulation of the drug, since it enhanced the partition of O6BG
molecules into the aqueous phase during emulsification, decreasing the encapsulation efficiencies
values [37]. Also, as already mentioned, higher amounts of PLGA polymer resulted in larger NPs and,
consequently, higher encapsulation of the drug. Also, the increased viscosity caused by higher PLGA
concentration mentioned above could complicate the diffusion of O6BG molecules into the aqueous
phase, enhancing the drug’s entrapment into the NPs’ polymeric matrix [36].
Response surface analysis and contour graphs (Figure 6) show that predicted optimal
nanoformulation with high O6BG molecules entrapment would fall into the high levels of PLGA and
low levels of surfactant concentration. No significant two-factor interactions were observed.
Figure 6. (A) Response surface plot and (B) contour plot showing the effect of two factors (amount of
PLGA and PVA, respectively) on the resulting EE values.
3.2. Nanoformulation Optimization and Physicochemical Characterization
The optimization process was performed by determining the optimal experimental values, which
were obtained by solving the three determined polynomial regression equations and grid searching in
the response surface graphs or contour plots applying the following criteria: to minimize the particle
size (Y1), and to maximize the EE values for both drugs (Y2 and Y3). The optimum levels of the
formulation factors are presented in Table 4.
Table 4. Optimal formulation parameters for the PLGA NPs determined by the experimental design.
Parameter Component Units Optimal Value
X1 mTMZ mg 1
X2 mO6BG mg 1
X3 %PVA % (w/v) 0.5
X4 VDCM mL 1
X5 mPLGA mg 15
A formulation checkpoint was prepared according to the predicted model to validate the reliability
and the precision of the factorial design, using these optimal experimental conditions. The checkpoint
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formulation was prepared in triplicates and the properties of the attained NPs were within the range
of the predicted values, as shown in Table 5.
Table 5. Validation of the model by comparing the predicted values with the observed experimental
values. The experimental data is given as the mean ± SD (n = 3).








Experimental values 177 ± 4 63 ± 4 90 ± 4
Experimental error 2% 7% 1%
Higher encapsulation verified for O6BG can be explained by its greater affinity for the organic
phase, compared with TMZ. While TMZ exhibits a log P value of 0.36, for O6BG, log P is 1.66 (values
obtained from Marvin Sketch Calculator software. ChemaxonTM,Version 16.4.25, Budapest, Hungary).
The developed NPs exhibit mean dimensions suitable for brain delivery. Although PdI and zeta
potential values were not considered for the model, they were also determined for the checkpoint
formulations. The developed NPs exhibited zeta potential values of −22 ± 1 mV and PdI values of
0.19 ± 0.01. The high negative zeta potential values are associated with low toxicity [38] and suggest
that the NPs are stable [39]. In fact, all the nanoformulations prepared in the 18 runs of the FFD (data
not shown) and the checkpoint formulations proved to be stable in storage conditions for at least six
weeks, as shown in Figure 7.
Figure 7. Stability of the prepared checkpoint nanoformulations. Black line: Graphical representation
of variations in zeta potential values over 6 weeks (data plotted on the left Y-axis); Red line: Graphical
representation of variations in mean sizes over 6 weeks (data plotted on the first right Y-axis); Purple
line: Graphical representation of variations in PdI values over 6 weeks (data plotted on the second
right Y-axis). Results are given as mean ± SD (n = 3).
The stability of the prepared colloidal suspension NPs is granted by a PVA layer on the NP’s
surface. During the NPs preparation, the PVA molecules adsorb on the surface of the resultant
nanodroplets acting as a mechanic barrier that prevent coalescence and avoid NPs’ aggregation [40].
TEM image (Figure 8) shows this stabilizer layer around the NPs’ surface. Also, the attained PdI values
suggest that the colloidal suspension is monodisperse. Therefore, it can be concluded that the method
followed for the preparation of PLGA NPs produced well-stabilized monodisperse O6BG+TMZ-loaded
PLGA NPs.
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Figure 8. TEM photograph showing the morphology of the developed PLGA NPs. Scale bar is 200 nm.
3.3. Drug Release from the PLGA NPs
For the evaluation of the in vitro release profile of the developed NPs, the dialysis method was
used. To simulate the physiological conditions (temperature, salt concentration, and pH), the release
studies were conducted at 37 ◦C in PBS (10 mM, pH 7.4). The release curves were plotted and are
shown in Figure 9.
Figure 9. In vitro release of TMZ and O6BG from PLGA NPs in PBS (10 mM, pH 7.4) at 37 ◦C. Free
TMZ and O6BG were used as control. Results are given as mean ± SD (n = 3). An enlargement of the
first time points—6 and 24 h—is presented to highlight the burst effect.
PLGA NPs showed an initial burst release for both drugs, due to the presence of the drug molecules
adsorbed at the NPs’ surface. As Figure 9 depicts, at the first 24 h, 48 ± 3% of the total TMZ and
43 ± 3% of the total O6BG were released. Then, both drugs located at the polymeric matrix of the NPs
were released in a slower and controlled manner that was prolonged for 20 days.
A faster release for TMZ was verified in comparison to O6BG. The PLGA NPs exhibited a release
of TMZ of 81 ± 1% after 20 days, while for O6BG, only about 79 ± 1% of the entrapped drug was
released at day 20 (Figure 9). This may occur due to the higher affinity of TMZ to the aqueous buffer
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(lower log P values). However, the release profile is similar for the two drugs, due to the erosion of the
polymer matrix that allows the release of both molecules.
The obtained release profile proved that the developed PLGA NPs are able to maintain the sustained
and controlled release of both TMZ and O6BG, and therefore could be used for the co-delivery of
entrapped molecules. Further optimization of the release profile to reduce the initial burst release may
improve the efficiency of the nanovehicle.
4. Conclusions
PLGA NPs as drug delivery systems have gained increasing interest in the last years, due to
their unique physicochemical properties, such as stability, biocompatibility, and biodegradability.
Encapsulating drugs in PLGA NPs allows them to maximize their therapeutic effects and to minimize
their side effects. Since the biological fate and toxicity of the NPs depend on their physicochemical
properties, the developed nanosystems must meet several criteria to be appropriate for brain delivery.
PLGA NPs for the entrapment of both TMZ and O6BG for further GBM treatment were developed
in this work. TMZ is the used drug for GBM chemotherapy, and despite its therapeutics effects being
well-known, the drug is not able to effectively cure GBM patients. Intrinsic resistance mechanisms
are of one of the major obstacles for GBM treatment, due to the DNA repair by the MGMT protein.
To overcome this issue, co-therapy with TMZ and an inhibitor of the MGMT protein, O6BG, was
proposed. O6BG is a guanine analogue able to inhibit the activity of the MGMT protein, hampering
the DNA repair. Thus, O6BG could decrease the resistance to TMZ’s therapy.
Hence, an optimized nanoformulation was developed in this work, and for that, FFD was used.
FFD proved to be a suitable approach for the design of co-loaded NPs allowing to optimize the single
emulsion solvent evaporation production process with a low replica number in a reliable and precise
manner. The regression analysis of the results proved to adequate to identify the main experimental
variables affecting the physicochemical properties of the developed NPs. The optimal experimental
conditions were chosen, and the optimal nanoformulation was prepared using 1 mg of both drugs,
0.5% (w/v) of PVA, 1 mL of dichloromethane, and 15 mg of PLGA.
The developed NPs exhibited high encapsulation efficiencies for both drugs and showed a
sustained drug release. Thus, it is expected that these nanocarriers will provide an effective brain
delivery, allowing the drug to reach the brain at desirable doses, leading to a significant improvement
on the GBM treatment.
PLGA NPs provide a novel and potentially efficient approach for the co-administration of TMZ
and O6BG, presenting a potential solution for the intrinsic resistance mechanisms to TMZ due to
MGMT high expression. Though these NPs could potentially overcome the limitations of the currently
available therapies, future in vitro and in vivo tests are necessary to assess the nanosystem efficacy.
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Abstract: In the present study, we examined properties of poly(lactide-co-glycolide) (PLGA)-based
nanocarriers (NCs) with various functional or “smart” properties, i.e., coated with PLGA, polyethylene
glycolated PLGA (PEG-PLGA), or folic acid-functionalized PLGA (FA-PLGA). NCs were obtained
by double emulsion (water-in-oil-in-water) evaporation process, which is one of the most suitable
approaches in nanoemulsion structural design. Nanoemulsion surface engineering allowed us to
co-encapsulate a hydrophobic porphyrin photosensitizing dye—verteporfin (VP) in combination
with low-dose cisplatin (CisPt)—a hydrophilic cytostatic drug. The composition was tested as
a multifunctional and synergistic hybrid agent for bioimaging and anticancer treatment assisted by
electroporation on human ovarian cancer SKOV-3 and control hamster ovarian fibroblastoid CHO-K1
cell lines. The diameter of PLGA NCs with different coatings was on average 200 nm, as shown by
dynamic light scattering, transmission electron microscopy, and atomic force microscopy. We analyzed
the effect of the nanocarrier charge and the polymeric shield variation on the colloidal stability using
microelectrophoretic and turbidimetric methods. The cellular internalization and anticancer activity
following the electro-photodynamic treatment (EP-PDT) were assessed with confocal microscopy and
flow cytometry. Our data show that functionalized PLGA NCs are biocompatible and enable efficient
delivery of the hybrid cargo to cancer cells, followed by enhanced killing of cells when supported
by EP-PDT.
Keywords: smart nanocarriers; folic acid; verteporfin; cisplatin; SKOV-3 cells; CHO-K1 cells;
electroporation; theranostic cargo; double emulsion approach
1. Introduction
Effective nanocarriers (NCs) for cancer treatment need both passive and active targeting approaches
to achieve highly specific drug delivery to cancer cells while avoiding rapid clearance by the
mononuclear phagocyte system and cytotoxicity to normal cells [1]. Recently, the field of biomedical
applications, including drug encapsulation, has raised much interest, in part due to the advancement of
the biomaterials and “smart” polymers, which enable preparation of containers with novel functional
properties (e.g., size, charge, interfacial functionalization) by means of nanoemulsion structural design.
Nanoemulsion systems (so-called submicron emulsions, parenteral emulsions, or miniemulsions)
are referred to in the literature as transparent or translucent (often bluish) isotropic dispersions of
water and oil, with nano-domains coexisting in high kinetic equilibrium due to the occurrence of
surfactant molecules at the oil/water interface [2,3]. Owing to their small size (usually in the range
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20–200 nm), high kinetic stability, and much lower surfactant concentration (typically 3–10%) required
for their formation in comparison to microemulsions (generally about 20% and higher, both oil-in-water
(o/w) and water-in-oil (w/o), nanoemulsions were found to be very attractive for droplet engineering
to obtain efficient nanocarriers with functional properties. The usefulness of these formulations as
raw structures for container fabrication based on their surface templating approaches, by means
of biocompatible polymers and polyelectrolytes, including very effective solvent evaporation and
layer-by-layer techniques, have been proved by many scientific investigations [4–7]. Consequently,
the structuration of the nanoemulsion droplets is typically carried out with three general approaches:
layering, embedding, and clustering [8]. In the embedding process, the double emulsion method
permits encapsulation of both hydrophilic and hydrophobic agents in the double compartment
structure [7]. Such a hybrid cargo can be loaded simultaneously or separately in the NC liquid core
and protected from the environmental conditions [9]. Additionally, the hybrid molecules may also
migrate from the outer to inner phase and form a reservoir that enhances spectroscopic or functional
properties of photodynamic therapy (PDT) and leads to synergistic anticancer activity. The biological
effectiveness of such multifunctional nanosystems in the combined anticancer therapy may be also
intensified by increasing their cellular uptake by the electroporation (EP) approach.
The electroporation method is widely used not only in chemotherapy for drug delivery but
also in molecular biology and microbiology for gene transfection. The latest data show combination
methods are used after electrochemotherapy, where plasmid electrotransfer is applied for stimulation
of the immune response for better recovery [10]. It is also crucial that the electroporation technique
significantly shortens the time of exposition to the “therapeutic substance”. This approach is definitely
safes then chemical methods because it does not introduce any additional components to the reaction
environment. The EP approach was shown to efficiently increase both the uptake and the photodynamic
activity of some second-generation photosensitive agents from the cyanine (e.g., AlPcS4) and chlorin
(e.g., Ce6) families for PDT application [11]. The beneficial impact of EP was also demonstrated in the
case of porphyrin-origin dyes (e.g., CoTPPS and MnTMPyPCl5), which were used against drug-resistant
breast and colon cancer cells [12]. These and other studies performed with phthalocyanines (AlPc and Pc
green) [13] showed the promising effect of EP in overcoming drug resistance. Moreover, electroporation
can be used for supported delivery or fusion of nanosystems containing multifunctional cargo,
which is not possible with chemical methods. Thus, the EP method was effective not only for drugs
and photosensitizers in free form but also for encapsulated ones [14]. Our previous study shows
that EP enhances delivery and photodynamic activity of encapsulated cyanine IR-780 combined
with flavonoids [15]. Thus, the available data clearly indicate a new trend in the application of
multifunctional methods in more specific drug delivery to cancerous cells.
Over the last years, different chemical compounds have been utilized in order to improve the
stability of double emulsion. This has included various mixtures of surfactants, two types of emulsifiers,
and co-surfactants or copolymers to support the final formulation [16,17]. Nevertheless, as has been
recently shown, the formation of the nanoemulsion interface by the solvent evaporation approach using
functionalized biopolymers, i.e., polyethylene glycol (PEG)-ylated polyesters, such as poly(d,l-lactic
acid) (PDLLA), poly(glycolic acid) (PGA), polycaprolactone (PCL), and poly(lactic-co-glycolic acid)
(PLGA), enhances the long-term colloidal stability of encapsulated bioactive compounds and extends
the functional performance of nanoscopic emulsion formulations, rendering them non-toxic and stable
in the bloodstream [7,18]. Furthermore, application of PLGA as one of the most promising Food and
Drug Administration (FDA)-approved polymers for human use, for example functionalized by folic
acid (FA) molecules with selective affinity to the folate receptor (FR), could be beneficial in treatment of
human carcinomas with overexpression of FR, including ovarian, breast, and lung cancer cells [19,20].
Thus, in the present study, we prepared NCs coated with PLGA, PLGA-PEG, or PLGA-FA by
means of the double emulsion (water-in-oil-in-water (w/o/w)) evaporation process, which enabled
co-encapsulation of a hydrophobic, porphyrin-origin photosensitizing agent—verteporfin (VP) in
combination with low-dose cisplatin (CisPt)—a hydrophilic chemotherapeutic drug. Obtained NCs
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were characterized using a variety of analytical methods and functional assays. Finally, their utility in
bioimaging as well as in anticancer applications upon human ovarian cancer SKOV-3 cells and control
hamster ovarian fibroblastoid CHO-K1 cells was also analyzed when combined with EP and PDT.
2. Materials and Methods
2.1. Chemicals and Reagents
Poly(lactide-co-glycolide), ester endcap L:G 50:50 (PLGA, Mw ~ 25,000–35,000),
poly(ethylene glycol) methyl ether-block-poly(lactide-co-glycolide) (PEG-PLGA, Mw ~ 5000:20,000),
poly(lactide-co-glycolide)-folate, L:G 50:50 (FA-PLGA, Mw ~ 25,000–35,000) employed as biocompatible,
“stealth” and functionalized “smart” polymers, respectively, for NC stabilization were obtained from
PolySciTech® (West Lafayette, IN, USA). Cremophor A25 and didodecyldimethylammonium bromide,
di-C12DMAB, applied as a hydrophilic non-ionic and a hydrophobic double chain cationic surfactant,
were obtained from BASF Care Creations (Monheim am Rhein, Germany) and Sigma Aldrich (Poznan,
Poland), respectively. Verteporfin (VP) and cisplatin (Cis-Pt), utilized as hybrid cargo, were from
Sigma-Aldrich (Poznan, Poland). Supplementary chemical compounds were of commercial grade
and were used as received. Doubly distilled water was purified using a Milli-Q purification system
(Millipore, Bedford, MA, USA).
2.2. Co-Encapsulation of Hybrid Agents in Polymeric Nanocarriers by Double Emulsion (w/o/w) Solvent
Evaporation Method
Polymeric NCs stabilized by PLGA, PEG-PLGA, FA-PLGA, and non-ionic and cationic surfactants
for co-encapsulation of a therapeutic (CisPt), as well as a diagnostic and therapeutic agent—VP (both
in the initial concentration of 130 μM)—were obtained using double emulsion (w/o/w) evaporation
method [7,21]. Generally, we emulsified an aqueous internal phase (with CisPt) in dichloromethane
(with VP, PLGA at a concentration of 5 mg/mL and di-C12DMAB) at 1:4 ratio using a homogenizer set
to 25,000 rpm for 5 min. Next, the primary water-in-oil (w/o) nanoscopic emulsion was poured into
1% Cremophor A25 aqueous solution (a hydrophilic surfactant), stirred in a homogenizer for 10 min
(25,000 rpm), and immersed in an ice-water bath to obtain the w/o/w emulsion. Then, we evaporated
the organic solvent under reduced pressure in a rotary evaporator (Hei-VAP Value Digital, Heidolph
Instruments, Schwabach, Germany) with a rotation speed of 150 rpm for 30 min at 25 ◦C and polymeric
NCs with a PLGA, PEG-PLGA, or FA-PLGA shell. The hybrid cargo were collected the following day.
2.3. Nanocarrier Size, Polydispersity, and Particle Charge
The main physicochemical parameters of NCs, such as hydrodynamic diameter (DH),
polydispersity index (PDI), and particle charge (ζ-potential), were analyzed by means of dynamic light
scattering (DLS) and microelectrophoretic methods using Zetasizer Nano Series (Malvern Instruments,
Worcestershire, UK) equipped with a He–Ne laser (632.8 nm). DLS measurements were conducted at
25 ◦C and the detection angle was 173◦, as previously described [7,21,22]. Each value was an average of
three runs, with at least 10–20 measurements. We applied the DTS (Nano) program for data evaluation.
2.4. Shape and Morphology
The morphology of the obtained NCs was studied by atomic force microscopy (AFM) and
transmission electron microscopy (TEM) according to our previous protocols [7,21]. The AFM
observations were conducted using a NanoScope Dimension V instrument with an RT ESP tube scanner
(Veeco Instruments, Plainview, NY, USA) Samples were analyzed at 0.5 Hz scanning speed using
a low-resonance-frequency pyramidal silicon cantilever resonating at 250–331 kHz at a constant force
of 20–80 N/m. The resonance amplitude was adjusted manually to the lowest possible amplitude
enabling stable imaging within the contamination layer on the surface. We prepared the samples by
adsorption of an NC droplet on mica that was freshly cleaved. After 18 h, the excess substrate was
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removed by rinsing the mica plates in double distilled water for 1 min and drying for 2 h at room
temperature. The TEM imaging of NCs was performed with an Field Electron and Ion Company
(FEI) Tecnai G2 20 X-TWIN electron microscope (FEI, Brno, Czech Republic) by placing a few drops of
diluted NCs on a Cu-Ni grid and leaving the specimens to dry for 20 h at room temperature.
2.5. Encapsulation Efficiency
The Ultraviolet - Visible (UV-VIS) absorbance of NCs with encapsulated VP and Cis-Pt was
measured with a Metertech SP8001 spectrophotometer with a 1-cm length path thermostated quartz cell
in order to evaluate the encapsulation efficiency (EE). The hybrid cargo concentration was calculated
using calibration curves according to our previous protocol [21,22]. We determined EE as follows:
EE =
Wadded −W f ree
Wadded
× 100 %
where Wadded is the amount of VP or CisPt added during the encapsulation procedure, and Wfree is the
amount of free cargo in the supernatant quantified by UV-VIS spectroscopy after separation of NCs by
centrifugation process (14,000 rpm for 30 min).
2.6. Colloidal Stability
The backscattering (BS) of pulsed near-infrared, IR light (l = 880 nm) was utilized to measure the
long-term colloidal stability of NCs (Turbi-ScanLabExpert, Formulaction SA, Toulouse, France) [7].
In general, two synchronous optical sensors (transmission and backscattering detectors) recorded light
transmitted through the sample (0◦ from the incident radiation) and light back-scattered by the sample
(1358 from the incident radiation). The scanning of the sample was performed in a cylindrical glass
cell at 25 ◦C by moving along the entire height of the cell. The BS profiles as a function of the sample
height were then collected and analyzed using the instrument’s software (Turbisoft version 2.0.0.33,
Formulaction SA, Toulouse, France). We measured BS for freshly prepared NCs and after 30 days of
the sample storage at 25 ◦C.
2.7. Cell Lines
The biological studies were performed on a human ovarian carcinoma cell line resistant to
diphtheria toxin, cisplatin, and adriamycin (SKOV-3), and a hamster ovarian fibroblastoid cell line
(CHO-K1) used as a model for transport studies in a pulsed electric field due to very low expression
of endogenous ionic channels [23]. The SKOV-3 and CHO-K1 cells were purchased from ATCC®
(American Type Culture Collection, distr. LGC Standards, Lomianki, Poland), cultured, and prepared
according to the conditions described previously by our group [15].
2.8. Uptake of Encapsulated Hybrid Cargo—Flow Cytometry Analysis
The ability to internalize free and encapsulated VP/CisPt by CHO-K1 and SKOV-3 cells was
analyzed by flow cytometry using fluorescence-activated cell sorter (FACS, Cube-6, SYSMEX EUROPE
GmbH, Warsaw, Poland). Cells were harvested on 12-well plates and after obtaining 80% of confluence,
appropriate nanosystems were added as follows. Free VP or NCs containing VP/CisPt were added
with a final VP concentration equal to 2.0 × 10−6 M. Then, the cells were incubated for 24 h at 37 ◦C in
a humidified atmosphere containing 5% CO2. In the next step, cells were detached with Trypsin-EDTA
(Sigma-Aldrich Merck-Group, Poznan, Poland), washed in PBS, and resuspended in 0.5 mL of PBS.
Flow cytometry analysis was performed using a Cube 6 flow cytometer (Sysmex, Warsaw, Poland).
The fluorescence of VP was measured with a FL-4-H detector. Data were collected and analyzed by
CyView software (Sysmex, Warsaw, Poland).
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2.9. Electroporation Protocol
Electropermeabilization of cell membranes alone and with free or co-encapsulated VP and Cis-Pt
was performed using Gene Pulser Xcell™ Electroporation System (BioRad Laboratories, Warsaw,
Poland). When cells reached 80% of confluency they were trypsinized and centrifuged (5 min, 1000 rpm).
Then, cells were counted and resuspended in 200 μL of electroporation buffer (EP buffer of low electrical
conductivity of 0.14 S/m) at cell concentration of 3 × 106/mL [15]. Cells were maintained in suspension
and pulsed in a cuvette (VWR) with two aluminum plate electrodes (4 mm gap). The following
parameters of electroporation were applied: electrical field intensity E(appl) = 500 V/cm, 5 rectangular
unipolar pulses of 1 ms duration. The EP conditions were established according to our previous
study [14]. The EP experiments were performed using Gene Pulser Xcell™ Electroporation System
165-2660 (BioRad). After the pulse delivery, cells were incubated for 10 min at 37 ◦C, then gently
centrifuged, resuspended in the cell culture medium (DMEM for SKOV-3 cells or HAM’s F10 for
CHO-K1 cells, Sigma-Aldrich Merck-Group, Poznan, Poland), and further analyzed by confocal
microscopy and subjected to photocytotoxicity studies.
2.10. Intracellular Internalization Studies by Confocal Microscopy
The internalization of co-encapsulated VP by cancer and normal cells was studied with confocal
microscopy. Briefly, SKOV-3 and CHO-K1 cells were seeded onto glass cover slips in Petri dishes
(Sarstedt - distr. Equimed, Wroclaw, Poland) at a density of 1× 104 cells per cover slip in a CO2 incubator
for 24 h. Next, the cells were treated with NCs at a concentration corresponding to 2.0 × 10−6 M of VP
and incubated at 37 ◦C for 24 h. For the EP-supported uptake, cells were first processed as described in
the Section 2.9 and then seeded onto cover slips, thus the time of exposition to nanosystems was only
10 min. After 24 h, all samples were fixed in 4% formaldehyde (Polysciences Inc., Hirschberg an der
Bergstrasse, Germany), washed, and placed onto basic glass slides (SuperFrost, Menzel, Braunschweig,
Germany) upon mounting in an anti-fade medium (Roth – distr. Linegal Chemicals Sp. z o.o,
Warsaw, Poland) with with 4′,6-diamidino-2-phenylindole (DAPI) for nuclei staining. Microscopy was
performed on a spinning disk confocal microscope (Cell Observer SD, Zeiss, Oberchochen, Germany).
DAPI was visualized with a 405 nm laser and 450/50 emission filter, while VP fluorescence was excited
with a 488 laser and collected with a 629/62 nm emission filter.
2.11. Photodynamic Activity Protocol
Photocytotoxicity of NCs in SKOV-3 and CHO-K1 cells was measured after standard photodynamic
procedure and PDT combined with the EP protocol described above by cellular mitochondrial activity
determined by the (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric
assay according to the manufacturer’s procedure and our previous experiments [12–15]. The cells
subject to PDT were irradiated after 24 h for 10 min with light in the range of 630–680 nm; the final
energy delivered to the cell monolayer was 10 J/cm2. The MTT assay was performed after 24 h post
irradiation for the NCs loaded with the theranostic cargo at a concentration equivalent to 1.0–5.0 ×
10−6 M of encapsulated VP. The measurements were performed on the GloMax® Discover multimode
microplate reader (Promega, Madison, WI, USA). The cell viability in each group was expressed as
a percentage of the value obtained for control (untreated) cells (average of three experiments).
2.12. Statistical Analysis
The results are presented as means ± standard deviation (SD) values for minimum n = 3 repeats.
The results were analyzed by two-way ANOVA for multiple comparisons and α = 0.05 GraphPad
Prism 7.05. The values where p ≤ 0.05 (marked with *) were considered as statistically significant.
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3. Results and Discussion
3.1. Characteristic of “Smart” PLGA Nanocarriers Obtained by Nanoemulsion Structural Design
The combination of biomaterials, “smart” polymers, and drug delivery systems for both therapeutic
and diagnostic (theranostic) approaches enables the development of intelligent devices and brings
enormous possibilities for biomedical applications [24]. Biodegradable polyesters, such as poly(glycolic
acid) (PGA), poly(lactic acid) (PLA), and their copolymers are the favorite synthetic polymers for
biomedical and pharmaceutical applications, since they were proved to be useful in the stabilization of
different drug delivery systems and have excellent biocompatibility and bioresorbability [25].
With this in mind, we have tested highly biocompatible polymers made of PLGA (the
FDA-approved copolymer of PGA and PLA, also functionalized with different moieties), namely PEG
and FA. The “smart” co-polymers were used to design NCs co-loaded with VP, playing a dual role of
a diagnostic and a therapeutic agent, and CisPt, a supporting chemotherapeutic drug. Engineered NCs
with encapsulated hybrid cargo had an improved colloidal stability and therapeutic activity, as well as
extended functional performance with unique attributes e.g., non-toxicity, stability in blood circulation,
and cancer-targeting ability. Thus, according to the first phase of our general strategy presented in
Scheme 1a, PLGA, PEG-PLGA, and FA-PLGA polymers were used for stabilization and structuration
of nanoemulsion droplets involving the three-step w/o/w double emulsion evaporation approach,
leading to co-encapsulation of the hybrid cargo, i.e., VP and CisPt in the NC’s double compartment.
The second step (Scheme 1b) involved EP-supported PDT upon improved internalization of NCs
by human ovarian cancer (SKOV-3) and normal ovary fibroblastoid (CHO-K1) cells. The SKOV-3 cells
were selected as difficult-to-treat cells, which are extremely resistant to the wide spectrum of cytostatic
drugs, but in particular to cisplatin. Consequently, in our study an attempt was made to design special
nanosystems to overcome drug resistance phenomena in human ovarian cancer and also very probable
secondary resistance to CisPt, and for rapid elimination of the drug from circulation [26]. The PLGA
nanocarriers proposed here can significantly diminish this process, causing good bioavailability and
the “willingness” of the cell to accept the natural carrier. Furthermore, as has been proved recently,
different drug delivery systems with a negatively charged surface are generally less toxic compared to
the positively charged ones, but their cellular uptake may be hindered due to the same negative charge
present on the surface of target cells. Thus, the electropermeabilization may enhance the transport of
theranostic cargo to target (malignant) cells in spite of their negative surface charge [15,27].
Accordingly, three types of PLGA-NCs loaded with theranostic cargo and three control NCs
(systems V1-V6, Table 1) were successfully synthesized. The main physicochemical characteristics
of the designed NCs are summarized in Table 1. We measured size (hydrodynamic diameter, DH),
polydispersity index (PdI), zeta potential (ζ), and encapsulation efficiency of VP (EEVP) and CisPt
(EECisPt). NCs with different PLGA shells displayed an average size between 187 and 200 nm, PDI of
approximately 0.1–0.2, and ζ from−4 mV to−17 mV, proving efficient assembly of NCs with PEG-ylated
and FA-functionalized shells [7,28]. Generally, loaded cargo did not significantly change the NC
charge (ζ), as observed for control NCs with a FA-PLGA shell, loaded with VP, CisPt, or empty ones.
Furthermore, the loaded NCs showed only a slightly larger size and less unimodal size distribution,
which was probably caused by the incorporated cargo molecules. The EE was about 95% for VP
and 90% for CisPt. The differences in the encapsulation of the hybrid cargo by PLGA, PEG-PLGA,
and FA-PLGA shells are presented in Figure 1 as UV-VIS spectra of the co-encapsulated VP and CisPt
compared to the control samples with only the cytostatic drug and with only the photosensitizer,
as well as empty NCs. In all nanosystems a characteristic peak at 280 nm for CisPt as well as peaks at
340 nm, 415 nm, and 680 nm for VP can be observed, providing evidence of effective encapsulation of
both ingredients.
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Scheme 1. The general strategy of conducted studies: (a) double emulsion (w/o/w) design for
co-encapsulation of Verteporfin (VP) and Cisplatin (CisPt) in various Poly(Lactide-co-Glycolide) (PLGA)
nanocarriers (NCs) and (b) electroporation (EP)-supported photodynamic therapy (PDT) using obtained
NCs against human ovarian cancer (SKOV-3) and hamster ovarian control (CHO-K1) cells.
Table 1. Physicochemical characteristics of VP and Cis-Pt co-loaded NCs with various PLGA shells.
System Composition DH [nm] PDI ζ [mV] EECisPt EEVP
V1 NCs-PLGA + VP + CisPt 193 ± 6 0.16 ± 0.01 −9 ± 1 92 ± 1 97 ± 3
V2 NCs-PLGA-PEG + VP + CisPt 187 ± 5 0.12 ± 0.01 −4 ± 1 88 ± 1 92 ± 1
V3 NCs-PLGA-FA + VP + CisPt 200 ± 7 0.20 ± 0.02 −15 ± 2 90 ± 2 95 ± 3
V4 NCs-PLGA-FA + VP 197 ± 7 0.22 ± 0.02 −16 ± 2 - 96 ± 3
V5 NCs-PLGA-FA + CisPt 194 ± 6 0.25 ± 0.02 −16 ± 2 92 ± 2 -
V6 NCs-PLGA-FA empty 189 ± 5 0.10 ± 0.01 −17 ± 3 - -
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Figure 1. Ultraviolet - Visible (UV-VIS) spectra and images of the VP and CisPt co-loaded nanocarriers
with various PLGA shells (samples V1–V3) compared to the control samples loaded only by the
cytostatic drug (V5), only by the photosensitizer (V4), and the empty NCs (V6). See descriptions for the
systems (V1–V6) in Table 1.
Meanwhile, the correct imaging of NCs is a key parameter in the design of any drug delivery system
dedicated to pharmaceutical applications. The obtained PLGA-stabilized NCs were characterized
by transmission electron microscopy (TEM) and atomic force microscopy (AFM)—quick, efficient,
and relatively non-invasive techniques that can provide evidence on shape and morphology and size
distribution of these polymeric nanosystems. The TEM and AFM images of the loaded PLGA-NCs are
shown in Figure 2. The TEM imaging demonstrated spherical particles with roughly uniform sizes
related to AFM. Furthermore, we observed some differences in morphology as visualized by TEM for
nanocarriers prepared with different PLGA shells. In the case of NCs covered by PLGA, the spherical
nanoobjects with relatively smoother surface morphology were discovered by both TEM and AFM
imaging, while the NCs stabilized by PEG-PLGA and FA-PLGA (Figure 2) had a typical core shell
morphology, where the darkest part relates to the denser polymeric/PEG-ylated corona, demonstrating
that these shells were successfully formed. The AFM tapping mode scanning presented as 2D and
3D images identified a semi-spherical shape of the NCs, being slightly less regular in the case of NCs
stabilized only by PLGA (Figure 2). However, we did not see increased aggregation as it was found
by TEM. The NC’s size range was smaller than the distribution obtained by the DLS measurement
presented in Table 1, as both TEM and AFM were carried out in dry conditions, and the obtained NCs
have a tendency to shrink, resulting in losing their primary shape and size [29].
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Figure 2. Imaging of VP and CisPt co-loaded PLGA (V1), PEG-PLGA (V2), and FA-PLGA (V3) NCs by
means of transmission electron microscopy (TEM) and atomic force microscopy (AFM). See descriptions
for the systems (V1–V3) in Table 1.
3.2. Evaluation of Colloidal Stability
The colloidal stability of NCs is one of the most critical factors for any potential biological
application, since these nanostructures, when not stabilized electrostatically, are usually metastable
due to short-range van der Waals attraction [30]. Consequently, to avoid NC aggregation due to their
low colloidal stability, steric or electrostatic repulsion may be applied for stabilization. The literature
data indicate the encapsulation of inorganic and organic molecules by surfactants and polymers as the
best strategy for the enhancement of any nanostructure colloidal stability and functionality, leading to
hybrid core/(polymer-)shell NCs [31]. However, the NC aggregation process is still hard to control,
especially in biological environments, which is of essential significance for in vivo applications [6,30].
The detailed estimation of the colloidal stability of different PLGA co-loaded and empty NCs was
conducted using turbidimetric method by means of time-dependent BS profiles. The BS levels expressed
in % are indicated on the ordinate axis. The investigated formulation level in the measurement vial was
expressed in mm and marked on the abscissa axis. By examining the BS profiles (Figure 3), we were
able to determine the dynamics of any decomposition processes occurring within the sample. This was
achieved through analysis of the distances between the curves in BS profiles of NCs at 0 days (freshly
prepared) and after 30 days of their storage at room temperature (Figure 3).
Typically, rapid destabilization phenomena can be recognized by a large distance between the
curves, while an overlap of the individual curves indicates the high stability of the analyzed sample
and a slow rate of the destabilization process [32]. Based on the graphs shown in Figure 3, we conclude
that the studied nanosystems have good colloidal stability, since no macroscopic changes in analyzed
samples (aggregation, sedimentation, or creaming processes) were observed at the last day of the
performed turbidimetric test.
145
Pharmaceutics 2019, 11, 405
Figure 3. Backscattering profiles of the various PLGA NCs co-loaded with VP and CisPt (a–c) (V1–V3)
and an empty (d) (V6) FA-PLGA nanosystem as a function of sample height (mm) analyzed over 30
days (T = 30) of the NCs’ storage. Solid lines represent measurement at 0 day (T = 0, freshly prepared
NCs), while dashed lines indicate data obtained after 30 days of storage. See descriptions of the systems
in Table 1.
3.3. Cellular Internalization—Flow Cytometry and Confocal Microscopy Evaluation
The evaluation of nanosystem uptake by cancer and normal cells is shown in Figure 4. The uptake
efficiency of NCs was estimated by flow cytometry after 24 h of exposition. SKOV-3 cells revealed
a higher uptake efficiency of VP-loaded NCs than CHO-K1 cells. The strongest fluorescent signal was
observed for V3 (VP + CisPt) and V4 (VP) nanosystems, which were functionalized by FA moieties,
proving the effective SKOV-3 targeting ability of the “smart” FA-PLGA-coated nanodevices [33].
The improved uptake in the case of nanosystem V3 can be explained by the content of isplaitin,
which can slightly sensitize exposed cells and provoke better internalization of VP.
The confocal microscopy was conducted on cells treated with NCs and electroporated.
The exposition time to treatment was much shorter and did not exceed 10 min. The acquired
microphotographs are presented in Figure 5. Upon EP, the uptake of encapsulated drugs increased,
in particular for FA-PLGA-coated NCs (V3 and V4) in both cell lines. Additionally, a stronger
fluorescent signal was also found for the V2 (NCs-PLGA-PEG) nanosystem in electroporated ovarian
cancer cells. A very low fluorescent signal was detected when cells were not electroporated. Thus,
we conclude that EP is favorable when a short time of incubation is required for the therapeutic
protocol. Moreover, FA significantly enhanced toxicity against ovarian cancer cells. Our results are in
good correspondence with other studies that also indicate functionalization as a promising factor in
anticancer protocols [32,34].
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Figure 4. Influence of the nanocarrier surface on the encapsulated cargo uptake by SKOV-3 and
CHO-K1 cells evaluated by flow cytometry analysis. The uptake of NCs was expressed as mean
fluorescence intensity of VP in the gated cell population after 24 h incubation of cells with the loaded
PLGA NCs (V1–V5), control cells (control), empty nanocarriers (V6). and free VP (Vp). See descriptions
of the systems in Table 1.
Figure 5. Intracellular distribution of nanosystems after 24 h incubation with NCs (upper panel) or
10 min exposition to NCs after EP (lower panel) in (a) CHO-K1 cells and (b) SKOV-3 cells.
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3.4. Evaluation of PDT and EP-PDT
The results of photocytotoxicity studies for SKOV-3 cells are presented in Figure 6a. The cellular
viability was assessed after 24 h of incubation with the NCs followed by irradiation. We found that the
photodynamic effect increased proportionally to the concentration of the applied nanosystems. Longer
time of incubation induced a significant decrease of cellular viability (60–80% decrease), in particular
for the mixed cargo, proving the supportive anticancer effect of CisPt [35]. In Figure 6b,c, both types of
cells were first electroporated and then exposed to NCs for 10 min.
Figure 6. Photodynamic treatment (PDT) in SKOV-3 after 24 h of incubation with NCs (a) and
photodynamic reaction facilitated by EP after 10 min exposition to nanosystems (CVP = 1 μM) in
SKOV-3 (b) and CHO-K1 (c) cells. The missing red bars for V6 and free Cpt represent non irradiated
negative controls. See description of the NCs in Table 1. Data represented as means ± SD for minimum
n = 3, where * p ≤ 0.05 was judged as statistically significant.
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After irradiation that followed EP, we observed a significant decrease of cellular viability in
ovarian cancer cells in a short time, even in the lowest concentration of the applied NCs (CVP = 1 μM).
This is in agreement with another study showing that EP enhances photodynamic reaction efficacy
in the case of encapsulated drugs [12]. Thus, EP might be a promising and PDT-supporting tool for
time-limited anticancer therapies. It is also worth noting that empty NCs (V6) with or without EP
showed no toxic effect in SKOV-3 and CHO-K1 cultures, even at higher NC concentration (cell viability
above 90%), proving the protective effect of the PLGA shell.
4. Conclusions
In this work, we demonstrate that a rationally designed double emulsion process leads to
formulation of long-lasting, biocompatible, and “smart” NCs containing hybrid theranostic cargo with
different hydrophobicity. We have designed, engineered, and characterized the effective polymeric
nanocontainers (size ~200 nm) for efficient co-encapsulation of Cis-Pt and VP enabling drug delivery
and synergistic anticancer activity via standard PDT and EP-enhanced PDT against human ovarian
(SKOV-3) cancer cells. Loading hybrid cargo inside the oil core of NCs minimized its interaction
with water environment, and thus, no drastic changes in physicochemical properties of the cytostatic
drug and photosensitizer were observed. This feature is very favorable from the point of view of
any bio-related application. Furthermore, EP with only 5 pulses and short time of loading exposition
(10 min) enhanced delivery of encapsulated VP with all types of NCs. The highest photodynamic
potential was noticed when VP was co-encapsulated with Cis-Pt and the “smart” NC functionalization
with FA led to improved internalization by the SKOV-3 cells. Control CHO-K1 cells were significantly
less sensitive to PDT, EP, and EP-PDT. In summary, the presented results reveal that the designed
polymeric PLGA shells and colloidal cores in our NCs significantly improve PDT and EP-PDT and
warrant future in vivo studies in animal models to fully prove their use for theranostic applications.
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Abstract: The (±)-α-Tocopherol (TP) with vitamin E activity has been encapsulated into biocompatible
poly(lactic acid) (PLA) and poly(lactide-co-glycolide) (PLGA) carriers, which results in the formation
of well-defined nanosized (d ~200–220 nm) core-shell structured particles (NPs) with 15–19% of drug
loading (DL%). The optimal ratios of the polymer carriers, the TP active drug as well as the applied
Pluronic F127 (PLUR) non-ionic stabilizing surfactant, have been determined to obtain NPs with a TP
core and a polymer shell with high encapsulation efficiency (EE%) (69%). The size and the structure
of the prepared core-shell NPs as well as the interaction of the carriers and the PLUR with the TP
molecules have been determined by transmission electron microscopy (TEM), dynamic light scattering
(DLS), infrared spectroscopy (FT-IR) and turbidity studies, respectively. Moreover, the dissolution of
the TP from the polymer NPs has been investigated by spectrophotometric measurements. It was
clearly confirmed that increase in the EE% from ca. 70% (PLA/TP) to ca. 88% (PLGA65/TP) results
in the controlled release of the hydrophobic TP molecules (7 h, PLA/TP: 34%; PLGA75/TP: 25%;
PLGA65/TP: 18%). By replacing the PLA carrier to PLGA, ca. 15% more active substance can be
encapsulated in the core (PLA/TP: 65%; PLGA65/TP: 80%).
Keywords: vitamin E; tocopherol; PLA; PLGA; core-shell nanoparticles; drug delivery; controlled
drug release
1. Introduction
The encapsulation of the pharmaceutical ingredients in a macro- or a nanocarrier is a key factor
in nanomedicine developments [1–3]. Utilization of drug delivery systems can increase and prolong
the efficiency of the active drugs. Due to the good biocompatibility and structural properties, several
materials such as proteins and mostly biodegradable polymers, e.g., chitosan, alginate, hyaluronic
acid, poly(lactide) or poly(lactic acid) (PLA), polycaprolactone (PCL), poly(trimetilene-carbonate)
(PTMC), etc., have been widely used as potential carriers of the nanosized drug delivery systems [4–12].
Many types of PLA copolymers, such as poly(lactide-co-glycolide) (PLGA), polylactide-poly(ethylene
glycol) (PLA-PEG), poly(caprolactone-ethylene glycol-lactide) (PCELA), etc., are also well-known as
drug carriers [13–17]. As a result of copolymerization, the hydrophilicity of the PLA can be remarkably
tuned, which opens the possibility of encapsulating active ingredients that have hydrophilic or
hydrophobic character into the polymer matrix.
The (±)-α-Tocopherol (TP) is one of the highest biological activity fat-soluble vitamins from the
vitamin E family and is composed of eight tocopherols and tocotrienols (alpha (α), beta (β), gamma (γ)
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and delta (δ) isomers for both cases) [18]. Several studies focus on the encapsulation of the TP, because
vitamin E can prevent and treat many chronic and age-related diseases, e.g., Alzheimer’s disease [19].
Furthermore, the TP is described as functioning as an antioxidant, and the higher vitamin E content is
associated with a lower risk of several cancer diseases (kidney, lung, bladder, etc.).
Alqahtani et al. synthesized TP-loaded PLGA50 NPs with an average size of ca. 130 nm using
Polyvinyl alcohol (PVA) as a stabilizer, but only 4–4.5% of drug loading (in mg drug/100 mg PLGA)
was achieved [20]. However, Zigoneanu and coworkers increased the TP loading to 8–16% using
the PLGA50 carrier and PVA and sodium dodecyl sulphate (SDS) surfactant stabilizing agents, but it
was confirmed that the 86% of the drug dissolved for NPs (d ~220–280 nm) with 8% TP loading,
while 36% of the TP drug released from the NPs when the loading was 16% after 1 h [19]. However,
Astete et al. synthesized Span80-stabilized TP-containing PLGA50-based nanosized particles in the
range of 150–200 nm and the effect of salt concentration on the size and morphology of the NPs has
been interpreted, but data for the drug loading and release were not presented [21]. Murugeshu and
coworkers also synthesized chitosan/PLGA50-based TP-containing NPs with 8%, 16% and 24% initial
loading, but the EE% was only 45–50% and the release studies were carried out in gastrointestinal
conditions (pH ~1.50) [22]. Simon et al. successfully encapsulated the TP into PLGA50 using PVA,
but only 2.5 mg drug/100 mg NPs can be obtained [23].
In our previous work, the TP as well as the water-soluble derivative of TP (D, α-Tocopherol
polyethylene glycol 1000 succinate (TPGS)) and the non-steroidal anti-inflammatory ketoprofen (KP)
have been successfully encapsulated into PLA and PLGA75 (lactide:glycolide ratio 75:25) and PLGA65
(lactide:glycolide ratio 65:35) nanocarriers [13]. Instead of the commonly used and above mentioned
PLGA50, the PLGA65 and PLGA75 derivatives have been firstly used as carriers for the encapsulation
of TP, and the hydrophilicity properties of the carriers and the model drugs on the EE% have been
studied in detail. The release measurements of nanocomposites including hydrophobic drugs are very
difficult to carry out. In order to facilitate the above-mentioned studies, stabilizing agents such as
surfactants have been widely used [5,19]. Non-ionic poloxamer Pluronic F127 was applied previously,
which stabilized the drug-containing polymeric NPs by increasing the biocompatibility. The optimal
ratios of the carrier, the drug and the stabilizing agent have a dominant effect on the structure and the
EE%, as well as the controlled drug release process of the nanosized drug delivery systems, which
were not studied previously.
In the present work, the results of the TP-containing nanocomposites, using PLA, PLGA65 and
PLGA75 carriers, have been completed and the determinative role of the concentration of the polymer,
the TP and the PLUR stabilizing agent on the structure of the drug-containing nanocomposites has
been investigated. Moreover, the drug release studies of the prepared TP-containing PLA, PLGA65
and PLGA75 core-shell NPs have also been interpreted.
2. Materials and Methods
2.1. Materials
Polylactide (PLA, Mw = 72,200± 15,000 Da) and two poly(lactide-co-glycolide) (PLGA) derivatives
with a lactide to glycolide ratio at 75:25 (PLGA75, Mw = 69,900 ± 4000 Da) and at 65:35 (PLGA65,
Mw = 93,000 ± 1000 Da) were synthetized according to the previously published procedure [13].
Pluronic F127 (PLUR), (±)-α-tocopherol (TP) and sodium phosphate monobasic monohydrate
(NaH2PO4 · H2O, ≥99%) were obtained from Sigma Aldrich (Budapest, Hungary). Sodium phosphate
dibasic anhydrous (Na2HPO4, ≥99%) and sodium chloride (NaCl, ≥99%) were purchased from Molar
Chemicals (Halásztelek, Hungary). All other reagents and solvents were of analytical grade and used
without further purification. The deionized water was obtained by Millipore purification apparatus
(18.2 MΩ cm at 25 ◦C).
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2.2. Preparation of TP-Loaded PLA/PLGA NPs
The TP-loaded PLA/PLGA NPs were prepared by nanoprecipitation method (Figure 1).
The detailed experimental conditions were presented previously [13]. Briefly, the PLA/PLGA and TP
with increasing concentrations (see Table 1) were dissolved in 1.5 mL of acetone, which was dropped
slowly (10 μL/5 s) into the aqueous solution of the PLUR stabilizer (15 mL) under room temperature
using magnetic stirring with 1000 rpm. In the interest of the evaporation of acetone, the prepared
samples were further stirred (350 rpm) for two days. The dispersion was centrifugated with 40 mL
MQ water at 12,000 rpm (t = 15 min, T = 25 ◦C). After the supernatant was removed, the NPs were
redispersed in MQ water and the washing methods were repeated two times. The obtained NPs
samples were freeze-dried by liquid nitrogen and lyophilized (by Christ Alpha 1-2 LDplus apparatus).
Table 1. The concentration of the components, the average particle diameter, the polydispersity index
(PI), the encapsulation efficiency (EE%) and the drug loading (DL%) of the TP-loaded PLA NPs.






dDLS ± SD 1
(nm)




1.25 2.5 0.1 120 ± 33 0.120 ± 0.043 – –
2.5 2.5 0.1 156 + 28 0.039 ± 0.012 – –
5.0 2.5 0.1 179 ± 35 0.082 ± 0.049 – –




10.0 0 0.1 188 ± 37 0.092 ± 0.059 – –
10.0 0.5 0.1 189 ± 34 0.048 ± 0.028 91.28 4.36
10.0 1.0 0.1 192 ± 30 0.062 ± 0.032 75.61 7.02
10.0 2.5 0.1 201 ± 38 0.095 ± 0.026 69.11 14.73




10.0 2.5 0 179 ± 40 0.315 ± 0.040 72.19 15.29
10.0 2.5 0.05 178 ± 21 0.304 ± 0.095 98.34 19.73
10.0 2.5 0.1 201 ± 38 0.095 ± 0.026 69.11 14.73
10.0 2.5 0.5 206 ± 36 0.089 ± 0.065 57.94 12.65
10.0 2.5 1.0 212 ± 36 0.066 ± 0.029 40.75 9.24
1 The experimental error of the peak maximum is below 2.5%.
Figure 1. Schematic representation of the preparation of TP-loaded PLGA NPs stabilized by PLUR
using nanoprecipitation technique.
2.3. Characterization Methods
The particle size was determined by dynamic light scattering (DLS) with Horiba Sz-100 (HORIBA
Jobin Yvon, Longjumeau, France) equipped with a diode pumped frequency doubled (532 nm, 10 mW)
laser. The measurements were carried out at 25 ± 0.1 ◦C with 90◦ of detection angle in every case.
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The transmission electron microscopy (TEM) images were obtained by Jeol JEM-1400plus equipment
(JEOL Ltd., Tokyo, Japan) at 120 keV accelerating voltage. The Fourier transform infrared (FT-IR) spectra
of the PLA/PLGA-TP NPs were registered by a Jasco FT/IR-4700 with ATR PRO ONE Single-reflection
accessory (ABL&JASCO, Budapest, Hungary). The experiments were performed at room temperature
from 600 cm−1 to 3600 cm−1. The resolution of the spectra was 2 cm−1, which was determined by
128 interferograms.
The particles were dissolved in 1,4-dioxane to determine the EE% and DL% of the composites.
The absorbance spectra of the prepared solutions were measured by a Shimadzu UV-1800 UV-Vis
double beam spectrophotometer. The spectra were registered in the range of 200–500 nm using 1 cm
quartz cuvette at room temperature. The characteristic absorbance band of the TP appeared at 294 nm.
The concentration of the encapsulated drug was determined from the calibration curve (Figure S1).
The data of the EE% in w/w% were calculated by the total drug mass used in the synthesis of the NPs
(Equation (1)), while DL% was calculated by the mass of the NPs (Equation (2)).
EE% =
encapsulated mass o f drug
total mass o f drug in synthesis
× 100 (1)
DL% =
encapsulated mass o f drug
total mass o f the nanoparticles
× 100 (2)
2.4. Determination of the Solubility Properties of TP Drug
In order to determine the solubility of TP, 100 μL of acetone solutions of TP (5 mg·mL−1) was
added dropwise to 10 mL of PLUR solutions (0.1–1.2 mg·mL−1), and the turbidity was followed with a
Precision Bench Turbidity Meter LP2000 (Hanna Ins. Service Kft., Szeged, Hungary). The experiments
were performed in a pure aqueous medium and in a phosphate (PBS) buffer (pH = 7.4, 0.9% NaCl)
solution at 25 ◦C and 37 ◦C.
2.5. Critical Micelle Concentration (cmc) Studies
The critical micelle concentration (cmc) of the applied PLUR was determined by inverse titration
method in Krüss K100MK2 type surface tension equipment. The computer-controlled apparatus
was supplied with a thermostat and an automatic burette. The Wilhelmy-plate method was applied.
A volume of 50 mL of a 1.6 mM surfactant solution was titrated with MQ water or PBS in an aliquot of
10 mL in 40 steps. Each experimental point was the average of at least 5 measurements.
2.6. In Vitro Release Study
The in vitro studies of the different TP-loaded PLA/PLGA NPs were carried out by a UV-Vis
spectrophotometer (500–200 nm). The release experiments were performed at 37 ◦C and a PBS buffer
(pH = 7.4, NaCl 0.9%) containing 1 mg·mL−1 of PLUR was used, which facilitated the easier feasibility
of the release studies [5]. The TP-loaded samples were placed into the cellulose membrane (Sigma
Aldrich) with 5 mL of PLUR/PBS medium inserted into 35 mL of a dissolution phase. During the
measurements, 3 mL of the release media were taken at specified intervals to measure the released
concentration of TP at 268 nm.
The release curves of the TP can be fitted by different kinetic models, such as the first order,
Korsmeyer–Peppas, Peppas–Sahlin and Weibull models [24–27]. The measured points were fitted
with a nonlinear regression by the QtiPlot 0.9.8.9 svn 2288 program. During the calculation session,
the program finds the best fitting function for the measured points. The results consist of the fitted
parameters, their standard deviation and the goodness of fitting (root mean squared error).
Depending of the release chemical condition (such as temperature, buffer solution, ionic strength,
etc.), the shape of the polymers and the solubility of the drugs, the dissolution curves can be described
with different kinetic models. For our calculation, the following kinetic models were used.
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First order equation is a frequently used kinetic model. This formula is well applicable for drugs
where the dissolution is continuously changing over time and depends only on the concentration.
ct = ce−kt (3)
where ct is the concentration of the solid drug in the matrix of the carried system at t time, c0 is the
initial concentration of the drug and k is the first order release constant.
The Korsmeyer–Peppas kinetic formula is a semi-empirical power law equation where the shape




where ct is the concentration of the dissolved drug at t time, c0 is the initial concentration of drug, km is
the kinetic constant and n is the diffusion dissolution index (for sphere shaped particles n = 0.42 for the
diffusion-controlled mechanism, n = 1 for the Case II relaxation controlled mechanism and 0.42 ≤ n ≤ 1
for both of them).
The Weibull equation is a general empirical formula which can be used for all release profiles.





where ct is the concentration of the released component in t time, Ti is the lag time between the initial of
measurement and the release of drug (in most cases Ti = 0), a is the time scale of the process and b is the
shape parameter (shape of the release curve is exponential if b = 1, parabola if b < 1 or sigmoid if b > 1).
The kinetic formula reported by Peppas and Sahlin specifies the diffusion and the relaxation
contribution in the drug dissolution process.
ct
c0
= k1tm + k2t2m (6)
where ct is the concentration of the dissolved drug in the t time, c0 is the initial concentration of the
drug and k1, k2 and m are constants: k1 is the Fick diffusion contribution, k2 is the Case II relaxation
contribution and m is the diffusion exponent (sphere shaped: m = 0.43, Fick diffusion mechanism;
m = 0.85, Case II relaxation transport mechanism; 0.43 ≤ m ≤ 0.85, anomalous transport mechanism).
3. Results
3.1. Effect of the Component Concentrations on the Core-Shell Structure
In order to determine the role of the component quantities of the nanocomposites on the size
and the structure, as well as on the EE% the concentration, only one building block (polymer carrier,
drug or stabilizing agent) has been modified during the synthesis while the other parameters have
been kept constant. The average particle diameters of the NPs were measured by DLS, and the
results are summarized in Table 1. In case of PLA concentration dependence, regardless of the
amount of the TP (c = 2.5 mg·mL−1), the diameter of the NPs permanently increases from 120 nm
(cPLA = 1.25 mg·mL−1 in aceton phase) to ca. 200 nm (cPLA = 10 mg·mL−1 in the acetone phase). The
morphology and the structure of the NPs have been investigated by TEM images as well (Figure 2).
The images clearly represent that the structure of the TP/PLUR NPs in the absence of a polymer
shows less amorphous structures and TP crystal-like objects are observed. Moreover, we established
that an increase in the polymer concentration results in the formation of a well-defined core-shell
structure at cPLA = 10.0 mg·mL−1. At lower polymer concentrations, this structure is not formed, and
because of the low polymer concentration, the purification (centrifugation) of the NPs is impracticable;
thus, the determination of the EE% was not possible. For TP that is concentration-dependent, the
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diameters show a slightly increasing tendency to 2.5 mg·mL−1, but for a 5 mg·mL−1 amount of TP,
a higher size is obtained (dDLS = 252 nm) (Table 1). The TEM images also confirm this observation
(Figure 2). The well-defined core-shell structure is formed at 2.5 mg·mL−1 of TP quantity. With a
further increase in the TP amount, the core, including the drug, shows a rather crystallized structure
instead of the previously confirmed amorphous form. The EE% and the drug loading were determined
for all composites. We obtained that the value of the EE% decreased from 91.28% (cTP = 0.5 mg·mL−1)
to 66.15% (cTP = 5 mg·mL−1), while the DL% increased from 4.36% (cTP = 0.5 mg·mL−1) to 24.85%
(cTP = 5 mg·mL−1). Considering the expected size of the NPs for optimal nanosized drug delivery
systems (ca. 200 nm) as well as the crystallization of the core, the 2.5 mg·mL−1 amount of TP will
be used for further studies at 10.0 mg·mL−1 of PLA polymer concentration. Besides optimizing the
amount of carrier and active drug, the ratio of the stabilizing PLUR surfactant was also studied.
It was clearly confirmed that in the absence of PLUR, the TP molecules were not capsulated into the
polymer core, only the binding of the TP drugs onto the surface of the polymer shell is observed
(Figure 2). Furthermore, it was established that the smallest particle diameter (d = 178 nm), as well
as the highest DL% (ca. 20%), is obtained at 0.05 mg·mL−1 of PLUR concentration. Increase in the
PLUR amount resulted in a higher particle size (212 nm) as well as a lower DL% values (9%). Most
probably, the increase in the PLUR concentration facilitated the solubility of the hydrophobic TP,
thus hindering the encapsulation process. In order to confirm the above-mentioned phenomena,
turbidity measurements were carried out (Figure S2). According to the TEM images (Figure 2) and the
turbidity studies (Figure S2), we can conclude that a low quantity (0.1 mg·mL−1) of PLUR surfactant is
advantageous for the formation of PLA-based core-shell NPs, but the presence of a higher amount of
PLUR (>0.1 mg·mL−1) results in the decrease of the EE%. Moreover, the presence of a higher amount
of stabilizer (≥1.0 mg·mL−1) causes aggregation (Figure 2).
Figure 2. Representative TEM images of the TP-containing PLA NPs using different component
concentrations (PLA: 1.25–10.0 mg·mL−1; TP: 0–5.0 mg·mL−1 and PLUR: 0–1.0 mg·mL−1).
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Besides the determination of the optimal ratio of the composite building blocks, the TP was
encapsulated in PLGA75 and PLGA65 copolymers that have increasing hydrophilicity. During the NPs
synthesis, the previously optimized concentrations of the polymer carrier (10.0 mg·mL−1), the PLUR
(0.1 mg·mL−1) and the TP (2.5 mg·mL−1) were used. Based on DLS studies, we established that the
particle size increases from 203 nm to 226 nm with a decrease of the lactide part in the polymer
(Figure 3A). Using the optimized component quantities, the core-shell structure was confirmed for
PLGA75 and PLGA65-based TP-containing NPs (Figure 3B). The EE% and DL% has been determined
for the PLGA75 and PLGA65-based system as well, and we observed that the replacement of the PLA
carrier to PLGA75 and PLGA65 polymers resulted in the increase in the EE% to 75.72% and 87.69%,
respectively. In addition, the drug loading also increased from 14.73% (PLA) to 15.92% (PLGA75) and
to 17.98% (PLGA65) with decreasing lactide content. The higher EE% and DL% can be explained by
the fact that the precipitation of the more hydrophilic PLGA carriers is slower than that for PLA and
TP, which helps the formation of the well-defined core-shell structure [13].
 
Figure 3. The particle size distribution of the TP-loaded PLA and PLGA NPs (a), and representative
TEM images of the PLGA75–(b) and PLGA65–(c) based composites.
3.2. Structural Characterization of the TP-Loaded PLA and PLGA Core-Shell NPs
To determine the interaction between the PLA and TP, the composites have been examined by
infrared spectroscopy measurements. Figure 4 displays the spectra of the PLA-based NPs in the
absence (Figure 4A) and in the presence of TP at different concentrations (Figure 4B,C). The TP-sensitive
bands appear in the range of 3050–2800 cm−1 and 1150–1000 cm−1. It is obvious that the intensity
of all the determinative bands systematically increase by increasing TP content. At 2994, 2944 and
2968 cm−1, the asymmetric and symmetric CH stretching vibrations of the –CH2 and –CH3 groups
of the drug appear. Due to the increasing TP concentration, these bands become more intense,
indicating the presence of TP molecules in the polymer NPs. The carbonyl group of the PLA appears
at 1750 cm−1 [28,29]. The TP does not contain a C=O group, thus this band could originate only from
the polymer. In the fingerprint region (ν ≤ 1500 cm−1), the deformation and bending vibration of the
–CH3 and –CH2 groups appear at 1453, 1381 and 1267 cm−1, while the band at 1181 cm−1 attributes to
the stretching mode of the C–O–C (ester). At around 1086 cm−1, further bands of the C–O–C stretching
vibration can be observed, which have shoulders (symmetric and asymmetric stretching vibrations).
Because of the Ar–O–C group in the TP, the intensity of this C–O–C symmetric stretching vibration at
around 1050 cm−1 is increased. The band at 865 cm−1 and 751 cm−1 is characteristic of the polymer
carrier, and no shift is observed. The IR measurements performed for PLGA75 and PLGA65 resulted
in similar spectra. A strong irreversible interaction between the PLA (or PLGA75, PLGA65) and the TP
cannot be discovered (Figures S3 and S4), which facilitates the spontaneous release of the TP active
drug from the polymer NPs, but the presence of the TP in the different composites were definitely
confirmed by IR.
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Figure 4. IR spectra of the TP-loaded PLA NPs (A: cTP = 0 mg·mL−1; B: cTP = 2.5 mg·mL−1;
C: cTP = 5 mg·mL−1, cPLA = 10 mg·mL−1 and cPLUR = 0.1 mg·mL−1).
Turbidimetric measurements were performed to investigate the interaction between the TP and the
PLUR stabilizing agent in a pure aqueous solution and in PBS at 25 ◦C and 37 ◦C (pH = 7.4, 0.9% NaCl);
the results are presented in Figure 5. In MQ water (Figure 5A), the turbidity of TP is systematically
decreased till ca. 0.9 mg·mL−1 of PLUR concentration. Over time, more and more TP can dissolve in
this medium. In contrast, in the PBS solution at 25 ◦C and at 37 ◦C, the titration curves exhibit steeper
decreasing intensity, which may be due to the reduced critical micellization concentration (cmc) of
PLUR in the presence of salt. In the case of the PBS solution, the turbidity remains constant from
0.7 mg·mL−1 at 25 ◦C, while an increase in the temperature to 37 ◦C 0.6 mg·mL−1 value is observed.
It is important to mention that the solubility of the TP scarcely depends on time at 37 ◦C, which allows
the possible use of the PLUR stabilizing agent for in vitro drug release measurements.
It is well known that the surfactant affects the solubility of the TP drug in the absence of a polymer
carrier. Namely, above cmc, due to the micellization ability of the PLUR, the solubilization of the
drug dominates forming TP-loaded individual micelles, while below cmc, only the solubility increases.
Accordingly, the cmc of the PLUR was measured by surface tension measurements (Figure 6). In the
literature, very different values can be found; the obtained range of cmc is 2–7 mg·mL−1 [30,31].
Similar values were measured, but we determined that at 25 ◦C, the obtained cmc is decreased
from 4.92 mg·mL−1 to 1.99 mg·mL−1 in the presence of the phosphate buffer. If the temperature rises
from 25 ◦C to 37 ◦C, these values are further decreased. We can conclude that the concentration of the
PLUR in the composites is significantly lower than the cmc (4.92 mg·mL−1) value, which excludes the
presence of TP-loaded individual micelles.
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Figure 5. The turbidity of the TP in the PLUR solution at 25 ◦C in an aqueous medium (a), in a PBS
buffer at 25 ◦C (b) and at 37 ◦C (c) (pH = 7.4, 0.9 w/w% NaCl) (cTP = 0.05 mg·mL−1).
Figure 6. Determination of PLUR cmc at 25 ◦C in MQ water and in a PBS solution.
3.3. In Vitro Drug Release Experiments
The determination of the exact TP amount released from the different composites was carried
out by the UV-Vis spectrophotometric method. The spectra of the TP and the calibration curve are
presented in Figure 7. The absorption bands of the TP appear in the UV range.
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Figure 7. UV spectra of the TP in the PBS solution (cPLUR = 1.0 mg·mL−1, 0.9 w/w% NaCl).
After the characterization of the TP-loaded PLA and PLGA NPs, the mechanism of the drug release
was investigated. The drug dissolution profiles and the fitting of these curves by different kinetic models
are demonstrated in Figure 8 (Figure S5). The suitability of several models like Korsmeyer–Peppas,
Peppas–Sahlin, the first-order and the Weibull models were investigated. The release curves clearly
show that a high amount of TP is retained in the polymers after 7 h. It was also observed that in
the first half an hour, the dissolution of the drug occurs relatively quickly, but after that, measurable
slow dissolution is observed. Moreover, we found that the active substance is released slowly with
a decrease of the lactide part (PLA, 35.0%, PLGA75, 28.3%, PLGA65, 19.8%) in 7 h. The slowest
dissolution occurred in the carrier-free TP (15%). Because of the higher hydrophobicity, a higher
amount of the non-encapsulated drug can be attached to the surface of the particles, which confirms
the above-mentioned dissolution order [13]. Thanks to the application of the nanosized drug carrier
systems (polymer NPs), the TP molecules can bind to the enhanced specific surface area of the NPs,
which facilitates the dissolution of more TP, in contrast to the bulk TP.
Figure 8. Release profiles and different kinetic models-predicted (Peppas-Sahlin model (a),
Korsmeyer-Peppas model (b)) for the release curves of TP from PLA and PLGA NPs in the PBS
buffer (pH = 7.4, 0.9 w/w% NaCl).
Taking into account the coefficient of the determination (R2), the Peppas–Sahlin model was the
best kinetic formula for our systems (Table 2). The values of the Case II relaxation contribution (k2)
were negative in all cases; therefore, this model does not provide complete information about the
dissolution of the TP, but the low diffusion exponent (m) is referred to for the Fickian release.
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Table 2. Determined parameters of the TP release by fitting several kinetic equations.
Peppas–Sahlin Formulation k1 (min–m) k2 (min–2m) m R2
PLA/TP NPs 0.1371 −0.01346 0.260 0.9974
PLGA75/TP NPs 0.1165 −0.01189 0.248 0.9986
PLGA65/TP NPs 0.0572 −0.00412 0.317 0.9974
TP 0.0304 −0.00124 0.366 0.9978
Korsmeyer–Peppas Formulation km (min–n) n R2
PLA/TP NPs 0.1339 0.182 0.9898
PLGA75/TP NPs 0.1120 0.175 0.9982
PLGA65/TP NPs 0.0592 0.223 0.9904
TP 0.0310 0.311 0.9977
Weibull Formulation a b R2
PLA/TP NPs 6.52 0.178 0.9896
PLGA75/TP NPs 7.85 0.166 0.9819
PLGA65/TP NPs 15.45 0.220 0.9898
TP 28.19 0.285 0.9945
First Order Formulation k (min–1) R2
PLA/TP NPs 0.0094 0.9792
PLGA75/TP NPs 0.0113 0.9532
PLGA65/TP NPs 0.0130 0.9514
TP 0.0079 0.9856
The second-best kinetic model was the Korsmeyer–Peppas model where the diffusion dissolution
index (n) gives the information about the diffusion and the erosion of the matrix. The values of the n are
increased from n = 0.182 (PLA) to n = 0.223 (PLGA65), which is referred to for the diffusion-controlled
quasi Fickian drug release. Furthermore, it is important to note that the value of the diffusion dissolution
index is lower than 0.42. This is caused by the high polydispersity of the particles (because they are
lyophilized) and the very low degradation of the polymers [32]. Presumably, the Case II relaxation
contribution from the Peppas–Sahlin model will be low by these effects.
During the slow degradation of the PLA/PLGA carrier, the drug diffuses with difficulty from
the core of the particles. The measured and calculated results clearly stated that the released drug
originates from the surface region of the particles. Based on this, we could calculate the approximate
quantity of the TP in the core of the particles after 7 h: 65.0% (PLA), 71.7% (PLGA75) and 80.2%
(PLGA65) from the encapsulated mass of the TP; therefore, a significant amount of the active ingredient
can be encapsulated inside the particles.
4. Conclusions
In the work presented here, the successful encapsulation of the hydrophobic α-Tocopherol, one of
the determinative natural forms of vitamin E, was carried out using the PLA, PLGA75 and PLGA65
biocompatible polymer carriers by increasing hydrophilicity. To the best of our knowledge, we first
proved the formation of well-defined nanosized TP-core PLA/PLGA-shell structured nanocomposites.
Optimization of the experimental conditions, such as optimal concentration of drug, polymer carrier
and stabilizing PLUR non-ionic surfactant, resulted in the formation of core-shell NPs within the
diameter range of ~200–220 nm. For the PLA-based system 14.7% of drug loading was achieved,
where most of the TP molecules are encapsulated in the core (65%), while the remaining part of the
active ingredient is located on the surface of the polymer shell. By replacing the hydrophobic PLA
to PLGA copolymers, both the drug loading (PLGA75: 16%, PLGA65: 18%) as well the EE% can be
increased (PLA/TP: 69.1%; PLGA75/TP: 75.7%; PLGA65/TP: 87.7%). Furthermore, the PLGA-based
composites contain 71.7% and 80.2% of the encapsulated TP in the core. Considering the slower
precipitation ability of the PLGA copolymers in contrast to the PLA and the active ingredient, the higher
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encapsulation efficiency can be explored. Besides the preparation and the characterization of the
composites, the drug release was also studied. The dissolution curves clearly show that depending on
the polymer, more than 65–80% of the TP is contained in the composites after 7 h. In the first half an
hour, the dissolution of the drug occurs relatively quickly, but after that, measurable slow dissolution
was observed. Moreover, we found that the active substance is released slowly with decreasing
lactide part (PLA, 35.0%; PLGA75, 28.3%; PLGA65, 19.8%) in 7 h. Thanks to the biocompatibility,
cost-effectivity and tuneable hydrophilic properties, the PLA/PLGA polymers are potential candidates
for controlled drug release and for the encapsulation of hydrophobic TP or similar sized and structured
molecules in core-shell nanosized particles.
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Abstract: One of the goals of the pharmaceutical sciences is the amelioration of targeted drug delivery.
In this context, nanocarrier-dependent transportation represents an ideal method for confronting
a broad range of human disorders. In this study, we investigated the possibility of improving the
selective release of the anti-cancer drug paclitaxel (PTX) in the gastro-intestinal tract by encapsulating
it into the biodegradable nanoparticles made by FDA-approved poly(lactic-co-glycolic acid) (PLGA)
and coated with polyethylene glycol to improve their stability (PLGA-PEG-NPs). Our study was
performed by combining the synthesis and characterization of the nanodrug with in vivo studies
of pharmacokinetics after oral administration in mice. Moreover, fluorescent PLGA-nanoparticles
(NPs), were tested both in vitro and in vivo to observe their fate and biodistribution. Our study
demonstrated that PLGA-NPs: (1) are stable in the gastric tract; (2) can easily penetrate inside
carcinoma colon 2 (CaCo2) cells; (3) reduce the PTX absorption from the gastrointestinal tract, further
limiting systemic exposure; (4) enable PTX local targeting. At present, the oral administration of
biodegradable nanocarriers is limited because of stomach degradation and the sink effect played by
the duodenum. Our findings, however, exhibit promising evidence towards our overcoming these
limitations for a more specific and safer strategy against gastrointestinal disorders.
Keywords: PLGA-NPs; nanomedicine; gastrointestinal tract; paclitaxel; in vivo imaging
1. Introduction
The generation of therapeutic methods that can improve the organ specificity of many different
types of therapeutic agents is one of the major challenges of 21st-century pharmacology [1].
The availability of transport systems that can successfully improve the targeted release of administered
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substances would be, indeed, crucial in mitigating or even virtually eliminating the toxic side
effects of already existing therapeutics. These improved transport systems can be used to limit the
off-target spread and, consequently, reduce the potential side effects deriving from an unnecessary
tropism [2]. Several strategies have been employed in the last years to improve the accuracy of drug
targeting. Quite recently, our group and others have demonstrated that the systemic administration of
anti-inflammatory and immunomodulatory agents, such as corticosteroids, can have a safer and more
effective pharmacological profile when linked to a nanometric vector [3,4]. The potential prospects of
nanocarriers for pharmacological purposes is extremely versatile complex. It is widely known that
even the slightest modification of basic physicochemical strictures, such as the dimension, shape, and
surface of the material itself, can indeed lead to a myriad of different results—causing a very vast
range of reactions amongst the cells and organs of the host [5]. One of the primary and certainly most
prominent, therapeutic strategies is the incorporation of the anti-neoplastic drug doxorubicin into
liposomes for the treatment of tumors [6]. The first generation of nanoparticles (NPs) used for these
purposes are mainly liposomes, polymeric micelles, and conjugates.
Since the turn of the century, the encapsulation of anti-neoplastic cytotoxic molecules inside
NPs has been occurring with greater frequency. In 2004, an original formulation for the creation
of nanocarriers to transport the anti-cancer drug paclitaxel (PTX) was developed [7,8]. In that case,
different from other carriers, the biodegradable copolymer poly(lactic-co-glycolic acid) (PLGA) was
utilized. In a more recent study, furthermore, it was shown that the systemic administration of
PTX inside poly(lactic-co-glycolic acid)-polyethylene glycol-nanoparticles (PLGA-PEG-NPs), when
functionalized with ANTI-EGFR, dramatically slows disease progression in triple-negative breast
cancer-bearing mice, thus confirming the high efficacy, safety, and tenability of this material [9].
Nanoparticles utilizing FDA-approved PLGA, exhibit some important advantages. In particular,
their biocompatibility causes low systemic toxicity in comparison to other polymers [10] and is highly
versatile, allowing them to encapsulate various drugs, including small molecules and therapeutic
biologics [11–13]. The importance of PLGA nanocarriers in biomedicine is further supported by
evidence of its potential benefits in assisting drug transportation across biological barriers [14,15].
Most of their applications concern intravenous administration [16], but, in the last decade, many
studies have been published regarding their potential efficacy in oral administration of drugs, even if
the absorption efficiency needs to be more deeply investigated and optimized [17].
Although the majority of studies dealing with biodistribution, disease targeting, and therapeutic
efficacy of NPs-based drug delivery systems has been conducted using systemic administration
of nanoformulation, more recently the exploration of alternative routes, including topical [18,19],
intranasal [20], intratracheal [21], and oral administration [22], are gaining increasing recognition.
Building on these advances, this work aimed to characterize the biodistribution of PTX alone
or encapsulated in PEGylated PLGA-NPs after oral administration in healthy mice. This approach
stems from the hope that, in so doing, the passage of the drug from the gastrointestinal (GI) tract to
the bloodstream might be reduced, although not completely eliminating its release in the gut. While
the active gastroduodenal absorption of PTX on oral ingestion is quite low, it is not possible to totally
exclude systemic toxicity of both circulating cells and filter organs in the case of high doses or repeated
cycles of chemotherapy. PLGA-NPs could, therefore, be useful to both protect the drug against gastric
degradation and, at the same time, reduce the uptake by mucosae villi or Peyer’s patches and the
consequent release into the blood, while PEG grafting is expected to improve both the NPs stability
and mucus-permeating properties in the GI tract [23,24]. In this study, PLGA-PEG-NPs were orally
administered either loaded with PTX or labeled with a fluorophore (Rhodamine B), which allowed for
the longitudinal tracking of NPs in both gastrointestinal and peripheral organs. This study could be of
interest to understand the potentials of local delivery of anti-cancer agents in GI tumors by the oral
administration of NPs, minimizing nonspecific absorption.
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2. Materials and Methods
2.1. Nanoparticles Synthesis
2.1.1. Materials
PLGA (Resomer® RG 504 H, 50:50 lactide:glycolide, acid terminal, MW 38,000–54,000 g/mol),
paclitaxel (PTX, MW 853.91 g/mol), rhodamine B (RhB, MW 479.01 g/mol); polyvinlyl alcohol (PVA,
MW 9000–10,000 g/mol, 80% hydrolyzed); N,N′-dicyclohexylcarbodiimide (DCC, MW 206.33 g/mol,
99%); N-hydroxysuccinimide (NHS, MW 115.09 g/mol, 98%); dimethylamino pyridine (DMAP,
MW 122.17 g/mol, 99%); ninhydrin (MW 178.14 g/mol); ethanolamine (MW 61.08 g/mol, ≥98%);
dichloromethane (DCM, ≥99.8%); dimethyl sulfoxide (DMSO, ≥99.9%); acetonitrile anhydrous (ACN,
99.8%); methanol (MeOH, ≥99.9%) were purchased from Sigma–Aldrich Co (St Louis, MO, USA).
Chloroform (≥99.8%) was purchased from Honeywell Riedel-de-Haën™ (Charlotte, NC, USA)).
Poly (ethylene glycol) diamine (NH2-PEG-NH2, 6000 Da) was obtained from Rapp Polymer GmbH,
(Tuebingen, Germany).
2.1.2. PLGA-PEG-RhB Synthesis
For activation of the carboxylic groups of PLGA, the polymer was dissolved in DCM (15 mL,
40 mg/mL) and the reaction was performed in a round flask for 4 h (250 rpm, RT, under inert gas) after
the addition of DCC (30 mg) and NHS (15 mg). Then, the solution was diluted with diethyl ether, and the
polymer was collected after precipitation (20 min, 6200× g, 4 ◦C) and evaporation of the residual organic
phase. Next, the conjugation with NH2-PEG-NH2 (molar ratio PEG/PLGA = 2.7) was performed in
10 mL of CHCl3 overnight (250 rpm, RT, under inert gas). To get rid of the unconjugated PEG, methanol
(30 mL) was added, and the polymer was collected after precipitation twice [25]. The residual organic
phase was then evaporated under reduced pressure, and the weight yield calculated (68.99 ± 14.94%).
The degree of labeling was determined using the colorimetric ninhydrin assay (primary amine
detection): Notably, 15 mg of the product (PLGA-PEG) was solubilized in DMSO (400 μL) then diluted
with 100 μL of ninhydrin solution (3.5 mg/mL). Ethanolamine (18.75 mg/mL) and PLGA solutions
were used as positive and negative controls, respectively. The samples were then incubated for 1 h at
65 ◦C (400 rpm), and the colored conjugate was detected by UV-Vis spectroscopy (Spectrophotometer
Fluormax-Horiba Scientific, Rome, Italy) (λ = 600 nm), and the yield calculated using a calibration
curve of ethanolamine standards. The obtained degree of labeling was 71.90 ± 12.70%.
Finally, RhB (molar ratio RhB/PLGA = 6.25) was added to the PLGA-PEG solution in CHCl3
(15 mL) with an excess of DCC and DMAP. The reaction was carried out overnight (250 rpm, RT, under
inert gas). At the end of the reaction, the solution was evaporated, and the product was solubilized with
DCM (10 mL) and purified thrice by precipitation (20 min, 4 ◦C, 6200× g) after diethyl ether addition
(20 mL). The reaction yield was 38.16 ± 13.50%. RhB linked was detected by fluorescence spectrometry
(λexitation 555 nm; λemission 574 nm) and the degree of labeling calculated by the comparison with a
calibration curve (1.43 ± 0.46 μg/mg).
2.1.3. Synthesis of PLGA-PEG-RhB-NPs and PTX-PLGA-PEG-RhB-NPs
NPs were synthesized according to the single emulsion method. PLGA-PEG-RhB solution (1 mL,
25 mg/mL in DCM) was emulsified with 8 mL of PVA 2% solution by sonicating twice (Sonifier
Sound, Branson Ultrasonics, Shanghai, China; 30 s and 38% intensity) in an ice bath. The product
was transferred immediately into a solution of PVA 2% (16 mL), allowing the organic solvent to
evaporate (4 h, RT, 750 rpm). For PTX-PLGA-PEG-RhB-NPs synthesis, 5 mg of PTX was dissolved
along with the polymer. After curing, NPs were collected by centrifugation at 19,500× g, 20 min, 4 ◦C
(Heraeus Fresco 21; Thermo Fisher Scientific, Göteborg, Sweden), washed thrice with double distilled
water and freeze-dried through an Alpha 1–2 LD freeze drier (Christ, Memmingen, Germany) at
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0.500 mbar, −53 ◦C, 12 h, without the addition of any cryoprotectant. The process yield was calculated
after the freeze-drying process, as the ratio between collected NPs and starting raw materials.
The amount of PTX loaded in the NPs was determined by HPLC analysis with UV detection
(Waters Associates, Milford, MA, USA, model 2487 Variable Wavelength Detector, Wavelength: 230 nm).
Briefly, 0.1 mL of the NPs solution was spiked with 5 μg of IS and extracted with 0.5 mL of CH3CN.
After vortex for 10 s, samples were centrifuged at 13,000 rpm for 10 min. The organic phase was
separated and dried under nitrogen, and the residues were dissolved with 250 μL of the mobile phase.
Fifty microliters of the reconstituted samples was injected into the HPLC system. The apparatus was
equipped with a Symmetry C18 column (5 μm, 4.6 × 150 mm), the mobile phase was composed of
50% ammonium acetate buffer (0.01 M, pH 5), 40% acetonitrile, and 10% methanol with a flux rate of
1.3 mL/min and 30 min run time. NPs solution without drug was used to prepare the calibration curve
by the addition of PTX in the range 10–100 μg/mL.
2.2. Nanoparticles Characterization
2.2.1. Dynamic Light Scattering (DLS) and Zeta Potential Measurements
All NPs were characterized in terms of size, size distribution, and Zeta potential through
dynamic light scattering (DLS, Zetasizer Nano ZS; Malvern Instruments, Cambridge, UK) in ultrapure
water at 1 mg/mL, at 25 ◦C. The scattered light from the NPs in suspension was used to calculate
NPs’ hydrodynamic diameter considering medium viscosity. NPs size distribution was described by
the polydispersity index (PDI), where PDI ≤ 0.2 corresponds to the monodisperse NPs population.
2.2.2. Scanning Transmission Electron Microscopy (STEM) Analysis
PLGA-PEG-RhB-NPs were observed by a Zeiss SEM-FEG Gemini 500, operating at 30 kV in
scanning transmission electron microscopy (STEM) mode (Zeiss, Germany). The NPs suspension was
deposited onto a formvar-coated 200-mesh copper grid (Ted Pella, CA, USA), negatively stained with
1% uranyl acetate and allowed to dry before examination.
2.2.3. In Vitro Release Studies
PTX-PLGA-PEG-RhB-NPs equivalent to 8.75 μg of PTX were suspended in 1 mL of Tween/PBS
and incubated at 37 ◦C with constant agitation. At predetermined time points (0.5, 1, 2, 4, 6, and 24 h),
the suspension was centrifuged at 19,500× g for 15 min to separate NPs pellets and supernatants. PTX
in the collected supernatants was analyzed with HPLC equipped with a UV detector (1260 Infinity
II Series, Agilent Technologies, Palo Alto, CA, USA) and an Atlantis C18 column (25 cm × 4.6 mm,
particle size 5 μm) (Supelco, St. Louis, MO, USA). The mobile phase was a mixture of acetonitrile and
water (50:50) run in the isocratic mode at a flow rate of 1 mL/min. PTX was detected at 227 nm. PTX
quantitation was performed using a calibration curve in a range of 1.25–40 μg/mL, and the results were
expressed as a percentage of cumulative release (mean ± SD; n = 4).
2.2.4. Nanoparticles Stability in Different Buffers
The hydrodynamic dimension of the nanocarrier was analyzed in different conditions: Artificial
saliva (pH 7.6; KH2PO4 1.9 mM, NaHCO3 17 mM, Na2HPO4 1.8 mM, NaCl 8.5 mM, KSCN 3.4 mM,
Urea 2.2 mM, alpha-amylase 0.007 mM), intestinal fluid (pH 6; KH2PO4 49.96 mM, NaOH 0.0154 M,
pancreatin 1 g/L), and gastric juice (pH 1.2; NaCl 300 mM, pepsin 0.9 mM, HCl 840 mM) that simulate
the media in GI tract. The NPs (15 mg/mL) were incubated for 0, 1, 2, 4, 6, and 24 h and analyzed by DLS.
Upon establishing the size stability, the samples were further analyzed with fluorescence spectroscopy
(λexitation 555 nm; λemission 574 nm) to monitor the stability of RhB conjugation. The release of RhB after
24 h was then calculated after PLGA-PEG-RhB-NPs removal by centrifugation (mean ± SD; n = 4).
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2.3. Cells
Carcinoma colon cells (CaCo2) are a cell line derived from human colorectal adenocarcinoma
and were purchased from ATCC® HTB-37™. CaCo2 cells were grown as a single layer in adhesion in
DMEM-High Glucose (Dulbecco′s Modified Eagle Medium High Glucose-Biowest, Nuaillé, France)
with the addition of 10% of fetal bovine serum (FBS) and 1% l-glutamine (200 mM), 100 U/mL
penicillin, 0.1 mg per mL streptomycin. Cells were maintained at 37 ◦C and in a 5% CO2 humidified
atmosphere. The ability of PLGA-PEG-RhB-NPs and free RhB to be internalized by CaCo2 cells
was evaluated. For each condition, the experiment was conducted in triplicate. Cells were seeded
at a density of 40,000 cells/well on 13 mm diameter slides in 24-well plates. Forty-eight hours
after sowing, CaCo2 cells were incubated with PLGA-PEG-RhB-NPs (100 μg/mL) and with RhB free
(0.06 μg/mL) for 1, 4, and 24 h, while the wells destined for control did not receive any treatment.
After incubation, the cells were washed with phosphate-buffer saline (PBS) three times and fixed with
a 4% paraformaldehyde solution dissolved in PBS (0.1 M, pH 7.4) for 40 min and the vital nuclear
dye Hoechst 33258 (2 μg/mL) was added to each well for 45 min. The slides thus obtained were
assembled and analyzed with the Olympus BX51 epifluorescence microscope (Olympus, Tokyo, Japan).
All acquisition parameters, including laser settings, were kept constant during all scans. To evaluate
a possible cytotoxic effect of PLGA-PEG-RhB-NPs and free RhB, the metabolic activity of CaCo2
cells was evaluated by RealTime-Glo™MT Cell Viability Assay (Promega, Madison, WI, USA). Cells
were seeded at 16,000 cells/well in 96 opaque-walled tissue culture plates and maintained at 37 ◦C.
The RealTime-Glo reagents were added at the same time as the test compounds, according to the
manufacturer’s protocol. At selected time points (4 and 24 h), the cell viability was monitored by
a plate-reading luminometer (GloMax® Discover Microplate Reader, Promega, Madison, WI, USA).
For each condition, 6 replicates were prepared. The viability was expressed as a percentage compared
to non-treated cells.
2.4. Animals
All procedures involving animals and their health were conducted so as to minimize the number of
mice used and their collateral suffering, in accordance with institutional guidelines, national laws (DL n.
24, 4 March 2014; Authorization No. 19/2008 A) and international laws and agreements (EEC Council
Directive 2010/63, 6 August 2013; NIH Guide to the Care and Use of Laboratory Animals, US National
Research Council, 2008). The research project was first reviewed by the Internal Ethics Committee of
the Mario Negri Institute and was subsequently approved by the ministry and designated with the
before mentioned code (42/2016-PR).
All animals were housed in SPF (specific pathogen-free) conditions. The housing rooms had
a temperature of 22 ± 1 ◦C, relative humidity values ± of 50 ± 10% and a 12 h light/dark cycle.
Furthermore, the animals were kept in cages with free access to water and food.
2.5. Treatments
As regards pharmacokinetics, six weeks old CD1 mice were treated by oral gavage with 20 mg/kg
of Cremophor PTX (n = 16) or PTX-PLGA-PEG-RhB-NPs (n = 16), three animals were treated with
saline solution as control. Blood was collected in heparinized tubes, 30 min, 1, 4, and 24 h after
treatment (4 animals for each group) and centrifuged to obtain plasma. After the mice were sacrificed,
the stomach, duodenum, colon, and liver were collected and stored at −20 ◦C until analysis.
For the biodistribution studies, we recruited 5 animals for each experimental group. To reduce
background fluorescence due to the food, mice were fed an AIN-76A diet without alfalfa (Mucedola
s.r.l., Settimo Milanese, Italy) for two weeks before the analyzes. The dose of the different formulations
was standardized on the quantity of RhB present and fixed at 0.6 mg/kg mouse based on previous
experimental studies. Vehicle treated mice received the same volume of saline solution. Mice were
sacrificed at 1, 4, or 24 h to follow the fate of RhB. The sacrifice was performed by cervical dislocation,
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and the stomach, intestine, liver, and blood were collected to perform ex vivo analyses. Plasma
for fluorometric analysis was obtained from the blood collected. Finally, a piece of liver and GI
tracts of three animals for each experimental group were frozen at −80 ◦C for cryostatic sections
and histological analysis.
2.6. Molecular Imaging and Histology
The in vivo biodistribution of the different formulations was monitored over time using an optical
fluorescence imaging system (IVIS Lumina XRMS, PerkinElmer, Waltham, MA, USA). Ex vivo scans
of organs from mice sacrificed at 1, 4, and 24 h after the treatment were performed by the same
instrument. The following acquisition parameters were used: Excitation filter: 580 nm, emission
filter: 620 nm, exposure time: Auto, binning factor: Medium, f/Stop: 2, Field of View: D (for the
gastro line—intestinal), C (for peripheral organs). Very importantly, the Living Image Software
4.3.1 (Perkin Elmer, Waltham, MA, USA) conjugated with the spectral unmixing system was used
to separate the RhB signal from tissue autofluorescence, image processing, and fluorescence signal
quantification analysis.
Longitudinal sections of 20 μm of thickness were prepared and then, after adhesion in glass slides,
were incubated with a PBS solution of Hoechst 33258 (2 μg/mL, Sigma–Aldrich) for 45 min and, after
three washes in PBS, observed at the Microscopy Virtual Slide (Olympus, Tokyo, Japan), to obtain
rapid organ scans of the whole section with high anatomical resolution.
2.7. NPs Characterization from Homogenates and Biological Fluids
The fluorescence of PLGA-PEG-RhB-NPs was analyzed in tissues explanted from previously
treated animals. The analyzed tissues were liver, stomach, intestine, and plasma. Each tissue sample
was weighed, homogenized in PBS 1X according to a 1:4 weight ratio, and centrifuged at 1200 rpm for
10 min at 4 ◦C. For all samples, the analysis was performed using the Infinite® M200 multimode plate
reader exciting at the wavelength of 500 nm and recording the signal at a range of emission wavelength
from 550 to 560 nm. For the stability studies in solutions mimicking gastrointestinal fluids, the NPs
were incubated in stock solutions as previously described [26].
2.8. Pharmacokinetics
The total concentration of PTX in the different biological matrices was determined by HPLC-UV, as
previously described [27]. For the determination of PTX in organs, tissues were previously homogenized
in 0.2 M CH3COONH4 pH 4.5. Each study sample (0.3 mL for plasma and 0.5 mL for homogenate
tissues) was assayed together with five points of a standard calibration curve prepared in the
corresponding control biological matrix obtained from untreated mice at concentrations ranging from
0.05 to 5 μg/sample. The limits of quantification (LOQ) were 0.16 μg/mL and 0.6 μg/g for plasma and
organs, respectively.
2.9. Statistical Analysis
All data were expressed as mean± SD, Student’s t-test and p values were done using the GraphPad
Prism version 6.00 for Windows (Graph-Pad Software, San Diego, CA, USA).
3. Results and Discussion
3.1. NPs Synthesis and Characterization
The protocol for the polymer modification was set up, and PLGA-PEG-RhB was employed to
synthesize the NPs to be used as carriers for PTX. The covalently bound RhB chromophore allowed the
tracking of the PLGA fate in vivo. The single emulsion method allowed us to obtain both unloaded and
PTX-loaded NPs, having controlled size and homogenous size distributions (Table 1). As measured
by DLS analysis, the encapsulation of PTX did not significantly change the dimensional features
172
Pharmaceutics 2019, 11, 658
of NPs. Moreover, a negative Z-potential was observed as opposed to PLGA-PEG-NPs, where the
free amines of PEG determined the surface properties. However, a small difference in net negative
charge values between PLGA-PEG-RhB-NPs and PTX-PLGA-PEG-RhB-NPs was attributable to the
intramolecular reorganization of portions of the polymer chains due to hydrophobic interaction with
PTX. PTX loaded NPs were further characterized by STEM, which showed pseudospherical shaped
nanoparticles with the size around 200 nm (Figure S1). PTX encapsulation efficiency detected by HPLC
analysis was 10.87 ± 1.13%, while the calculated loading efficiency was 4.77 ± 0.15%, in line with
previous studies [28]. The drug release performance was evaluated, and the test was conducted in
PBS containing 0.2 v/v % Tween 80, considering both its poor solubility and the analysis detection
limits [29]. As previously reported with similar experimental settings, a fast PTX dissolution was
observed (80% within 4 h) (Figure S2) [30].
Table 1. NPs characterization and process yield. Data represent mean ± SD (n = 3).
Formulations
Size




(%, w/w ± SD)
PLGA-PEG-NPs 190.3 ± 12.7 0.078 ± 0.032 +17.9 ± 5.9 53.3 ± 7.7
PLGA-PEG-RhB-NPs 205.6 ± 18.6 0.168 ± 0.030 −18.2 ± 1.5 50.1 ± 13.4
PTX-PLGA-PEG-RhB-NPs 201.6 ± 26.2 0.205 ± 0.032 −13.3 ± 1.7 39.3 ± 7.3
Stability in Mimicking Biological Fluids
The first study was carried out to verify the potential role of PEG on the fate of PLGA-NPs
in solutions mimicking saliva, gastric, and proximal intestinal fluid, respectively (Figure 1A,B).
Longitudinal measurement of the NPs size by DLS was possible because, diversely from the serum,
they are very poor in macromolecules, and the interference on the recording is almost zero. Figure 1A
shows that the presence of the PEG confers to PLGA-NPs a long-lasting stability for at least 24 h after
incubation. In contrast, the lack of PEG rapidly induced aggregation in NPs incubated in gastric fluid
and, to a lesser extent in intestinal fluid. Since we aimed to conserve considerable stability up until the
large intestine, we decided to carry on our studies using pegylated PLGA-NPs exclusively.
Figure 1. Graphics showing the diameter, measured by dynamic light scattering (DLS), after incubation
of (A) pegylated or (B) not pegylated poly(lactic-co-glycolic acid)-nanoparticles (PLGA-NPs) in artificial
fluids mimicking the saliva (green lines), the gastric juice (blue lines), or proximal intestinal fluid
(yellow line). For all conditions, the measurements were carried out at 1, 2, 4, 6, 24 h from the starting point.
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Then, the stability of the RhB conjugation was performed by measuring the dye release in the
same conditions (Figure 2A). After 24 h of incubation, the released RhB was below 15% in all cases,
suggesting the system reliability for in vitro and in vivo NPs tracking. Additionally, as reported in
Figure 2B, the fluorescence intensity of PLGA-PEG-RhB-NPs was not greatly affected by the incubation
media showing that, once conjugated, the dye abolishes its pH-dependent emission properties [31].
 
Figure 2. Graphics showing (A) the amount of RhB released from PLGA-PEG-RhB-NPs after
24 h incubation in artificial fluids mimicking the saliva, the gastric juice, or proximal intestinal
fluid (mean ± SD; n = 5); (B) emission spectra of poly(lactic-co-glycolic acid)-polyethylene
glycol-RhB-nanoparticles (PLGA-PEG-RhB-NPs) incubated in different media.
3.2. Pharmacokinetics
To understand the possible influence of the nanoformulate on the biodistribution of drugs, we
performed a pharmacokinetic study of the well-known anti-cancer agent, paclitaxel, administered
orally as a free drug (PTX) or loaded into NPs (PTX-PLGA-PEG-RhB-NPs). PTX release Figure 3 shows
the levels of PTX measured in the stomach (A), in the duodenum (B) and in the colon (C) of mice
sacrificed 30 min, 1 and 4 h after treatment with PTX free (blue bars) or with PTX-PLGA-PEG-RhB-NPs
(red bars). The drug concentration in the samples collected at 24 h after treatment resulted under the
limit of detection. Overall, the drug concentration measured in all the gastrointestinal tissues was
comparable between the two formulations and higher in the stomach and duodenum compared to
the colon. Despite the comparable tissue drug level, interestingly, the nano-formulation reduced the
systemic absorption of the drug. The measurement of the plasmatic levels, in fact, showed a clear
reduction of systemic absorption of PTX when administered as PTX-PLGA-PEG-RhB-NPs, leading to a
consequent reduction of liver accumulation, as shown in Figure 3D,E. Similarly to previous results
achieved by our group [32,33], no evidence of acute toxicity was observed in mice receiving the single
administration of PTX-PLGA-PEG-RhB-NPs.
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Figure 3. Comparison of the paclitaxel (PTX) distribution in (A) stomach, (B) duodenum,
(C) colon, (D) plasma, and (E) liver of mice after administration of a single treatment of PTX or
PTX-PLGA-PEG-RhB-NPs (20 mg/kg p.o.). The bars are the mean value ± SD (n = 4).
3.3. NPs Biodistribution and Nanosafety
To better understand the mechanisms that govern the different behavior of the free and
NPs-encapsulated drug, we decided to monitor the NPs transit at the digestive tract level, the
interactions with the gastric and intestinal structures, the possible transition to the bloodstream and
penetration into filter organs by marking PLGA with a fluorescent molecule, RhB. Since the monitoring
of biodegradable NPs through an indirect method, such as fluorescence analysis, presents the risk
of artifacts caused by the dye release or degradation [34], all studies were carried out by comparing
animals that received PLGA-PEG-RhB-NPs with those animals treated with the same dose of free RhB.
As the in vitro studies suggested, the stability and reliability of this indirect approach (see Figure 2),
enable us to obtain further evidence from the biodistribution study that explains the different behavior
between an orally administered small molecule and our nanocarrier.
Figure 4A shows the distribution of the signal associated with the GI tract in animals sacrificed 1,
4, and 24 h after treatment with the vehicle (left) or RhB (upper blue panel), and PLGA-PEG-RhB-NPs
(lower red panel), respectively. The power of the excitation laser was set in vehicle-treated mice to
avoid any possible overlapping between RhB and tissue autofluorescence. In each panel, it is possible
to see an upper region shaped like a sack, which represents the stomach. The small intestine is the
snake-like shape in the middle. The enlargement in the last part of the intestine includes cecum, colon,
and rectum and is called “large intestine”. The signal associated with RhB is clearly detectable in
both groups receiving the same amount of dye. As expected, in both groups, it is also possible to
see a progressive decay of signal and a shift from the distal part of the GI tract. However, in mice
treated with NPs, the presence of the dye was more persistent, in particular in the distal part of the
small intestine and in the large intestine. The quantification of the signal (Figure 4B) confirmed this
observational study: In particular, the levels of the signal in the intestine at the 4th hour after the
treatment was markedly higher in animals receiving the nanoformulation.
To better understand the interaction between PLGA-PEG-RhB-NPs and the GI tract
structures, histological evaluation was carried out, also exploiting the presence of RhB to track
them along the anatomic path and their development in time. Even in this case, the same doses of RhB
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free were injected into a further group of mice to exclude any possible misinterpretation of the results
due to the possible loss of NPs stability and the release of the dye.
 
Figure 4. Signal distribution in the gastrointestinal (GI) tract of mice treated with RhB or
PLGA-PEG-RhB-NPs. (A) Representative ex vivo scanning of the excised organs after washing
with saline solutions to remove debris of feces. Animals were sacrificed at 1, 4, and 24 h after the
treatment with the same dose of RhB. In the left column, a vehicle-treated mouse was shown to
demonstrate the lack of the auto fluorescent component in this analysis. The interval of fluorescence
signal intensity associated with the scale of colors is reported on the right. Five animals for each
experimental group were used. (B) The quantification of the signal associated with the treatment
was performed, dividing each sample into three tracts, as shown in the panel. The bars are the value
of signal normalized to 100, considering the mean value measured in the stomach of mice treated
with RhB alone and sacrificed 1 h after the oral administration. The bars are the mean value ± SD
(n = 5). The Student’s t-test was used to compare the levels between the two groups for each time point.
*** p < 0.0001.
Figure 5A, upper panels, shows representative images taken from gastric sections of mice sacrificed
1, 4, and 24 h after PLGA-PEG-RhB-NPs administration. Although a progressive reduction of the
signal can be seen, it is important to underline that the anatomical localization of the signal remains
almost exclusively confined outside the gastric cells that are characterized by the intense blue staining
due to the presence of the nuclear dye Hoechst 33258. Opposite, the RhB alone, Figure 5A lower
panels, deeply penetrated inside the gastric parenchyma as clearly evidenced by the purple staining
due to the merge between the red and the blue signal. This is more pronounced at the first hour
and, interestingly, it does not involve the whole structure of the stomach, but it is almost confined
to the superficial region of the gastric mucosa (left part of the picture at 1 h). At the 4th hour, the
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signal is lower but more penetrated and homogeneously spread in the parenchyma, whereas after one
day, as already demonstrated by ex vivo quantification (Figure 4B), the fluorescent intensity strongly
decreased. The different pattern of staining shown at the 4th and 24th hour strongly suggests that, in
spite of the gastric activity, PLGA-PEG-RhB-NPs remain stable enough to avoid the release of the free
dye. This is in line with the results reported in Figure 1A by DLS in solutions mimicking gastric juice.
The stability of the nanoparticles inside the stomach is essential to transport any encapsulated
drug to the intestine. In Figure 4B, the signal measurement along the whole small intestine was
evaluated, whereas histological analysis was focused on the more proximal part of the intestine, the
duodenal region. The duodenum is one of the most critical portions of the GI for the absorption of
metabolites and drugs. The active uptake by mucosae villi and Peyer’s patches allows the absorption of
many substances into the bloodstream and their consequent systemic distribution. Even if this process
is required to provide energy and nutrients and to distribute therapeutic agents orally administered,
it can be a hurdle for a localized gut delivery. In Figure 3, we have reported that the encapsulation
in PLGA-PEG-RhB-NPs dramatically reduces the PTX absorption. This suggests that these kinds of
NPs are able to pass through this first part of the intestine, maintaining their stability. Representative
images from coronal sections of the duodenum from mice sacrificed 1 h after the treatment (lower panel
on the left and higher magnification right in Figure 5B) shows that NPs are in the lumen and inside
the intervilli space but are not absorbed by mucosa. A deeper interaction with villi can be seen at
the 4th hour after treatment. However, even in this case, the red and blue signals are close but do
not overlap. An overlapping was indeed clearly seen in distinction from mice treated with the same
amount of RhB free at least up to the first 4 h after ingestion. A higher magnified picture furthermore
confirms the restricted interaction between the red signal and the peripheral region of villi 1 h after
treatment. As reported in the measurement of the intestinal levels by ex vivo scanning (Figure 4B),
an almost complete disappearance of the red signal can be seen 24 h after the treatment in both
experimental groups.
By histology, we found that RhB-free treated mice showed deep red staining in villi, whereas
the red signal remained in the lumen of the intestinal tube in animals receiving RhB with NPs. Since
enterocytes in villi are tightly connected to the vessels, it is, therefore, possible to hypothesize that
RhB can easily penetrate the circulatory tree. To confirm that NPs can dramatically reduce the passage
from the small intestine to the bloodstream, we compared the RhB levels both in plasma and in the
liver of mice treated with PLGA-PEG-RhB-NPs or RhB free. Figure 6A, where plasmatic levels of
RhB-related signals were normalized to the value measured in mice treated with RhB-free during the
first hour of analysis, clearly reveals that the nanoformulation (red bars) leads to an almost complete
abolishment of hematic absorption of RhB. This striking difference between the two groups supports
the hypothesis that these NPs are stable and almost completely eradicate the absorption of themselves
and of the relevant cargo by gastric and intestinal mucosae. The fast and quite elevated half-life of RhB
in the blood led to an expected accumulation of the dye in the main filter organ, the liver, Figure 6B.
Similar to the results obtained from the blood, the animals treated with RhB exclusively showed a well
detectable red signal in liver sections (Figure 6C).
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Figure 5. Representative images showing the distribution of RhB in (A) stomach and (B) duodenum of
mice treated with either PLGA-PEG-RhB-NPs or RhB alone. (A) In the upper panels, the localization
of signal (red) in gastric sections (blue) is shown 1, 4, and 24 h after the oral administration of
PLGA-PEG-RhB-NPs. The same procedure has been used to track the presence of the dye in mice
receiving the same amount of RhB (lower panels). Scale bar 100 μm. (B) Representative images of
the duodenum are shown of PLGA-PEG-RhB-NPsand RhB-treated mice in upper and lower panels,
respectively. Scale bar 200 μm. The thicker and more intense blue staining in the periphery of the
sections represents the basal layer of the duodenum where the exchanges of tissue/blood occur. The red
signal is more concentrated to the center, likely corresponding to the lumen close to the apical side of
the villi. A higher magnified picture from a mouse sacrificed 1 h after the ingestion of NPs confirms the
weak interaction between NPs and villi. In the duodenum of RhB-treated mice, a deep overlapping
between the villi and the RhB was observed at both 1 and 24 h after treatment. A higher magnified
image confirms the penetration of the dye into the external side of the villi. Scale bar 50 μm.
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Figure 6. Signal measurement in (A) the plasma and (B) the liver of mice orally treated with RhB
(blue bars) or PLGA-PEG-RhB-NPs (red bars). Animals were sacrificed at 1, 4, and 24 h after the
treatment with the same dose of RhB. Five animals for each experimental group were used. In both
graphics, quantification of the signal was normalized to the RhB level at 1 h and expressed as 100.
The bars are the mean value ± SD (n = 5). The Student’s t-test was used to compare the levels between
the two groups for each time point. *** p < 0.0001. (C) Representative images of the signal related to
the dye in a section of liver from mice treated with PLGA-PEG-RhB-NPs (upper panel) or RhB alone
(lower panel), both sacrificed 1 h after the treatment. Scale bar 50 μm.
The last part of the study was carried out to investigate if these NPs were able to penetrate into
CaCo2 cells and where they localize inside the cells. This experiment was aimed at exploring the
possible application of our results to future local treatment of colorectal cancer. Figure 7A shows the
progressive process of internalization of NPs (orange spots). The quantification of the occupied area of
NPs inside the cell cytoplasm is reported in Figure 7B. Progressive penetration of NPs occurs and, at
the 4th hour after incubation, they already occupied the 2% to 3% of the whole cell area. Although
relatively low, this percentage in terms of a potential release of a therapeutic cargo cannot be considered
negligible. The red arrow in Figure 7A and the higher magnified picture in Figure 7D confirm that NPs
are deeply penetrated (orange spots) and the deep internalization of NPs inside the cell cytoplasm
starting from the 4th hour of incubation. Moreover, the cell viability assay confirmed the safety of
the materials we selected for this study. Indeed, neither RhB nor PLGA-PEG-RhB-NPs alone modify
the healthiness of the cells for the whole duration of the treatment (Figure 7C).
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Figure 7. Longitudinal study to evaluate PLGA-PEG-RhB-NPs internalization in CaCo2 cells. (A) Low
magnified pictures showing the progressive penetration of NPs in cells. Representative images have
been selected from non-treated cells (NT, left panel). For each image, the nuclei were stained with
Hoechst 33258 (blue), whereas high excitation with the laser at the wavelength of 488 nm will allow
unveiling the border of the cells by exploiting their auto fluorescent profile (green). Starting from the
1st hour, it is possible to see orange spots obtained by the merge between the red signal referred to the
RhB and the green background. These spots became more evident 4 and 24 h after incubation. Scale
bar 70 μm. (B) Quantification of the percentage of the area (pixels) occupied by NPs for every single
cell at the different time-points. Data are expressed as mean value ± SD, n = 10. (C) Quantification of
the viability of the cells of CaCo2 after exposure to RhB (orange line), PLGA-PEG-RhB-NPs (yellow
line), and Benserazide as inner control (purple line) measured by RealTime-Glo™MT Cell Viability
Assay (Promega kit) 4 and 24 h after incubation The values obtained from non-treated cells were
normalized to 100 for each time point. Values are expressed as mean ± SD (n = 6). The Student’s
t-test was used to compare the levels among the two groups for each time point. *** p < 0.0001
compared to NT. (D) Higher magnification pictures showing the same field of view achieved 24 h after
PLGA-PEG-RhB-NPs incubation. In the left panel, the cell nucleus, in the middle panel, the red spots
associated with NPs, and in the right panel, the merge between the three channels. The dotted line is
the border of the cell. Scale bar 15 μm.
4. Conclusions
The current study sought to evaluate the effect of the nanocarrier on the transport of a drug and
its behavior within the gastrointestinal tract and absorption to the bloodstream. It is important to
note, however, that although RhB was originally used as a tracer to visualize NPs. The results obtained
by comparing the biodistribution in mice of the free fluorophore and linked to the NPs is of further
relevance for future developments. It is, in fact, interesting how PLGA-PEG-NPs manage to preserve
the gastroduodenal absorption by using chemically different molecules along with different loading
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approaches to the nanocarrier. The low systemic exposure and, at the same time, equivalent drug
concentration at the intestinal level, with even a trend to increase in the colon 4 h after the treatment,
could have a significant positive outcome on the safety of a wide range of drugs targeting inflammatory
and neoplastic diseases.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/12/658/s1,
Figure S1: STEM image of PTX-PLGA-PEG-RhB-NPs, Figure S2: Release kinetics of PTX loaded NPs in PBS
containing 0.2 v/v% Tween 80. PTX-PLGA-PEG-RhB-NPs equivalent to 8.75 μg of PTX were suspended in 1 mL of
release medium and incubated at 37 ◦C with constant agitation. At predetermined time points (0.5, 1, 2, 4, 6 and
24 h), the NPs were separated by centrifugation and the supernatant analyzed by HPLC. The results are the mean
value ± SD (n = 4).
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Abstract: For parenteral controlled drug release, the desired zero order release profile with no lag
time is often difficult to achieve. To overcome the undesired lag time of the current commercial
risperidone controlled release formulation, we developed PLGA–lipid microcapsules (MCs) and
PLGA–lipid microgels (MGs). The lipid phase was composed of middle chain triglycerides (MCT) or
isopropylmyristate (IPM). Hydroxystearic acid was used as an oleogelator. The three-dimensional
inner structure of Risperidone-loaded MCs and MGs was assessed by using the invasive method
of electron microscopy with focused ion beam cutting (FIB-SEM) and the noninvasive method
of high-resolution nanoscale X-ray computed tomography (nano-CT). FIB-SEM and nano-CT
measurements revealed the presence of highly dispersed spherical structures around two micrometres
in size. Drug release kinetics did strongly depend on the used lipid phase and the presence or absence
of hydroxystearic acid. We achieved a nearly zero order release without a lag time over 60 days with
the MC-MCT formulation. In conclusion, the developed lipid-PLGA microparticles are attractive
alternatives to pure PLGA-based particles. The advantages include improved release profiles, which
can be easily tuned by the lipid composition.
Keywords: controlled release; PLGA; risperidone; microparticles; microcapsules; oleogels;
electron microscopy; three-dimensional X-ray imaging; nano-CT; biodegradable polymers;
hydroxy-stearic acid
1. Introduction
The use of parenteral controlled release drug delivery systems (CR-DDS) is a highly attractive and
rational way to improve drug therapy. Potential benefits include decrease of administration frequency,
increase of bioavailability and less side effects. Polylactic acid (PLA) and poly(lactic-co-glycolic acid
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(PLGA) products have existed for several decades and are, by far, the most widely used polymers
for CR-DDS [1,2]. The major clinical use is the peptide-based treatment of GnrH-dependent diseases
such as breast and prostate cancer. Other important and increasingly used applications include the
local delivery of drugs to the eye [3], the brain [4], or the inner ear [5,6]. An important application of
CR-DDS is also the controlled release of antipsychotic compounds to treat schizophrenia. Long-acting
parenteral controlled release of antipsychotic drugs overcomes the poor compliance of patients with
oral administration [7,8]. Risperidone is an important drug in the treatment of schizophrenia. Several
oral and one parenteral controlled release formulations are available and a PLGA based CR-DDS
formulation is marketed (Risperdal® Consta®). According to the treatment schedule [9], patients
initially have to take tablets, although the CR-DDS has already been injected. This situation is not a
favorable scenario of pharmacotherapy, because schizophrenia patients do frequently not comply and
double medication should be avoided. The release mechanisms of Risperdal® Consta® have been
studied in detail by the group of Burgess and good in vitro and in vivo correlations have been observed
by means of scaling factors [10,11]. Initially, a lag phase with almost no release is observed, followed
by a faster release. The group clearly showed that the release onset is related to the water penetration
and polymer degradation-induced drop of the polymer glass transition temperature Tg to 37 ◦C.
Several publications describe alternative PLGA formulations for the controlled release of
risperidone. However, commonly, the presence of lag times, sigmoidal release curves, and rather
short release times (<1 month) have been observed [10–15]. Souza et al. tested different formulations
with single or repeated doses in vivo [16]. For single dose injections, peak maxima were observed
after around one week. Unfortunately, no in vitro release data were published in the paper [16].
Therefore, it is clearly still desirable to develop biodegradable DDS with better risperidone release
kinetics. The CR-DDS should provide a constant release over the 1–2 months without a lag time and
the need for initial oral comedication. It should also be cost effective. Unfortunately, the selection
possibility for biodegradable materials for parenteral controlled release is rather limited. In addition to
PLA and PLGA, there are few other polymers and lipids. Liquid lipids are used clinically, but they
provide only release control for a short period of few days. Solid lipids are also attractive as parenteral
depot systems [17], but their use is often linked with problems of polymorphic transitions and limited
enzymatic degradability due to the crystalline structure of the lipid. The use of polymer–lipid hybrid
structures—compared to pure polymer or pure lipid-based DDS—offers additional opportunities.
For example, increased drug loads may be achieved by the lipid component and the release rate
might be controlled by the polymer shell. The incorporation of liquid oil into a microparticle might
compromise the mechanical stability of the particle and could potentially lead to oily leakage and loss
of release control. The incorporation of solid lipids will overcome this problem, but this advantage is at
the cost of drug solubility in the crystalline lipid matrix and the problem of polymorphic transitions. It
is desirable to combine the advantages of a liquid lipid phase with high mechanical stability. Therefore,
we decided to investigate oleogels as possible alternatives. A suitable oleogelator for parenteral
applications is 12-hydroxystearic acid (HS). Hydroxystearic acid induces gel formation in lipids due to
its precipitation as a HS-fiber network [18,19]. Preclinical studies on injectable oleogels demonstrate
the good biocompatibility and degradability of HS-oleogels in vivo [20,21].
We selected PLGA Expansorb® 75-7E from Merck KGaA (Darmstadt, Germany), which has the
following properties: lactide/glycolide (L/G) ratio of 75/25, a molecular weight (MW) 80–115 kDa, and
the end groups are esterified. The physical chemical properties of Expansorb®75-7E were similar to
the PLGA in the market product Risperdal Consta® which contains a lactide/glycolide (L/G) ratio of
78/22, a molecular weight (MW) ~111 kDa and the end groups are esterified [22]. As the oil phase, we
incorporated isopropyl myristate (IPM) or middle chain triglycerides (MCT) to form a microcapsule
(MC) structure. Oily components with saturated fatty acids were used to avoid the danger of oxidation
problems connected with unsaturated fatty acids.
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The properties and the release kinetics of the micro-DDS will depend on the general structure and
the physicochemical state of the drug and the excipients. Possible structures of (drug-free) micro-DDS
are shown in Figure 1.
Figure 1. Possible structures of poly(lactic-co-glycolic acid (PLGA) and PLGA/lipid microparticles:
I: PLGA microparticle; II: microcapsule with core–shell structure; III: microcapsule with multiple oily
droplets; IV: microgel with core–shell structure; microgel with multiple gelled lipid domains.
PLGA microparticles are expected to form a homogeneous polymer matrix (structure I).
Microcapsules composed of PLGA and oil could show structures with a single oily core and a
PLGA shell (structure II) or multiple oily droplets encapsulated in PLGA (structure III). The addition
of the oil gelator will increase the viscosity, but again, the oily phase could exist as a single core
(structure IV) or as multiple cores (structure V). The drug could be dissolved in the polymer and the oil
and/or exist as an own solid (crystalline or amorphous) phase. A rational development of the DDS
requires an appropriate characterization. For particle sizing of micro-DDS, static light scattering is
the standard method. We decided to use X-ray diffraction for the detection of crystalline structures
in our DDS. In addition, we wanted to explore the microstructure inside the DDS. For this purpose,
we used two complementary imaging techniques, which were focus ion beam scanning electron
microscopy (FIB-SEM) and Zernike phase-contrast X-ray nano-computed tomography (nano-CT).
By means of focused ion-beam preparation, we could cut the particles in situ and we were able to
visualize the morphology of the microstructure at the location of the cut. In addition, we performed
nano-CT experiments. Due to the high penetration depth of X-rays, nano-CT provided high-resolution
three-dimensional images of the DDS and we were able to visualize their internal structures at any
virtual slice without the need for cutting or slicing them.
In summary, the main goals of this work were:
(i) development of risperidone loaded PLGA–lipid microcapsules (MCs) and PLGA–lipid microgels
(MGs) with an optimized release profile (no lag time, constant release rate)
(ii) characterization of the three-dimensional inner structure of risperidone-loaded MCs and MGs by
using focused ion beam (FIB) preparation and three-dimensional X-ray imaging (nano-CT).
2. Materials and Methods
2.1. Materials
Expansorb DLG 75-7E, batch number C100010962, (Merck, Darmstadt, Germany) PVA 4-88
(Merck, Darmstadt, Germany) Risperidone 95+% (Activate Scientific, Shanghai, China), Pioneer MCT
(middle chain triglycerides) batch number: 1132229 (Hansen & Rosenthal, Hamburg, Germany);
isopropylmyristate Ph-Eur. batch number: 1407015-01, (Euro OTC Pharma GmbH, Bönen, Germany);
dichloromethane 99.9% (Carl-Roth, Karlsruhe, Germany); hydroxystearic acid was a gift from
Alberdingk Boley GmbH, (Krefeld, Germany). Risperdal Consta® 50 mg batch number: GCSK002,
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(Janssen-Cilag GmbH, Neuss, Germany); 2.5 mL GASTIGHT® syringe (Hamilton Germany GmbH,
Planegg, Martinsried, Germany), syringe pump (Pump 11 Elite, Harvard Apparatus, Holliston,
MA, USA).
2.2. Methods
2.2.1. Preparation of PLGA Microcapsules (MC) and PLGA Microgels (MG)
Risperidone-loaded microcapsules were prepared using an oil-in-water (o/w) emulsion solvent
extraction/evaporation technique.
For this purpose, 100 mg PLGA 75-7E, 100 mg of the oil phase (MCT or IPM), and 50 mg of
Risperidone were weighted into a 4 mL glass vial and dissolved into the final volume of 2 mL
dichloromethane by vortexing. The organic solutions were drawn up into a 2.5 mL GASTIGHT®
syringe (Hamilton Germany GmbH, Planegg, Martinsried, Germany) and injected with a flow rate
5.2 μL/min by a syringe pump (Pump 11 Elite, Harvard Apparatus, Holliston, MA, USA) directly into
300 mL of aqueous PVA 4-88 (Merck, Darmstadt, Germany) solution 0.25% (w/v) stirred with a Rotating
Paddle, USP at 240 rpm at room temperature. The aqueous phase contains double distilled and filtrated
water with 0.25% polyvinyl alcohol PVA 4-88 (Merck, Darmstadt, Germany). When particle formation
was completed, the suspensions were transferred into a 500 mL round bottom flask and the remaining
DCM were removed under vacuum 40 mbar for 20 min. Thereafter, sedimented microcapsules were
transferred by a glass pipette into a 15 mL tube and the supernatants were removed carefully. Then,
the microcapsules were washed thrice with sterile filtrated double distilled water, filled up to the final
volume of 1 mL and lyophilized.
2.2.2. Lyophilization
For freeze-drying, the samples were frozen rapidly with liquid nitrogen at −196 ◦C and lyophilised
on a Christ Alpha 2–4 freeze dryer (Martin Christ Gefriertrocknungsanlagen GmbH, Osterode am Harz,
Germany) in combination with a Vacuubrand RC 6 vacuum pump (Vacuubrand GmbH, Wertheim,
Germany) for 24 h. The chamber was evacuated to 0.05 mbar, corresponding to −48 ◦C on the
sublimation curve of ice. The prepared microcapsules were stored at −20 ◦C until further use.
2.2.3. Static Light Scattering Measurements
Routine measurements of the size distribution were carried out by laser diffractometry on a
Mastersizer 2000 (Malvern Instruments, Malvern, United Kingdom) combined with a Hydro 2000 S wet
dispersion unit. The samples were measured at a laser obscuration of 5%, corresponding to 11%–15%
obscuration of the blue laser, in purified water. A series of five runs was evaluated by the Mastersizer
2000 software version 5.60, using the Mie theory, assuming spherical particles with a refractive index
of 1.44, absorption of 0.001, and a refractive index of 1.33 for the dispersant as optical properties.
2.2.4. Powder XRD
XRD analysis was performed on a Bruker D8-Advance diffractometer, equipped with a
one-dimensional silicon strip detector (LynxEye) operating with Cu Kα radiation. Diffraction was
measured from 2θ= 5◦ to 70◦ with a step size of 0.01◦ and a counting time of 1 s.
2.2.5. High-Performance Liquid Chromatography (HPLC)
A HPLC Agilent 1100 Series (Agilent, Santa Clara, CA, USA) was used. Separations were carried
out using a BDS-Hypersil® C18 5 μm 250 × 4.6 column (Thermo Fisher Scientific, Waltham, MA, USA)
and a mobile phase of 75% (v/v) methanol/25% (v/v) water, 1% (v/v) tetramethylammoniumhydroxid
pentahydrate solution 25% w/v. Runs were carried out at 0.5 mL/min over 16 min and the absorption at
280 nm was recorded. The retention time of risperidone was 7.5 min. Injection volumes of 20 μL were
used for determination of drug loading.
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2.2.6. Drug Loading and Encapsulation Efficiency (EE)
Risperidone-loaded microcapsules were weighed and diluted in methanol to get a final
concentration of 0.5mg/mL. All the samples were sonicated for 10 min to accelerate the dissolving of
MC. Thereafter all samples were diluted 0.05 mg/mL and filtered (Minisart SRP 4, 0.45 μm syringe
filter, Sartorius Stedim Biotech GmbH, Göttingen, Deutschland). The concentration of risperidone was
determined via HPLC. Drug loading and EE were calculated as following equations from literature:
Drug loading = (weight of drug entrapped/weight of MC used) × 100%; EE = (experimental drug
loading/theoretically drug) × 100% [23].
2.2.7. In Vitro Drug Release Assay
The in vitro release of risperidone from MCs was carried out in a heated bath shaker (Memmert
GmbH + Co. KG, Schwabach, Germany) at 37 ◦C and constant shaking at 50 rpm. A total of 6 mg of
formulation I-IV and 3 mg of Risperdal Consta® were suspended in 1 mL of 10 mmol phosphate buffer
saline (PBS) at pH 7.4 and transferred into a Spectra Por Float-A_Lyzer ® G2 1000kD. The float-A Lyzer
was placed into a 100 mL measuring cylinder and filled up with PBS to the final volume of 60 mL so
that the float-A Lyzer is submerged in PBS. To maintain sink conditions, the buffer solution was drawn
off half (half change) when the risperidone concentration reaches 7%–8% of the solubility in PBS. Drug
quantity was determined by UV-1800 spectrophotometer (Shimadzu, Kyoto, Japan). All measurements
were performed in triplicate and the measurement points were represented as the mean ± SD.
2.2.8. Scanning Electron Microscopy and Focused Ion Beam Preparation
High resolution investigations of the microparticle morphology were done by scanning electron
microscopy (SEM) using a Quanta 3D FEG (field emission gun) instrument from FEI Company,
(Hillsboro, OH, USA). The microparticles were carefully placed on SEM sample holders using carbon
tape and subsequently coated with a thin layer of platinum using a magnetron sputtering system
(HVD, Dresden, Germany) to achieve a conducting surface. The SEM images were obtained under
high vacuum conditions using an acceleration voltage of 5 keV, a working distance of 6–10 mm and
electron beam currents of 12 pA determined with an Everhart–Thornley detector.
The microscope is designed as a dual beam (electron and ion beam) which gives the possibility
to perform FIB preparations in the same device. Here, the gallium ion beam and the electron beam
operate independently of each other. The point of coincidence of the two beams is located at a working
distance of 10 mm. The angle between both beams is 52◦. To allow vertical cutting with the FIB, the
sample was tilted by this angle. Thus observation of the cross-sections with the electron beam was
also done at an angle of 52◦. After screening the samples by conventional SEM, the particle of interest
was selected for cross-sectional preparation (target preparation). As the first step in cross-section
preparation at predefined areas of interest coarse material was ablated with gallium ions accelerated at
30 kV with ion currents of 15 nA. After this coarse milling step lower beam currents of Afterwards,
1–0.5 nA were used to polish the cross sections. The samples were not cooled during FIB milling.
The patterning conditions used conform to the standard patterning conditions for silicon materials.
The SEM observation can be done during ion milling or after subsequent milling steps.
2.2.9. Nano-CT
X-ray imaging experiments were performed at the Institute of Physics, Martin Luther University
Halle-Wittenberg, in a Carl Zeiss Xradia 810 Ultra (Cr source, 5.4 keV, for instrument details see [24]).
Phase-contrast imaging mode was used with a phase-ring positioned near the back focal plane of
the zone plate. In each experiment, a total of 901 projections with a field-of-view (FOV) of 65 μm
were obtained over 180◦, with an exposure time of 15 s per projection, a detector binning of 2, and
voxel size of 128 nm. Image reconstruction was performed by filtered back-projection algorithm
using the software integrated into the Xradia 810 Ultra. For each sample, two or three imaging
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experiments were performed, moving the sample vertically to enable the visualization of one entire
microsphere in one single direction (from now on named Z-direction). For each sample’s datasets,
the brightness and contrast were adjusted in ImageJ® and the datasets were then stitched together
using the Merge module of the Thermo Fisher Scientific Avizo® software (version 9.2, Thermo Fisher
Scientific, Hillsboro, OR, USA). Median denoising and nonlocal mean filter were applied to the datasets.
The 3D renderings presented here were created using either the commercial software arivis Vision4D®
(version 2.12.6, arivis AG, Rostock, Germany) or Avizo®. For the dispersed internal spherical structures
(ISS) evaluation, a volume located in the center of the 3D image was extracted consisting of 325 × 325 ×
Z voxels. Z varies among the samples, as it is almost equal to the number of pixels of the microsphere
diameter, but is smaller than it to prevent voxels that do not consist of sample to be added to the
calculation. The results obtained here represent the ratio of ISS compared to the total extracted volume
of the sample (PLGA+ISS). For binarization of the datasets into PLGA and ISS, automatic thresholding
with IsoData criterion was used, followed by island removal for the removal of small clusters of voxels
(<15). A surface was generated from the segmented dataset in order to smooth sharp voxel edges and
the specific surface area (SSA) values obtained represent the ratio of the constructed surface area (SA)
to the volume (V) for each sample.
3. Results and Discussion
3.1. Preparation of MCs and MGs
For the preparation of MCs and MGs, the conventional oil-in-water (o/w) emulsion solvent
evaporation method was used [2,25]. All components were dissolved in dichloromethane.
The components of the four different formulations are listed in the Table 1. In general, the composition
followed a 2:2:1 mass ratio of PLGA/Lipid/Risperidone. Therefore, the theoretical drug load was 20%
[m/m]. High encapsulation efficiencies (>92%) were achieved, as seen in Table 1.
















MC-IPM 100 50 0 100 0 92.62 [0.94]
MG-IPM 100 50 0 90 10 100.82 [5.50]
MG-MCT 100 50 90 0 10 96.05 [3.98]
MC-MCT 100 50 100 0 0 92.79 [3.23]
MC = microcapsule, MG = microgel, PLGA = poly(lactide-co-glycolide), MCT = middle chain triglycerides,
IPM = isopropylmyristate, HS = hydroxystearic acid.
To get reproducible particle sizes, it was important to keep all size-influencing parameters
constant, e.g., the o-phase volume and solvent, the concentration and type of polymer, the volume of
the continuous phase and the type and concentration of stabilizer, the temperature, and the stirring
speed [26]. After lyophilization the MCs did not agglomerate and were resuspendable in water.
3.2. Characterization
3.2.1. Particle Size Measurements
The particle size and morphology of MC are key factors which potentially affect EE, drug release
rate, and the biodistribution [27,28]. The optimal size range for microparticles with controlled release
characteristics is considered to be 10–200 μm. Particles in the lower micron range will show a faster
drug release, and they are also more easily phagocytosed by immune cells [29]. Sizes larger than
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200 μm are difficult to inject and will show more inhomogeneous degradation [30]. The particle size
distribution is shown in Figure 2.
Figure 2. Volume-averaged particle sizes of microcapsules, microgels, and the reference product.
The particle size of the microcapsule formulations MC-IPM and MC-MCT are very similar (D(0.5)
= 172.8 μm and 169.5 μm). The particle sizes for the corresponding microgels MG-IPM and MG-MCT
were smaller compared to the microcapsules, but again very similar between IPM and MCT (D(0.5) =
MG-IPM 157.2 μm; MG-MCT 155.9 μm), as seen Figure 2 and Table 2. It can be concluded, therefore,
that the incorporation of hydroxystearic acid leads to slightly smaller particles, probably due to the
impact on the surface tension during particle formation. The determined D(0.5) of the market product
is 89.1 μm, which is in line with a size range between 25 and 150 μm reported in the literature [31].
The particle size distribution of the commercial product is considerably broader compared to our
formulations (Span Risperdal Consta® 1.165 vs. span values between 0.612 and 0.637), as seen in
Table 2.
Table 2. Particle size distributions determined by static light scattering.
Sample D(0.1) (μm) D(0.5) (μm) D(0.9) (μm) Mean D(4,3) (μm) Span Uniformity
Risperdal
Consta®
50.7 89.1 154.5 96.9 1.165 0.36
MC-IPM 126.1 172.8 236.3 178.1 0.637 0.202
MG-IPM 116.4 157.2 212.6 161.2 0.612 0.193
MG-MCT 115.3 155.9 211.8 160.2 0.620 0.196
MC-MCT 123.7 169.5 230.8 174.4 0.631 0.197
3.2.2. Scanning Electron Microscopy and Focused Ion Beam Investigations
SEM images of Risperdal Consta® are shown in Figure 3. The market product Risperdal Consta®
shows a high heterogeneity of particle size, shape, and surface structures. Surprisingly, structures
showing partial engulfment, as seen in Figure 3d, and collapsed structures are visible, as seen in
Figure 3c. Larger magnification of the surface indicated the presence of anisotropic material, which are
most likely drug crystals, as seen in Figure 3e,f.
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Figure 3. Electron microscopic pictures of Risperdal Consta®. The pictures at lower magnifications
(a–d) show the presence of different particle sizes and shapes. Most particles show wrinkled surfaces;
some have a smooth surface. High magnification shows the presence of small anisotropic material on
the surface (e,f).
The microcapsules and microgels do not show the irregular structures of the commercial product.
Most of MCT microcapsules are spherical, some show an elongated shape, which probably results
from the coalescence of two particles, as seen in Figure 4a, white stars. The surface of the MC-MCT
microcapsules shows a pattern similar to golf balls, as seen in Figure 4b,c. Very rarely, small anisotropic
structures are found on the particle surface, as seen in Figure 4c, top middle, which most likely
represent risperidone crystals. Cutting of the particles by focused ion beam (FIB) provides insights
into the internal structure, as seen in Figure 4b,d. A multicore structure with dimensions in the lower
micron range becomes visible. Within the internal structures, anisotropic shapes are visible which
most likely present precipitated drug crystals, as seen in Figure 4d.
The electron microscopic pictures of the corresponding microgel MG-MCT shows spherical
particles with a structured surface that appears smoother compared to the MC-MCT surface (Figure 5).
In contrast to the MC-MCT microcapsules, we could not detect elongated shapes, as indicated by white
stars in Figure 4a, which emerge from the coalescence of two particles. The pictures obtained by FIB
cutting of the particles show internal multicore structures with dimensions in the lower micron range,
as seen in Figure 5b,d.
IPM-loaded microcapsules (MC-IPM) have a spherical shape, as seen in Figure 6a. The surface
appears similar to the MC-MCT capsules. Very rarely, small crystals can be detected on the particle
surface, as seen in Figure 6c. After FIB cutting, multicore structures in the lower micron range become
visible, as seen in Figure 6b,d.
The electron microscopy investigation on MG-IPM microgels shows the presence of spherical
particles, as seen in Figure 7a. Higher magnifications of the particle surface show surface dips (“golf
ball structure”) similar to the MG-MCT microgels. In addition, elongated “hair-like” structures are
visible, as seen in Figure 7c,d, which are not detectable in the other samples. Most likely, they are mainly
composed of hydroxystearic acid, which is known to induce gel formation by elongated structures.
Again, FIB cutting was used to explore the interior of the particles. Multicore microdomains became
visible, as seen in Figure 7b, similar to the MG-MCT microgel particles with dimensions in the lower
micron range.
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Figure 4. Electron microscopic pictures of MC-MCT microcapsules, (for composition details see Table 1).
Intact particles are presented at lower (a,c) higher magnification. Focused ion beam (FIB) cut particles
are shown at lower magnification in (b) and after deeper FIB milling and higher magnification in (d).
The white stars in (a) indicate anisotropic particles, which were most likely formed by coalescence of
two particles.
 
Figure 5. Electron microscopic pictures of MG-MCT microgels (for composition see Table 1). Intact
particles are presented at lower (a,c) higher magnification. FIB cut particles are shown at lower
magnification in (b) and at higher magnification at (d).
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Figure 6. Electron microscopic pictures of MC-IPM microcapsules (composition details are given in
Table 1). Intact particles are presented at lower (a,c) higher magnification. FIB cut particles are shown
at lower magnification in (b) and at higher magnification at (d).
 
Figure 7. Electron microscopic pictures of MG-IPM microgels (sample composition is given in Table 1).
Intact particles are presented at lower (a,b) and higher (c,d) magnifications. A FIB cut particle is shown
in (b). Elongated, “worm like” structures (most likely precipitated hydroxyl-stearic acid) are visible
in (c,d).
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The crystallinity of the formulations was evaluated by X-ray diffraction. The diffractograms of
PLGA, the pure drug risperidone, the commercial product, and the developed microcapsules and
microgels are shown in Figure 8. It is known that the drug can exist in different polymorphs [32–34].
As expected, the polymer PLGA does not show sharp peaks, but only broad lines, indicating an
amorphous state. The pure drug shows multiple sharp peaks. The X-ray diffractograms of the
commercial product Risperdal Consta® and the developed formulations show a similar pattern, but
they are different from the pure drug. From the measurements, it can be concluded that risperidone
exists in all formulations at least partially in the crystalline state. The crystalline state in the formulation
is different from the crystal structure of the parent drug, but very similar to the crystal form of
risperidone, which has been observed after micronization with supercritical fluids [33].
Figure 8. Wide angle X-ray diffractograms of microcapsules, microgels, Risperdal Consta®, and the
pure drug risperidone.
4. X-Ray Nano-Imaging (Nano-CT)
X-ray imaging comprises a class of nondestructive techniques that are used to visualize the internal
structure of different materials. In conventional X-ray imaging, differences in the X-ray absorption
cross-section of different materials results in the image contrast [35,36]. Therefore, if the different parts
composing one sample show only small differences in the X-ray attenuation, a poor image contrast
will be obtained in conventional absorption-based X-ray imaging. This is specially the case for samples
composed of elements with low electron density, making the characterization of the structures and
visualization of the sample features a very hard task. Alternatively, phase-contrast imaging methods
enable the visualization of features of weakly absorbing objects [35,37,38]. X-ray phase-contrast
imaging is based on a different physical principle, and the contrast of the image is generated by the
detection of the changes in the phase of the wavefront [36,39]. In this work, we imaged the different
microspheres using Zernike phase-contrast imaging in a benchtop nano-CT scanner (Xradia Ultra
810). Phase-contrast nano-CT was used to characterize the inner structure of the commercial product
Risperdal Consta® (Figure 9) and the developed microcapsules and microgels (Figure 10). Videos
Supplementary Videos S1–S5 show the inner 3D structure of the microparticles. The diameter and
volume distributions of the internal structures are presented in Supplementary Figures S1 and S2.
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Figure 9. Volumetric representation the inner part of one reconstructed microsphere of Risperdal
Consta® imaged with nano-CT. The left picture shows the X-ray signal in gray and the microsphere
PLGA matrix pseudocolored in yellow. On the right, the small colored structures represent the dispersed
internal spherical structures (ISS), which can be attributed to the dispersed drug particles. The volume
of the ISS is about 13% of the total volume of the particle.
 
Figure 10. Volumetric representation of the inner part of the microspheres imaged with nano-CT. On the
top from left to right, the MC-IPM, MG-IPM, MG-MCT, and MC-MCT microspheres pseudocolored in
yellow are shown, with the dispersed internal spherical structures (ISS) represented in different colors.
On the bottom, the volume used for the estimations done with nano-CT are shown for all samples.
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All microgels and microcapsules show internal spherical structures (ISS) in the submicrometer
range, with sphericity values close to unit. However, the volume percentage of the ISS in the
microcapsules is between 35% and 46% and is, therefore, much higher than the volume percentage
of the ISS phase in the Risperdal Consta® particles. The ISS phase can be attributed to the dispersed
lipid phase for the microgels and microcapsules. In contrast, the ISS consists of risperidone only for
the Risperdal Consta® system. A quantitative treatment of the 3D images indicates that the ISS have
diameter around 2 μm for lipid-based systems and around 800 nm for the Risperdal Consta® product,
as seen in Table 3. The ISS diameter and volume distributions are shown in Figures S1 and S2.
Table 3. Volume, diameter and sphericity of the internal dispersed phase (ISS), assessed by nano-CT.
Sample Volume ISS ISS Diameter ISS Sphericity
Risperdal Consta® 13% 0.8 ± 0.2 μm 0.95 ± 0.02
MG-MCT 35% 2.0 ± 0.9 μm 0.8 ± 0.2
MC-MCT 46% 2.2 ± 0.8 μm 0.7 ± 0.1
MC-IPM 39% 1.9 ± 1.3 μm 0.8 ± 0.2
MG-IPM 43% 2.3 ± 1.0 μm 0.8 ± 0.3
Compared to other imaging techniques, Zernike phase-contrast nano-CT has the advantage of
producing high-resolution three-dimensional images of low-absorbing samples, which enables the
estimation of the values shown here. As with most high-resolution imaging techniques, nano-CT has
the disadvantage of producing images limited to a small field of view, thus, to obtain the images of one
single microparticle, it was necessary to image the sample two or three times and stitch the datasets.
One of the benefits of phase-contrast nano-CT for imaging low-absorbing samples is that it does not
require any special sample preparation procedure or induce any sample damage within the imaged
area, in contrast with FIB-SEM. Overall, the results obtained by FIB-SEM correlate well with those
obtained by nano-CT, and the same structures were observed. Both methods indicate the presence
of a high percentage of internal structures (ISS) with sizes around two micrometers. Therefore, the
microcapsules and microgels represent structures III and V of Figure 1, respectively.
5. Drug Release
The in vitro release of risperidone from the commercial product in the developed formulations is
shown in Figure 11. For all formulations, a low percentage of the drug (<10%) is initially released.
Most likely, drug molecules on the surface (which were observed by electron microscopy) are released
very quickly. After the initial release, there is almost no release detectable for two weeks for Risperdal
Consta®. Thereafter, the release accelerates. The developed formulations show different release
profiles. The fastest release was observed for the MG-IPM microgel. The slowest release rate observed
for the lipid formulations was for the MC-IPM microcapsules system. Therefore, it can be concluded
that the oleogelator hydroxystearic acid had a strong impact on the release kinetics. The impact of the
oleogelator hydroxystearic acid is also visible for the MCT systems, but to a smaller extent. Again,
the microparticles with the incorporated oleogel (MG-MCT) release faster compared to the HS-free
microcapsules (MC-MCT). The desired release profile was obtained with the MC-MCT microparticles:
an almost linear release profile over two months with no lag time has been achieved.
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Figure 11. In vitro release profiles of Risperidone microcapsules (MC), microgels (MG), and Risperdal
Consta®.
6. Conclusions
The results of our study show that lipid–PLGA hybrid systems are interesting alternatives to
pure PLGA microparticles. The saturated liquid lipids MCT and IPM were incorporated in the form
of microcapsules and microgels. Hydroxystearic acid (HS) was used as an oleogelator. The particle
structure was investigated by FIB-SEM and nano-CT imaging. Both methods support the existence
of a highly dispersed internal phase with spherical particle sizes of around 2 micrometers. The
noninvasive nano-CT imaging enabled the production of 3D representations of the microparticles’
structures in high-resolution images. After image processing and segmentation, it was possible to
estimate the amount, size distribution, and sphericity of the internal structures. The presence of
hydroxystearic acid accelerated the drug release. The drug release kinetics can be tuned by the
lipid composition. An almost ideal release profile for risperidone was achieved with PLGA–MCT
microcapsules (MC-MCT). In contrast to Risperdal Consta®, no lag time and an almost linear release
over 60 days was observed. Therefore, the developed systems are suitable candidates to overcome the
need for double medication (injected microparticles and tablets), which is currently needed due to the
release lag time of Risperdal Consta®.
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Abstract: To enhance ocular drug bioavailability, a rapidly dissolving dry tablet containing alginate
and drug-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles was proposed. For hygienic
and easy administration of an accurate drug-dose with this tablet, the use of a preocular applicator
was suggested. Herein, a dry tablet was prepared by embedding dexamethasone-loaded PLGA
nanoparticles in alginate, which was deposited on the tip of the applicator. The nanoparticles
were loaded with 85.45 μg/mg drug and exhibited sustained drug release for 10 h. To evaluate
in vivo efficacy, dexamethasone concentration in the aqueous humor was measured after topical
administration of the dry tablet, with the applicator, to rabbit eyes and was compared to that achieved
with Maxidex®, a commercially-available dexamethasone eye drops. When applied with the preocular
applicator, the dry tablet containing alginate could be fully detached and delivered to the eye surface.
In fact, it showed up to 2 h of nanoparticle retention on the preocular surface due to tear viscosity
enhancement, causing an estimated 2.6-fold increase in ocular drug bioavailability compared to
Maxidex®. Therefore, the preocular applicator combined with a dry alginate tablet containing PLGA
nanoparticles can be a promising system for aseptically delivering an accurate dose of ophthalmic
drug with enhanced bioavailability.
Keywords: PLGA; nanoparticles; alginate; ophthalmic drug delivery; dexamethasone
1. Introduction
Topical drug administration is an easy route for ocular drug delivery. However, an ophthalmic
drug, prepared as a solution and suspension, is known to clear very rapidly from the eye surface
(<3 min), leading to a short preocular residence time, ultimately limiting drug bioavailability [1,2].
Less than 5% of a topically-applied drug can reach the interior target tissue of the eye [3,4]. Micro- or
nano-particles have thus been suggested as ophthalmic drug carriers to achieve prolonged preocular
residence time as well as sustained drug release [5]. Nevertheless, when formulated in the aqueous
suspension, an additional fluid added to the eye would accelerate tear clearance, which would also
expedite the drainage of the drug-loaded particles [6]. Therefore, an alternative strategy has been
suggested and it includes a dry tablet formulation, where the drug-loaded particles are embedded
in a tablet medium of a rapidly-dissolving polymer [7]. When applied to the eye surface, the tablet
medium would dissolve in the tear fluid to free the drug-loaded particles on the preocular surface.
The dissolution of the tablet medium would thus increase tear viscosity to delay tear clearance, which
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in turn would improve the preocular retention of drug-loaded particles. However, applying a dry
tablet to the sensitive eye may not be convenient for patients. In addition, this administration route
might not be hygienic, as the tablet would be retrieved with the bare fingers [8,9].
Herein, a combined system of a preocular applicator and a rapidly-dissolving dry tablet containing
drug-loaded nanoparticles was proposed. The applicator was designed to contain two compartments
(i.e., a handle plus a tip to hold the dry tablet). Thus, for administration, a dry tablet on the tip could
approach and touch the eye surface while the handle is held by one’s fingers. The tablet would then be
separated from the tip and its medium would be dissolved in the tear fluid to free the drug-loaded
nanoparticles. This would provide an easy way to topically administer the dry tablet and importantly,
allow tablets to remain aseptic during administration.
To test the system and strategy, a preocular applicator using the biocompatible
polydimethylsiloxane (PDMS) was prepared in this study. The shape and dimension of the applicator
herein was designed to be similar to that of the commercially-available, one-time use applicator
of artificial tear fluid based on patients’ familiarity [10]. The commercially-available applicator is
basically a container of liquid; however, a dry tablet formulation was loaded at the tip of the applicator
proposed in this work. For the formulation, poly(lactic-co-glycolic acid) (PLGA) nanoparticles were
prepared to be loaded with dexamethasone, a widely used corticosteroid drug for the treatment of eye
inflammation [11,12], to achieve sustained drug release. The nanoparticles were then suspended in a
solution containing a mixture of water-soluble polymers, polyvinyl alcohol (PVA), and alginate, which
was then freeze-dried on top of the applicator tip to produce a rapidly-dissolving dry tablet. PLGA has
been widely used for sustained drug delivery due to its high biocompatibility and degradability to
non-toxic by-products [13,14]. PVA has already been approved for clinical use in various ophthalmic
applications [15,16]. In the present study, alginate was also employed in the tablet medium as a
viscosity enhancer of tear fluids. Alginate is a highly-biocompatible polymer [17] that can form a gel in
the presence of the multivalent cation, Ca2+, which is abundant in the tear fluid [18,19]. Due to this
unique property, when dissolved in the tear fluid, alginate can further increase tear viscosity, thereby
synergistically improving the preocular retention of the drug-loaded nanoparticles.
Dexamethasone-loaded PLGA nanoparticles (DX/NP) were prepared by the solid-in-oil-in-water
(S/O/W) emulsion method and characterized by scanning electron microscopy (SEM) and dynamic light
scattering (DLS), which were employed to assess nanoparticle size and morphology. The cytotoxicity
of DX/NP was examined using human corneal epithelial cells (HCECs). To examine the effect of
alginate on tear viscosity enhancement, two distinct tablet formulations containing DX/NP were
prepared with media containing both PVA and alginate (DX/NP AL_TAB) and PVA alone (i.e.,
without alginate) (DX/NP TAB), respectively. For in vivo experiments, these tablet formulations were
applied to rabbit eyes, and drug concentration in the aqueous humor was assessed and compared
to the commercially-available ophthalmic dexamethasone medication, Maxidex®, (i.e., an aqueous
suspension of dexamethasone itself).
2. Materials and Methods
2.1. Materials
PLGA (lactic acid:glycolic acid = 50:50; i.v. = 48,000) was purchased from Evonik Industry (Essen,
Germany). Dexamethasone and Nile red were purchased from Tokyo Chemical Industry (Tokyo,
Japan). PVA (87–89% hydrolyzed), phosphate buffered saline (PBS) tablets, tween 80, trifluoroacetic
acid (TFA; >99%), and calcium chloride dihydrate (>99%) were obtained from Merck (St. Louis,
MO, USA). Dichloromethane (DCM; >99.5%), N,N-dimethylformamide (DMF; >99.5%), and acetone
(>99.5%) were supplied by DaeJung (Siheung-si, Korea). Acetonitrile (ACN; >99.9%) was purchased
from J.T. Bakers (Phillisburg, NJ, USA). PDMS (Sylgard 184) was obtained from Sewang Hitech Silicone
(Bucheon-si, Korea). Alcaine® (0.5% proparacaine hydrochloride ophthalmic solution) and Maxidex®
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(0.1% dexamethasone ophthalmic suspension) were purchased from Alcon-Couvreur (Fort Worth,
TX, USA).
2.2. Preparation of Drug-Loaded Nanoparticles
DX/NP was prepared via S/O/W emulsification [20]. Briefly, 300 mg PLGA and 100 mg
dexamethasone were dissolved in 7 mL DCM. The resulting solution was then added to 8 mL
of 1% w/v PVA solution, which was emulsified with a sonicator (Sonic Dismembrator Model 500, Fisher
Scientific, Illkirch-Graffenstaden, France) at 160 W for 10 min. The emulsion was transferred into
100 mL of 1% w/v PVA solution at room temperature and stirred at 400 rpm under vacuum (−10 psi)
for 60 min for solvent evaporation. The final suspension was then centrifuged at 200 rpm for 10 min,
where the precipitates were eliminated and only the suspension at the top was collected. The collected
suspension was then washed with deionized (DI) water three times via centrifugation at 13,000 rpm for
10 min. Thereafter, the suspension was lyophilized for 20 h to obtain dry DX/NP. PLGA nanoparticles
loaded with Nile red (NR/NP) instead of dexamethasone were also prepared to evaluate its in vivo
preocular retention properties. As such, 5 mg Nile Red and 500 mg PLGA were dissolved in 7 mL
DCM for emulsification.
2.3. Preparation of Tablet-Loaded Preocular Applicators
A preocular applicator with a dry tablet on the tip was prepared, as depicted in Figure 1. To prepare
a preocular applicator, two different molds were first made to fabricate a handle and tip (Figure 1a).
In the molds, a mixture of a PDMS base and its curing agent (10:1, v/v) was poured and cured slightly at
80 ◦C for 2 h. Then, each of the constituent pieces was assembled and cured further at 80 ◦C for another
2 h to allow for their bonding. In this work, two different tablets, with media containing both PVA
and alginate, and PVA alone, were produced to yield DX/NP AL_TAB and DX/NP TAB, respectively.
To prepare the DX/NP AL_TAB, 20 mg/mL DX/NP were suspended in a solution containing 0.1%
w/v PVA and 2% w/v alginate. Above this alginate concentration, the solution became too viscous to
properly distribute the DX/NP. To prepare the DX/NP TAB, 20 mg/mL DX/NP were suspended in a
solution of 0.1% w/v PVA only. Twenty μL of the resulting suspension was then poured in the reservoir
that was made by tightly fitting a cylindrical connector with open ends to a tip of the applicator
(Figure 1b). The whole piece was then rapidly frozen using liquid nitrogen, which was then lyophilized
for 5 h at 0.01 mbar with the collector temperature set at −80 ◦C (FreeZone 6 Dryer system, Labconco,
Kansas City, MO, USA) [21–23]. After that, a connector was carefully removed to produce the preocular
applicator loaded with the tablet formulation. To evaluate the in vivo preocular retention properties,
NR/NP was embedded instead of DX/NP to produce tablets of NR/NP AL_TAB and NR/NP TAB,
prepared under the same condition employed for DX/NP AL_TAB and DX/NP TAB, respectively.
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Figure 1. Schematic illustration of the fabrication of the DX/NP tablet-loaded applicator. (a) Fabrication
of the PDMS applicator. (b) Tablet preparation on the tip of the applicator.
2.4. Characterization
The morphology of DX/NP was examined by SEM (JSM-7800F Prime, JEOL, Tokyo, Japan). Its size
distribution was determined using DLS (ELS-2000ZS, Otsuka Electronics, Osaka, Japan) and a zetasizer
(Nano ZS, Malvern, UK) with a particle suspension prepared in DI water [24]. To measure the drug
loading amount, the solution of dexamethasone that was fully extracted from the DX/NP and tablet
was respectively prepared. Briefly, 4 mg of DX/NP was completely dissolved in 4 mL DMF. The
tablet at the applicator tip was fully immersed in 1 mL DMF, sonicated for 2 h, and centrifuged at
13,000 rpm. The supernatant was then diluted with ACN in a 1:1 ratio. Drug concentration in each
resulting solution was measured using high-performance liquid chromatography (HPLC; Agilent 1260
series, Agilent Technologies, Santa Clara, CA, USA) with a Diamonsil C18 column (5 μm, 150 × 4.6
mm). Column temperature and absorbance wavelength were set at 37 ◦C and 240 nm, respectively.
Injection volume and flow rate were 20 μL and 1.5 mL/min, respectively. The mobile phase was
comprised of 0.1% TFA and ACN mixed in a 65:35 ratio. Given with the loading amount of the DX/NP,
the encapsulation efficiency (EE) was calculated by the equation.
EE (%) =
Amount of drug loaded in nanoparticles
Initial amount of drug
× 100 (1)
The thicknesses of the tablets herein were measured using a caliper (ABSOLUTE Digimatic Caliper,
Mitutoyo, Kanagawa, Japan). To assess the particle distribution in the tablet, the NR/NP TAB and
NR/NP AL_TAB were imaged with a fluorescence microscope (Leica DMI4000 B, Leica Microsystems,
Wetzlar, Germany). To examine the effect of the tablet medium, DX/NP AL_TAB and DX/NP TAB
were each immersed in 1 mL of the medium mimicking tear fluid, i.e., PBS containing Ca2+ (10 mM,
pH 7.4, [Ca2+] = 39.4 μg/mL) [25], for 10 min at 37 ◦C. The viscosity of the resulting solution was
then measured using a rheometer (Advanced Rheometric Expansion System, Rheometric Scientific,
New Castle, DE, USA), where gap separation, temperature, and shear rate were set at 0.8 mm, 25 ◦C,
and 100 s−1, respectively.
2.5. In Vitro Drug Release Study
To examine the in vitro drug release profiles, 400 μg DX/NP, two different tablets containing the
DX/NP (i.e., DX/NP TAB and DX/NP AL_TAB) and Maxidex®, all of which contained the same amount
of about 35 μg DX were each placed in a dialysis membrane bag (SnakeSkinTM Dialysis Tubing, 10 kDa,
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Thermo Scientific, USA). The bag was then immersed in 5 mL pH 7.4 PBS containing 39.4 μg/mL
Ca2+ and 0.5% w/v Tween 80 to meet the sink condition of DX [26]. While being incubated at 37 ◦C,
at scheduled times, 1 mL of the release medium was collected and the same volume of fresh PBS was
added back. The amount of released dexamethasone was measured using HPLC as described above.
2.6. Cytotoxicity Evaluation
The in vitro cytotoxicity of DX/NP was evaluated using HCECs (PCS-700-010, ATCC, Manassas,
VA, USA). HCECs were grown in a corneal epithelial cell basal medium (PCS-700-030, ATCC, USA)
with supplements (PCS-700-040, ATCC) at 37 ◦C in a humidified environment with 5% CO2. Prior to
the assay, HCECs were seeded in a 96-well plate at 1 × 105 cells/well and grown for 24 h. Subsequently,
100 μL of the DX/NP suspension, which was prepared in the cell growth medium at concentrations of
5, 10, 25, 50, 100, 250, 500, and 1000 μg/mL, was added to each well and incubated at 37 ◦C for 24 h.
The medium was then completely removed and replaced with 100 μL of fresh medium. Thereafter,
10 μL of an EZ-Cytox solution was added to each well and incubated at 37 ◦C for 2 h under dark
conditions. Cell viability was measured using a microplate reader, with absorbance and reference
wavelengths of 450 nm and 600 nm, respectively (VersaMax ELISA Microplate Reader; Molecular
Devices, San Jose, CA, USA).
2.7. Animal Experiments
In vivo experiments were conducted with the healthy eyes of male New Zealand White rabbits
(weight 2.1–2.5 kg). Rabbits were granted free access to food and water and were housed in a controlled
environment: temperature; 21 ± 1 ◦C, humidity; 55 ± 1%, and light/dark cycle; 12 h/12 h. The in vivo
experimental protocols were approved by the Institutional Animal Care and Use Committee at Seoul
National University Hospital (IACUC No. 19–0133, date: 30 July 2019).
First, the in vivo preocular retention properties of the nanoparticles were evaluated after topical
administration to the eye. The preocular retention properties were assessed as reported in our previous
studies, with slight modifications [27,28]. Briefly, the NR/NP AL_TAB or NR/NP TAB on the applicator
tip was applied on the lower cul-de-sac of the left eye of rabbits. At scheduled times, the rabbit eye
was anesthetized by topical administration of a drop of Alcaine® and the entire preocular surface was
thoroughly wiped with a surgical sponge (PVA spear; Sidapharm, Thessaloniki, Greece) to collect the
NR/NP. The sponge was then fully immersed in 5 mL DMF and sonicated for 2 h to fully dissolve
the NR/NP. The amount of Nile red in the sample was measured using HPLC-mass spectroscopy
(LC-MS) with a Polaris 5 C18-A (2.7 μm pore size, 4.6 × 150 mm) and the following conditions:
column temperature, 30 ◦C; absorbance wavelength, 243 nm; injection volume, 20 μL; and flow rate,
0.45 mL/min. The mobile phase was prepared by mixing 0.1% formic acid and ACN in the ratio, 55:45.
For statistics, four animals (i.e., one left eye for each rabbit) were assigned per time point for each
formulation. With the NR/NP AL_TAB and NR/NP TAB, the in vivo profile of tablet disintegration
was also assessed. For this, the eye was imaged using a digital camera (Galaxy S10, Samsung, Seoul,
Korea) at 0 and 30 s after topical administration of the tablet to rabbit eyes.
To assess the in vivo ocular drug bioavailability, each of the three formulations (i.e., the DX/NP
AL_TAB and DX/NP TAB in the applicator, and 35 μL Maxidex®) with the same dose of dexamethasone
(ca. 35 μg dexamethasone) was administered onto the lower cul-de-sac of rabbit eyes. At scheduled
times, the rabbit was anesthetized with a subcutaneous injection of a cocktail containing 20 mg/kg
ketamine and 10 mg/kg xylazine. Thereafter, approximately 100 μL of aqueous humor (AH) was
collected using a 31 G needle (BD Ultra-Fine II, Becton Dickinson and Company, Franklin Lakes, NJ,
USA). Drug concentration in AH was analyzed by LC-MS as described above. For statistics, three
animals (i.e., the left eye of each rabbit) were assigned per time point for each formulation.
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2.8. Statistical Analysis
Statistical analysis was performed using the amount of particles remaining on the preocular
surface and drug concentration in AH by the Mann–Whitney U-test. A p-value < 0.05 was considered
to indicate statistical significance (SPSS version 22, IBM, Armonk, NY, USA).
3. Results
3.1. Characterization of the Formulations
DX/NP was prepared using the emulsion method. As a result, the drug-loaded nanoparticles
were found to display a spherical shape, as shown in Figure 2a. Particle diameter was 336.92 ± 5.56 nm
(Figure 2b) while drug-loading amount was 85.45 ± 5.44 μg/mg (i.e., EE = c.a. 25.6%). The size
and shape of NR/NP were similar to those of DX/NP (Figure S1 in the Supplementary Information).
As shown in Figure 2c, the zeta potential of the blank PLGA nanoparticles was measured to be −3.9 mV,
which was shifted to −27.2 mV with the DX/NP due to a negative charge of the encapsulated drug,
DX [29]. Figure 3a shows the tablets prepared in the present experiment (i.e., the DX/NP TAB and
DX/NP AL_TAB). They displayed a cylindrical shape and were well attached at the tip applicator.
As shown in Figure 3b, the tablets loaded with the NR/NP exhibited a evenly-distributed fluorescent
signal throughout the medium, implying a homogenous distribution of the particles in the tablet.
As the same amount of DX/NP was embedded during tablet preparation, the drug loading amount
per tablet was similar between DX/NP TAB and DX/NP AL_TAB (34.11 ± 0.48 and 34.89 ± 0.28 μg,
respectively). For the same reason, the thicknesses of the DX/NP TAB and DX/NP AL_TAB were also
similar, which were measured to be 1.02 ± 0.03 and 1.02 ± 0.06 mm, respectively. When tablets were
dissolved in Ca2+-containing PBS, the solution with DX/NP AL_TAB (i.e., the tablet containing 400 μg
alginate) had a higher viscosity of 0.93 Pa s than that with DX/NP TAB (i.e., the tablet without alginate)
of 0.01 Pa s. However, both tablets herein were observed to be disintegrated in 30 s by dissolution in
tear fluid when topically administered to rabbit eyes (Figure 3c).
Figure 2. Characterization of DX/NP. (a) Representative scanning electron micrographs of DX/NP.
(b) Particle size distribution of DX/NP measured by the dynamic light scattering (DLS) method;
Polydispersity index = 0.056. (c) Zeta potentials of the blank PLGA nanoparticles () and DX/NP ().
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Figure 3. Characterizations of tablets. (a) Representative optical images of the applicator with the
DX/NP TAB and DX/NP AL_TAB. White arrows indicate the dry tablets prepared on the applicator
tip. (b) Representative fluorescence images of the NR/NP TAB and NR/NP AL_TAB. (c) Disintegration
profiles of the NR/NP TAB and NR/NP AL_TAB administered topically to rabbit eyes.
3.2. In Vitro Evaluation Results
Figure 4 shows the in vitro drug release profiles of DX/NP and the tablet formulations, which
displayed sustained drug release for up to 10 h. The release profiles did not differ among the
formulations as the tablet medium dissolved rapidly to achieve almost instantaneous freeing of DX/NP.
Drug release was slightly more suppressed with DX/NP AL_TAB, which could be due to a slight
increase in the viscosity of the release medium in a dialysis membrane bag owing to the interaction
between algnate and Ca2+. On the other hand, Maxidex®, which is basically a suspension of DX,
exhibited almost complete dissolution of the drug in 2 h. When tested with HCECs, the DX/NP
exhibited a cell viability greater than 90% at all testing concentrations (Figure 5), suggesting that the
DX/NP was non-cytotoxic.
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Figure 4. In vitro drug release profiles of Maxidex® (), DX/NP (), DX/NP TAB (), and DX/NP
AL_TAB ().
Figure 5. In vitro cytotoxicity of DX/NP on human primary corneal epithelial cells.
3.3. In Vivo Experimental Results
To examine the effect of alginate on preocular retention of the nanoparticles, two different tablets
embedded with the Nile red-loaded nanoparticles (i.e., NR/NP TAB and NR/NP AL_TAB) were
employed for in vivo evaluation. As shown in Figure 6, by incorporating alginate in the tablet, the
amount of nanoparticles remaining at the preocular surface increased. For the tablet without alginate,
the average percent of remaining particles was relatively low (i.e., 4.8 and 0.2% at 15 min and 1 h,
respectively). However, owing to the presence of alginate in the tablet, 33 and 12% of particles
remained at 15 min and 1 h, respectively, and could still be detected until 2 h. As conventional eye
drops are known to completely disappear in 5 min [1], such findings suggest a greater improvement in
drug retention at the eye surface. For the tablet with alginate, there was a high variability in particle
retention observed at 1 h. Right after the tablet medium dissolved in the tear fluid to interact with Ca2+
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ions, the tear viscosity increased to allow for an evident retention of the NP at the preocular surface.
However, as the time progressed, the tear fluid with alginate would be continuously diluted with a
newly-generated fresh tear, which would vary greatly depending on the subject. After 2 h, almost all
particles would be cleared from the preocular surface.
Figure 6. In vivo preocular retention profiles of NR/NP TAB () and NR/NP AL_TAB () on rabbit
eyes. * indicated statistical significance between the formulations at each time point (p < 0.05).
The pharmacokinetic profiles of the tablet formulations were assessed and compared with that of
the commercially-available dexamethasone eye drops, Maxidex®. Figure 7 and Table 1 display the
drug concentration profiles in the AH and their pharmacokinetic parameters, respectively. At 30 min,
Maxidex® had a Cmax of 285.93 ng/mL; however, this value rapidly decreased to an undetectable
level at 6 h after the administration. Interestingly, albeit formulated in a dry tablet, the DX/NP TAB
without alginate exhibited a much lower drug bioavailability. In addition, its area under the drug
concentration-time curve (AUC) and Cmax were less than a half of those with Maxidex®. Such finding
could be due to a lower amount of drug exposure at the eye surface, where the DX/NP disappeared
relatively rapidly and only a small portion of drug within the particles was actually released during
the early period post-administration. On the other hand, 100% drug would be exposed right after a
bolus administration with Maxidex®.
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Figure 7. Dexamethasone concentration in the AH of rabbit eyes after the administration of Maxidex®
(), DX/NP TAB (), and DX/NP AL_TAB (). * DX/NP AL_TAB was significantly different from
Maxidex®.
Table 1. Pharmacokinetic parameters of dexamethasone in the AH.
Formulations Tmax (h) Cmax (ng·mL−1) AUC a (ng·h·mL−1)
Maxidex® 0.5 285.93 388.51
DX/NP TAB 1 62.18 165.93
DX/NP AL_TAB 2 370.33 981.23
a calculated using the trapezoidal rule.
The highest drug bioavailability was observed with the DX/NP AL_TAB. In fact, its AUC was
2.5-fold greater than that of Maxidex®. By incorporating alginate in the tablet, it appeared to increase
the viscosity of the tear fluid, enabling a larger amount of DX/NP to be retained in the preocular space
for a longer period. During this period, the DX/NP would release and expose a significant amount of
dexamethasone in a sustained manner. As a result, the drug concentration in tear would gradually
increase before being absorbed into the AH to shift the time to reach Cmax (Tmax) to a later point (i.e.,
2 h) and further increase the value of Cmax itself, compared to that of Maxidex®. Due to prolonged
retention and sustained drug release, drug clearance from the AH was delayed, demonstrating that
drug concentration in the AH was statistically significantly higher than that of Maxidex® at 4–10 h
(p < 0.05). All tablets tested in this experiment were almost instantaneously fully detached and released
from the applicator tip to the preocular surface when they were in contact with the lower cul-de-sac of
rabbit eyes (Figure S2 in Supplementary Information).
4. Discussion
Topical drug administration is considered to be an easy route for ophthalmic drug delivery.
However, for conventional formulations of drops and suspensions, the additional liquid accelerates
tear clearance to further lower drug bioavailability in the eye [30,31]. To overcome this, a dry tablet
loaded with microparticles had been proposed as topical drug-delivery formulations [7]. The tablet
was prepared by compressing the medium of mannitol together with drug-loaded microparticles
composed of PLGA and a mucoadhesion promoter, PEG. Thus, dissolution of mannitol increased
the tear viscosity to allow for a prolonged time of interaction between PEG in particles and mucin in
the preocular surface. However, the tablet with a high density appeared to dissolve in tear fluid in
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minutes, during which a relatively large tablet could cause eye irritation. Therefore, the formulation
was upgraded to be able to dissolve rapidly in tear fluid and for this, the dry tablet was prepared
by freeze-drying [7]. In this way, the tablet medium could possess a porous structure and thus, after
administration, it dissolved almost instantaneously in tear fluid to free the drug-loaded particles in
the preocular surface. With this strategy, the particles still maintained a preocular retention property,
as well as showing sustained drug release, hence improved drug bioavailability in the eye.
Herein, a rapidly-dissolving dry tablet formulation embedded with drug-loaded PLGA
nanoparticles (i.e., the DX/NP) was proposed again for topical drug delivery to the eye. Owing
to the presence of alginate in the tablet medium, tear viscosity increased because of the interaction
between alginate and Ca2+. This hampered tear clearance, leading to a higher preocular retention
of DX/NP (Figure 6). Therefore, in addition to residing longer in the preocular space, DX/NP could
continuously release the drug to tear fluids, providing more time for drug diffusion into the eye and
eventually improving ocular drug bioavailability (Figure 7).
In the present study, the tablets were prepared by freeze-drying the DX/NP suspension; this
allowed the tablet medium of the water-soluble polymers to be highly porous for rapid dissolution
of the tablet in the tear fluid. Considering commercialization, the moisture content in the tablet
may need to be minimized further to provide with an appropriate shelf-life of the product. Owing
to the nano-sizes of DX/NP, the sensitive eye surface would not be irritated [32]. Therefore, with
the alginate content employed for the tablet herein, any sign of eye irritation or discomfort was
observed during in vivo experiments. By using the applicator, the tablet could be delivered without
being touched, thereby achieving a hygienic application. PDMS was employed as the constituent
material for the applicator because of its biocompatibility, should the applicator touch the eye surface.
More importantly, PDMS is inherently hydrophobic and it is known to possess a low surface release
energy [33]. Therefore, the dry tablet composed of hydrophilic polymers could be separated almost
instantaneously without loss when wet with tear fluids (Figure S2), thereby enabling the delivery of an
accurate drug dose to the eye using the tablet formulation.
5. Conclusions
Herein, a formulation consisting of a dry tablet containing alginate and drug-loaded PLGA
nanoparticles is derived to improve the bioavailability of drugs that are topically delivered to the
eye. Owing to the ease and hygienic administration of the developed tablet formulation, the use of a
preocular applicator is suggested. Based on the hydrophobicity and low surface release energy of the
constituent material, PDMS, the applicator could almost instantaneously cause full separation of the
dry tablet composed of hydrophilic polymers when applied to the eye surface. After topical delivery,
the tablet medium dissolved rapidly to free the drug-loaded nanoparticles in the tear fluid, where
alginate could react with Ca2+ to increase its viscosity. Such findings suggest that the drug-loaded
PLGA nanoparticles can be better retained in the preocular space and the drug can be subsequently
released in a sustained manner, ultimately enhancing ocular drug bioavailability. Therefore, it is
concluded that the combination of a dry tablet formulation with an alginate medium, drug-loaded
PLGA nanoparticles, and a preocular applicator is a promising strategy to achieve patient-friendly,
topical drug delivery to the eye, with enhanced drug availability.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/12/651/s1;
Figure S1: Characterizations of NR/NP; Figure S2: Images of rabbit eyes.
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Abstract: For Huntington’s disease (HD) cell-based therapy, the transplanted cells are required
to be committed to a neuronal cell lineage, survive and maintain this phenotype to ensure their
safe transplantation in the brain. We first investigated the role of RE-1 silencing transcription
factor (REST) inhibition using siRNA in the GABAergic differentiation of marrow-isolated adult
multilineage inducible (MIAMI) cells, a subpopulation of MSCs. We further combined these cells to
laminin-coated poly(lactic-co-glycolic acid) PLGA pharmacologically active microcarriers (PAMs)
delivering BDNF in a controlled fashion to stimulate the survival and maintain the differentiation of
the cells. The PAMs/cells complexes were then transplanted in an ex vivo model of HD. Using Sonic
Hedgehog (SHH) and siREST, we obtained GABAergic progenitors/neuronal-like cells, which were
able to secrete HGF, SDF1 VEGFa and BDNF, of importance for HD. GABA-like progenitors adhered
to PAMs increased their mRNA expression of NGF/VEGFa as well as their secretion of PIGF-1, which
can enhance reparative angiogenesis. In our ex vivo model of HD, they were successfully transplanted
while attached to PAMs and were able to survive and maintain this GABAergic neuronal phenotype.
Together, our results may pave the way for future research that could improve the success of cell-based
therapy for HDs.
Keywords: tissue engineering; Huntington’s disease; siRNA; nanoparticles; microcarriers;
mesenchymal stromal cells
1. Introduction
Huntington’s disease (HD) is a genetic neurodegenerative disorder caused by the abnormal
repetition of CAG nucleotides in the Huntingtin (HTT) gene. This leads to a pathological expansion of
polyglutamine (polyQ) and aggregation of the mutated HTT protein in the brain, more specifically in
the striatum [1,2]. HD is characterized by a progressive degeneration of striatal GABAergic medium
spiny projection neurons, followed by a progressive degeneration extending throughout the brain [3].
Clinically, this results in involuntary movements, cognitive impairment and psychiatric manifestations,
culminating in death around 15–20 years after the onset of motor symptoms [4,5]. Currently, there is
no proven medical therapy to alleviate the onset or progression of HD [6].
Mesenchymal stromal cells (MSCs), have emerged for clinical transplantation studies due to their
easy availability, their immune-modulatory properties [7] and their capacity to release neurotrophic
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factors and to create a neuroprotective microenvironment [8]. Clinical trials using MSCs in the central
nervous system are now underway for many neurological disorders and have shown the feasibility
of this approach [9]. Pre-clinical studies with HD models have shown improvement in behavior
and a reduced lesion volume after MSC implantation. These beneficial effects could be explained
by the secretion of neurotrophic factors including brain-derived neurotrophic factor (BDNF), ciliary
neutrotrophic factor, nerve growth factor, insulin-like growth factor 1 and epidermal growth factor
(EGF) [10,11]. The trans-differentiation of MSCs into a neural/neuronal lineage, even if possible in vitro,
is far less efficient in vivo and their functional maturity remains too scarce [12]. The rationale for
their transplantation does not lie on their capacity to replace the damaged neuronal cells, but on
their ability to neuroprotect and repair by their paracrine effects on the surrounding environment [8].
Even though they are not used in a cell replacement strategy demanding electrophysiolocally functional
connections, if the cells are to be safely used in clinical trials, it is important that they blend into
the microenvironment of the brain and present the same neuronal phenotype. Therefore, MSCs are
required to be committed to a neuronal cell lineage and maintain this phenotype to ensure their safe
transplantation in the brain. In this regard, REST/NRSF a repressor transcription factor functioning as
a master negative regulator of neurogenesis by binding to a specific DNA domain named RE1 motif is
an interesting target to inhibit and thus induce a neuronal specification [13,14]. It was thus recently
shown that the silencing of REST, obtained by a recombinant lentivirus carrying a small interfering
RNA (siRNA) for REST, induced a neural/neuronal differentiation of MSCs [15,16].
Nanoparticles have been developed to efficiently and safely deliver siRNA both in vitro and
in vivo and to avoid insertional gene mutations and viral toxicity issues. We recently designed lipid
nanocapsules (LNC) able to encapsulate siRNAs complexed to lipids, thus protecting the siRNA from
degradation. LNCs consisting of a lipid liquid core of triglycerides and a rigid shell of lecithin and
polyethylene glycol (PEG) can be formulated by a simple and easily industrialized solvent-free process
based on the phase inversion of an emulsion [17,18]. They have a high stability and can destabilize
lysosome’s membranes by a proton sponge effect [19]. We also demonstrated that LNCs associated
with siREST in MSCs were able to induce their neuronal commitment with a better efficiency than the
commercial reagent Oligofectamine® [9]. However, MSCs are a heterogeneous population presenting
different differentiation properties. A homogeneous subpopulation of MSCs, termed marrow-isolated
adult multilineage inducible (MIAMI) cells, which present a unique genetic profile expressing several
pluripotency markers (Oct4, Sox2, Nanog, SSEA4), share many proteins with embryonic stem cells,
secrete more tissue repair factors than MSCs, protect the neurovasculature and can be induced to
differentiate into cells from all three germ layers [20–22], emerge as a good alternative for cell therapy
studies. MIAMI cells can be specified into the neuronal lineage with epidermal growth factor (EGF)
and fibroblast growth factor-2 (FGF-2) [23] and induced to an immature neuronal dopaminergic
phenotype presenting appropriate electrophysiological properties, regardless of the donor age, with a
three-step protocol in vitro requiring neurotrophins [24,25]. In addition, laminin (LM) was shown to
enhance the neuronal differentiation of these cells [8]. However, further efforts are needed to maintain
a differentiated phenotype and increase engraftment/survival after transplantation in the brain.
Pharmacologically active microcarriers (PAMs) are biodegradable and biocompatible
poly(lactic-co-glycolic acid) PLGA-based microspheres covered with extracellular matrix molecules
(ECM) such as fibronectin or laminin providing an adequate three-dimensional (3D) biomimetic
surface for the transplanted cells and thus enhancing their survival [22,24]. Moreover, PAMs can
also release in a controlled manner an encapsulated growth factor allowing a better cell engraftment
by stimulating the transplanted cells and/or the microenvironment [22,26]. In this context, PAMs
transporting human stem cells and delivering different growth factors have been shown to be beneficial
in several animal models of neurological disorders, cartilage and cardiac pathologies [27–30]. In this
regard, BDNF, which is involved in neuronal GABAergic differentiation and neuronal survival [30–32]
may maintain the differentiated phenotype and increase the survival of the transported MIAMI cells.
Moreover, in the case of HD, several studies demonstrated that the expression of BDNF is reduced in
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the patient’s brains [33]. Promising results show that BDNF supplementation increases the survival of
enkephalin-immunoreactive striatal neurons, reduces striatal interneuronal loss and improves motor
function in HD animal models [31,34,35]. PAMs would have the benefit to prevent BDNF degradation
while providing for its controlled release over time, hence maximizing the possible benefits of BDNF
for neuroprotection in HD.
In this study, we aim to first improve the neuronal differentiation of a subpopulation of MSCs,
the MIAMI cells, as well as to study their behavior after combining them with PAMs releasing BDNF
in vitro and on organotypic brain cultures. We first evaluated the impact of siREST LNC transfection on
the neuronal commitment of EGF/FGF-2 pre-treated MIAMI cells. We set up a differentiation protocol
based mainly on sonic hedgehog (SHH) treatment followed by BDNF as previously described [36,37],
to evaluate the GABAergic differentiation potential of these cells in vitro; GABAergic cells being
the predominant cell type present in the striatum. We thus also studied the effects of the REST
nanocapsule-silencing on MIAMI cells induction towards the GABAergic phenotype. The secretome
and neuronal marker expression of MIAMI cells adhered onto LM-coated PAMs releasing BDNF
was also studied in order to assess their potential therapeutic effect. We finally evaluated their
behavior in an ex vivo organotypic model of HD. Therefore, the novelty of our paper lies in the
combinatorial strategy using siREST silencing nanoparticles and cell transporting biodegradable
polymeric PAMs releasing BDNF to achieve neuronally-committed MSCs releasing growth factors for
a safe neuroprotective/neurorepair strategy for HD.
2. Materials and Methods
2.1. siRNA-LNCs
LNCs were formulated, as previously described [38] by mixing 20% w/w Labrafac® WL 1349
(caprylic-capric acid triglycerides, Gatefossé S.A. Saint-Priest, France), 1.5% w/w Lipoid S75-3® (Lecithin,
Ludwigshafen, Germany), 17% w/w Kolliphor® HS 15 (Polyethylene glycol-15-Hydroxystearate
PEGHS BASF, Ludwigshafen, Germany), 1.8% w/w NaCl (Prolabo, Fontenay-sous-Bois, France)
and 59.8% w/w water (obtained from a Milli-Q system, Millipore, Paris, France) together under
magnetic stirring. Briefly, three temperature cycles between 60 and 95 ◦C were performed to
obtain phase inversions of the emulsion. A subsequent rapid cooling and dilution with ice cold
water (1:1.4) at the last phase inversion temperature led to blank LNC formation. For liposome
preparation, a cationic lipid DOTAP (1,2-dioleyl-3-trimethylammoniumpropane) (Avanti® Polar
Lipids Inc., Alabaster, AL, USA), solubilized in chloroform, was mixed at a 1/1 molar ratio with
the neutral lipid DOPE (1,2-dioleyl-sn-glycero-3-phosphoethanolamine) (Avanti® Polar Lipids Inc.)
to obtain a final concentration of 30 mM of cationic lipid. After chloroform vacuum evaporation,
the lipid film was rehydrated and liposomes sonicated. A simple equivolume mix of liposomes
and siRNA resulted in lipoplexes characterized by a charge ratio of 5 between the positive charge
of lipids and the negative charge of nucleic acids. To obtain siRNA-LNCs, the water introduced at
the last phase inversion temperature was replaced by lipoplexes, i.e., REST siRNA: (sense sequence:
5′-CAG-AGU-UCA-CAG-UGC-UAA-GAA -3′; Eurogentec, Seraing, Belgium) and control (scrambled)
siRNA (sense sequence: 5′-UCUACGAGGCACGAGACUU-3′; Eurogentec) complexed with cationic
liposomes in a defined charge ratio as described above. To avoid the possible denaturation of siRNA
the addition of lipoplexes was performed at 40 ◦C.
2.2. Fluorescent siRNA-LNCs-DiD
To formulate fluorescent siRNA-LNCs, a solution of DiD (1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine perchlorate; em. = 644 nm; exc. = 665 nm) (Invitrogen, Cergy-Pontoise,
France) solubilized in acetone at 25 mg/mL was prepared.
For in vitro experiments, the DiD concentration was fixed at 200 μg/mL of LNC suspension
or corresponding to 1.36 mg of DiD per grams of Labrafac®. The adequate volume of DiD
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solubilized in acetone was incorporated in Labrafac® and acetone was evaporated at room temperature.
The formulation process was unchanged, and formulation was stored at 4 ◦C, protected from light. For
siRNA fluorescent LNCs, a fluorescent Alexa 488 siRNA (Eurogentec) was used.
2.3. BDNF-Releasing, Laminin (LM)-Coated PAMs
Synthesis and characterizations of PLGA-P188-PLGA polymer were performed using Synbio3
platform supported by GIS IBISA and ITMO Cancer. BDNF-releasing PAMs were prepared as
previously described using a solid/oil/water emulsion solvent extraction-evaporation method [30].
Briefly, BDNF and human serum albumin were first nanoprecipitated separately and nanoprecipitated
proteins were dispersed in the organic phase containing the polymer at a protein loading of 1 μg of
protein and 5 μg of human serum albumin/mg of PAMs. The suspension was emulsified in a poly(vinyl
alcohol) aqueous phase and after solvent extraction in an aqueous phase, the microspheres were
filtered and freeze-dried. Blank microspheres, without protein, were prepared following a similar
process. To obtain LM-covered PAMS (LM-PAMs), PLGA-P188-PLGA microspheres were coated with
LM and poly-d-Lysine (PDL) as previously described [29]. Briefly, the coating solutions prepared in
Dulbecco’s Phosphate-Buffered Saline (DPBS) were mixed under rotation with the microspheres at a
final concentration of the coating molecules of 16 μg/mL of LM and 24 μg/mL of PDL (corresponding to
a 40:60 ratio of LM:PDL). In vitro BDNF release from PAMs was performed as previously described by
incubation of 5mg PAMs in citrate buffer and dosage by ELISA of collected fractions of the supernatant
over time [30].
2.4. LNC and PAM Characterization
The size and Zeta potential of LNCs (N = 3) were measured by using the Dynamic Light Scattering
(DLS) method using a Malvern Zetasizer® apparatus (Nano Series ZS, Malvern Instruments S.A.,
Worcestershire, UK) after dilution at a ratio of 1:200 with deionized water. PAM’s size was measured
with a Multisizer® coulter counter (Beckman Coulter, Roissy France), zeta potential was measured by
DLS [30]. The laminin surface was characterized by confocal microscopy (Leica TCS SP8, France) after
LM immunostaining as previously described [30]. Lyophilized PAMs were incubated for 30 min at
room temperature (RT) under 15 rpm stirring in DPBS containing 4% bovine serum albumin (BSA), 0.2%
Tween 20 (DPBS BT). After washing, anti-LM mouse monoclonal antibody (Sigma-Aldrich, St-Louis,
MO, USA, 100 μg/mL in DPBS) was added for 1.5 h under rotation at 37 ◦C. After washing, biotinylated
anti-mouse IgG antibody (2.5 μg/mL in DPBS BT) was added for 1 h, at RT, washed and incubated
with streptavidin–fluoroprobe 547 (1:1000 in DPBS) at RT, for 40 min. (N = 3, n = 3)
2.5. MIAMI E/F Cells
MIAMI cells were isolated from human bone marrow (Lonza, donor #3515) and expanded on
fibronectin (Sigma-Aldrich) coated flasks at 120 cells/cm2 in low oxygen tension (3% of O2 and 5% of
CO2) in Dulbecco’s Modified Eagle Medium-low glucose (DMEM, Gibco, Life Technologies, Paisley,
UK), supplemented with 3% of Foetal Bovine serum (FBS), 100 μM of ascorbic acid and a mixture of
lipids, as previously described [20]. Using the same density of cells and culture condition, a 10 days
treatment with an addition of 20 ng/mL of EGF and 20 ng/mL of FGF-2 (both from R&D systems, Lille,
France) and 5 μg/mL of Heparin (Sigma-Aldrich) was used to enhance neuronal specification [23] and
these cells were named MIAMI E/F cells. Every three days, half of the culture medium was replaced.
2.6. MIAMI E/F Cell Transfection
MIAMI E/F cells were seeded at 2000 to 3000 cells per cm2 in wells coated with LM (2 μg/cm2,
Sigma-Aldrich). Experiments were performed in Opti-MEM® media (Life technologies, France).
SiRNA-LNCs were incubated with cells at 37 ◦C in a humidified atmosphere with 3% O2 and 5% CO2
for 4 h before serum addition. Cells were harvested after appropriate time and assayed for mRNA
expression levels by RT-qPCR or protein expression level by immunofluorescence.
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2.7. LNC Cell Time Retention
MIAMI cells (2000 to 3000 cells per cm2) were seeded on glass slides coated with LM (2 μg/cm2,
Sigma-Aldrich). SiRNA fluorescent LNCs were incubated with cells at 37 ◦C in a humidified atmosphere
with 3% O2 and 5% CO2 for 4 h in Opti-MEM® media before DPBS washing and paraformaldehyde
fixation (4% of paraformaldehyde during 15 min at 4 ◦C) or FBS addition. At Day 0 and before fixation,
100nM LysoTracker Red (Molecular Probes, Eugene, OR, USA.) was added to the media. After washing,
cells were visualized from Day 0 to Day 6 post-transfection using a fluorescence confocal multispectral
imaging, FCSI (Leica TCS SP8).
2.8. MIAMI E/F Cell Neuronal Differentiation
MIAMI E/F transfected with siRNA-LNC cells were seeded (2000–3000 cells per cm2) on 175 cm2
cell culture flasks for Step 1 and on glass slides on 6 well plates for Step 2 coated with LM (2 μg/cm2,
Sigma-Aldrich, St-Louis, MO, USA) and different conditions tested to obtain the best two-step
GABAergic differentiation protocol (Figure 1). The first step was performed with DMEM/F12 (Glutamax,
Gibco, Life Technologies, Paisley, UK) supplemented with 5% of N2 (1X) (both from Gibco, Life
Technologies), and 200 ng/mL of sonic hedgehog (SHH, Peprotech, Rocky Hill, USA) for 14 days and
35 mL of media was used per flask. These cells are named MIAMI-SHH. Second step: Neurobasal
media (Neurobasal, Gibco, Life Technologies) supplemented with or without 1 mM of Valproic acid
(Sigma-Aldrich) and with or without 30 ng/mL of BDNF (Peprotech) for 14 days and 3 mL of media
was used per well. Length and surface area were quantified using MetaVue software®. 6 pictures from
each condition (24 in total) were taken with a 10× objective and used to determine total area and length.
Only cells responding to the treatment (with neurite-like structures) were analyzed in this experiment.
 
Figure 1. Media tested for the GABAergic differentiation of marrow-isolated adult multilineage
inducible (MIAMI) cells.
2.9. Formation of PAMs-Cell Constructs
Cell adhesion studies were performed based on previous published protocols [22,24]. At the end
of Step 1, MIAMI-SHH-siREST cells were detached and resuspended in DMEM-F12 supplemented
with either 3% FBS (Lonza, Verviers, Belgium), 5% of N2 (1X) (Gibco, Life Technologies, Paisley, UK) or
2% of B27 (1X) (Gibco, Life Technologies). Lyophilized PAMs (0.5 mg) were resuspended in coated
microcentrifuge tubes (Sigmacote, Sigma) containing DMEM-F12 (Gibco, Life Technologies), and mixed
with 0.5 mL of cell suspension (2.5 × 105 cells/0.50 mg PAMs). The mixture was then gently flushed
and plated in 1.9 cm2 Costar ultra low adherence plate (#3473, Corning, Avon, France). Plates were
incubated at 37 ◦C during 4 h for MIAMI E/F, to allow cell attachment on PAM surface (covered with
FN). PAMs/cell aggregates were pelleted by centrifugation at 200 g for 2 min. Cell adhesion to PAM
surface was assessed by microscopic observation and cells adhered to PAMs were quantified using the
Cyquant cell proliferation assay (CyQuant Cell proliferation Assay kit, Invitrogen). Complexes were
further studied using light and confocal microscopy and scanning electron microscopy. Samples were
prepared for scanning electron microscopy analysis as previously described [24].
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2.10. Preparation of Brain Organotypic Slices
Organotypic cultures were prepared as previously described by our team [39]. Briefly,
Albinos wild-type Sprague–Dawley rats from the SCAHU (Service Commun d’Animalerie
Hospitalo-Universitaire, N◦49007002, Angers University, France) were used. Postnatal 9–11 (P9–11)
days old Sprague–Dawley pups were used to generate the ex vivo model of HD. Animals were rapidly
euthanized after anesthesia, by intraperitoneal injection of 80 mg/kg of ketamine (Clorketam 1000,
Vetoquirol, Lure, France) and 10 mg/kg of xylazine (Rompum 2%, Bayer Health Care, Kiel, Germany).
Brains were removed and rapidly dissected before being glued onto the chuck of a vibratome cooled
with a bath of Gey’s balanced salt solution supplemented with 6.5 mg/L of glucose and antibiotics.
400 μm thick slices were cut using a vibratome (Motorized Advance Vibroslice MA752, Campdem
instruments) in different configurations to obtain a progressive degeneration of the GABAergic medium
spiny neurons (MSNs). Each hemisphere was mechanically separated to culture 8 organotypic brain
slices total (4 from each hemispheres). Obtained slices were next transferred to 30 mm diameter
semi-porous membrane inserts (Millicell-CM, Millipore, Guyancourt, France) within a 6-well plate,
containing Neurobasal medium (Gibco, Life Technologies) supplemented with 6.5 mg/L of glucose,
1 mM of l-glutamine, 1x B27 supplements (Gibco, Life Technologies) and antibiotics. Slices were
incubated at 37 ◦C and 5% CO2 up to 30 days and half of the medium was removed every 2–3 days.
Each slice was cultured on a single membrane to increase their survival over time.
2.11. Injection of the Cells-PAMs Constructs into Organotypic Slides
Three days after organotypic slice preparation, the cells-PAMs were injected into the striatum
using a 22-gauge Hamilton needle (Hamilton, Bonaduz, Switzerland) connected to a micromanipulator.
The total injection volume consisted of 2 μL of culture medium containing approximately 75,000 cells
alone or adhering to 0.1 mg of PAMs. The injections were done at an infusion rate of 0.5 μL/minute.
The needle was left in place for 5 min before removal to avoid the cells being expelled from the
organotypic slices.
2.12. Reverse Transcription and Real Time Quantitative PCR
Experiments were performed following the guidelines of the PACeM core facility ("Plate-forme
d’Analyse Cellulaire et Moléculaire”, Angers, France). Total RNA of cells was extracted, purified using
RNeasy Microkit (Qiagen, Courtaboeuf, France), treated with DNase (10 U DNase I/μg total RNA) and
the concentration determined with a ND-2000 NanoDrop (Thermo Fisher Scientific, Wilmington, DE,
USA). RNA integrity was verified on Experion RNA StdSens chip (Bio-Rad). First strand complementary
DNA (cDNA) synthesis was performed with a SuperScriptTM II Reverse Transcriptase (Invitrogen),
in combination with random hexamers, according to the manufacturer’s instructions. cDNAs were
purified (Qiaquick PCR purification kit, Qiagen) and 3 ng of cDNA mixed with MaximaTM SYBR Green
qPCR Master Mix (Fermentas) and primer mix (sense and antisense at 0.3 μM, Table 1 (Eurofins MWG
Operon, Ebersberg, Germany) in a final volume of 10 μL. Amplification was carried out on a LightCycler
480 (Roche): denaturation step at 95 ◦C for 10 min and 40 cycles of 95 ◦C for 15 s, 60 ◦C for 30 s. Specificity
of the primers was controlled. The GeNormTM freeware (http://medgen.ugent.be/-jvdesomp/genorm/)
was used to choose GAPDH and ACTB, as the most stable housekeeping genes. The relative transcript
quantity (Q) was determined by the delta Cq method: Q = E(Cq min in all the samples tested − Cq of
the sample), where E is related to the primer efficiency (E = 2 if the primer efficiency = 100%). Relative
quantities (Q) were normalized using the multiple normalization method (Vandesompele et al., 2002).
Q normalized = Q/(geometric mean of the stable housekeeping genes Q). The 2(−ΔΔCt) method was
retained, using a housekeeping gene and gene of interest (Livak and Schmittgen, 2001) tested on
control sample and treated sample.
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Table 1. Primer sequences used for RT-qPCR.




BDNF Brain-derived neurotrophic factor NM_001143816
F: CAAACATCCGAGGACAAGG
R: TACTGAGCATCACCCTGG
DARPP32 Dopamine- and cAMP-regulated phosphoprotein NM_181505
F: GAGAGCCTCAGGAGAGGG
R: CTCATTCAAATTGCTGATAGACTGC
Dlx2 Distal-less homeobox 2 NM_004405
F: GACCTTGAGCCTGAAATTCG
R: ACCTGAGTCTGGGTGAGG
GAD67 Glutamic Acid Decarboxylase 67 NM_000817
F: GGTGGCTCCAAAAATCAAAGC
R: CAATGTCAGACTGGGTAGCG
GAPDH glyceraldehyde-3-phosphate dehydrogenase NM_001289745.1
F: CAAAAGGGTCATCATCTCTGC
R: AGTTGTCATGGATGACCTTGG
GDNF Glial cell line-derived neurotrophic factor NM_011675.2 Qiagen, ref #QT00001589
Pax6 Paired box 6 NM_000280
F: TTTCAGCACCAGTGTCTACC
R: TAGGTATCATAACTCCGCCC
NGF Nerve growth factor NM_002506 Qiagen, ref #QT00043330
REST RE1-silencing transcription factor NM_001193508.1
F: ACTCATACAGGAGAACGCC
R: GTGAACCTGTCTTGCATGG







After treatment, cells were fixed with 4% paraformaldehyde (PFA, Sigma, St Louis, MO, USA)
in DPBS (Lonza, Verviers, Belgium) pH 7.4 during 15 min at 4 ◦C, washed and non-specific sites
were blocked with DPBS, Triton 0.1% (DPBS-T, Triton X-100, Sigma), bovine serum albumin 4%
(BSA, Fraction V, PAA Lab, Austria), normal goat serum 10% (NGS, Sigma) during 45 min at RT.
A mouse anti-human β3-tubulin (2 μg/mL, clone SDL.3D10, Sigma), a mouse anti-human neurofilament
medium (NFM, 1:50, clone NN18, Sigma-Aldrich), a monoclonal rabbit anti-human dopamine- and
cAMP-regulated neuronal phosphoprotein (DARPP32, 0,6 μg/mL, clone EP721Y, Abcam, Paris, France),
a mouse anti-glutamic acid decarboxylase-67 antibody (GAD67, 2 μg/mL, clone 1G10.2, Millipore
SA), and a rabbit anti-GABA transporter 1 (GAT1 500 ng/mL Millipore SA) were used to characterize
cell differentiation. Cells were incubated overnight with the primary antibody diluted into DPBS-T,
BSA 4% at 4 ◦C. After washes, slices were incubated with the biotinylated mouse (2.5 μg/mL, Vector
Laboratories, Burlingame, CA, USA) or rabbit secondary antibody (7.5 μg/mL, Vector Laboratories)
for 1 hour at RT. Then slices were washed and incubated with Streptavidin Fluoroprobes 488 or 547H
(Interchim, Montluçon, France) diluted 1:1000 or 1:500 respectively in DPBS for 1 h before mounting
and observation using a fluorescence microscope.
2.14. Immunofluorescence
Immunofluorescence of brain slices was performed as previously described [39].
Immunofluorescence was performed using antibodies against human mitochondria (hMito) (10 ng/mL,
mitochondrial cytochrome C oxidase subunit II, Abcam), rabbit anti-human dopamine- and
cAMP-regulated neuronal phosphoprotein DARPP32 (DARPP32, 0.6 μg/mL, clone EP721Y, Abcam)
and a mouse anti-GAD67 (5 μg/mL, clone 1G10.2, Millipore SA). Isotypic controls were performed for
each antibody. Free-floating slices were incubated in 1% DPBS-T (Sigma-Aldrich). After pre-blocking
for 4 h with 4% BSA (fraction V, PAA Laboratories, Piscataway, NJ, USA), 10% NGS (Sigma-Aldrich) in
DPBS-T, slices were incubated for 48 h at 4 ◦C with monoclonal antibodies against DARPP32, GAD67
or hMito with diluted in 4% BSA DPBS-T. After washing, the sections were incubated for 2 h slices with
the biotinylated mouse (2.5 μg/mL, Vector Laboratorie,) or rabbit secondary antibody (7.5 μg/mL, Vector
Laboratories) at room temperature. Then, slices were washed and incubated for 2 h with Streptavidin
Fluoroprobes 488 or 547H (Interchim) diluted 1:500 or 1:1000 respectively in DPBS. Finally, the sections
were washed mounted using fluorescent mounting medium (Dako, Carpinteria) and observed in a
confocal microscopy.
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2.15. MIAMI Cell Secretome Analysis
A Luminex® Multiplex secretome assay was used to quantify cytokines and growth factors
secreted by MIAMI cells under different conditions. 72 h before the experiment, media was completely
removed and replaced by media without serum for MIAMI E/F or appropriate media for the other
conditions. The media was collected and frozen at 72 h. The secretome of MIAMI cells was compared
to the secretome of E/F pre-treated MIAMI cells cultured for 7–10 days. The secretome of E/F MIAMI
cells was then analyzed after exposure to different conditions: after commitment into GABA-like
progenitors (transfected by the si-REST and exposure during 14 days to SHH, and adhered on
PAMS during 72H with Neurobasal media and 1 mM of Valproic acid. Eight human growth factors
(Brain-derived neurotrophic factor (BDNF), beta polypeptide-Nerve growth factor (b-NGF), stem
cell factor (SCF), Leukemia inhibitory factor (LIF), Hepatocyte growth factor (HGF), Placenta growth
factor-1 (PlGF-1), Stromal cell-derived factor 1 alpha (SDF-1alpha), Vascular endothelial growth
factor-A (VEGFa)) were quantified using 2 Luminex® Multiplex assay panels: ProcartaPlex® Human
Chemokine Panel I 9 Plex (#EPX090-12187-901, ThermoFisher), ProcartaPlex® Human Chemokine
Panel 11Plex (#EPX110-12170-901, ThermoFisher). Samples were centrifuged at 4 ◦C for 10 min at
10,000 g and prepared as per the manufacturer’s recommendations using a Bio-Plex Pro wash station
(Bio-Rad, Hercules, CA). No sample dilution was performed. Quantification of growth factors was
performed on a Magpix apparatus (Bio-Rad) and analyzed with the Bio-Plex Manager Version 3.0
software (Bio-Rad). Appropriate media were used as control and to determine the background.
Background subtraction was performed with appropriate media depending on the sample, N = 2,
n = 2. N represents one independent experiment done at one moment using 375,000 MIAMI cells
adhered to 0.5mg of PAMs for each condition tested, n is the number of samples for each condition.
2.16. Data Analysis
Data are presented as the mean value of three independent experiments +/− standard deviation
(SD) unless otherwise stated. Significant differences between samples were determined using an
ANOVA test, followed by Dunnett’s multiple comparison tests, unless otherwise stated. Luminex data
was analyzed with Kruskal–Wallis test followed by pair-wise comparison. Threshold p-value was set
to 0.05 and significant differences was depicted with a “*”.
3. Results
3.1. MIAMI E/F Cell Transfection
LNCs carrying REST siRNA of around 85 nm size and a positive surface charge of +7 mV were
used for the incorporation of siREST into MIAMI E/F cells. To better understand the increase of
neuronal markers in MSCs with siREST-LNCs [38], fluorescence confocal multispectral imaging was
used to characterize LNC uptake and siRNA delivery on MIAMI E/F cells (Figure 2A). Triple-labeled
LNCs, siRNA and lysosomes were generated, with respectively DiD, Alexa-488 and lysotracker to
follow the distribution and localization of siRNA-LNCs over time. Four hours after the contact between
LNCs and MIAMI E/F cells, referred to as Day 0, a heterogeneous distribution of LNCs within MIAMI
E/F cells was observed (Figure 2A). LNCs (DiD-positive) co-localized with lysosome staining from
Day 2 to Day 6 but the same co-localization of the siRNA (Alexa 488) was not observed confirming
the results previously published by our team [40]. The number of fluorescent cells for the LNCs and
siRNA decreased progressively from Day 0 until Day 9 (Figure 2B). Twelve percent of cells were
still DiD-positive at Day 6 (Figure 2B). REST mRNA was quantified by RT-qPCR (Figure 2C) and
down-regulated to 70.7% with the siREST at Day 5 when compared to the control cells (siCTRL),
receiving a scrambled siRNA.
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Figure 2. Cellular uptake and cell time retention of siRNA-LNC in MIAMI E/F cells. (A) After 4 h
incubation, confocal microscopy was performed on MIAMI cells with siRNA-LNCs. Cells were fixed on
glass slide and nucleus and lysosome staining were performed with DAPI (blue) and lysotracker (Red).
Double fluorescent probes were used to follow siRNA and LNCs: lipophilic DiD (yellow) and Alexa488
siRNA (green). Scale bar represents 10μm. Analysis confirmed the internalization of siRNA-LNCs and
its presence until Day 6. (B) DiD-positive cells representing the LNC-positive cells were counted using
imageJ. 6 images per conditions in 10× objective were selected. (C) The expression of REST, measured
by RT-qPCR, was decreased significatively (Fold decrease: 4.80 ± 1.80) at Day 5 after transfection
compared to the control. N = 3. * Significantly different means at p < 0.05.
3.2. MIAMI E/F Cells Commitment into GABA-Like Progenitors
To ensure that the transplanted cells have a similar phenotype to the neurons in the striatum and
thus warrant the safety of their transplantation in that area, the MIAMI E/F cells have been differentiated
into GABA-like neurons. Cell density during the first steps is important and the confluence has to be
maintained under 30% to induce cell differentiation. The MIAMI E/F cells were transfected with siREST
or with a negative control, scrambled siRNA, followed by sonic hedgehog (SHH) treatment (Figure 3A).
Some of the MIAMI E/F cells exhibited small neurite-like structures. Fourteen days after transfection,
most of the MIAMI-SHH-siREST cells exhibited very long neurite-like structures. The majority of the
MIAMI-SHH-siREST cells presented a total length of around 600 μm. In comparison MIAMI-SHH
siCTRL cells showed a flat morphology (Figure 3B). REST expression, detected by RT-qPCR, was
diminished over time during the treatment when compared to the MIAMI E/F cells. As expected at
this time-point no difference in REST expression was observed between the cells transfected with
siREST and siCtrl. Pax 6 and Dlx2, transcription factors detected in the ventral telencephalon, were
expressed by MIAMI E/F cells and decreased slightly 14 days after the treatment (Figure 3C), The
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GABAergic marker, GAD67, was slightly increased following the treatment, at the mRNA and protein
level (Figure 3C) and not detected in MIAMI E/F cells, as for DARPP32. No major differences were
detected between the siREST and siCtrl conditions at this long-term time point, although there was a
tendency in the MIAMI-SHH-siREST cells to express more GAD67 at the mRNA and protein level
(Figure 3C,D). The early and late neuronal markers, β3-tubulin and NFM, respectively were expressed
by the MIAMI-SHH-siREST cells and were only very slightly detected in MIAMI-SHH-siCtrl as shown
by the immunofluorescence staining (Figure 3D).
Figure 3. MIAMI E/F cell commitment into GABA-like progenitors. (A) For GABA-like progenitors
commitment, a simple protocol has been designed using siREST and SHH. Transfection of MIAMI E/F
was performed with 250 ng/mL of siCtrl and siREST-LNCs. (B) After the culture period of 14 days,
MIAMI-SHH-siREST emitted long neuritis exhibiting a neuron-like morphology compared to the flat
morphology of MIAMI-SHH-siCtrl. (C) The expression of neuronal commitment genes (REST, PAX-6,
and Dlx2) and of genes of GABAergic-like neurons (DARPP32 and GAD67) was quantified at 14 days
by RT-qPCR in MIAMI E/F, MIAMI-SHH-siREST and MIAMI-SHH-siCTRL cells (N = 3). (D) After
immunofluorescence staining, the neuronal commitment of MIAMI-SHH-siREST cells was confirmed
by the expression of β3-tubulin and NFM and a very slight expression of GAD67, all of which are not
detected in MIAMI-SHH-siCTRL cells. ND: not detected. * Significantly different means at P < 0.05.
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3.3. MIAMI E/F Cell Commitment into GABAergic-Like Neurons
The GABA-like progenitors were exposed to Valproic acid (VPA) from Day 14 for seven days
and BDNF from Day 21 for seven more days or during 15 days to VPA and BDNF in the same time,
without SHH (Figure 4A) in order to obtain GABAergic-like neurons. At this step, no morphological
change was observed between cells transfected with siCtrl or siREST, but the cells differentiated using
VPA and BDNF in the same time exhibited longer neurite-like structure than the cells receiving the
protocol using VPA and then BDNF (data not shown). In the same way, the expression of GABA
markers detected by RT-qPCR (Figure 4B) is higher with the protocol using VPA together with BDNF
compared to the sequential protocol (VPA then BDNF). At the end of the differentiation period, a low
expression of Dlx2 and REST was detected by RT-qPCR (data not shown). Moreover, the inhibition of
REST had no effect on the expression of GABAergic neuron markers with a tendency to be diminished
for GAD67. The majority of the GABA-like neurons were positive β3-tubulin and some for DARPP32,
GAD 67 and GAT1 after immunofluorescence, a feature of medium spiny neurons (Figure 4C).
 
Figure 4. Differentiation and Characterization of GABA-like neurons. (A) Schematic procedure of
GABAergic differentiation. For both protocols, the concentration of VPA was 10 mM and 30 ng/mL
of BDNF). (B) The characterization of the differentiation was realized by RT-qPCR. The expression
of genes DARPP32 and GAD67 was quantified at the end of the differentiation (N = 2, n = 1). (C)
In vitro immunofluorescence against β3-tubulin, DARPP32, GAD67, GAT1 on GABA-like neurons
was performed.
3.4. Adherence of MIAMI E/F SHH-siREST on PAMs
The particle size of PAMs measured using a Multisizer Coulter Counter was around 30 μm, as also
observed using SEM (Figure 5A). LM completely covered the whole surface of PAMs in small patches
(Figure 5B) and a continuous release of BDNF was observed over time. Up to 3000 ng/mL of BDNF
was progressively released during 40 days from 5 mg PAMs (Figure 5C). During the commitment
and the differentiation, no serum and no antibiotics were used. In order to respect these conditions,
different media for cell adherence were tested (Figure 5D). Unfortunately, a high proportion of cells
were observed floating in the media or adhered to the plastic, particularly with N2 and also with
B27 media (Figure 5D). On the contrary, with the 3% serum, the cells adhered nicely onto the PAMs
(Figure 5D). Different times of adherence were tested, and it was observed that the adherence of the
GABA-like progenitors increased over time; it was better after 6 h and 72 h in contact with PAMs
compared to only 4 h (Figure 5E). At 4 h, a large quantity of cells was not combined to the PAMs, but
cell/PAM aggregates could be observed from 6 h onwards. (Figure 5E). Since the cells completely
surrounded the PAMs in Figure 5E, the PAMs could not directly be seen anymore. Using SEM, MIAMI
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E/F SHH-siREST cells were observed to adhere onto the PAMs with their lamellipodia surrounding the
PAMs to form three-dimensional complexes (Figure 5F). The percentage of cells adhered onto PAMs’
surface at the end of the cell attachment protocol (72 h) was about 95.2 ± 2.7%, as measured using the
CyQUANT DNA quantification method.
 
Figure 5. PAM characterization and adherence of GABA-like progenitors on PAMs. (A) PAMs
observed using SEM and (B) laminin overlay onto PAMs observed by confocal microscopy after
immunofluorescence. (C) Controlled release of BDNF from PAMs, measured using ELISA. (D) Different
media were tested for the adher ence: 2% of B27, 15% of N2 and 3% of FBS. The last condition has been
chosen for the rest of the experiments. (E) The cells were incubated with PAMs and pictures taken by
brightfield microscopy at 4 h, 6 h and 72 h. (F) Observation of microspheres and cells-PAMs complexes
by scanning electronic microscopy showing the cells adhering onto the PAMs. White arrows point at
PAMs associated with cells.
3.5. Characterization of MIAMI-SHH-siREST on PAMs
MIAMI E/F cells secreted a few growth factors, but interestingly SHH/siREST exposure affected
the secretory profile of MIAMI E/F cells, which secreted more hepatocyte growth factor (HGF) and had
a tendency to secrete more leukemia inhibitory factor (LIF) and vascular endothelial growth factor-a
(VEGFa). They also secreted SDF-1α (Figure 6A, Table A1). As observed using RT-qPCR, the GABA-like
progenitors expressed less BDNF and nerve growth factor (NGF), but after 72 h of adherence of these
cells on the PAMs, the expression of BDNF, NGF and VEGFa increased (Figure 6B). The expression of
GAD67 also tended to increase, while DARPP32 remained very low (23.00 ± 12.82 mRNA arbitrary
units) At the protein level, the secretome analysis confirmed the release by the cells adhered onto
PAMs of the above mentioned growth factors in the media as well as FGF2, EGF and stem cell factor
(SCF). There was more placental growth factor (PIGF-1) and of course BDNF when the cells adhered
onto PAMs releasing BDNF compared to blank PAMs (Figure 6C, Table A1).
226
Pharmaceutics 2019, 11, 526
Figure 6. Characterization of the secretome profile of the GABA-like progenitors combined with PAMs.
(A) Media collected from MIAMI E/F cells or MIAMI-SHH-SiREST cells were analyzed by the Luminex
apparatus for the quantification of growth factors and cytokines (N = 2, n = 2). (B) The expression
of GABAergic genes and GAD67 and growth factors (BDNF, NGF and VEGFa) was quantified by
RT-qPCR 72H after adherence to the PAMs (N = 3). (C) Media collected 72 h after adherence between
cells and PAMs were analyzed by the Luminex apparatus for the quantification of growth factors and
cytokines (N = 2, n = 2) N represents one independent experiment with all the conditions, n the number
of samples/condition. * Significantly different means at P < 0.05.
3.6. Behavior of PAMs and MIAMI-SHH-siREST in Huntington’s Disease Model
MIAMI-SHH-siREST alone, pre-treated with BDNF, or complexed to PAMs or BDNF-PAMS
were grafted in the recently reported ex vivo HD model [39] at Day 5 when 30% of GABAergic
striatal cell degeneration has occurred. Immunofluorescence against human mitochondria was used to
visualize MIAMI-SHH-siREST cells in the rat brain (Figure 7A) and antibody against human DARPP32
was used to localize GABAergic-like neurons 15 days after grafting in the HD organotypic slices
(Figure 7B). Immunofluorescence staining was faint with cells alone, suggesting that some cells died.
PAMs delivering or not BDNF improved cell survival and BDNF administered to the cells before
transplantation also seemed to slightly improve survival. Moreover, the cells receiving BDNF showed
an elongated morphology with neurite-like structures (Figure 7A). Some of the transplanted cells
expressed DARPP32 in all the conditions studied except for the cells transplanted alone (Figure 7B).
GAD67 and DARPP32 immunostaining of the GABAergic rat striatal cells was more intense after
transplantation of MIAMI-SHH-siREST cells on PAMs particularly when delivering BDNF (Appendix A
Figure A1).
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Figure 7. Behavior of MIAMI-SHH-siREST grafted into an ex vivo model of HD. (A) Black and white
picture at lower magnification showing the PAMs with the transplanted cells within the tissue. All the
cells are visualized by DAPI staining and the transplanted cells by immunohistofluorescence against
human mitochondria. (B) Immunohistofluorescence against human mitochondria (in red) and (C)
human DARPP32 (in red) for MIAMI cells 14 days after grafting, either alone, or exposed to BDNF for
three days before grafting, or on LM-blank PAMs for three days before grafting or on LM-BDNF PAMs
for three days before grafting. Red circles were suggested on the images to emphasize the localization
of PAMs. DAPI staining (in blue) was used to visualize all the cells. Scale bar is 10 μm.
4. Discussion
Mesenchymal stromal cell-based neuronal therapies can provide a limitless, easily accessible
source of cells but survival and differentiation remain a drawback. Combinatorial strategies with nano-
and microvectors designed to improve stem cell differentiation and engraftment are necessary. In this
study, we used a combinatorial cell and drug delivery approach. We showed that a subpopulation of
MSCs, the MIAMI cells, can differentiate towards the neuronal GABAergic lineage by an epigenetic
RNA interfering approach inhibiting REST expression combined to GABAergic inducers. Moreover,
GABA-committed MIAMI cells adhered onto PAMs maintained the GABAergic phenotype and secreted
neural tissue repair factors. They could furthermore be transplanted while attached to PAMs delivering
BDNF in an ex vivo model of HD, and were able to survive and maintain this GABAergic neuronal
phenotype, particularly in response to BDNF.
Our strategy to differentiate MIAMI cells into striatal-like neurons was developed based on the
simplifying scheme that the normal course of neuronal differentiation may be separated into three
successive steps: namely, (i) neural induction, (ii) regional commitment, and (iii) neuronal maturation.
To obtain neural induction, we pre-treated MIAMI cells with EGF and FGF-2 as previously published by
our group [23]. As expected, MIAMI E/F expressed Pax6 and slightly Dlx2, showing their progression
towards a neural/neuronal phenotype. To induce a strong GABAergic commitment and further
neuronal maturation, we chose to combine REST inhibition with adapted published protocols for
pluripotent stem cells [41,42]. REST expression is progressively reduced during neuronal differentiation
in neural stem cells [14] and its inhibition engaged MSCs into a neuronal pathway [15,38]. We chose to
transiently inhibit REST with siREST carried by nanoparticles as previously performed [38]. Permanent
down-regulation of REST with strategies such as ShREST would likely not be satisfactory since REST
inhibition is only transient during normal brain development [43]. The siREST-LNCs inhibited REST
expression for at least 5 days, probably due to their long retention time within the cells. After this
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transient REST inhibition together with SHH treatment followed by the combination of VPA and BDNF,
we first obtained GABA-like progenitors and then immature neurons expressing striatal markers such
as GAD67, DARPP32 and GAT1. The main difference observed after REST inhibition was a clear
neuronal commitment of the GABAergic-like progenitors, which expressed the neuronal markers
B3-tubulin and NFM. To our knowledge, our strategy is the first to describe a direct non-epigenetic
transient modulation of REST with nanoparticles to direct MSCs toward a GABAergic lineage. Other
approaches used to inhibit REST are burdened by intrinsic limitations such as the HIV origin of the
product and host genome integrations of lentivirus or oligodeoxynucleotides, which may lead to
unwanted side effects.
MIAMI cells committed or not towards a neuronal phenotype easily adhere onto PLGA PAMs
with a biomimetic surface composed of extracellular matrix molecules in the presence of low serum
concentrations [26,29,30]. Different serum free media were evaluated for the formation of PAM/cell
complexes to avoid washing steps before implantation to dispose of the undesired serum. Moreover,
in this way, the implantation procedure is simplified, and the cells implanted in their own conditioned
media already containing some BDNF secreted by the cells and delivered from the PAMS. However, the
GABA-like progenitor cells only adhered to PLGA-P188-PLGA PAMs with a LM biomimetic surface in
the presence of 3% serum. In this study, we observed that MIAMI E/F derived GABA-like progenitors
express more GAD67, a constitutive striatal marker, when adhered onto PAMs compared to the cells
in a 2D culture. The laminin-covered PAMs stimulate this differentiation as it has been shown that
laminin stimulates neuronal differentiation of MSCs [44] and of MIAMI cells [8]. Nevertheless, the 3D
condition should also contribute as our previous results showed that PAMs offering a 3D biomimetic
surface stimulate MIAMI cells neuronal differentiation [30]. In a similar manner neural stem/progenitor
cells also more efficiently differentiated to neurons in a collagen/hyaluronan 3D matrix compared to a
2D culture condition [45].
MSCs have recently emerged as a promising cell population to protect degenerating neuronal cells
and increase the function of the remaining cells in various neuronal disorders. In HD preclinical models,
the functional recovery observed after MSC transplantation could be explained by the secretion of
neurotrophic factors including BDNF, CNTF, NGF, insulin-like growth factor 1 and EGF [10,11]. Within
this line, previous studies have shown that MIAMI cells, which are a homogeneous population of cells
with an unique genetic profile, express several pluripotency markers (Oct4, Sox2, Nanog, SSEA4) and
other proteins also expressed by embryonic stem cells, release more tissue repair factors than MSCs or
embryonic stem cells and protect the neurovasculature [45]. Compared to naïve MIAMI cells, MIAMI
cells pre-treated with E/F secreted more tissue repair factors such as VEGFA, NGF, LIF and HGF [30],
and we observed that SHH/siREST treatment further increased the expression of HGF, but also of
BDNF and SDF-1α. SDF-1α is an indispensable chemoattractant for neuron migration in different
brain regions (CXCR4 regulates interneuron migration in the developing neocortex.). Moreover, it
has been demonstrated that SDF-1 coexists in GABA-containing vesicles in the terminals of basket
cells, regulates the strength of GABAergic input to nestin+-type 2 neural progenitors in hippocampal
dentate gyrus, and plays a crucial role in adult neurogenesis [46], while laminin also enhances the
chemotactic activity of SDF-1 in the thymus [47].
We previously demonstrated that PAMs delivering neurotrophin-3 can improve MIAMI cells
survival, thereby preserving neural function in a Parkinson’s disease animal model [8,22]. PAMs
encapsulating BDNF and composed of a triblock copolymer of PLGA-P188-PLGA were used in this
study as we previously showed that it allowed for a complete release of functionally active growth
factors from the microspheres [28,30]. Exposure of MIAMI E/F cells to SHH/siREST and adhesion to
PAMs had a drastic effect on the expression of NGF and VEGF at the mRNA level, and we also observed
an augmentation at the protein level of BDNF and PIGF-1 in the media when cells were attached to
BDNF-loaded PAMs compared to blank PAMs. The increase in BDNF in the media was likely due
to the release of BDNF from PAMs since no difference was observed at the mRNA level in MIAMI
SHH/siREST attached to PAMs with or without encapsulated BDNF. VEGF and NGF are known to
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increase neurogenesis [48], while VEGF, NGF, and PIGF-1 also all share in common the possibility of
being of benefit to enhance reparative angiogenesis [49,50]. In this regard, we demonstrated in another
study that VEGF secreted by MIAMI cells can improve vascularization maintenance after grafting in an
ex vivo model of Parkinson’s disease [22]. These findings thus support the use of PAMs to enhance the
benefit of MIAMI SHH/siREST in the context of HD. In this study, we tested this innovative strategy
combining mesenchymal stromal cells and biomaterials in an ex vivo model of HD [39]. The benefit of
this model is that it preserves cell graft-host tissue crosstalk, while maintaining the cytoarchitecture of
the original tissue. We here demonstrated the screening capacity of this HD model for new therapeutic
strategies. After grafting, GABA-like progenitors alone did not survive while if associated to PAMs the
3D support seemed to stimulate the survival of the cells after transplantation as already demonstrated
by our group [22–24]. BDNF pre-treatment also stimulated cell survival while the combination of the
BNDF delivery and the 3D polymeric support, provided by the PAMs, seemed to further enhance
this survival. Moreover, these GABA-like progenitors submitted to BDNF, known to induce neuronal
survival and differentiation [30–32] showed an elongated morphology with neurite-like structures
suggesting the maintenance of their neuronal phenotype. In this regard, they also expressed DARPP32,
a GABAergic marker. Finally, the combination of cells and PAMs delivering BDNF seemed to delay the
degeneration of GABAergic neurons in the HD model, thereby demonstrating the potential benefits of
this strategy for the treatment of HD. Further studies in a transgenic mouse model of HD are however
needed to obtain confirmation that this combinatorial therapeutic strategy leads to neurorepair and
provides a functional benefit.
5. Conclusions
We here demonstrated the therapeutic potential of this novel combinatorial strategy using
LNC-delivered siREST and neuronally-committed MSCs transported by laminin-covered microcarriers
delivering BDNF. We showed the capacity of MIAMI E/F cells to differentiate into GABAergic-like
neurons by using REST inhibition and the appropriate media cues in vitro. GABA-like progenitors
adhered to PAMs increased their mRNA expression of NGF/VEGF-a as well as their secretion of PIGF-1,
three chemokines known for their potential to enhance reparative angiogenesis. Together, our results
indicate that MIAMI cell/PAMs complexes survive after transplantation in an ex vivo HD model,
maintain a GABAergic-like phenotype and may alleviate cell damage in the context of HD through
chemokine secretion.
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Appendix A
Immunohistochemistry. A mouse anti-GAD67 (5 μg/mL, clone 1G10.2, Millipore SA, Guyancourt,
France) and a mouse anti-DARPP32 (0.25 μg/mL, clone 15, BD Bioscience, Le Pont de Claix, France)
antibodies were used to observe striatal-GP GABAergic neurons. Isotypic antibodies were used to
control background staining. After 2 h of saturation in DPBS, 4% BSA, 1% triton and 10% NGS,
slices were incubated 48 h with the primary antibody diluted in DPBS, 4% BSA and 1% triton at 4 ◦C.
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After washes, slices were incubated with the biotinylated anti-mouse secondary antibody (2.5 μg/mL
Vector Laboratories, Burlingame, CA, USA). Then slices were washed, and quenching of peroxidase
was performed with 0.3% H2O2 (Sigma, Saint Quentin Fallavier, France) in DPBS, at room temperature
for 20 min. After DPBS washes, slices were incubated with Vectastain ABC reagent (Vector Laboratories,
Eurobio, Les Ulis, France) in DPBS at room temperature for 2 h. Sections were then washed and revealed
with 0.03% H2O2, 0.4 mg/mL diaminobenzidine (DAB, Sigma, Saint Quentin Fallavier, France) in DPBS,
2.5% nickel chloride (Sigma, Saint Quentin Fallavier, France) and dehydrated before mounting.
 
Figure A1. Neuroprotective effect of cells injection on the GABAergic degeneration.
Immunohistochemistry against striatal GAD67-positive neurons and DARPP32-positive neurons
at Day 25 after injection of media, cells alone, cells on blank PAMs and cells on BDNF PAMs in the ex
vivo model of HD. Scale bar is 100μm (N = 2).
Table A1. Raw data of the secrotome analysis. Media collected from MIAMI E/F cells,
MIAMI-SHH-SiREST cells or 72 h after adherence between cells and PAMs were analyzed by the
Luminex apparatus for the quantification of growth factors and cytokines (N = 2, n = 2).
Heading BDNF PIGF-1 b-NGF HGF SDF-1 LIF VEGF-A
MIAMI E/F media (Control) 4.55 ± 0.294 14.36 ± 0.20 0.00 124.93 ± 1.52 481.95 ± 3.27 49.35 ± 3.43 34.21 ± 0.676
Supernatant MIAMI E/F 1.85 ± 0.139 24.38 ± 1.25 51.07 ± 72.22 152.87 ± 42.87 385.73 ± 52.87 65.80 ± 2.54 482.53 ± 32.54
Step 1 Media (Control) 0.00 0.00 0.00 0.00 13.61 ±0.65 0.00 0.00
supernatant MIAMI E/F SHH
siREST 5.95 ± 0.59 11.70 ± 0.26 46.68 ± 66.05 304.12 ± 216.21 1746.64 ± 63.87 63.78 ± 64.24 2205.48 ± 505.54
Step 2 Media without BDNF
(Control) 0.00 0.00 0.00 0.00 14.76 ± 0.01 0.00 0.00
supernatant MIAMI E/F SHH
siREST on LM-blanks PAMS 7.21 ± 0.19 14.73 ± 0.46 128.04 ± 12.21 192.08 ± 25.37 1567.67 ± 92.07 195 ± 39.81 11,028.92 ± 2576.19
supernatant MIAMI E/F SHH
siREST on LM-BDNF PAMS 13.77 ± 0.35 29.02 ± 0.41 148.30 ± 6.18 219.43 ± 15.76 1467 ± 138.48 180.11 ± 20.07 11,003.58 ± 1189.29
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Abstract: Developing multifunctional and biocompatible drug delivery nanoplatforms that integrate
high drug loads and multiple imaging modalities avoiding cross-interferences is extremely challenging.
Here we report on the successful chemical reaction of the high quantum yield biodegradable and
photoluminescent polyester (BPLP) with the poly(lactic-co-glycolic acid) (PLGA) polymer to fabricate
biocompatible photoluminescent nanocapsules (NCs). Furthermore, we transform the PLGA-BPLP
NCs into a magnetic resonance (MR)/photoluminescence dual-modal imaging theranostic platform
by incorporating superparamagnetic iron oxide nanoparticles (SPIONs) into the polymeric shell.
In vitro phantoms confirmed the excellent MRI-r2 relaxivity values of the NCs whilst the cellular
uptake of these NCs was clearly observed by fluorescence optical imaging. Besides, the NCs (mean
size ~270 nm) were loaded with ~1 wt% of a model protein (BSA) and their PEGylation provided a
more hydrophilic surface. The NCs show biocompatibility in vitro, as hCMEC/D3 endothelial cells
viability was not affected for particle concentration up to 500 μg/mL. Interestingly, NCs decorated
with SPIONs can be exploited for magnetic guiding and retention.
Keywords: PLGA nanocapsules; magnetic resonance imaging; photoluminescence; drug delivery
systems; magnetic targeting; multimodal imaging; theranostics
1. Introduction
Nanomedicine, which refers to the application of nanotechnology in medicine, offers valuable
new tools for the diagnosis and treatment of many diseases. Nanoparticles are increasingly important
by assisting to expedite the development of contrast agents, therapeutics, drug delivery vehicles,
and theranostics in the context of nanomedicine [1]. Polymer-based nanoparticles are frequently
proposed as drug carriers due to their biocompatibility and biodegradability, as well as the possibility of
customizing their physicochemical properties for a specific drug or delivery route [2–4]. Among them,
poly(lactic-co-glycolic acid) PLGA nanoparticles have gathered particular attention, since they
encompass a number of interesting features: (i) FDA and European Medicine Agency approval
in drug delivery systems for parenteral administration; (ii) well described formulations and methods
of production adapted to various drugs i.e., hydrophilic or hydrophobic, small molecules, or
macromolecules; (iii) protects the loaded drugs from degradation and possibility of sustained release;
and, (iv) easy to modify to include targeted delivery or to provide tuned performance in a specific
biological environment [5,6].
Theranostics is an emerging field that combines diagnostics and therapeutics into multifunction
nanoparticle systems [7]. Drugs and nanocarriers in vitro/in vivo fate can be monitored while using
noninvasive imaging techniques, such as magnetic resonance imaging (MRI) and fluorescent imaging,
in order to optimize the route of delivery, biodistribution, and drug accumulation, among other
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factors [4,8,9]. PLGA nanoparticles can be used in diagnostic and therapeutic imaging by the addition
of the imaging moieties during the particle synthesis. To date, large efforts have been devoted to
conjugating PLGA with semiconducting quantum dots and organic dyes to create photoluminescent
PLGA nanocarriers [9–11]. However, conventional approaches for physically blending imaging probes
within the nanoparticles can lead to incomplete conclusions or misinterpretations on the nanoparticles’
biodistribution and fate [12,13]. Moreover, the inevitable photobleaching and low dye-to-polymer
labeling ratios of organic dyes and the innate toxicity of quantum dots prevent their practical use
in vivo [14,15]. Recently, a series of biodegradable photoluminescent (PL) polyesters (BPLPs) could
derived inherently photoluminescent PLGA-BPLP copolymers with excellent biocompatibility, tunable
luminescence and degradation rates, and good thermal and mechanical properties, thus expanding the
biomedical applications of PLGA to highly desired optical imaging [16,17].
Here, we present PLGA nanocapsules (NCs) as a dual-modal imaging theranostic platform
for magnetic targeting protein delivery (Figure 1). We report on the protocol for the fabrication of
magnetic PLGA-BPLP NCs with intrinsic photoluminescence and MRI capacity being endowed by
the incorporation of superparamagnetic iron oxide nanoparticles (SPIONs). Moreover, the NCs are
functionalized with poly(ethylene glycol) (PEG), providing a hydrophilic surface that could result
in an enhanced stealth effect. Unlike solid PLGA nanoparticles [4,18,19], in our NCs, the functional
moieties are incorporated into the polymeric shell matrix to minimize interferences with the cargo being
placed inside the NC; this is especially important for delicate payloads, such as proteins, enzymes,
or microRNAs. In this study, bovine serum albumin (BSA) has been used as a model protein for
evaluating the protein loading capability and release kinetics of the proposed nanocarrier.
 
Figure 1. Schematic illustration of poly(lactic-co-glycolic acid)-biocompatible photoluminescent
polymer nanocapsule (PLGA-BPLP NC) as a dual-modal imaging theranostic platform.
2. Experimental Section
All of the reagents were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany)
unless specified otherwise.
2.1. Synthesis of PLGA-BPLP Copolymer
The PLGA-BPLP copolymer was synthesized by a slight modification of Yang’s method [16,17].
Step one involves the synthesis of a hydroxyl terminated BPLP pre-polymer. Briefly, citric acid,
1,8-octanediol, and l-cysteine with the molar ratio of 1:1:0.2 (5.76 g, 4.38 g, 0.72 g) were added into
a flask of 50 mL with a stirring bar. Under a constant flow of argon, the reactants were melted by
heating to 140 ◦C until a clear solution formed. The solution was allowed to react at this temperature
for 80 min. and then stopped before the stirring bar stopped stirring completely in the increasingly
viscous solution by adding 25 mL of 1,4-dioxane to dilute the produced prepolymer. The product was
purified by dropwise precipitation from the 1,4-dioxane solution in water to remove the unreacted
monomers. The final BPLP product was collected by centrifugation and then lyophilized.
In the second step, the PLGA-BPLP copolymer was synthesized while using the BPLP as a
macroinitiator to react with l-lactide and glycolide via a ring-opening polymerization that was
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catalyzed by Tin (II) 2-ethylhexanoate (Sn(OCt)2). Briefly, l-lactide, glycolide and BPLP with the
molar ratios of (75:25):1 or (50:50):1 were added into a reaction tube. Subsequently, Sn (OCt)2 (0.1 wt%
of l-lactide and glycolide mixture) was added as a solution in dichloromethane which was then
evaporated in vacuum. The tube was flushed with argon and capped and subsequently immersed in
a 160 ◦C oil bath for 48 h. The obtained product was dissolved in chloroform and then purified by
dropwise precipitation into pure ethanol to remove unreacted raw materials. Finally, the PLGA-BPLP
copolymer was recovered by centrifugation and then dried in vacuum at room temperature. All of the
PLGA-BPLP mentioned in the text were with molar ratios of (75:25):1, unless specified otherwise.
2.2. Synthesis of Oleic Acid Coated SPIONs
The SPIONs were synthesized by microwave assisted thermal decomposition in a microwave
synthesizer (Discover SP, CEM Corporation, Matthews, NC, USA), and then coated by oleic acid
(OA) [20]. The process to obtain homogeneous OA-SPIONs with an average diameter of 9 nm was as
follows: 3.5 mmol of iron precursor Fe (acac)3 was dissolved in 4.5 mL of benzyl alcohol in a microwave
reaction glass tube. Microwave irradiation was initiated at 60 ◦C for 5 min. to fully dissolve the
precursor and, subsequently, the irradiation was kept at 210 ◦C for 30 min., and the reaction was then
stopped and cooled down to room temperature. 4 mL of oleic acid in toluene (0.8 mmol/mL) was added
immediately into the as-synthesized SPIONs dispersion followed by incubation under ultrasound for
1 h. Subsequently, the obtained OA-SPIONs were separated by centrifugation in five-fold of acetone.
The pellet was redispersed in 4 mL of toluene in a glass vial and a magnet was attached on the wall for
5 s, the un-adsorbed suspension containing SPIONs with smaller size was discarded and the adsorbed
pellet was redispersed in 6 mL of dichloromethane (DCM), followed by centrifugation at 4000 rpm
for 5 min. to sediment the unstable big particles. Finally, the stable OA-SPIONs (9 nm) dispersion in
DCM was centrifugated in five-fold of acetone and the pellet product was dried under vacuum and
redispersed in DCM at the concentration required for use.
2.3. Fabrication of Functional PLGA-BPLP NCs and Encapsulation of BSA
Functional PLGA NCs encapsulating BSA were prepared by a double emulsion solvent evaporation
method. Briefly, 50 μL of inner aqueous phase (W1) containing BSA (30 mg/mL) was emulsified in
500 μL of DCM organic phase (O) that was composed of 50 mg of different proportions of PLGA
(RG502H, Mn 12,000)/PLGA-BPLP/PLGA-PEG (PLGA Mn 7000, PEG Mn 5000) and a certain amount
of OA-SPIONs by sonication (VC505, Sonics & Materials Inc., Newtown, CT, USA) at 200 W for 28 s
to form the first emulsion (W1/O). Afterwards, 2 mL of external aqueous phase (W2) with polyvinyl
alcohol (PVA) (20 mg/mL) was added and the second emulsion (W1/O/W2) was formed by sonication
for another 28 s. The temperature during the whole emulsion process was kept at 4 ◦C by using an
ice bath. The resulting double emulsion was poured into 50 mL of MilliQ water and mechanically
stirred at RT for 2 h to allow for complete evaporation of the organic solvent DCM and the formation of
NCs. Finally, the NCs were washed three times with MilliQ water and lyophilized in 6 mL of trehalose
aqueous solution (2 mg/mL). The as-obtained powder was stored at 4 ◦C with desiccant silica gel.
The non-PEGylated and PEGylated NCs have been labelled, as follows: NC1.non PEGylated
(90 wt% PLGA-BPLP + 10 wt% PLGA) and NC2.PEGylated (90 wt% PLGA-BPLP + 3 wt% PLGA +
7 wt% PLGA-PEG), both containing ~6 wt% of SPIONs, as gathered in Table 1.
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Table 1. Summary of the two main formulations for the NCs. Oleic acid coated-SPIONs and PLGA-BPLP
and PLGA-PEG were mixed in the organic phase during the double miniemulsion process.
NCs Type









EE%PLGA PLGA-BPLP * PLGA-PEG d. nm PdI
NC1.non-PEGylated 10 90 / 5.7 4.0 272 0.11 0.96 38.5
NC2.PEGylated 3 90 7 6.0 4.2 265 0.05 1.01 41.3
* PLGA-BPLP from initial molar ratios (LA:GA):BPLP = (75:25):1.
2.4. Physicochemical Characterization of PLGA-BPLP, SPIONs, and NCs
2.4.1. Absorption Spectroscopies of the Polymers
Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) characterization of the
polymers was performed on a Bruker Vertex 70 FTIR spectrometer with a Pike Miracle Single-Bounce
diamond crystal plate accessory at room temperature. The FTIR spectra were recorded over a
wavelength range of 4000–500 cm−1 with a resolution of 4 cm−1. UV-Vis absorbance of the fluorescent
polymers was recorded on a Varian Cary-5000 UV-Vis spectrophotometer while using a quartz cuvette
with an optical path of 1 cm.
2.4.2. Size Distribution and Disperse Stability of the NCs
Dynamic light scattering (DLS) (Zetasizer Nano ZS, Malvern Panalytical, Madrid, Spain)
measurement of the hydrodynamic diameter and size distribution of NCs by intensity was performed
by redispersing 0.5 mg of lyophilized NCs powder into 1 mL of MilliQ water.
Turbiscan (Turbiscan Lab, Formulaction, Toulouse, France) is used to detect the destabilization of
the NCs suspension. 15 mL of 2 mg/mL NCs in the Turbiscan cell were scanned at all of the heights
of the suspension with a time interval of 2 min. during 24 h. The back scattering signals at different
heights of the cell were recorded and the delta of back scattering intensity was calculated by subtracting
the reference time 0 s. The bottom part was defined as 1/5 of the liquid level.
Nanosight (NS300, Malvern Panalytical, Madrid, Spain) is used to measure the averaged size and
concentration of the NCs water suspension. 0.2 mg/mL of NCs with 50 times dilution was pumped
into the cell and the data were acquired and analyzed through the Nanoparticle Tracking Analysis
(NTA) software along with the instrument.
2.4.3. Electron Microscopies
Field emitting scanning electron microscope (SEM, FEI Quanta 200 FEG, Thermo Fisher Scientific,
OR, USA) and transmission electron microscope (TEM, JEM-1210, JEOL Ltd., Tokyo, Japan) were used
to study the morphologies of SPIONs and NCs. 0.5 mg of lyophilized powder was redispersed into
1 mL of MilliQ water and centrifuged at 4000 rpm for 10 min. for the SEM sample preparation of NCs.
Subsequently, the supernatant was discarded to remove the trehalose (used for cryopreserving during
lyophilization) and 1 mL of fresh water was added, the pellet of NCs was redispersed in water with
ultrasound. Finally, 6 L of the slightly turbid suspension was deposited onto a small slice of silicon
wafer stuck on the top of a carbon layer and dried at room temperature overnight. The sample was
sputtered with Au-Pd (20 mA 2 min, Emitech K550, Quorum Technologies Ltd., East Sussex, UK).
The TEM samples were prepared by placing and drying one drop of the corresponding NCs or SPIONs
dispersion on a copper grid at room temperature.
2.4.4. Magnetometry
Superconductive quantum interference device (SQUID, MPMS5XL, Quantum Design, San Diego,
CA, USA) was used to measure the magnetization of NCs and SPIONs and calculate the SPIONs loading
(wt%-SPIONs) of the magnetic NCs. Zero-field cooling and field cooling (ZFC-FC) measurement were
used to determine the blocking temperature (TB) of the SPIONs. A gelatin capsule filled with about
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7 mg of samples, together with some cotton wool, was inserted into the SQUID magnetometer sample
holder and the hysteresis loop was measured from −50 kOe to 50 kOe. The saturation magnetization
of the NCs (MS-NCs, emu/g) and of SPIONs (MS-SPIONs, emu/g) was used to calculate wt%-SPIONs,
as follows:
wt%-SPIONs = MS-NCs/MS-SPIONs× 100%
2.4.5. Fluorescence Properties
Fluorescence spectra of the polymers and NCs were acquired on a spectrofluorometer (LS45,
PerkinElmer Inc., Waltham, MA, USA). The excitation and emission slit widths were both set at 10 nm.
The quantum yield of the polymers was measured by the Williams’ method [16]. Briefly, a series of
BPLP/PLGA-BPLP solutions in the corresponding solvents were prepared with gradient concentrations.
Maximal excitation wavelength was determined, which generated the highest emission intensity.
The fluorescence spectra were collected for the series of solutions in the 10 mm fluorescence cuvette
(Figure S1). The integrated fluorescence intensity, which is the area of the fluorescence spectrum, was
calculated and then noted. Afterwards, the UV-Vis absorbance spectra were collected with the same
solutions and the absorbance at the maximal excitation wavelength within the range of 0.01–0.1 Abs
units was noted (Figure S1). The graphs of integrated fluorescence intensity vs. absorbance were









where, Φ = quantum yield; Slope = slope of the straight line obtained from the plot of intensity vs.
absorbance; n = refractive index of the solvent; s = subscript denotes the sample; and, r = subscript
denotes the reference used. Here, anthracene (Φ = 27% in ethanol when excited at 366 nm) was used
as the reference.
The fluorescence intensities of different concentrations of NCs in water were quantified in a
96-well by a microplate reader (Spark, Tecan Group Ltd., Männedorf, Switzerland). The NCs were
excited at the maximal excitation wavelength and the fluorescence signal was collected by area scan at
the maximal emission wavelength.
Photostability was measured by continuously illuminating the polymer or NCs in a fluorescent
confocal microscope (Leica SP5, Leica Microsistemas S.L.U., Barcelona, Spain) while using UV diode
405 nm excitation at different laser power (10%, 20%, 100%). The fluorescence images were acquired
at a time interval of 1 s for 10 min., changes of mean fluorescence intensity of six region of interests
(ROIs) in 10 min. were calculated while using software Las AF. The real laser power (W) at different
percentage during 10 min. was monitored using a laser power meter.
2.5. MRI Phantoms of the NCs
In vitro agarose phantoms of NCs were prepared in Eppendorfs where a series of concentrations
of NCs were vortexed and sonicated in agarose water solutions before the gel formed. The volume was
kept at 1 mL with 0.63 wt% of agarose (Conda, Madrid, Spain). The corresponding iron doses (mmol/L)
were calculated according to the wt% of SPIONs in each sample. T2 maps of the phantoms were
acquired at 7 T in a 70/30 Bruker USR Biospec system (Bruker GmbH, Ettlingen, Germany), as follows:
multi-slice multi-echo (MSME) sequence with echo time (TE) = 13 ms, repetition time (TR) = 4000 ms,
field of view (FOV) = 5.5 × 11 mm, and three slices of 1 mm thickness. The quantitative T2 values were
obtained from hand-drawn ROIs by using curve fitting in the Image Sequence Analysis (ISA) software
along with the instrument.
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2.6. In Vitro Toxicity Evaluation of the NCs
Two parallel methods assessed the toxicity of the NCs on human brain endothelial cells
(hCMEC/D3): a viability assay based on WST-8 tetrazolium salt reduction (cell counting Kit-8,
Dojindo) and direct cell counting. First, 104 viable cells per well were seeded on a 24-well plate
pre-treated with collagen (rat tail type I, Corning) in 400 μL of endothelial growth medium (EGM2
from Lonza with 2% fetal bovine serum and half the amount of the growth factors that were included
in the kit). After incubation for 72 h at 37 ◦C with 5% of CO2, the cells were at 80–90% confluence
and medium was changed to endothelial basal medium (EBM2, Lonza) containing NCs at 25, 50, 100,
500, and 1000 μg/mL. After 48 h, the cells were washed and incubated with 10% WST-8 solution for
two hours. Culture supernatants were centrifuged at 20,000 rpm for 5 min. to remove NCs detritus
that could interfere with the dye absorption before determining the absorbance at 450 nm. Cells were
trypsinized and resuspended in growth medium and diluted 1:1 in Trypan Blue in order to perform
cell counting in a Neubauer chamber. Cell viability and count are expressed as the percentage of
absorbance or number of cells as compared with the control (vehicle without NCs). ANOVA test and
Dunnett’s multiple comparisons post-hoc test was performed vs. the control.
2.7. In Vitro Observation of NCs Cellular Uptake
The hCMEC/D3 endothelial cells were seeded in cover-slips that were pre-treated with collagen
(2 × 104 cells/well in 24 well plates) and 24 h later were exposed to 50 μg/mL of empty fluorescent NCs.
After an additional 24 h of culture, the wells were washed with PBS, fixated with 4% paraformaldehyde,
and mounted with Vectashield antifade mounting medium (Vector Laboratories) with propidium iodide
for nucleic acid counterstaining. Additionally, some of the cells were stained with PKH26 lipophilic
fluorescent dye for cell membrane labeling according to the manufacturer’s protocol. Images at
63× were obtained on a fluorescent confocal microscope (LSM 980 with Airyscan 2 detector, Zeiss,
Oberkochen, Germany).
2.8. BSA Loading in NCs and Release Kinetics
The albumin content of the NC was directly determined while using the CBQCA protein assay
kit (Invitrogen™ ref. C6667), which determines the protein concentration based on the production of
fluorescent products measurable at λex/λem = 450 nm/550 nm via non-covalent interaction between
CBQCA and primary aliphatic amines of proteins. This highly sensitive fluorescence-based method
showed compatibility with DMSO, SPIONs, detergents, and other substances that interfere with other
commonly used protein determination methods. Lyophilized NCs encapsulating albumin as well
as empty NCs as control were fully dissolved in DMSO at 100 mg/mL. The protein contents in the
NCs lysates were measured and calculated based on the difference in fluorescence with the control
and a calibration curve drawn with standard albumin solutions, the protein contents in the BSA
solutions used for encapsulation were also measured. As listed in Table 1 for the two types of NCs,
at least two replicate NCs batches of each were measured for the BSA loading and encapsulation
efficiency (EE%) calculation. All of the measurements were performed in duplicate for each NCs batch.
The experimental BSA loading in the NCs is expressed as μg of BSA per mg of NCs (μg/mg) or the wt%





For the release studies, lyophilized NCs were resuspended in phosphate buffered saline (PBS)
(pH 7.4, Sigma ref. D1408) at 10 mg/mL in low protein binding microcentrifuge tubes (Thermo
Scientific© ref. 90410). NCs solutions were incubated at 37 ◦C in a vertical rotator for different time
measures to simulate the in vivo environment: right after the resuspension (time 0), and after three
hours, six h, one day, and seven days of incubation. In all cases, an aliquot of 200 μL was frozen
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at −80 ◦C until protein determination. Before the CBQCA assay, the aliquots were centrifuged at
15,000× g rcf to separate supernatant and pellet. The amount of protein release was directly calculated
as total released protein and indirectly from the remaining protein in the pellet as indirect measure.
For this purpose, the pellets were fully dissolved in DMSO and then compared with the intact NCs
fully dissolved in DMSO (100 mg/mL) used as the 100% release set up. Four BSA-loaded NCs batches
and one of H2O-NCs batch as control were used and measures done in duplicate. The release profiles
were expressed in terms of cumulative release and plotted vs. time.
3. Results and Discussion
3.1. Photoluminescent PLGA-BPLP Copolymer
BPLPs are degradable oligomers synthesized from biocompatible monomers, including citric
acid, aliphatic diols, and various amino acids via a convenient and cost-effective polycondensation
reaction. BPLPs present some advantages over the traditional fluorescent organic dyes and quantum
dots due to their cytocompatibility, minimal chronic inflammatory responses, controlled degradability,
and excellent fluorescence properties [16]. Here, l-cysteine was selected and introduced into
the polyester structure that was made of biocompatible monomers of citric acid and aliphatic
1,8-octanediol, since previously reported BPLP from this starting amino acid exhibited the highest
quantum yield (62.3%) [16]. The fluorophore structure of BPLP was verified as a fused ring structure
((5-oxo-3,5-dihydro-thiazolopyridine-3,7-dicarboxylic acid, TPA) [21]. ATR-FTIR was also used to
confirm the chemical structure of the as-synthesized BPLP (Figure 2A). Strong absorptions from the
molecular backbone of the polyester were observed i.e., peaks at 1044 cm−1, 1176 cm−1, and 1716 cm−1
are attributed to the C=O stretch, C–O asymmetrical, and symmetrical stretches of the ester bond,
respectively, the peaks at 2930 cm−1 and 2856 cm−1 are attributed to the C-H stretches of alkane from
1,8-octanediol and the band near 3467 cm−1 is from the −OH. NH bending of the secondary amide at
1527 cm−1 and −SH at 2575 cm−1 confirm that l-cysteine is chemically bound to the poly(diol citrate)
chain. The shoulder band near 1635 cm−1 is attributed to the C=O stretching of the tertiary amide
from the TPA ring. The average molecular weight (Mw) of BPLP measured by matrix-assisted laser
desorption/ionization time of flight mass spectroscopy (MALDI-TOF-MS) was 1044 g/mol (Figure S2).
The BPLP oligomer served as a macroinitiator to react with l-lactide and glycolide via a ring-opening
polymerization to produce PLGA-BPLP [17]. The as-synthesized PLGA-BPLP (75:25):1 with molar
ratios equal to 75:25 for l-lactide to glycolide and equal to 1:100 for BPLP to total l-lactide and glycolide
was reported to have desirable glass transition temperature (Tg, 32.5 ◦C), mechanical properties,
fluorescence properties, and degradation rate of the resulting product [17]. Moreover, we have proved
here that the 75:25 formulations are more suitable for the fabrication of NCs by a double mini-emulsion
method than the PLGA-BPLP (50:50):1 one, as shown in the following section.
The obtained PLGA-BPLP copolymer (Figure 2B inset) exhibits the inherent photoluminescence
from the BPLP. The similarities of bands and shapes of the IR spectra of the as-synthesized PLGA-BPLP
and commercial PLGA (Figure 2B), for instance, bands at 1084 cm−1, 1165cm−1, and 1747 cm−1 from
the ester bonds in PLGA indicate their similar chemical structure, given the fact that BPLP is a very
small portion of the PLGA-BPLP copolymer.
The fluorescence of the as-synthesized BPLP and PLGA-BPLP was evaluated and Figure 3A,B depict
the excitation and emission spectra. The similar spectra further confirm the inherent photoluminescence
of PLGA-BPLP from BPLP. Importantly, the fluorescence intensity of PLGA-BPLP only slightly decreased
(10%) after 10 min. of continuous illumination under confocal microscope at 10% of laser power
(0.40 ± 0.01 μW) (Figure 3C). When considering the laser power applied to observe stained cells is
generally less than 10%, our photoluminescent polymer would exhibit good photostability at in vitro
conditions. The calculated high quantum yields of BPLP (64%) and PLGA-BPLP (33%) from Figure 3D
are consistent with the previously reported values [16,17]. The remarkable fluorescence properties that
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are shown here endow the PLGA-BPLP copolymer with high potential for the fabrication of functional
photoluminescent NCs.
Figure 2. Attenuated total reflectance-Fourier transform infrared (ATR-FTIR) spectra of the
as-synthesized biocompatible photoluminescent polymer (BPLP) and PLGA-BPLP copolymer confirming
their chemical structures and the successful synthesis. (A) BPLP; (B) PLGA-BPLP and commercial PLGA
as reference. Inset: fluorescence of the PLGA-BPLP under a UV lamp.
 
Figure 3. (A,B) excitation and emission spectra of the as-synthesized BPLP and PLGA-BPLP. Insets:
fluorescence of BPLP and PLGA-BPLP dispersed in solutions under a UV lamp; (C) photostability
evaluation of PLGA-BPLP powder under confocal microscope at different laser power, fluorescence
intensity expressed as the percentage vs. the value at the initial time; and, (D) fluorescence
intensity-absorbance curves of BPLP, PLGA-BPLP, and anthracene used as a reference used to calculate
quantum yields.
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3.2. Fabrication of PLGA-BPLP NCs Combining Other Functional Moieties
PLGA-based NCs with BSA encapsulated were prepared by a double emulsion solvent evaporation
method with slight modifications from our previously reported method [22]. Functional moieties, such
as PLGA-BPLP for the fluorescence imaging, PLGA-PEG to increase hydrophilicity and sealthness,
and SPIONs for magnetic targeting and MRI (Figure 4A,B) can be incorporated to the organic phase
during the NCs fabrication process (see Table 1). The first important remark is that NC morphology
was not affected, even when using 100 wt% of PLGA-BPLP (75:25):1 (Figure S3A). A formulation
with 90 wt% of PLGA-BPLP (75:25):1 was selected to allow for NC PEGylation by the addition of
7 wt% of PLGA-PEG and for the benefit of higher fluorescence intensity (Figure S4). Note that 7 wt%
of PLGA-PEG (3 wt% PEG, Figure S3B) (NC2) was found to be the maximum amount that can be
mixed in the organic phase during the NCs fabrication process, due to the amphiphilic property of
PLGA-PEG. For a larger wt% of PLGA-PEG, the morphology and size of NCs were not maintained.
As shown in the SEM image (Figure 4C), non-PEGylated and PEGylated NCs, as listed in Table 1, both
contain ~6 wt% of SPIONs and depict homogeneous spherical morphologies and sizes (d.nm ~270)
being similar to other reported PLGA systems that are suitable for intravenous administration [23].
The upper inset in Figure 4C shows a representative broken NC, exposing the hollow core where the
protein drug is loaded. We have also found that the PLGA-BPLP (50:50):1 polymer from using initial
molar ratio of LA:GA = 50:50 and BPLP:(LA + GA) = 1:100 was not as suitable for the fabrication of
NCs. NCs with homogeneous morphology and narrow size distribution were attained only up to a
maximum of 30 wt% of modified PLGA (Figure S3C) and without the possibility of further adding
PLGA-PEG when using PLGA-BPLP (50:50):1 (Figure S3D). These results are in accordance with the
higher glass transition temperature and better mechanical properties of PLGA-BPLP (75:25):1 over
those of PLGA-BPLP (50:50):1 [17]. As expected, the NCs with a higher fraction of PLGA-BPLP (75:25):1
(90 wt%) show higher fluorescence intensity than the ones that were obtained with PLGA-BPLP
(50:50):1 (30 wt%) at the same concentration (Figure S4).
Regarding magnetic loading, up to 6 wt% of SPIONs could be loaded without affecting the NCs
morphology and yielding a saturation magnetization (MS) value of around 4 emu/g NCs (Figure 4D).
In addition, the lower blocking temperature (TB, 33 K) of SPIONs in the NCs (Figure 4D inset) than the
SPIONs of dry powder (55 K, Figure 4B inset) further demonstrates that the SPIONs are well dispersed
in the polymer matrix. Note that a high magnetic loading is desirable for the magnetic retention of NCs.
This is illustrated in the inset images of Figure 4D, where the darker-coloured water suspension of NCs
with 6 wt% of SPIONs were adsorbed faster to the tube wall on the magnet side than the NCs with
1 wt% SPIONs loading at the same concentration, promisingly benefiting the magnetically targeted
drug delivery as compared to the previously reported results [4,24]. Note that the superparamagnetic
behaviour of NCs at room temperature (lack of coercivity, Figure S5) ensures no magnetic interactions
among NCs in the absence of an external magnetic field, minimizing the risk of embolization during
i.v. administration.
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Figure 4. (A) Representative transmission electron microscope (TEM) image of the oleic acid (OA)
coated SPIONs with the upper inset showing the selected area electron diffraction (SAED) pattern of
maghemite and lower inset a size distribution histogram of the particles in the image; (B) hysteresis
loop (5 K) and ZFC-FC (inset) for the OA-superparamagnetic iron oxide nanoparticles (OA-SPIONs),
inserted picture shows the stable OA-SPIONs in dichloromethane attracted by an external magnet;
(C) representative SEM image of lyophilized NCs with the upper inset showing the hollow core of a
nanocapsule and lower inset a TEM image of three NCs with the SPIONs visible as black spots well
distributed in the polymer matrix; (D) hysteresis loop (5 K) and ZFC-FC (inset) for the lyophilized
nanocapsule batch NC1, inserted pictures show the water suspension of these NCs (2 mg/mL) where
the 6 wt% loading of SPIONs were adsorbed faster to the tube wall on the magnet (diameter 8mm,
surface field ~0.4 T) side than that of 1 wt% loading.
It is well reported that the surface PEGylation of engineered nanoparticles provides them
with stealth character increasing blood circulation time since nanoparticles are less visible to the
reticulo-endothelial system [6]. We evaluated the flocculation regime of the NCs with a Turbiscan to
confirm successful surface modification with PEG, since the long hydrophilic PEG chains (Mn 5000) on
the surface of the NCs are expected to increase the stability of the NCs in water suspension and decrease
the sedimentation rate. Sedimentation of the NCs suspension was monitored for 24 h. Figure 5A
shows that, as NCs sedimentation progresses, the back scattering signal of the bottom part of the
suspension increases from an increasingly higher concentration of NCs, while the signal of the top
part decreases. The sedimentation rates of non-PEGylated and PEGylated NCs were compared with
or without a physiological concentration of BSA (0.5 mM) in Figure 5B, as expected the bottom back
scattering signal of the PEGylated NCs media increases at a slower rate than the non-PEGylated ones
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both with and without BSA, which demonstrates a better dispersibility of the NCs due to the surface
hydrophilic PEG chains. Note that the sedimentation rates of non-PEGylated and PEGylated NCs both
slow down with the physiological concentration of BSA probably due to the interaction of NCs with
the dense BSA solution. Additionally, in Figure 5A, the back scattering signal of the middle part did
not vary with time, which means that the NCs were monodispersed at the physiological concentration
of BSA and flocculation or coalescence did not occur during the 24 h period. This is in consistent with
the DLS size distribution results that are shown in Figure 5C, both non-PEGylated and PEGylated NCs
remained monodisperse at the physiological concentration of BSA, which is of great advantage for the
i.v. administration and in vivo blood circulation. Nanosight was also used as an additional technique
for the determination of size and the concentration of the NCs (Figure 5D). The results show a similar
size distribution as obtained by DLS. From the number concentration of the NCs, we can determine a
mean mass of 1.06 × 10−11 mg/NC.
Figure 5. (A) Back scattering intensity change of the NC2 PBS suspension (shown inset) containing
0.5 mM of BSA at different height of the vial along 24 h measured by Turbiscan; (B) quantified back
scattering intensity change of the bottom part of the vial along 24 h for NCs suspension in different
media measured by Turbiscan; (C) dynamic light scattering (DLS) size distributions of NC1 and NC2
PBS suspensions with 0.5 mM of BSA along 24 h; (D) quantitative number concentration and size
distribution of the nanocapsules measured by Nanosight (n = 3, mean ± SD with error bar).
3.3. Imaging Performance of the Magnetic Photoluminescent NCs
The fluorescence of the NCs was evaluated, and Figure 6A depicts the excitation and emission
spectra. The spectra are similar to those of the PLGA-BPLP polymer shown in Figure 3B. Importantly,
the incorporation of SPIONs in the polymer matrix does not quench the fluorescence of NCs. Note that
a small displacement of the emission peak wavelength was observed for aqueous dispersed fluorescent
NCs when compared to the emission peak of the polymer in a chloroform solution (Figure 3B), which we
ascribe to the different interaction of the fluorescent probe with the two solvents. The fluorescence
intensities of NCs show a linear dependency on the NCs concentration within a range of 0.1 to
1.0 mg/mL; at higher concentrations the fluorescence shows a trend towards saturation (Figure 6B).
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NCs can be clearly imaged with a fluorescence confocal microscope and they show a very good
photostability while using 10% of laser power, which is ideal for the observation of in vitro cellular
uptake (Figure 6C). The strategy used here confers intrinsic photoluminescence to the PLGA NCs
without introducing any cytotoxic quantum dots or photo-bleaching organic dyes when compared
to other more conventional approaches that physically blend imaging probes within the carrier that
can lead to misinterpretations on the tracing of the carrier [12,13], which may greatly expand the
applications of this drug carrier.
 
Figure 6. (A) Excitation and emission spectra of the nanocapsules (NCs) water suspension;
(B) fluorescence intensity of different concentrations of NCs measured by microplate reader (n = 2,
values represent mean± sd and subtract values of control non-fluorescence NCs); and, (C) photostability
evaluation of NCs under confocal microscope at 10% laser power, fluorescence intensity expressed as
the percentage vs. the value at the initial time, inset: NC1 water suspension observed at 60× lens.
Phantom studies were conducted to confirm the MRI performance of the capsules. Phantoms of
NCs that were dispersed in agarose gel at various concentrations were prepared (Figure 7A).
Spin-spin relaxation time (T2) maps clearly exhibit signal decay in a concentration dependent manner.
The calculated transverse relaxivity (r2) values at 7 Tesla of both non-PEGylated NC1 (263 mM−1s−1)
and PEGylated NC2 (237 mM−1s−1) are similar as those seen in Figure 7B, as expected, further
demonstrating the similar loading and distribution of SPIONs in the polymer shell matrix for both
systems. When compared with other clinically used SPIONs systems, such as Feridex (98 mM−1s−1)
and Resovist (151 mM−1s−1) [25], the much higher r2 value of our NCs formula is expected to be useful
for in vivo MRI tracking of the NCs.
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Figure 7. (A) T2 maps of a series of concentrations of NC1 in agarose phantoms; (B) r2 relaxivity
evaluation for the NCs.
3.4. Cell Viability after NCs Uptake
Photoluminescent NCs were incorporated by brain endothelial cells after several hours in culture,
as seen in Figure 8A, with cytoplasmic localization of the NCs in perinuclear structures compatible
with Golgi bodies and endosomes. This subcellular localization was confirmed by Z-stack images
(Figure 8B). Importantly, this cellular uptake was biocompatible for endothelial cells, as the main
exposed cells during NCs circulation in blood vessels, since viability tests did not show signs of cell
toxicity at a wide range of NCs concentrations up to 500 μg/mL (Figure 8C,D) and 48 h exposure.
Only extremely high doses (1000 μg/mL) with noticeable occupying space difficulties for cell culturing
showed a significant reduction in cell viability and number.
 
Figure 8. NCs uptake and cytotoxicity in human brain endothelial cells. (A) Representative images
of hCEMC/d3 cells stained with membrane dye PHK26 and exposed to 50 μg/mL of NC1 for 24 h
(63×magnification); (B) Orthogonal view of a Z-stack of Propidium Iodide (PI) stained cells (showing
the cell nuclei) and the fluorescent NCs; (C,D) hCEMC/d3 cells were treated for 48 h with different
concentrations of NC1 and cell viability was determined with WST-8 reduction assay or tripsinized
and counted in a Neubauer chamber, (n = 3–4, values represent mean ± SEM, ** p < 0.01).
3.5. Protein Loading and In Vitro Release
Protein loading and encapsulation efficiency were determined by lysing NCs with DMSO and
measuring total protein content. The BSA loading content was determined as ~10 μg BSA/mg NCs
(1 wt%) with an EE% of around 40% for both NC2.PEGylated and NC1.non-PEGylated systems, as
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listed in Table 1, which indicated that the incorporation of PEG does not affect the protein encapsulation
process. Note that a protein loading of 1 wt% is much higher than other reported values (0.03 wt% of
vessel endothelial growth factor (VEGF) loaded PLGA NCs) [22] and the EE% of 40% is comparable to
the PLGA NCs loaded with neurotrophin-3 or brain-derived neurotrophic factor (47%) [26].
BSA-loaded NCs were able to release protein cargo over time at physiological temperature in PBS
media (32% protein release in one week). Figure 9A shows a fast BSA release within the first hours, but
not after one day, which could be related to the protein degradation in ex vivo conditions of our assays.
The amount of released protein in one week was similar when indirectly measured from the pellet
retained protein (Figure 9B,C), although the release profile showed a more sustained pattern over time,
which could be associated to the protein that was trapped within the PLGA polymer.
 
Figure 9. Protein release temporal profile of the NCs. (A–C) NC1 in PBS (10 mg/mL) were incubated at
37 ◦C in rotation and the released BSA quantified as total mass of protein released (A) together with
BSA content in the remaining NCs pellet by DMSO lysis (B) and the released BSA calculated indirectly
from the pellet values (C). The percentage was calculated versus intact unreleased NCs lysated also in
DMSO (n = 8, values represent mean ± SEM).
By using the model protein BSA, here we were able to prove the loading capacity and release
kinetics of the drug carrier, yet the preservation of protein functionality after the encapsulation process
still needs to be investigated. Nevertheless, in a previous work, we have shown that VEGF could be
encapsulated following a similar route and VEGF effect on cell proliferation could be determined [22],
which implied the preserved protein functionality.
4. Conclusions
We here transform PLGA nanocapsules (NCs) into a highly sensitive, MRI/photoluminescence
dual-modal imaging theranostic platform for drug delivery by integrating the biocompatible and
photoluminescent polyester BPLP into the PLGA molecular structure, as well as by incorporating
superparamagnetic iron oxide nanoparticles (SPIONs). Furthermore, we have shown that PEGylation
provides a hydrophilic surface to the NCs slowing down their flocculation rated and without modiying
the size, SPIONs content or protein loading capacity of the NCs. In all cases, the functional moieties
are embedded in the PLGA shell with minimal interferences between them or with the therapeutic
protein. The developed magnetic PLGA-BPLP NCs show biocompatibility in vitro. In this regard,
the NCs did not affect the viability of endothelial cells in culture for concentration up to 500 μg/mL
and 48 h incubation. Finally, we have shown that the NCs can contain 1 wt% of protein in their core
achieved at fabrication level and that one third of the encapsulated protein is released in the first
week. Interestingly, the NCs decorated with SPIONs can be exploited for magnetic retention and
magnetic guiding.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/12/1/16/s1.
Figure S1: UV-Vis absorbance spectra and fluorescence spectra of the as-synthesized A/B) BPLP, C/D) PLGA-BPLP
and E/F) reference anthracene at a series concentrations for fluorescence quantum yield calculation, Figure S2:
Matrix-assisted laser desorption/ionization time of flight mass spectroscopy (MALDI-TOF-MS) was used to
determine the average molecular weight (Mw) of BPLP. Average Mw calculated from the mass spectrum of BPLP
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is 1044 g/mol. For the analysis, the sample was spotted in a MALDI plate with 1,8,9-Antracenotriol (Ditranol) and
analyzed using a mass spectrometer (Bruker Daltonics Ultraflex TOF/TOF) in reflectron mode, Figure S3: SEM
images and DLS size distributions of NCs fabricated by different types of PLGA-BPLP, Figure S4: Fluorescence
intensity of different concentrations of NCs measured by microplate reader at the maximal emission wavelengths
(values have subtracted values of control non-fluorescence NCs), Figure S5: Hysteresis loop (300 K) and ZFC-FC
(inset) measurements of the lyophilized nanocapsule batch NC2.
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Abstract: Today, efficient delivery of sorafenib to hepatocellular carcinoma remains a challenge for
current drug formulation strategies. Incorporating the lipophilic molecule into biocompatible and
biodegradable theranostic nanocarriers has great potential for improving the efficacy and safety of
cancer therapy. In the present study, three different technologies for the encapsulation of sorafenib into
poly(d,l-lactide-co-glycolide) and polyethylene glycol-poly(d,l-lactide-co-glycolide) copolymers were
compared. The particles ranged in size between 220 and 240 nm, with encapsulation efficiencies from
76.1 ± 1.7% to 69.1 ± 10.1%. A remarkable maximum drug load of approximately 9.0% was achieved.
Finally, a gadolinium complex was covalently attached to the nanoparticle surface, transforming the
nanospheres into theranostic devices, allowing their localization using magnetic resonance imaging.
The manufacture of sorafenib-loaded nanoparticles alongside the functionalization of the particle
surface with gadolinium complexes resulted in a highly efficacious nanodelivery system which
exhibited a strong magnetic resonance imaging signal, optimal stability features, and a sustained
release profile.
Keywords: gadolinium; drug release; polymeric nanocarrier; sorafenib; theranostic nanoparticles
1. Introduction
Liver cancer, of which the majority of cases are hepatocellular carcinoma (HCC), is a life-threatening
disease and, according to global cancer statistics, the third leading cause of cancer-related mortality
worldwide [1]. To date, sorafenib is the only drug able to prolong the lives of patients with HCC [2],
although at the expense of severe side effects due to uptake of the drug into healthy tissues [3].
Sorafenib is a multi-kinase inhibitor targeting various receptor tyrosine kinases and rapidly accelerated
fibrosarcoma (RAF) kinases. The pronounced lipophilicity of the molecule is responsible for its poor
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bioavailability and the distribution of the compound into healthy tissues [3]. As a consequence, patients
are treated using high doses of the drug and suffer from a number of side effects.
Nanocarrier-based delivery of sorafenib has the potential to improve drug therapy significantly.
Theranostic nanodelivery systems offer a versatile combination of therapeutic and diagnostic features,
and have previously been applied to this task [4]. A variety of contrast agents, such as gadolinium
diethylenetriamine pentaacetic acid (Gd-DTPA), shorten the longitudinal relaxation time, and have
been widely used for both vascular and tumor magnetic resonance imaging (MRI) [4,5]. One major
limitation of this technique lies in the short half-life of the contrast agent, as well as its poor specificity
for the target site.
In this context, Gd-DTPA-conjugated human serum albumin (HSA) nanoparticles improved the
contrast of MRI compared to free Gd-DTPA aqueous solution in vivo, due to negative contrasting
of the tumors [5]. Even after conjugation of polyethylene glycol (PEG) to the particle surface, HSA
nanoparticles exhibited only a short circulation time [6] and the scale-up potential of this technology is
rather limited [7].
Block copolymers comprising polylactic-co-glycolic acid (PLGA) and PEG have been processed
to nanoparticles in pilot scale using either microfluidic technologies [8] or emulsion techniques [9].
Recently, targeted nanotherapeutic formulations successfully passed phase 1 clinical trials [10]. A major
shortcoming of nanocarrier delivery is limited drug loading, resulting in high excipient concentrations
and administration volume [11].
Several preparation techniques of PLGA nanoparticle preparation have been described in the
literature. Previous investigations reported the loading of sorafenib into PLGA nanoparticles, achieving
a drug load of 1.4% oil-in-water single emulsion–solvent evaporation method [12]. Preparations made
with a nanoprecipitation–dialysis technique using a block copolymer comprising dextran and PLGA
resulted in a drug load of 5.3% [13]. To attain synergistic effects of cytostatic agents, co-delivery of
drug molecules has been considered. By employing a sequential freeze–thaw method followed by
ethanol coacervation, a core–shell construct was manufactured [14]. After preparation of a polyvinyl
alcohol (PVA)-doxorubicin nanocore, a thin shell of HSA covering sorafenib was used as a second drug
molecule. A drug load of 2.4% was reached. Lipid–polymer hybrid nanoparticles were synthesized for
the co-delivery of doxorubicin and sorafenib to enhance efficacy in HCC therapy [15].
Other approaches have focused on theranostic drug delivery systems containing gadolinium
(Gd) and sorafenib. Theranostic liposomal carriers with a drug content of 4.3% (m/m) have
been produced [16]. Another system used a multiblock polymer comprising (poly(lactic
acid)-poly(ethylene glycol)-poly(l-lysine)-diethylenetriamine pentaacetic acid and the pH-sensitive
material poly(l-histidine)-poly(ethylene glycol)-biotin. A drug content of 2.4% (m/m) of sorafenib was
reached, and the MRI signal intensity was more beneficial than that of Magnevist® in vivo [12].
In the present study, the impact of three different preparation techniques on the physicochemical
features of poly(d,l-lactide-co-glycolide) (PLGA) and polyethylene glycol-copolymer (PEG-PLGA)
nanocarriers were compared. Nanocarriers loaded with sorafenib were manufactured using the
nanoprecipitation, single emulsion, and double emulsion–solvent evaporation methods. Nanoparticles
manufactured using the single emulsion–solvent evaporation method were further optimized with
regards to the intended target product profile. In vitro cytotoxicity and cellular uptake were investigated
in HepG2 cells. Finally, the nanoparticles were modified on their surface using a gadolinium
complex, resulting in a theranostic nanocarrier system. For this purpose, the encapsulation of HSA
into nanoparticles and the covalent modification of the surface using HSA or polyethylene imine
were considered.
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2. Materials and Methods
2.1. Materials
Resomer® RG 502H (PLGA, lactide: glycolide: 50:50, inherent viscosity: 0.16–0.24 dL/g),
Resomer® RG 752H (PLGA, lactide:glycolide: 75:25 inherent viscosity 0.14–0.22 dL/g), and block
copolymer Resomer® RGP d5055 (PEG-PLGA, PEG content: 3–7% (m/m), inherent viscosity: 0.93 dL/g)
were obtained from Evonik Industries AG (Essen, Germany). PVA (Mw = 30,000–70,000, 87–90%
hydrolysed), polysorbate 80, Triton X-100, Pluronic F127, poly(methacrylic acid sodium salt) emulsifiers,
dichloromethane (DCM), acetone, dimethyl sulfoxide (DMSO), sodium azide, D-trehalose dehydrate,
mannitol, polyethyleneimine (PEI) (MW 25 kDa), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC), N-hydroxysuccinimide (NHS), Gd-DTPA, and HSA were obtained from Sigma Aldrich (St. Louis,
MO, USA). Sorafenib (free base) was purchased from LC Laboratories (Woburn, MA, USA). Magnevist®
was purchased from Bayer AG (Leverkusen, Germany). The micro bicinchoninic acid (μBCA) protein
assay kit was bought from Pierce Biotechnology, Inc. (Waltham, MA, USA).
2.2. Cell Culture Experiments in HepG2 Cells
The human hepatoma cell line HepG2 was grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS), 100 U/mL penicillin, and 100 μg/mL streptomycin. The
cells were cultured at 37 ◦C in a humidified atmosphere containing 5% carbon dioxide. The cells were
trypsinised, resuspended, and precultured before use.
2.3. Preparation of Nanoparticles Using Nanoprecipitation
In brief, 5 to 10 mg of Resomer® RG 502 H, Resomer® RG 752H or Resomer® RGP d5055 and 0.5
to 4 mg of sorafenib were dissolved in between 0.5 and 1.0 mL of acetone under magnetic stirring.
A water phase with a volume of 2.0 to 4.0 mL was composed of an aqueous solution (0.5 to 2.0% w/v)
of emulsifying agent (polysorbate 80, poly(methacrylic acid sodium salt), Triton X-100, or Pluronic®
F127), and added as a one-shot to the organic phase. Afterwards, the organic solvent was evaporated
over a time period of 12 h at room temperature and 1 bar under constant stirring. The nanoparticles
were centrifuged (Eppendorf 5424 R, Hamburg, Germany) at 37,565 g for 25 min, washed thrice and
redispersed in an equal volume of purified water.
2.4. Preparation of Nanoparticles Using the Single Emulsion Technique
For the preparation of nanoparticles with the single emulsion–solvent evaporation method, the
organic phase was prepared in two steps. An measure of 1 to 2 mg sorafenib was dissolved in 0.1 to
0.2 mL of acetone, and this solution was poured into a solution comprising 5 to 20 mg of Resomer® RG
502 H, Resomer® RG 752H, or Resomer® RGP d5055 in 1 to 2 mL DCM.
A volume of 4 to 8 mL of an aqueous solution of PVA (1 to 2% w/v) was added and sonicated
using a Sonoplus HD2070, MS73 probe (Bandelin, Berlin, Germany) at an amplitude of 10% for 60 s.
The organic solvent was evaporated over 2 h at atmospheric pressure and room temperature. The
nanoparticles were purified as described above.
2.5. Preparation of Nanoparticles Using Double Emulsion–Solvent Evaporation Technique
The double emulsion–solvent evaporation technique was tested for the co-encapsulation of HSA
into the sorafenib nanoparticles. The entrapped protein was further used for the covalent modification
of the particle surface using the Gd-DTPA complex. In principle, the inner water phase was formed
of 2.5 mg HSA in a volume of 0.1 mL of purified water. This solution was added to the organic
phase, composed of 15 mg of Resomer® RG 752H or Resomer® RGP d5055 dissolved in 1.5 mL
DCM, combined with 1.5 mg of sorafenib dissolved in 0.15 mL acetone. The first emulsification
was performed by sonication using a Sonoplus HD2070, MS73 probe (Bandelin, Berlin, Germany)
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at an amplitude of 10% for 30 s. Afterwards, the water-in-oil emulsion was pipetted into 6.0 mL of
an aqueous solution of PVA (1% (w/v)). A water-in-oil-in-water emulsion was formed by a second
sonication step at an amplitude 15% for 45 s. The organic solvents were evaporated over a time period
of 2 h under magnetic stirring at atmospheric pressure and room temperature. The nanoparticles were
centrifuged at 37,565 g for 25 min (Eppendorf Centrifuge 5424 R), washed thrice and redispersed in
0.5 mL of phosphate buffer (pH 8), and, after gravimetric analysis, the suspensions were diluted to
20 mg·mL−1 nanoparticle concentration.
2.6. Particle Morphology and Particle Size Analysis
The morphology of the nanospheres was investigated after centrifugation and redispersion in the
described medium. The samples were examined using a FEI Talos F200XG2 high-resolution analytical
microscope operated at 200 keV (Thermo Fischer Scientific, Waltham, MA, USA).
Additionally, the particle size and size distribution were determined using a Zetasizer Nano ZS
(Malvern Instruments, Malvern, UK) equipped with a backscatter detector at an angle of 173◦. The
particles were characterized for their intensity mean diameter and polydispersity index (PDI). Dynamic
light scattering (also known as photon correlation spectroscopy) is based on the Brownian motion
of particles dispersed in a liquid. The particle diameter is calculated from the intensity fluctuations
of light scattered at the particle surface. The Zetasizer Nano ZS uses a HeNe gas laser to generate a
signal of these intensity fluctuations, from which the size is calculated by applying the Stokes–Einstein
equation. Consequently, the resulting size distribution is an intensity distribution.
2.7. Storage Stability of Nanoparticle Formulations
To improve the physical stability of the colloidal dispersion during storage, the nanoparticles were
freeze-dried, and their storage stability was investigated after 6 months of storage. A concentration of
3% (w/v) of two lyoprotectors (trehalose dihydrate or mannitol) was evaluated. The solid concentration
was adjusted to 7 mg·mL−1 of nanoparticles and the samples were put into a Christ Epsilon 2–7 freeze
dryer (Martin Christ GmbH, Osterode am Harz, Germany). The lyophilisation was conducted in two
drying steps.
Initially, the temperature was decreased to −60 ◦C for 1 h to freeze the samples. Afterwards,
primary drying was initiated by evacuating the chamber to 0.94 mbar. In parallel, temperature was
raised to −30 ◦C over a time period of 150 min. The pressure was then reduced to 0.006 mbar and the
temperature was increased to −10 ◦C over a time period of 60 min. These conditions were maintained
for 35 h. The second drying was accomplished at a temperature of 10 ◦C for 60 min and at 20 ◦C for
10 h. The freeze dried samples were stored at 4 ◦C for a total duration of 6 months, and reconstituted
in the same volume of purified water. The nanocomposite size and size distribution after redispersion
were characterized by triplicated measurement.
2.8. Nanoparticle Yield and Encapsulation Efficiency
The nanoparticle yield was determined by microgravimetry. The drug loading and encapsulation
efficiency were investigated dissolving 10 mg nanoparticles in 1 mL of DMSO. The solution was
diluted using DMSO to be within the detectable linear calibration range (1–20 μg/L). The absorbance
of the solutions was measured spectrophotometrically (Hitachi U-3000, Tokyo, Japan) at 285 nm. A
concentration range of HSA solution in DMSO was prepared in order to correct the absorbance of
HSA-loaded nanoparticles, also measured at 285 nm.
2.9. Biorelevant In Vitro Drug Release Test Using the Centrifugation Method
The biorelevant in vitro drug release test was conducted using the centrifugation method. In brief,
1.5 mg of the sorafenib-loaded nanocomposites was re-suspended in 1 mL of human blood plasma
containing 0.03% sodium azide as a preservative. The nanoparticle formulations in release medium
were filled into 2 mL tubes, and incubated at a temperature of 37 ◦C in a Thermomixer (Eppendorf,
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Hamburg, Germany) for 12 days at 700 rpm. At predetermined time points, 0.2 mL samples were
collected. After each sampling time point the medium was replenished. The nanoparticles were
separated from the plasma by centrifugation (Eppendorf Centrifuge 5424 R, 20 min at 37,565 g). The
concentration of free sorafenib was determined using direct quantification of the drug remaining in
the particle system. For this purpose, the nanoparticle pellets were dissolved in DMSO and the drug
amount was detected spectrophotometrically.
2.10. Surface Modification Using Human Serum Albumin and Polyethyleneimine
The nanoparticle dispersions prepared by single emulsion technique were centrifuged and
redispersed in phosphate buffer (pH 8), resulting in a nanoparticle concentration of 20 mg·mL−1. To
increase the number of free amino groups on the particle surface, HSA or PEI were covalently bound to
the nanoparticle surface. A 50-fold molar excess of EDC and the same excess of NHS, both calculated
to the molar polymer concentration, were dissolved in 0.5 mL phosphate buffer (pH 8) and incubated
for 60 min, centrifuged and washed three times, and redispersed in 1.5 mL phosphate buffer (pH 8).
The obtained carbodiimide-activated nanoparticle dispersion was added into 0.5 mL phosphate
buffer (pH 8) solution containing equimolar amounts of HSA or PEI, and shaken overnight at 20 ◦C in
an Eppendorf Thermomixer (Hamburg, Germany) at 700 rpm. Afterwards, the nanoparticles were
dialysed for 2 h against 400 mL of purified water, using a 100 kDa membrane to remove residues of the
dissolved polymers HSA or PEI, respectively. The dialysis step was repeated with purified water.
2.11. Conjugation of Nanoparticles Using the Gd-DTPA Complex
The Gd-DTPA complex was covalently attached to either HSA or PEI after activation using the
carbodiimide. In order to activate the carboxyl groups of the gadolinium complex, a 10-fold molar
excess of Gd-DTPA (calculated on the amount of the Resomer®) was dissolved in 1 mL of buffer (pH 8)
and combined with a 5-fold molar excess of EDC and a 5-fold molar excess of NHS (calculated on
the amount of Gd-DTPA). The resulting solution was incubated for 50 min and added to the purified
nanoparticle suspension overnight. The preparation was purified by dialysis twice, using a membrane
with a MWCO of 3.5 kDa and 500 mL of purified water for 2 h. The dialysed nanoparticle suspension
was centrifuged and redispersed in 1.5 mL phosphate buffer.
2.12. Quantification of Human Serum Albumin Using the Micro Bicinchoninic Acid Method
The crosslinked or co-encapsulated HSA content of the nanocomposites was determined by the
μBCA method after centrifuging 0.1 mL nanoparticle dispersion and removing the supernatant, while
the pellet was dissolved in 0.5 mL DMSO. This solution was diluted 10-fold with purified water, and
incubated for 1 h at 60 ◦C with the same volume of freshly prepared μBCA reagents mixture. DMSO
was added to the calibrating HSA solution with the same ratio. After cooling the colored mixtures
to room temperature for 20 min, their absorbance was evaluated by spectrophotometry at 562 nm
(Hitachi U-3000, Tokyo, Japan).
2.13. Quantification of Gadolinium Using Inductively Coupled Plasma Optical Emission Spectroscopy
The Gd concentration was measured using a Spectro Genesis ICP-OES (Kleve, Germany)
simultaneous spectrometer with axial plasma observation. Multielemental standards (Merck, standard
solutions for ICP, Darmstadt, Germany) were used for calibration. The limits of detection of the element
were calculated according to Equation (1):
Limit o f detection = Background signal + 3× SDBackground × fdilution (1)
The purified nanoparticles were dissolved in 5 M hydrochloric acid and diluted to the desired
calibration range.
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2.14. In Vitro Investigation of Diagnostic Features by Magnetic Resonance Imaging
In vitro MRI was carried out using box analysis to compare the contrast achieved with the
nanoparticle suspension with that of Magnevist® (Gd-DTPA complex with meglumine) solution.
A calibration was achieved by diluting Magnevist® to 0.01–2.5 mg·mL−1 concentration. MR imaging
was performed on a 3.0-T scanner (Siemens Magnetom Trio, Siemens Medical Solutions, Erlangen,
Germany). The measurement conditions were T1-weighted 3D gradient echo sequences (fast low-angle
shot) with the following parameters: TE (echo time) = 3.31 ms, TR (repetition time) = 8.67 ms, field of
view = 100 × 78 mm, matrix acquisition = 640 × 480, slice thickness = 0.3 mm, flip angle = 16◦, fat
suppression = fat saturated, and bandwidth = 180 Hz/Px.
2.15. Labeling of Nanoparticles with a Fluorescent Dye
A volume of 1.0 mL of the nanoparticle suspension (12 mg·mL−1) in phosphate buffer (pH 8) was
added to 0.1 mL phosphate buffer (pH 8) containing a 25-fold molar excess of EDC and NHS (calculated
on the amount of Resomer®) and incubated for 60 min, centrifuged, and washed, and redispersed in
1.0 mL phosphate buffer (pH 8). The obtained carbodiimide activated nanoparticle dispersion was
given to 0.1 mL phosphate buffer (pH 8) solution containing 1 mg·mL−1 Cyanine5 amine fluorescent
(Cy5) dye, and shaken for 1 h at 20 ◦C in an Eppendorf Thermomixer (Hamburg, Germany) at 700 rpm.
The nanoparticle dispersion was then centrifuged in an Eppendorf Centrifuge 5424 R (Hamburg,
Germany) at 37,565 g for 25 min, washed three times, and redispersed in phosphate-buffered saline to
a nanoparticle concentration of 10 mg·mL−1.
2.16. In Vitro Cellular Uptake and Cytotoxicity
Cellular uptake of the nanoparticles into the HepG2 cells was evaluated using flow cytometry.
The cells were cultured in 24-well plates at a cell density of 2 × 105 cells per well at 37 ◦C and 5% CO2
for 24 h. After cultivation, 100 μg nanoparticles/well (10 mg/mL nanoparticle suspension was diluted
to 100 μg/mL) was pipetted to the cells and incubated for 24 h. The cells grown without nanoparticles
were used as control. The cells were washed in phosphate-buffered saline (PBS), trypsinised, and
redispersed in PBS containing 2% (m/v) of bovine serum albumin. Flow cytometry was performed on a
Cytoflex S cytometer (Beckman Coulter, Brea, CA, USA).
To further analyze cellular uptake and intracellular localization, fluorescence microscopy of
HepG2 cells plated on cover slides and incubated with either Cy5-labeled PLGA or PEG-PLGA NP
for 4 h and 24 h was employed. Membrane staining was performed by using Alexa488 concanavalin
A (2.5 μg/mL; Thermo Fisher Scientific, Schwerte, Germany) and nuclei were counterstained with
4’,6-diamidino-2-phenyl-indole (DAPI) solution (Merck, Darmstadt, Germany). Finally, slides were
mounted with Vectashield mounting medium (Biozol, Eching, Germany) and images were obtained
using an AxioImager Z1 microscope and Axiovision 4.6 software (Carl Zeiss, Jena, Germany).
The in vitro cytotoxicity in HepG2 cells was determined using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. Cells were seeded (50,000 cells/well) in 96-well plates.
At 24 h pre-incubation, the media were replaced with 100 μL of fresh Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 10% FBS and sorafenib-loaded nanoparticles. Three different sorafenib
concentrations (6.25 μg/mL, 12.5 μg/mL, and 25 μg/mL) were used, while the control samples contained
the same amounts of free sorafenib in DMSO solution. After 24 h of incubation, a volume of 10 μL
per well of MTT solution (5 mg MTT/mL) was added, followed by further incubation for 2 h. The
supernatant was removed, and 0.2 mL MTT lysis solution was added into each well. The absorbance
of cell suspension was determined at 595 nm using a spectrophotometer (EnVision 2104 Multilabel
Reader, Perkin Elmer, Waltham, MA, USA). The percentage of viable cells was calculated by comparing
the absorbance of treated cells against the untreated cells (negative control). The DMSO solution and
the blank nanoparticle suspensions served as positive controls. The data are presented as mean and
standard deviation with five replicates.
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2.17. Statistics
All data are expressed as the mean value ± standard deviation (SD), which were calculated and
plotted using Microsoft Excel (Microsoft, Redmond, WA, USA) and SigmaPlot 11.0 (Systat Software
GmbH, Erkrath, Germany), respectively. All nanoparticle formulations were produced as three batches
(n = 3).
3. Results and Discussion
In recent years, a variety of preparation methods have been evaluated for the synthesis of
nanocarrier devices. The current study produced advanced theranostic drug carriers and compared
the impact of manufacturing technology and surface modification on their physicochemical properties
and in vitro features.
Initially, a particle size between 100 and 300 nm [17], a zeta potential of more than −15 mV [18,19],
and a high drug load and particle yield were identified as key criteria for formulation development.
Due to the enhanced permeability and retention (EPR) effect, these nanoparticles may be capable
of targeting tumor tissues [17]. While smaller nanoparticles can be rapidly excreted by the kidneys,
larger colloids with a size of more than 300 nm are quickly recognized by the macrophages of the
reticuloendothelial system [11]. Among other aspects, the encapsulation efficiency and particle size
play an important role in nanocarrier delivery. Selecting biodegradable polymers of the Resomer®
type, three different techniques for the encapsulation of sorafenib were compared (Figure 1).
Figure 1. Scheme of the nanoparticle preparations with the preparation technique, materials used, and
surface functionalization (from the left to the right). Each preparation technique was evaluated with
the presented materials. Surface coating was undertaken for preparations manufactured by single
emulsion technique only.
3.1. Manufacture of Sorafenib-Loaded Core Particles Using Nanoprecipitation Technique
The manufacture of sorafenib-loaded nanoparticles by nanoprecipitation using Triton X-100 or
Pluronic® F127 stabilizers in aqueous solution resulted in a pronounced aggregation for all three
polymers. Similar observations have been made at the medium scale, suggesting poor ‘scalability’
during the later stages of production [8]. Changing the stabilizer to polysorbate 80, similar aggregation
occurred with Resomer® RG 502H and Resomer® RG 752H, respectively.
The use of Resomer® RGP d5055 (and polysorbate 80) resulted in nanoparticles within the
desirable size range (153 ± 14 nm, Figure 2, upper micrographs). However, the PDI of more than
0.27, an encapsulation efficiency below 20%, and a particle yield between 20 and 40% were the major
disadvantages of this formulation design. A lower density of the particle system due to the hydrophilic
side chains of the polymer is the most likely explanation.
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Figure 2. Scanning/transmission electron micrographs of nanoparticles comprising sorafenib in
a Resomer® RG 752H (upper left) or Resomer® RGP d5055 (upper right) matrix prepared by
nanoprecipitation, in a Resomer® RG 752H (middle left) and Resomer®, RGP d5055 (middle right)
matrix prepared by single emulsion–solvent evaporation technique using polyvinyl alcohol (PVA) as a
stabilizer, or in a Resomer® RG 752H-HAS (lower left) and Resomer®, RGP d5055-HSA (lower right)
matrix by double emulsion–solvent evaporation technique using PVA as a stabilizer.
In comparison, the nanoprecipitation technique using PVA in combination with Resomer® RG
502H or Resomer® RGP d5055 led to particle systems broadly distributed in size, as indicated by
elevated polydispersity indices ranging between 0.27 and 0.46. This was also confirmed by the
intensity distributions, exhibiting a second and third fraction of larger particles in the micrometer
range (Figure 3). The zeta potential of sorafenib-loaded Resomer® RG 502H or Resomer® RGP
d5055 nanocomposites by nanoprecipitation and PVA emulsifier was found to be 13.2 ± 0.7 mV and
12.1 ± 1.2 mV, which also explains the poor stability resulting in a pronounced aggregation. Under
similar conditions, crystallization of the drug accompanied by an increased PDI between 0.21 and
0.35 was reported by Lin et al. [18]. When applying the nanoprecipitation technique, a particle size
in the desired range (196 ± 10 nm) as well as a reduced PDI of 0.21 ± 0.03, was achieved when using
a polymer concentration of 10 mg·mL−1 of Resomer® RG 752H and 1 mg·mL−1 of sorafenib in the
acetone phase.
Considering the difficulties in nanoparticle preparation when using the nanoprecipitation method,
later efforts were focused on nanoparticle manufacture by single and double emulsion techniques.
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Figure 3. Size distribution by intensity of nanocomposites containing sorafenib in Resomer® RG 502H
(green line) and Resomer® RGP d5055 (red line) matrix nanoparticles prepared by nanoprecipitation,
using PVA as an emulsifier.
3.2. Manufacture of Sorafenib-Loaded Core Particles by Single Emulsion Technique
For the preparation of nanoparticles utilizing the single emulsion method, the hydrophilic phase
was composed of a 1% or 2% (w/v) aqueous solution of PVA in purified water (Table 1). A polymer
concentration of 10 mg·mL−1, an initial drug amount of 10% (m/m), and a water-to-dichloromethane
(DCM) ratio of 4:1 led to acceptable properties for each of the three polymers (Table 1). The morphology
of the nanoparticles was tested by scanning/transmission electron microscopy. They were of spherical
shape and within the expected size range (Figure 4).















PVA (% w/v) 1 1 1 2 2 2
Mean size by intensity (nm) 235 ± 2.0 227.7 ± 3.3 228.3 ± 8.0 231.4 ± 15.6 231.3 ± 30.1 243.4 ± 40.4
PDI 0.14 ± 0.04 0.18 ± 0.01 0.12 ± 0.02 0.15 ± 0.06 0.19 ± 0.04 0.15 ± 0.14
Encapsulation efficiency (%) 70.4 ± 3.5 76.2 ± 2.1 76.7 ± 2.6 78.8 ± 4.4 76.6 ± 2.7 75.2 ± 6.7
Drug loading (%) 9.0 ± 0.5 10.2 ± 0.3 10.0 ± 0.4 12.0 ± 0.2 11.2 ± 0.1 8.9 ± 0.4
Zeta potential (mV) −21.3 ± 2.4 −22.4 ± 2.4 −19.7 ± 1.1 −19.8 ± 3.3 −22.2 ± 1.8 −19.5 ± 1.6
Figure 4. Size distribution by intensity of sorafenib-containing nanoparticles prepared from Resomer®
RG 502H (black line) and Resomer® RG 752H (red line) polylactic-co-glycolic acid (PLGA) polymers as
well as Resomer® RGP d5055 (green line) by single emulsion method.
With an encapsulation efficiency ranging between 70.4 and 78.8% (Table 1) and a monomodal
size distribution (Figure 4), the emulsion method was superior compared to the nanoprecipitation
technique. The drug loading (8.9–12.0% m/m) almost reached the initial drug ratio (10% m/m) (Table 1).
Further increase of the drug amount from 10% (m/m) to 20% (m/m) resulted in elevated PDI values due
to the formation of larger aggregates.
The best outcomes were achieved by using Resomer® RG 752H or Resomer® RGP d5055 as
matrices (Figure 2, middle micrographs). Resomer® RG 752H resulted in a particle yield of 73.7%,
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an encapsulation efficiency of 76.6%, and a drug load of 11.2% (Figure 5). For Resomer® RGP d5055,
similar promising results were achieved. A particle yield of 76.1%, an encapsulation efficiency of 75.2%,
and a drug load of 8.9% were obtained using a 2% m/v emulsifier concentration. These nanocomposites
were selected for further surface modification and cellular uptake and cytotoxicity studies (Figure 5).
The zeta potential indicated high colloidal stability, which was also confirmed during further processing.
It is likely that the surface charge resulted from the high number of carboxyl groups present in the
PLGA polymers. However, there were no major differences between the zeta potential values of the
employed polymers even when the nanocarriers were manufactured from the PEGylated derivative.
This indicates that PEGylation did not significantly reduce the number of the carboxyl groups. These
nanoparticle preparations were further processed and evaluated for their release behavior.
Figure 5. Selected formulations for surface modification and further tests.
3.3. Co-Encapsulation of HSA Using Double Emulsion Method or Surface Modification
To covalently bind the Gd-DTPA complex to the particle surface, amino groups were introduced
into the polymeric matrices. In a first approach, HSA was co-encapsulated into the nanoparticles
using the double emulsion–solvent evaporation method. Although there was no significant difference
between the diameters of nanoparticles manufactured from Resomer RG 752H (mean diameter 210.6
nm, PDI 0.113) and Resomer®, RGP d5055 polymers (mean particle diameter 210.3 nm, PDI 0.099),
incorporation of the protein resulted in smaller particle sizes than the single emulsion method.
The detected size range was confirmed by electron microscopy (Figure 2, lower micrographs). All
nanocomposites were of spherical shape (Figure 3). The particle yield was much lower compared to the
methods described earlier. A particle yield of 50.4 ± 1.0% for Resomer® RG 752H and 49.0 ± 5.3% for
Resomer® RGP d5055 was achieved. A similar amount of HSA was incorporated into both polymers
(Resomer® RG 752H 10.6 ± 1.1%, Resomer® RGP d5055, 9.4 ± 1.2%). The formation of smaller particles
with reduced density could be responsible for the decreased particle yield.
However, the incorporation method resulted in a high protein loading and an increased number
of functional groups available for the EDC reaction. In comparison, an amount of 1.0 ± 0.3% HSA for
Resomer® RG 752H and 1.9 ± 0.5% HSA for Resomer® RGP d5055 was bound to the particles using
the surface coating technique.
3.4. Surface Modification with Gadolinium
The Gd-DTPA complex was conjugated to the amino groups of the HSA molecules after
incorporation or covalent binding of the protein to Resomer® RG 752H and Resomer® RGP d5055
nanoparticles, respectively. As expected, the modification of nanocomposites with Gd-DTPA was
limited by the availability of functional groups on the particle surface.
The nanoparticles modified on their surface with HSA were characterized by poor protein binding,
with an amount of approximately 1.5 mg gadolinium per g Resomer® RG 752H, and 1.4 mg gadolinium
per g Resomer® RGP d5055. Nanoparticles comprising HSA as part of their matrix structure exhibited
a much higher binding of 2.3 mg gadolinium per g Resomer® RG 752H and 3.2 mg gadolinium per g
Resomer® RGP d5055.
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Nevertheless, further increase of the gadolinium content was achieved using a method described
previously [20] with some modification. The binding of PEI to the surface resulted in a significant
increase of the gadolinium content, with 15.7 mg gadolinium per g Resomer® RG 752H and 10.7 mg
gadolinium per g Resomer® RGP d5055.
3.5. Evaluation of Contrast Signal Using In Vitro MRI
The MRI properties of theranostic nanocarriers were investigated in vitro. Magnevist® aqueous
solutions were used as a reference. There was a linear correlation (R2 = 0.9724) between the MRI
signal and the gadolinium content in the range between 0.02 and 0.3 mg·mL−1 (with MRI intensities of
470–670 at 0.02 mg·mL−1, and 1520–1750 at 0.3 mg·mL−1). For nanoparticles exhibiting the highest
content of gadolinium, the theoretical particle concentration (calculated from a maximum injectable
particle concentration of 10 mg·mL−1 and the gadolinium load) fell into this calibration range. The
signal intensities measured for the T1-weighed MRI were in good accordance with the inductively
coupled plasma optical emission spectroscopy (ICP-OES). Earlier studies reported a loading of 4.7 to
8.5 mg gadolinium per g HSA nanoparticles after covalent binding of DTPA. This amount was found
to be considerably high for in vivo MRI studies [5].
3.6. Storage Stability of Theranostic Nanocomposite Formulations
To freeze dry Resomer® RG 752H and Resomer® RGP d5055 nanoparticles manufactured by
the single emulsion method, a concentration of 3% (w/v) of the lyoprotectors sucrose, trehalose, and
mannitol has been previously applied [21]. The sorafenib-loaded nanoparticles with a drug load
of approximately 10% were freeze dried in the presence of 3% (w/v) of trehalose or mannitol. The
nanospheres remained stable over the time of storage. An increase in the PDI values was observed
for formulations freeze-dried with mannitol. On this basis, trehalose at a concentration of 3% was
identified to be the optimal lyoprotector for the developed particle system (Figure 6).
Figure 6. Size distribution by intensity of Resomer® RGP d5055 nanoparticles after preparation (red
line), and following reconstitution after freeze-drying in the presence of 3% of trehalose (blue line) and
3% of mannitol (yellow line).
3.7. Evaluation of In Vitro Drug Release of Sorafenib from Theranostic Nanocomposites
For nanoparticles comprising polymers from the Resomer® family, a biphasic release pattern has
been previously reported [22]. Preliminary investigations indicated a less pronounced burst release
for Resomer® RG 752H compared to Resomer® RG 502H. After the initial release phase, a sustained
release behavior was observed.
Consequently, the drug release of sorafenib-loaded Resomer®RGP d5055 and Resomer® RG
752H particles was investigated over a time period of 12 days in human blood plasma. Both of
the nanocomposites were prepared under optimized conditions, that is, using the single emulsion
method with an encapsulating polymer concentration of 10 mg·mL−1, an initial drug amount of
10% (m/m), a water-to-DCM ratio of 4:1, and 2% (w/v) of PVA. The initial burst release was higher
with nanoparticles manufactured from Resomer® RG 752H polymer (18.2 ± 2.9%) compared to
Resomer®RGP d5055 copolymer, from which 8.8 ± 2.1% of the drug was released during the first hour.
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Afterwards, a continuous release was observed for both composites (Figure 7). Surprisingly, the release
from Resomer®RGP d5055 was substantially slower, reaching a plateau at 50.6 ± 9.2%. A specific
interaction of sorafenib with the hydrophilic side chain of the block copolymer could be responsible
for this behavior.
Figure 7. Sorafenib release from Resomer® RG 752H (green line) and Resomer® RGP d5055 -sorafenib
(PEG-PLGA-SFB) nanocomposites (blue line) in human blood plasma. Data are presented as mean ± SD
from three independent samples for each concentration.
3.8. Cellular Uptake and Cytotoxicity
For the cellular uptake and cytotoxicity studies, sorafenib-loaded Resomer®RGP d5055 and
Resomer® RG 752H nanocomposites were prepared by the single emulsion method at a polymer
concentration of 10 mg·mL−1, an initial drug amount of 10% (m/m), a water-to-DCM ratio of 4:1, and
2% (w/v) of PVA. The internalization rates of sorafenib-containing nanoparticles in HepG2 cells were
quantified by flow cytometry. Additionally, fluorescence microscopy was conducted to confirm the
localization of the particles inside the cells (Figure 8).
Figure 8. Cellular uptake of either Cy5-conjugated Resomer® 752H or Resomer® RGP d5055
nanoparticles (red). Membrane staining was performed by using Alexa488 concanavalin A (green).
Nuclei were stained with 4′,6-diamidino-2-phenylindole (DAPIblue).
As expected, the uptake of drug-loaded nanoparticles prepared by using the PEGylated polymer
was significantly lower (3.9 ± 3.3%, Figure 9B) than for Resomer® RG 752H nanoparticles (49.9 ± 4.9%,
Figure 9C). The biocompatibility of nanomedicines is an important feature with regards to clinical
success and commercialization.
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Figure 9. Flow cytometry diagrams of untreated cell control (A), sorafenib-loaded Resomer®RGP
d5055 (B), and Resomer® RG 752H nanocomposites (C).
The cytotoxicity of the unloaded and the drug-loaded nanoparticles was investigated in HepG2
cells. Solutions of the drug in dimethyl sulfoxide (DMSO), the organic solvent alone, and an
untreated negative control were used as references. As shown in Figure 10, the viability of the cells
remained at approximately 90% when exposed to 100 μg/well of both types of unloaded nanoparticles
(50,000 cells/well). The non-toxic features of Resomer® polymers have been verified previously [4].
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Figure 10. Viability of HepG2 cells treated with different concentrations of sorafenib (SFB) or Resomer®
RG 752H or Resomer® RGP d5055 nanoparticles, and that of untreated cells (negative control).
As expected, sorafenib exhibited a concentration-dependent cytotoxicity in the HepG2 cells.
Similar concentrations of sorafenib resulted in higher cytotoxicity for the free drug compared to the
particle formulations (Figure 10), which could have been due to the slow release of the drug from the
particle matrix.
4. Conclusions
Theranostic nanocomposites comprising PLGA or PEG-PLGA were loaded with the anti-tumor
drug sorafenib and modified on their surface with the contrast agent Gd-DTPA. The single emulsion
technique was found to be the most appropriate method for the effective preparation of monodisperse
nanocomposites. These nanospheres exhibited superior properties compared to the particle systems
described in the literature. Finally, the top-down manufacture combined with a modification of the
particle surface using PEI and Gd-DTPA resulted in a strong MRI signal, optimal stability features, and
a sustained release profile. On this basis, further investigations will focus on the in vivo performance
of these nanocarriers.
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Abstract: Nanotechnology is being increasingly utilised in medicine as diagnostics and for drug
delivery and targeting. The small size and high surface area of nanoparticles (NPs), desirable properties
that allow them to cross biological barriers, also offer potential for interaction with other cells and
blood constituents, presenting possible safety risks. While NPs investigated are predominantly based
on the biodegradable, biocompatible, and FDA approved poly-lactide-co-glycolide (PLGA) polymers,
pro-aggregatory and antiplatelet effects have been reported for certain NPs. The potential for toxicity
of PLGA based NPs remains to be examined. The aims of this study were to determine the impact of
size-selected PLGA-PEG (PLGA-polyethylene glycol) NPs on platelet activation and aggregation.
PLGA-PEG NPs of three average sizes of 112, 348, and 576 nm were formulated and their effect
at concentrations of 0.0–2.2 mg/mL on the activation and aggregation of washed human platelets
(WP) was examined. The results of this study show, for the first time, NPs of all sizes associated
with the surface of platelets, with >50% binding, leading to possible internalisation. The NP-platelet
interaction, however, did not lead to platelet aggregation nor inhibited aggregation of platelets
induced by thrombin. The outcome of this study is promising, suggesting that these NPs could be
potential carriers for targeted drug delivery to platelets.
Keywords: PLGA-PEG; nanoparticles; platelet; activation; aggregation; binding; uptake
1. Introduction
Biocompatible and biodegradable nanoparticles (NPs) continue to be extensively investigated for
the diagnosis, prevention, and therapy of various diseases, for cellular and molecular imaging, and for
tissue engineering applications [1–5]. NPs have been reported to target various therapeutic agents to
the central nervous system (CNS), tumour sites, and the vascular compartment [6–10]. The small size
and high surface area of NPs are desirable properties that allow them to cross biological barriers, but
also offer potential for interaction and interference with other cells and blood constituents, presenting
possible safety risks. While the NPs investigated are predominantly based on the biodegradable,
biocompatible and FDA approved poly-lactide-co-glycolide (PLGA) polymers, irrespective of their
intended destination, NPs introduced into the bloodstream will interact with endothelial cells as well as
blood constituents. It is therefore important to understand the bio-distribution of such NPs in human
blood and their interaction with various blood components such as platelets [6,11,12]. Previous studies
report that grafting a polyethylene glycol (PEG) chain to a PLGA polymer backbone significantly
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increases the circulation half-life of the modified copolymer, as it remains camouflaged from the
macrophage [13,14]. The longer duration of exposure to blood components can result in enhanced
interaction potential with blood cells, and in particular with platelets, maximising the possibility of
modulating platelet, activation, secretion, and aggregation [15,16].
NP physicochemical characteristics, such as size and net charge (zeta potential (ZP)) that are
reported to be key factors enhancing their efficacy, can substantially affect their bio-distribution [17,18].
Variations in NP characteristics may result in a diverse range of platelet reactivity but unfortunately, only
a few studies regarding the interaction of NPs with washed platelets (WPs) have been published [18–20].
We previously reported that biodegradable micro and NPs of PLGA, PLGA-PEG, and chitosan,
of median diameter (D50%) of 2–9 μm and 100–500 nm, and with various surface morphology did not
induce or inhibit platelet aggregation at particle concentrations of 0.1–500 μg/mL [20]. In contrast, silica
NPs of 10 nm, 50 nm, and 150 nm, were shown to cause platelet hyper-aggregability, promoting the
risk of thrombus deposition, while particles of 500 nm did not pose such a risk [21]. Mixed carbon NPs,
carbon nanotubes, single-walled nanotubes, and multi-walled nanotubes were reported to stimulate
platelet aggregation by the upregulation of GPIIb/IIIa receptors on platelets, inducing subsequent
vascular thrombosis [19]. In a separate study, the contribution of silver NPs to the effective inhibition
of integrin-mediated WPs responses, such as aggregation, secretion, and adhesion to immobilized
fibrinogen or collagen, was established [22].
The pro-aggregatory effects of some NPs and the antiplatelet effects of others raise questions
regarding the safety of biodegradable nanomaterials in terms of interference with the haemostatic
equilibrium [20,23]. To date, the potential interactions of PLGA-PEG NPs with blood elements remains
scant. In particular, the effect of their size on blood constituents, as well as any potential hazard
they may pose, have not been studied. Platelet activation is a precisely regulated event, critical for
maintaining normal blood flow. When designing drug-loaded NPs intended to be delivered to the
systemic circulation, a major consideration is to maintain platelets in an inactive state [22].
The aims of this study were to determine the impact of size-selected PLGA-PEG NPs on platelet
activation and aggregation. Coumarin-6-labelled PLGA-PEG NPs of three average sizes of 112, 348,
and 576 nm were formulated using the solvent dispersion technique [20]. The effect of NP size and NP
concentration of 0.01–2.2 mg/mL on the activation and aggregation profiles of washed platelets (WP)
were examined using platelet aggregation assays and flow cytometry. Confocal imaging was carried
out on NPs incubated with WP to characterise the interaction of NPs with platelets in the resting and
activated states.
2. Materials and Methods
2.1. Materials
Albumin, from human serum, Coumarin-6 (98%), Polysorbate 80 (Tween® 80), Dextrose, Sodium
Chloride (NaCl), Sodium bicarbonate (NaHCO3), Potassium Chloride (KCl), Sodium Citrate (Tribasic,
10 dehydrate (HOC(COONa)(CH2COONa)2, KH2PO4 (monobasic potassium phosphate anhydrate
or potassium dihydrogen phosphate), Calcium Chloride (CaCl2), Magnesium Chloride hexahydrate
MgCl2·6H2O, and HEPES (N-2-Hydroxyethylpiperazine-N’-2-Ethanesulfonic Acid) were purchased
from Sigma-Aldrich Dublin, Ireland. PLGA-PEG containing PEG at 10% w/w (poly-d, l-lactic-co-glycolic
acid-polyethylene glycol diblock copolymer 50:50 mPEG; 33 kDa with inherent viscosity: 0.05–0.15 dL/g,
Lakeshore Biomaterials™, was purchased from Evonik Industries AG, Essen, Germany. Deionised
water was used throughout the experiments.
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2.2. Methods
2.2.1. Preparation and Characterisation of PLGA-PEG NPs
PLGA-PEG NPs containing a fluorescent marker, coumarin-6, were prepared using the solvent
dispersion method [24]. Briefly, PLGA-PEG polymer was dissolved in acetone to form 10, 55,
and 100 mg/mL solutions, and coumarin-6 at 0.05% w/w of the polymer was dissolved in the PLGA-PEG
solutions. The polymer solutions were added dropwise to an external aqueous phase containing
Tween 80® at 2% w/v, under constant stirring. The NPs formed were recovered by centrifugation at
11,000 rpm for 20 min (Rotina 35 R centrifuge, Hettich Zentrifugen, Tuttilingen, Germany). NPs were
washed with deionised water, centrifuged, and the pellet resuspended in deionised water and stored at
4 ◦C. The average particle size (PS), polydispersity index (PDI), and zeta potential (ZP) of the NPs were
determined by dynamic light scattering technique, using a Malvern Zetasizer Nano ZS 90 (Malvern
Instruments, Worcestershire, UK). After centrifugation, NPs were suspended in deionised water, placed
in disposable voltable zeta cells (DTS 1060) for analysis using DLS. Viscosity and refractive index of
the dispersants were taken into account. For each sample, the average of five measurements was
calculated. Results were expressed as an average of five measurements ± standard deviation.
The morphologies of NPs were examined under a MIRA3 variable pressure field emission scanning
electron microscope (Tescan, Brno-Kohoutovice, Czech Republic) at an accelerating voltage of 5.0 kV
and magnification of 30,000 to 50,000×. Samples of lyophilised NPs were applied onto aluminium
stubs using a double-sided conductive tape and were sputter-coated with gold.
2.2.2. Preparation of Washed Platelets
Venous whole blood was obtained from healthy human volunteers, free from aspirin and other
non-steroidal anti-inflammatory agents for the previous 7–10 days. Ethical approval was obtained
from the Research Ethics Committee, Royal College of Surgeons in Ireland. The blood obtained
was centrifuged at 180 g for 12 min, to separate the platelet-rich plasma (PRP) that was acidified to
pH 6.5 and the plasma pelleted by centrifugation at 720 g for 12 min. Washed platelets were then
adjusted to approximately 250 × 109 platelets per millilitre by resuspending the pellets in HEPES
(N-2-Hydroxyethylpiperazine-N’-2-Ethanesulfonic Acid) platelet buffer and leaving to stand for 30 min
before adding calcium chloride (CaCl2) at a final concentration of 1.8 mM.
2.2.3. Effect of Size and Concentration of NPs on Platelet Aggregation
Platelet aggregation was determined by measuring the change in the optical density of stirred
WPs in the absence or presence of 0–2.2 mg/mL PLGA-PEG NPs of different sizes, following the
addition of the platelet agonist, thrombin. Platelets were incubated with NPs for 4 min prior to the
addition of 0.1 U/mL thrombin. Platelet aggregation data was analysed using an eight channel platelet
aggregometer,-PAP-8 (Bio/Data Corporation, Horsham, PA, USA). Aggregation results were expressed
as final percent aggregation (% PA) at the end of the reaction time of 12 min. Data are presented as
mean of n = 4–6 ± SEM.
2.2.4. Effect of Size and Concentration of NPs on Platelet Activation
WPs (250 × 103/μL) were incubated with 20 μL phycoerythrin (PE)-labelled CD62P antibody and
mixed with PLGA-PEG NPs of different sizes, in the absence and presence of 0.1 U/mL thrombin
and incubated for 4 min at 37 ◦C. At predetermined time points, samples were fixed using 1% v/v
formaldehyde (FA) and platelet activation was measured by flow cytometry. Platelet activation was
determined by measuring the level and extent of CD62P antibody binding to the platelet surface,
expressed as percent positive cells (% PP) and mean fluorescence intensity (MFI). Platelets with and
without CD62P were used as negative controls and platelets activated with thrombin at 0.1 U/mL for
4 min was the positive control. Data are average of n > 3 ± SEM.
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2.2.5. Confocal Microscopy of the Effect of Incubation Time on The Interaction of PLGA-PEG NPs with
Washed Platelets
Coumarin-labelled NPs of 112, 348, and 576 nm, at 0.1 and 2.2 mg/mL, were incubated with
resting WPs in suspension for 1, 5, 15, and 30 min. At each time point, samples were fixed with 1%
formaldehyde, stained red with phalloidin-tetramethylrhodamine isothiocyanate (phalloidin-TRIT-C)
and examined using confocal laser scanning microscopy (CLSM), (Carl Zeiss, Jena, Germany). WPs
were also incubated with coumarin-labelled NPs of the three different sizes at 2.2 mg/mL for 1, 5,
and 30 min, and allowed to attach to fibrinogen-coated glass slides (20 μg/mL). At each time point,
samples were fixed with 1% formaldehyde, platelets stained red with phalloidin-TRITC, and examined
by CLSM.
2.2.6. Statistical Analysis
Statistical analysis was carried out using GraphPad Prism (version 7.00 for Windows; GraphPad
Software, San Diego, CA, USA). One-way ANOVA and unpaired student T tests and One-way ANOVA
followed by post hoc analysis using Dunnett’s Tests were used to determine differences between
samples and groups. A p value <0.05 was considered to be statistically significant.
3. Results
3.1. Characterisation of NPs Formulated
The size, PDI, and zeta potential of the NPs increased with increasing PLGA-PEG concentration
(Table 1, Figure 1A–C). A PDI value of 0.10 indicating a nearly monosized distribution was observed
for the smallest NPs of 112 nm, while larger PDI values of 0.54 and 0.70 were observed for the 348 and
576 nm NPs, respectively. A larger size distribution is expected for larger size NPs formulated using
high polymer concentration. In Figure 1A, the SEM shows the ~100 nm NPs with a distinct spherical
shapes and smooth surfaces, exhibiting a narrow range of sizes at different fields of view. In Figure 1B,
the NPs of ~350 nm display an interparticular bridging/fusion. In Figure 1C, the NPs of ~600 nm
average size maintain a spherical appearance similar to that for the NPs in Figure 1A. The SEMs did
not show any internal or external porosity at different magnifications. Calculations by Image J software
from SEM analysis showed an average size, which were lower than the sizes measured by DLS. SEM is
a tool primarily utilised to analyse particle morphology. The obtained PS determined by microscopy
techniques is usually considered the lower limits of PS [25].
Table 1. Physicochemical characteristics of nanoparticles (NPs) used in platelet aggregation studies.
n = 5 batches ± SD. PLGA = poly-lactide-co-glycolide; PEG = poly ethylene glycol.
PLGA-PEG
(mg/mL)
PS (nm) PDI ZP (mV)
10 111.55 ± 5.81 0.10 ± 0.02 −22.20 ± 5.71
55 348.00 ± 23.61 0.54 ± 0.04 −12.40 ± 6.30
100 576.19 ± 6.82 0.70 ± 0.06 −9.50 ± 14.56
PLGA: poly-lactide-co-glycolide; PEG: polyethylene glycol; PS: Particle size; PDI: Polydispersity Index, ZP:
Zeta Potential.
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Figure 1. Scanning Electron Microscope Images of PLGA-PEG NPs of average size of (A) 112nm,
(B) 348 nm, and (C) 576 nm. Each SEM image is representative of all images taken.
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The 112 nm NPs had a net negative charge of −22.20 ± 5.71 mV indicating good colloidal stability,
whereas the two larger NPs displayed moderately stable colloidal suspensions, with surface charges
from −12.40 ± 5.47 to −9.50 ± 14.56 mV. The ZP values of the larger NPs decreased to within the range
of −16 to −23 mV on dilution to the concentrations used in the study. The stability of the NPs generated
was examined over a 28-day time period to ensure stability over the time period of use. It was noted
that storage-induced instability was minimal, particularly in the batches formed of NPs of small and
mid-level particle diameters (~100 nm and ~350 nm), with no significant changes in particle properties.
Particle PS and PDI properties were retained over this period of 28 days and for the largest size NPs
over at least 14 days, revealing a reasonable stability profile for the NPs. This approach in examining
the stability of NPs over time is supported by recent studies by Fornaguera and Solans [26].
3.2. Effect of Size and Concentration of NPs on Platelet Aggregation
Incubation of NPs with platelets for 4 min in absence of the agonist, thrombin, showed that,
irrespective of the size and concentration of NPs (0.05–2.2 mg/mL), spontaneous platelet aggregation
was not detected (0 ± 0 % PA, p > 0.05, n = 3–6). The addition of 0.1 U/mL thrombin, at 4 min in
absence of NPs, resulted in a % PA of 72.25–74.75 (Table 2). In presence of 112 nm NPs, no significant
difference in % PA was observed after 12 min incubation at all NP concentrations tested (Table 2).
Similarly, larger NPs of 348 and 576 nm showed no significant effect on the % PA over the 12 min
incubation at the lower NP concentrations of 0.01–1.0 mg/mL and 0.01–1.5 mg/mL for the 348 and
576 nm NPs, respectively (Table 2). At the higher NP concentrations of 1.5 and 2.2 mg/mL, the % PA
was significantly lower at 28.40 ± 3.47 and 27 ± 3.10, respectively, when incubated with 348 nm NPs
(p value < 0.001). Similarly, at the highest concentration of 2.2 mg/mL, NPs of 576 nm resulted in a
significantly reduced % PA of 49.00 ± 5.18 (p < 0.05) (Table 2).
Table 2. Effect of size and concentration of PLGA-PEG NPs on percent platelet aggregation (% PA).
Data are the average of n = 4–6 experiments ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with
0.1 U/mL thrombin (control), one-way ANOVA, and unpaired student t-test, at each time point.
PLGA-PEG NPs
(mg/mL)
% PA (112 nm) % PA (348 nm) % PA (576 nm)
0 (Control) 72.75 ± 1.89 74.75 ± 1.93 72.25 ± 0.62
0.05 72.00 ± 0.91 73.50 ± 1.88 75.00 ± 4.63
0.1 73.00 ± 1.23 76.20 ± 2.99 69.75 ± 8.22
0.25 69.00 ± 1.68 66.00 ± 5.11 74.00 ± 4.89
0.5 73.50 ± 0.96 70.25 ± 4.13 68.00 ± 4.97
1 72.75 ± 0.85 62.50 ± 3.59 71.25 ± 5.27
1.5 72.25 ± 1.55 28.40 ± 3.47*** 68.75 ± 2.10
2.2 71.00 ± 1.80 27.00 ± 3.10*** 49.00 ± 5.18*
Examination of the platelet aggregation time profile showed no delay in platelet aggregation for
the smallest NPs of 112 nm at any of the concentrations tested (Figure 2A). However, the reduced % PA
observed at the higher NP concentrations of 348 and 576 nm NPs was associated with a significant
delay in platelet aggregation at the earlier time points following addition of thrombin to the sample.
Platelet aggregation proceeded significantly more slowly for the 348 and 576 nm NPs at the higher NP
concentrations of 1.5 and 2.2 mg/mL (Figure 2B,C), respectively.
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Figure 2. Effect of PLGA-PEG NPs of (A) 112 nm, (B) 348 nm, and (C) 576 nm at 0.05, 1.5, and 2.2 mg/mL
on platelet aggregation profile for 4 min following the addition of thrombin. Data are the average of
n = 4–6 experiments ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with 0.1 U/mL thrombin
(control), one-way ANOVA, and unpaired student t-test, at each time point.
3.3. Effect of Size of NPs on Platelet Activation Profile
The percent positive platelets (% PP) and mean fluorescence intensity (MFI) associated with
resting WPs in the absence of NPs were not significantly different when incubated with or without
CD62P antibody (Figure 3A,B). On addition of the agonist, thrombin, the % PP and MFI significantly
increased as expected, indicating activation of platelets with secretion of CD62P, which binds to the
CD62P antibody (p < 0.0001 for % PP; p < 0.05 for MFI) (Figure 3A,B).
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Figure 3. Effect of size of PLGA-PEG NPs at 2.2 mg/mL on platelet activation measured by flow
cytometry (A) % positive platelets (% PP) (B) Mean fluorescence Intensity (MFI). Data are the average
of n = 3–5 experiments ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001 compared with washed platelets
(WPs) + Ab (control), one-way ANOVA followed by post hoc Dunnett’s test.
In the presence of PLGA-PEG NPs, a significant increase in % PP for the smallest sized NPs of
112 nm was observed over the 30 min incubation period. However, for the larger NPs of 348 and
576 nm, a significant increase in % PP was only observed at the incubation time of 30 min, (p < 0.05,
n = 3), (Figure 3A). No significant difference in MFI values for platelets incubated with the NPs was
observed over the 30 min except for the 348 nm NPs at 30 min incubation (Figure 3B).
3.4. Effect of size of NPs on Thrombin Activation of Washed Platelets
In absence of NPs, an increase in the percentage of CD6P-positive platelets (% PP) and in CD62P
binding level (MFI) were observed following the exposure of WPs to thrombin, as expected, confirming
activation of WPs in response to the agonist. The presence of NPs at any of the sizes tested did not result
in a significant change in the % PP or MFI following exposure of the WPs with thrombin. (Figure 4A,B).
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Figure 4. Effect of size of PLGA-PEG NPs at 2.2 mg/mL on thrombin activation of washed platelets
measured by flow cytometry (A) % positive platelets (% PP) (B) Mean fluorescence Intensity (MFI).
Data are the average of n = 3–5 experiments ± SEM. * p < 0.05, compared with WPs + Ab (control),
one-way ANOVA followed by post hoc Dunnett’s test.
3.5. Confocal Microscopy of the Effect of Incubation Time on the Interaction of NPs and Washed Platelets
A rapid interaction of NPs and WPs, within the first minute, was observed at all NP sizes tested
and at both the low (0.01 mg/L) and high (2.2 mg/mL) concentrations of NPs (Figure 5). The percent
of platelets bound to NPs of 112 nm was in the order of 44 ± 5.7% and 53.7 ± 7.1% at t = 1 min for
low and high concentrations, respectively. Increasing the incubation time or concentration of NPs
at any of the sizes tested, did not result in significant change in the percent of NPs-bound platelets.
The observed interaction between resting platelets and PLGA-PEG NPs of the three sizes tested did
not lead to any apparent morphological alteration of the shape of the platelets or development of
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pseudopods, indicating no effect on platelet activation. This observation was relevant to both low and
high concentrations of NPs tested.
Figure 5. Confocal microscopy images of WPs (red) in suspension incubated with coumarin-PLGA-PEG
NPs at 2.2 mg/mL) (A) 1 min, (B) 5 min, (C) 15 min, and (D) 30 min, at RT; Magnification 100×. Scale
bar represents 10 μm.
Confocal microscopy of platelets layered onto fibrinogen at 20 μg/mL showed the typically formed
filopodial projections and heterogeneity expected for adhered platelets. In the presence of NPs, of all
of the three sizes and over the incubation times tested, similar attachment of platelets to fibrinogen
with alteration in the shape of the platelets and development of extended filopodia projections were
observed. The majority of NPs, at all sizes tested, were observed to be bound to platelets (Figure 6).
This association of NPs to platelets was of the order of 53.7 ± 1.5% to 59 ± 14.1%, respectively, for 1
and 30 min incubation for 112 nm NPs, at 51 ± 6.1%, and 43 ± 11.3% for 1 and 30 min incubation
times, respectively, for the 348 nm NPs. For the 576 nm NP, NP binding was 35.3 ± 5.7% at 1 min and
increased to 52.7 ± 2.1% after 30 min incubation. The NP interaction with platelets was maintained
upon activation through to adhesion (Figure 6).
Figure 6. Confocal microscopy images of WPs (red) incubated with coumarin-PLGA-PEG NPs at
2.2 mg/mL and adhered to fibrinogen coated slides: (A) 1 min, (B) 5 min, and (C) 30 min. Magnification
100×. Scale bar represents 10 μm.
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4. Discussion
The average NP sizes formulated were 112, 348, and 576 nm and were significantly different
(p < 0.05). This ensured a reasonable comparison of the effects of size of NPs on how platelets may
respond when in the presence of NPs with varying sizes. Addition of thrombin at 0.1 U/mL to washed
human platelets produced a platelet aggregation of 72–74, which is similar to the percent platelet
aggregation of 74 ± 7.8 reported [27]. Incubation of PLGA-PEG NPs, of any size or concentration
tested, with WPs for 4 min did not cause any platelet aggregation. This is similar to the results reported
for 50 μM silver NPs incubated with WPs for 2 min at 37 ◦C [22]. In the current study, the 112 nm
NPs did not influence the thrombin-induced platelet aggregation profile. Similarly, the larger NPs
showed no significant effect on the thrombin-induced platelet aggregation profiles at the lower NP
concentrations of 0.01–1.0 mg/mL and 0.01–1.5 mg/mL for the 348 and 576 nm NPs, respectively.
Interestingly, a tendency of inhibiting or slowing platelet aggregation was observed for the 348 nm
and 576 nm PLGA-PEG NPs at their highest concentrations. This may be related to the presence of
NPs in the medium, acting as a physical barrier preventing platelet-platelet contact, hence delaying
and reducing platelet activation and aggregation. As the NPs have a negatively charged surface,
they may interact with the positively charged thrombin, lowering the free thrombin concentration in
the suspension medium, hence reducing the exposure of platelets to thrombin. The surface charge,
rather than size, was reported to be the key factor governing this subcategory of NPs’ interaction with
platelets [28]. Physiological or non-physiological agents can initiate various signalling pathways in
platelets. Platelet activation can also be induced by biomaterials interacting with the specific intrinsic
coagulation pathway, which leads to thrombin generation and ultimately platelet activation. However,
such mechanisms still remain unexplored [29].
The influence of size-selected NPs on the expression of CD62P on the surface of platelets was
analysed by flow cytometry. CD62P is a 140 kD glycoprotein stored in the secretory α-granules of the
platelets, mediating leukocyte rolling and platelet–leukocyte aggregation.
The percentage of positive platelets (% PP) for the antibody marker reflects the proportion of
activated cells in the total platelet population; this was used to quantify platelet activation in the
presence of the NPs. The incubation of the smallest NPs (~113 nm) with WPs resulted in a significant
increase in platelet activation, almost similar to the activation observed for thrombin-induced platelet
activation. Interestingly, no significant effect on platelet activation was observed in the presence of the
larger NPs of 348 nm and the 576 nm. Smaller sized NPs have a higher surface area per unit mass,
which result in enhanced interaction potential with platelets. Silica NPs at the smallest PS of 10 nm,
at a concentration of 200 μg/mL, were reported to increase CD62P abundance on the platelet surface,
while 50 nm-sized NPs did not show any influence [21]. Similarly, of the 10, 50, 113, and 150 nm-sized
NPs of silica exposed to platelets, the smallest NPs (10 nm) induced the upregulation of CD62P when
used at a low concentration of 10 μg/mL [15,21]. The tendency of 26 nm carboxylated-polystyrene
NPs to activate platelets was reported, while particles of larger sizes showed no influence on platelet
activation [30].
The presence of NPs of any of the three sizes tested did not influence the % PP or the CD62P
abundance on the surface of thrombin-activated platelets. This suggests the investigated NPs did not
limit the access of the PE-labelled marker to the WPs surface, irrespective of their sizes.
CLSM performed in this study showed a rapid physical interaction of NPs, of all three sizes
examined, with platelets in resting state. This interaction appeared to progress to possible NP uptake
by platelets over time. This NP-platelet interaction, however, did not lead to platelet aggregation
nor inhibit aggregation of platelets induced by the agonist, thrombin. In contrast, a previous study
regarding latex microspheres interaction with platelets suggested platelet activation to be a prerequisite
in order to interact with and internalise those inert microparticles (MPs) [31].
The interaction and binding of the investigated NPs to the surface of platelets as well as possible
internalisation of NPs into platelets is interesting. In view of their unique small sizes and their curvature,
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NPs have been shown to enter various human cells and organs, a desirable characteristic for drug
targeting [9,24,32].
In the present study, in the presence of PLGA-PEG NPs, variable morphologies of platelets from
dendritic spread to the fully spread shape were displayed when platelets were layered onto fibrinogen.
This indicates that the NPs did not affect platelet adhesion to fibrinogen. Similarly, silver NPs at
different concentrations were reported to have no impact on platelet spreading on fibrinogen [22].
5. Conclusions
The results of this study show that while the smallest NPs demonstrated a tendency to result
in platelet activation and the larger NPs, at the highest concentrations, to delay platelet aggregation,
the three sizes of PLGA-PEG NPs examined had little or no effect on platelet aggregation. The NPs
did not interfere with the activation status of platelets and did not inhibit platelet aggregation by
the agonist thrombin. Importantly, the rapid binding of the studied PLGA-PEG NPs to platelets
is promising, suggesting that these NPs could be potential carriers for targeted drug delivery to
platelets in certain disease states. The data presented here supports the use of such NPs as targeting
carriers of anti-platelet agents or thrombolytics. It is clear from this study that the question of whether
these NPs would be consumed by resting and/or activated platelets remains unanswered. Future
strategies may include a more sensitive analysis of the potential for these NPs, pre-loaded with
therapeutic drug-candidates, to be internalised by platelets. A number of imaging modalities may
be considered such as z stacking, the use of transmission electron microscopy (TEM), or using a
combination of high resolution confocal microscopy with flow cytometric analysis that has the potential
to provide a precise evaluation of whether NPs are internalised or adsorbed onto the platelets surface,
as described by Vranic et al. [33]. With respect to the effects of the interactions of PLGA-PEG NPs at
the studied sizes on normal platelet functions, the use of a more sensitive platelet aggregation assay,
such as flow-induced platelet aggregation in the presence of PLGA-PEG NPs, should be considered
in future studies. An example would include a flow-mimicking technique such as quartz crystal
microbalance with dissipation (QCM-D), which operates under similar flow conditions encountered in
microvasculature [34]. Further understanding of the interaction between platelets and NPs is required
to aid in the development of a safe platelet-targeted drug delivery system in the future.
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Abstract: Polymeric particles made up of biodegradable and biocompatible polymers such as
poly(lactic-co-glycolic acid) (PLGA) are promising tools for several biomedical applications including
drug delivery. Particular emphasis is placed on the size and surface functionality of these systems
as they are regarded as the main protagonists in dictating the particle behavior in vitro and in vivo.
Current methods of manufacturing polymeric drug carriers offer a wide range of achievable particle
sizes, however, they are unlikely to accurately control the size while maintaining the same production
method and particle uniformity, as well as final production yield. Microfluidics technology has
emerged as an efficient tool to manufacture particles in a highly controllable manner. Here, we
report on tuning the size of PLGA particles at diameters ranging from sub-micron to microns using a
single microfluidics device, and demonstrate how particle size influences the release characteristics,
cellular uptake and in vivo clearance of these particles. Highly controlled production of PLGA
particles with ~100 nm, ~200 nm, and >1000 nm diameter is achieved through modification of flow
and formulation parameters. Efficiency of particle uptake by dendritic cells and myeloid-derived
suppressor cells isolated from mice is strongly correlated with particle size and is most efficient for
~100 nm particles. Particles systemically administered to mice mainly accumulate in liver and ~100 nm
particles are cleared slower. Our study shows the direct relation between particle size varied through
microfluidics and the pharmacokinetics behavior of particles, which provides a further step towards
the establishment of a customizable production process to generate tailor-made nanomedicines.
Keywords: PLGA; drug delivery systems; microfluidics; nanoparticles; microparticles
1. Introduction
As evidenced by the dramatic increase in the number of studies and clinical applications over time,
polymeric particles play a crucial role in drug delivery, providing improved stability, targeted delivery,
and sustained release of loaded therapeutic agents without causing off-target toxicities in vivo [1–5].
Drug delivery particles based on poly(lactic-co-glycolic acid) (PLGA) are among the most commonly
studied vehicles due to excellent biocompatibility, tuneable degradation characteristics, and long
clinical history of PLGA [6–8]. The remarkable physicochemical properties and high versatility of
PLGA have proven to address several challenges in drug delivery. PLGA can be processed into almost
any size and shape [7] and can encapsulate molecules of virtually any size such as small drugs [9–13],
proteins [14–18], nucleic acids [19–23], and vaccines [24–29]. The colloidal features such as size and
surface functionality have a direct influence on the cellular uptake, biodistribution, and thus therapeutic
efficacy of the particles, dictating the in vivo fate of therapeutic cargo [30,31]. These colloidal features
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are particularly important in cancer immunotherapy as the efficacy of any given therapeutic agent
is highly dependent on its ability to reach either the tumor microenvironment (TME) or the lymph
nodes. The incomplete endothelial lining due to rapid angiogenesis at the tumor site results in the
formation of large and irregular pores (0.1–3 μm) [32], through which nanoparticles can escape from
the circulatory stream and accumulate at the TME via a so-called enhanced permeability and retention
(EPR) effect [32]. Toy et al. demonstrated that, within the size range of 60–130 nm, smaller particles
exhibited greater lateral drift towards the blood vessel walls, which is a prerequisite for interaction
with the tumor vascular bed and essential for escape into the TME [33]. Furthermore, both blood
clearance and uptake by the mononuclear phagocyte system (MPS) at the liver and spleen depend on
the size and composition of PLGA carrier systems. The slit size in the inter-endothelial cells of the
spleen is about 200 nm, which facilitates the leakage and circulation of smaller particles for longer
time periods [34] or enables their entry to the lymphatic system through direct drainage to the lymph
nodes [35]. On the other hand, larger particles, which are not eligible for intravenous administration
due to their excessive size, are more likely to be taken up by immune cells at the injection site, such as
in the case of subcutaneous or intramuscular pathways [36].
Surface functionality also influences drug pharmacokinetics in vivo. The use of polyethylene
glycol (PEG) has been shown to significantly increase circulation time in several studies [36–38]. When
attached to nanoparticles’ surface (a process so-called PEGylation), the hydrophilicity of PEG chains
recruits specific proteins from plasma, that cloak and limit the interactions of particles with MPS
cells, hence prolonging blood circulation (‘stealth effect’) [39,40]. The decrease in the aggregation,
opsonization, and phagocytosis of particles entails the extension of their circulation time. Morikawa et al.
reported additional benefits of PEGylation such as reduced particle size and improved encapsulation
efficiency for curcumin-loaded nanoparticles [41].
In addition to particle size and surface functionality that have a large influence on the therapeutic
efficacy in vivo, particle uniformity in terms of size and encapsulated cargo is also an important aspect
particularly for the clinical translation of polymeric drug delivery formulations [42,43]. The uniformity
of particles depends largely on the utilized manufacturing approach. The conventional production
techniques based on emulsion solvent diffusion, emulsion solvent evaporation, and nanoprecipitation
are suitable for the production of sub-micron and micron-size PLGA particles [7,8]; however, these
methods lack the precision and full control over the particle size and uniformity particularly for larger
scale processes [8]. In recent years, microfluidics technology has emerged as an effective tool to produce
particles in a highly controllable manner [44,45]. Major advantages of microfluidics-based particle
manufacturing include the requirement of low sample volumes, high surface area, and reduced system
footprint [46]. This technology allows for rapid fluid mixing at the nanoliter scale and production of
PLGA particles with highly specific sizes as well as surface functionalities only by altering specific
parameters such as concentration of the starting materials or fluid flow rates through micron-size
channels [41,47–52]. Additionally, traditional small-scale laboratory synthesis techniques suffer from
batch-to-batch variations while microfluidics technology provides a precise size control, a high degree of
particle uniformity, and reproducibility. Furthermore, formulations can be scaled up by increasing the
quantities of fluids pumped through the system or by parallelizing multiple microfluidic mixers [53].
In this study, we report on the use of microfluidics technology as a platform for the production
of PEGylated PLGA particles. We explored the feasibility to generate different sizes of particles with
low polydispersity index (PDI) by varying process and formulation parameters such as total flow rate
and flow rate ratio of organic and aqueous phases as well as surfactant and polymer concentration.
We tuned the particle size at sub-micron (~100 nm and ~200 nm) and micrometer (>1000 nm) length
scales, which represent biologically-relevant cut-off values that influence the particle biodistribution
and clearance in vivo. A fluorescent dye was used as a model drug to assess encapsulation efficiency,
release profile, and uptake by mouse-derived immune cells. Clearance of systemically administered,
fluorescently labeled particles was also studied on a mouse model through in vivo imaging.
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2. Experimental
2.1. Materials
PLGA (Resomer RG 502H), with a 50:50 ratio of lactic acid:glycolic acid and Mw 7000–17,000 Da was
obtained from Evonik Nutrition and Care GmbH (Darmstadt, Germany). PEG-PLGA copolymer (PEG
Mn 5000, PLGA Mn 7000), polyvinyl alcohol (PVA, 9000–10,000 Mw, 80%, hydrolyzed) and cholesteryl
BODIPY™ FL C12 were obtained from Thermo Fisher Scientific (Waltham, MA, USA). Near-infrared
emitting fluorescent dye VivoTag-S 750 was purchased from Perkin Elmer Inc. (Waltham, MA, USA)
and acetonitrile (ACN, 99.95%) was from VWR International (Radnor, PA, USA). Ultrapure Milli-Q®
water (18.2 MΩ.cm) was used where necessary (Merck KGaA, Darmstadt, Germany). Roswell Park
Memorial Institute (RPMI) 1640 medium, Anti-Anti (AA), and ß-mercaptoethanol were obtained from
Gibco (Thermo Fisher Scientific, Waltham, MA, USA). Granulocyte-macrophage colony-stimulating
factor (GM-CSF) was obtained from Peprotech Inc. (Rocky Hill, NJ, USA). X-Vivo medium and
ultraglutamine were from Lonza Group (Basel, Switzerland). Fetal bovine serum (FBS) was purchased
from Hyclone Laboratories Inc. (GE Healthcare, Chicago, IL, USA).
2.2. Equipment
The microfluidics system was set up by connecting syringe pumps (Harvard PHD-2000 infusion
70–200) to a Y-junction mixer with staggered herringbone ridges (NanoAssemblr™, Precision
Nanosystems Inc., Vancouver, Canada) through 0.8 mm polytetrafluoroethylene (PFTE) tubing (ID
0.8 mm, OD 1.58 mm) obtained from Sigma-Aldrich (St. Louis, MO, USA). A detailed characterization
of the mixing geometry was reported in [44]. Two 20 mL NORM-JECT Luer Lock syringes were
connected to 0.8 mm diameter needles (Braun Sterican 0.8 × 120 mm), which were inserted in the
fittings connected to the inlets of the mixing cartridge. A PFTE tubing connected to the chip outlet was
used for sample collection.
2.3. Preparation of PLGA Particles
Prior to particle production, the pipes and the mixing chip were primed first with the solvents
(ACN for the organic phase inlet and MilliQ for the aqueous phase inlet) and then with the appropriate
phases for 1 min at organic: aqueous flow rates of 2:2. After the priming step, pumps were operated
at the desired flow rates. The product obtained within the first 2 min was discarded. The collected
particles were left stirring overnight (350 rpm) at room temperature for organic solvent evaporation.
A schematic representation of the process is shown in Scheme 1.
Scheme 1. Schematic illustration of the particle generation process via nanoprecipitation method
using a Y-junction mixing cartridge. PLGA: poly(lactic-co-glycolic acid); ACN: acetonitrile; PVA:
polyvinyl alcohol.
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The particle size was tuned via varying the flow rates of organic and aqueous phases as well as
PLGA and PVA concentrations. Upon determination of the optimized parameters for each target size,
PEGylated PLGA particles encapsulating fluorescent dyes emitting either at visible or near-infrared
regions were prepared by the following methods:
>1000 nm particles: the organic phase (5 mL ACN) contained 233.1 mg PLGA, 99.9 mg PEG-PLGA,
and 50 μL of 1 mg/mL fluorescent dye in ethanol. A 3% PVA solution was used as the aqueous phase.
Particles were produced at 6:2 organic:aqueous flow rates in triplicate.
~200 nm particles: the organic phase (5 mL ACN) contained 116.6 mg PLGA, 50 mg PEG-PLGA,
and 50 μL of 1 mg/mL fluorescent dye in ethanol. A 1% PVA solution was used as the aqueous phase.
Particles were produced at 2:6 organic:aqueous flow rates in triplicate.
~100 nm particles: the organic phase (8 mL ACN) contained 93.5 mg PLGA, 40 mg PEG-PLGA,
and 80 μL of 1 mg/mL fluorescent dye in ethanol. A 1% PVA solution was used as the aqueous phase.
Particles were produced at 4:6 organic:aqueous flow rates in triplicate.
After evaporation of the organic solvent, particles were washed three times with MilliQ water by
centrifugation at 15,000 rpm for 35 min (for >1000 nm and ~200 nm particles) and by spin filtration
using a 100,000 kDa MW cut-off centrifugal filter device (Millipore, Merck KGaA, Darmstadt, Germany)
for ~100 nm particles. Particles were then lyophilized.
2.4. Colloidal Characterization of PLGA Particles
In total, 1.25 mg of lyophilized particles were dispersed in 1 mL of MilliQ water to determine the
size distribution and polydispersity index (PDI) with dynamic light scattering using a Nanotrac Flex
(Microtrac GmbH, Krefeld, Germany). Zeta potential measurements were obtained with a Zetasizer
Nano ZS (Malvern Instruments, Malvern, United Kingdom). Prior to measurements, particles were
suspended in a 50 mM NaCl solution. The average of three measurements were used to report the size,
PDI, and Zeta potential for each sample.
Atomic force microscopy (AFM) images of particles were obtained with a Catalyst BioScope
(Bruker, Billerica, MA, USA) coupled to a confocal microscope (TCS SP5II, Leica Mycrosystems, Wetzlar,
Germany). Then, 50 μL of 10 mg/mL particle suspension was dried on clean glass substrates and
particles were imaged in peak-force tapping mode using a silicon nitride cantilever with a nominal
spring constant of 40 N/m (Bruker). AFM images were analyzed using NanoScope analysis software
(Bruker, Billerica, MA, USA).
2.5. Determination of Encapsulation Efficiency
Dye loading was quantified by construction of a calibration curve using a BODIPY-C12 standard.
A series of dye concentrations (in 0–0.25 mg/mL range) were prepared in a solvent composed of equal
parts of ACN and MilliQ and fluorescence intensities were measured for each standard. The fit function
applied to the linear portion of the curve was used for the calculation of the dye content of particles.
The encapsulation efficiency was determined by comparing the total amount of dye in the lyophilized
particles to the initial amount of dye supplied for the collected volume.
2.6. In Situ Release Profile
PLGA particles containing BODIPY-C12 were suspended in PBS in 5 mg/mL concentrations and
were dialyzed at 37 ◦C for 14 days using dialysis tubes with a 1000 Da molecular weight cut-off
membrane (GE Healthcare, Chicago, IL, USA). At different incubation times, the dialysis medium
was collected for fluorescence measurements using an LS 55 Perkin Elmer fluorescence spectrometer
(Waltham, MA, USA). Samples were excited at 488 nm and emission was recorded between 500 nm
and 700 nm. After each measurement the dialysis medium was refreshed. Samples were studied
in triplicate.
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3. In Vitro Cellular Uptake Experiments
3.1. Generation of Bone Marrow-Derived Dendritic Cells (BMDCs)
Dendritic cells were generated from mouse bone marrow cells by culturing them in full RPMI
medium containing 5 mL 200 mM l-glutamine (Gibco, Thermo Fisher Scientific, Waltham, MA, USA),
5 mL 100× antibiotics and antimycotics (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), 10% fetal
bovine serum (Gibco, Thermo Fisher Scientific, Waltham, MA, USA), and 500 μL β-mercapto ethanol
(Sigma-Aldrich, St. Louis, MO, USA). Then, 5.0 × 106 cells in 13 mL of full medium were cultured
in the presence of 20 ng/mL GM-CSF for 7 days. At day 3, 4 mL of complete medium containing
37.9 ng/mL GM-CSF was added. At day 6, 1 mL complete medium containing 158 ng/mL GM-CSF was
added. Cells were used for uptake experiments at day 7.
3.2. Isolation of Myeloid-Derived Suppressor Cells (mMDSCs) and Polymorphonuclear Myeloid-Derived
Suppressor Cells (pmnMDSCs)
Gr-1dimLy-6G− monocytic and Gr-1highLy-6G+ polymorphonuclear myeloid-derived suppressor
cells (mMDSCs and pmnMDSCs, respectively) were isolated from the spleen of tumor-bearing mice
using an isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according to manufacturer’s
instructions. Briefly, the spleen was isolated under sterile conditions and meshed through a 100 μm cell
strainer with a syringe plunger. The cell suspension was spun at 400× g for 5 min and resuspended in
3 mL of 1× ammonium chloride solution for the lysis of erythrocytes. After 5 min of incubation at room
temperature, cells were washed with 10 mL of PBS. The cells were incubated with an Anti-Ly-6G-Biotin
antibody and Anti-Biotin MicroBeads and were subsequently applied to a magnetic-activated cell
sorting (MACS) column, which retained the pmnMDSCs. The flow-through containing mMDSCs were
eluted as the positively selected cell fraction and were further purified by applying them to a second
MACS column.
3.3. In Vitro Cellular Uptake
Firstly, 1.0 × 105 cells in 500 μL complete medium were transferred to 5 mL propylene round
bottom tubes (Falcon). Then, 10 μg of particles containing BODIPY-C12 water were added to the round
bottom tubes and were incubated for time periods of 1, 2, 4, 6, 24, and 48 h. After incubation, particle
uptake was determined by flow cytometry analysis on a FACSVerse (BD Biosciences, Franklin Lakes,
NJ, United Sates).
4. In Vivo Clearance Studies
All animal experiments were performed according to guidelines of Radboud University’s Animal
Experiment Committee and Central Authority for Scientific Procedures on Animals (project number
2015-019TIL, date September 2015) in accordance with the ethical standards described in the Declaration
of Helsinki. Wild-type BALB/cAnNCrl mice, aged 8–12 weeks, were obtained from Charles River,
Germany and maintained under specific pathogen-free conditions at the Central Animal Laboratory
(Nijmegen, The Netherlands). Drinking water and food were provided ad libitum. Mice were warmed
either in a heating chamber or under a heating lamp and 1 mg PLGA nanoparticles (~200 nm and
~100 nm) containing VivoTag-S 750 were injected in 200 μL of phosphate-buffered saline (PBS) solution
through a lateral tail vein using a 1 mL syringe with a 29 G needle. Then, 0.5, 3, 24, and 48 h after
injections mice were shaved and imaged in an IVIS Lumina II (Perkin Elmer) system. Mice were
euthanized, and organs were dissected and imaged separately at 24 and 48 h. Imaging settings were:
exposure time: 3 s; binning: medium; F/stop: 2; fluorescent excitation filter: 745 nm; fluorescent
emission filter: 810–885 nm. A fluorescent background acquisition was performed for each time
point. Living Image software (Caliper Life Sciences, Hopkinton, MA, USA) was used for data analysis.
Background values were subtracted from measurement values. Same sized regions of interest (ROI)
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were applied on the liver and bladder for full body image analysis; also, same sized ROIs were applied
on the isolated liver and spleen. Total flux (photon/s) per each ROI was calculated.
Statistical Analysis
An unpaired t-test was used to determine the significance of the difference in mean particle size
values among the compared groups using GraphPad Prism.
5. Results and Discussion
5.1. Preparation of Particles
A commercially available NanoAssemblr™ cartridge [8] connected to syringe pumps was used for
the production of PLGA particles through nanoprecipitation. In this method, water-miscible organic
solvents are used to dissolve the polymer which, once at the interface between the aqueous medium and
the organic solvent, will start to precipitate. Polymer deposition caused by fast diffusion of the solvent
leads to instantaneous formation of a colloidal suspension and particle size is mainly determined by
solvent diffusion coefficient (D) and mixing time (tmix) [54]. The architecture of the mixing chip also
plays a crucial for the generation of a hydrodynamic-focusing flow pattern and the mixing process can
be controlled by varying the width of the focused stream (wf ) as shown in Equation (1) [44]:




By varying the ratio of flow rates, the lateral width of the focused stream can be adjusted very
accurately, which leads to a highly controlled diffusion and mixing at the interface of organic and
aqueous phases. In our study, acetonitrile (ACN) was used as the organic phase and particles were
formed upon rapid mixing of organic and aqueous phases in micron-size channels. Due to rapid
diffusion of ACN to the aqueous phase, PLGA precipitated and was subsequently stabilized by PVA
present in the aqueous phase. Process parameters such as (total) flow rates of organic and aqueous
phases as well as formulation parameters such as PLGA and PVA concentration were varied to tune
the size of PLGA particles from sub-micron to micron-scales.
The first process parameter tested was the flow rate of the organic phase composed of a 33.3 mg/mL
PLGA solution in ACN. The organic phase flow rate was varied between 2 mL/min and 6 mL/min while
the aqueous flow rate was kept constant at 2 mL/min for a 1% PVA solution (Figure 1A). A gradual
increase in the particle size from ~400 nm to ~900 nm was observed with an increase of the organic
phase flow rate. This was most likely caused by precipitation of higher amounts of PLGA at a given
mixing time when relatively higher organic phase flow rates were used. Similarly, increasing the
flow rate of the aqueous phase for a given set of formulation parameters and organic phase flow rate
resulted in the formation of smaller particles (Figure 1B). Doubling the aqueous flow rate to 4 mL/min
resulted in particles almost half the size of those produced at 2 mL/min. However, increasing the
aqueous flow rate up to 6 mL/min did not result in a notable change in particle size.
Another process parameter affecting particle size was the total flow rate of the organic and aqueous
phases. With the equal flow rate of organic and aqueous phases, the increase of the total flow rates from
4 mL/min (2:2) to 8 mL/min (4:4) led to a decrease in the particle size (Figure 1C). Increasing the total
flow rate further to 12 mL/min (6:6), however, did not cause any notable difference in the particle size
other than a slight improvement in the PDI. Increasing the total flow rates from 8 mL/min to 12 mL/min
apparently did not cause a relevant variation of solvent diffusion time to induce a significant change in
particle size. The total flow rate determines both the mixing time of the two phases in the cartridge
and the collection rate of the particles at the outlet channel. Faster mixing by increasing the total flow
rates has also been reported in other studies to result in the formation of smaller particles [41,47].
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Figure 1. (A–C) Influence of process and formulation parameters on the particle size. The variation of
particle size at different flow rates for 33.3 mg/mL PLGA as organic phase and 1% PVA as aqueous
phase. (D) The influence of PLGA concentration on the particle size (organic:aqueous flow rate of 4:4
mL/min, 3% PVA as aqueous phase). Bars: intensity-averaged particle size; green dots: polydispersity
index (PDI). QO: flow rate of organic phase, QA: flow rate of aqueous phase. Significant: *: p < 0.05;
**: p < 0.005; ***: p < 0.001; ****: p < 0.0001. Non-significant (n.s.): p > 0.05.
Overall, particles in the sub-micron size range were obtained by varying only the flow parameters.
Furthermore, we varied the PLGA and PVA concentrations in order to increase the particle size to
micron scale. A representative data set in Figure 1D shows that particle size almost tripled when the
PLGA concentration was doubled. In these batches, the PVA concentration was increased as well
and organic:aqueous flow rates were kept equal (4:4 mL/min). The larger particle size obtained with
a higher PLGA concentration can be explained by the higher viscosity of the organic phase, which
resulted in a slower diffusion of ACN to the aqueous phase and an increased mixing time [55].
For all tested conditions, a good batch-to-batch reproducibility and a small PDI (≤0.2) was
observed. After several trials, the optimal conditions and parameters were determined to obtain
particles of sizes >1000 nm, ~200 nm, and ~100 nm. These parameters were then used to prepare
particles with a surface functionalized with polyethylene glycol (PEG) and encapsulating a fluorescent
dye (Table 1).
Table 1. Optimized formulation and process parameters to obtain PLGA particles with indicated size.
PEG: polyethylene glycol.
Parameters >1000 nm ~200 nm ~100 nm
PLGA (mg/mL) 66.6 33.3 16.7
PLGA:PEG-PLGA ratio 70:30 70:30 70:30
PVA (w/v%) 3% 1% 1%
Flow rates (mL/min) (QO:QA) 6:2 2:6 4:6
Fluorescent dye (v/v%) 1% 1% 1%
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For fluorescent labeling, two different fluorescent dyes with visible (BODIPY™ FL C12, green,
510 nm) and near-infrared (VivoTag-S 750, red, 750 nm) emission wavelengths were used. BODIPYs
are low-polarity dyes with stable fluorescence emission properties [56] and are commonly used in
fluorescence detection and photodynamic therapy applications [57]. VivoTag-S 750 is a near-infrared
emitting (NIR) fluorochrome extensively used for in vivo imaging applications [58,59]. PLGA particles
labeled with the green fluorescent dye were used for in situ release and in vitro uptake experiments,
whereas those labeled with the red dye were used for in vivo imaging studies.
5.2. Colloidal Characterization
A detailed colloidal and functional characterization of PEGylated PLGA particles encapsulating
BODIPY-C12 is shown in Figure 2. Both atomic force microscopy (AFM) images (Figure 2A–C) and
dynamic light scattering (DLS) measurements (Figure 2D) revealed the formation of monodisperse
particles (PDI ≤0.2) within the desired size range (i.e.; >1000 nm, ~200 nm, ~100 nm) also upon
PEGylation and fluorescent dye encapsulation. It should be noted that although PDI values smaller
than 0.3 are considered acceptable for drug delivery applications, more specific standards and guidelines
have yet to be established by regulatory authorities.
Figure 2. Atomic force microscopy height images of (A) >1000 nm, (B), ~200 nm, and (C) ~100 nm
PLGA particles. The scale bars display the Z-range and the scan sizes are shown on the x-axis. (D) Size
distribution and (E) ζ potential values of PLGA particles measured using dynamic light scattering. (F)
Release profile of BODIPY-C12 from >1000 nm, ~200 nm, and ~100 nm particles. Data obtained for
>1000 nm, ~200 nm, and ~100 nm particles are represented in orange, blue, and red, respectively.
The micron-sized particles showed an average size of 1690 nm (±60 nm), while the sub-micron
particles were 250 nm (±48 nm) and 106 nm (±5 nm) in diameter. For ease of reporting, we will continue
referring to them as >1000 nm, ~200 nm, and ~100 nm particles. Slightly negative ζ potential values
that spanned a range between −5 mV and −15 mV were observed for all particle types (Figure 2E).
While the variation of ζ potential was negligible among sub-micron particles (i.e., ~200 nm, ~100 nm),
the micron-size particles displayed the most negative value. PLGA nanoparticles stabilized with PVA
have also been reported to bear a slightly negative ζ potential (−5 mV) [60] due to the presence of
residual PVA on the particle surface, which affects the number of carboxylic acid end groups [61].
The hydrophobic acetate moieties in partially hydrolyzed PVA can lead to its entrapment within the
PLGA matrix on the particle surface, thereby masking the surface charges to almost neutral ζ potential
values [62]. Therefore, the more negative ζ potential obtained for micron-size particles can be related
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to differences in the PVA content and the flow rate of the aqueous phase for micron-size particles
compared to sub-micron particles, as well as higher PLGA content. Apparently, these variations in
formulation and process parameters influence not only the particle size but also the particles’ surface
properties, which collectively determine the pharmacokinetic properties, cellular uptake, and particle
biodistribution [63].
Encapsulation efficiency of BODIPY-C12 was determined using fluorescence spectroscopy by
comparing the initial amount of dye supplied during particle production and the total amount of
dye detected in the entire yield. The efficiency of dye encapsulation was significantly higher for
smaller particles with the highest efficiency at 44% for ~100 nm particles, which decreased gradually
to 21% and 13% for ~200 nm and >1000 nm particles, respectively. It should be noted that each
particle type was produced using different formulation and process parameters, which equally play a
role in determining the encapsulation efficiency [64]. An efficient encapsulation requires the rapid
precipitation of polymer with the fluorescent dye to restrict the dye within the polymer matrix and
prevent its diffusion to the aqueous phase. The micron-size particles with the lowest encapsulation
efficiency were prepared using the highest polymer concentration and the highest organic:aqueous
phase flow rate ratios. The high viscosity of the organic phase as well as the relatively low fraction
of the aqueous phase probably resulted in a slower polymer precipitation, and therefore a lower
encapsulation efficiency for micron-size particles.
The functional characterization of particles was achieved by monitoring the dye release. For
this study, particles dispersed in PBS were dialyzed at 37 ◦C for a period of 14 days. At certain time
points, fluorescence intensities of the dialysis media were measured using fluorescence spectroscopy.
The dialysis medium was replaced with a fresh medium after each measurement. Each formulation
type showed a distinct release profile that was strongly correlated with the particle size. After an initial
burst, the release was steady for all particles (Figure 2F). The magnitude of burst release was higher for
~100 nm particles (approx. 30%), which was found as ~15% and ~10% for ~200 nm and >1000 nm
particles, respectively.
In addition to the highest burst release, the overall release rate was also faster for ~100 nm particles
such that they already released the majority of their content (~80%) by day 4. On the other hand, the
released content of ~200 nm and >1000 nm particles barely reached 50% and 20%, respectively, by
the end of the entire release period (two weeks). Indeed, several different release patterns such as
mono-, bi-, and tri-phasic release are reported for PLGA particles, which are mainly regulated by the
physicochemical properties of the cargo, PLGA type (molecular weight, lactide/glycolide ratio, etc.),
and particle morphology (size, porosity, etc.) [65]. Since the same cargo and polymer type were used
for the preparation of particles, the main reason for different release rates observed was the particle size.
Larger surface area/volume ratio of smaller particles facilitated the faster diffusion of dye molecules
located on or close to the surface. Such inverse relation between the release rate and particle size is in
good agreement with the general trends reported in other studies [66–68].
5.3. In Vitro Uptake Experiments
Particle size and surface functionality are among the key parameters that influence their interactions
with cells [69]. In this work, we used mouse-derived cells, namely bone marrow-derived dendritic
cells (BMDCs), CD103+ dendritic cells (CD103+), and myeloid-derived suppressor cells (MDSCs)
of monocytic (mMDSCs) and polymorphonuclear (pmnMDSCs) sub-types to study the uptake of
fluorescently labeled, PEGylated PLGA particles of varying sizes (Figure 3).
Particles incubated with BMDCs for different time periods were analyzed using flow cytometry
(Figure 3A). In our previous study we reported that, once taken up by the cells, the integrity of PLGA
particles is compromised before 72 h of incubation [70]. Hence, in the present work, we monitored
particle uptake up to 48 h in order to avoid possible variations in the mean fluorescence intensities
(MFIs) due to particle degradation at later time points. For ease of comparison, MFI data were
normalized to 1 for the values obtained at 48 h of incubation time. A clear correlation between the
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particle size and the trend in particle uptake was observed. For sub-micron particles (~100 nm and
~200 nm) a stable MFI was observed within the first 6 h, which increased at later time points (Figure 3A,
red and blue curves). On the other hand, micron-size particles (>1000 nm) showed a time-dependent
uptake behavior. For these particles, the intracellular MFI increased gradually within the first 6 h,
reaching a plateau until the end of the incubation period (Figure 3A, orange curve).
Figure 3. (A) Intracellular mean fluorescence intensity (MFI) values obtained for >1000 nm (orange),
~200 nm (blue), and ~100 nm (red) PLGA particles incubated with bone marrow-derived dendritic
cells (BMDCs) for different time periods, and (B) correlation between the particle size and intracellular
MFI after 2 h of incubation with CD103+ dendritic cells, (C) monocytic myeloid-derived suppressor
cells (MDSCs), and (D) polymorphonuclear MDSCs isolated from mouse. Data were obtained using
flow cytometry.
Overall, the uptake of sub-micron particles was more efficient compared to micron-size particles.
The MFI obtained at 1 h of incubation already corresponded to ~75% and ~50% of the total MFI for
100 nm particles (Figure 3A, red) and 200 nm particles (Figure 3A, blue), respectively. It should be noted
that each type of PLGA particles had different dye loading ratios. In this uptake study, equal amounts of
PLGA particles with different total fluorescence intensities were used. Although normalization of MFI
enabled a fair comparison of the particle uptake trend for different sizes, we further investigated the
particle uptake on other types of mouse-derived immune cells using particles with equal fluorescence
intensities instead of equal particle mass in order to compensate for the variations in dye encapsulation
(Figure 3B–D). Flow cytometry histograms of the data presented in Figure 3B–D are shown in Figure S1.
A clear correlation between the particle size and intracellular MFI was observed for the cells that
were either generated in vitro (Figure 3B) or were isolated from the spleen of tumor-bearing mice
(Figure 3C,D). After 2 h incubation period, the uptake of ~100 nm particles was ~1.5 fold higher than the
>1000 nm particles for CD103+ dendritic cells (Figure 3B) and mMDSCs (Figure 3C), and the difference
was even higher (almost three-fold) for pmnMDSCs (Figure 3D). Similar studies also reported the lower
uptake efficiencies of micron-size particles compared to sub-micron particles by dendritic cells [71],
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which could be due to different uptake mechanisms associated with different particle sizes. The uptake
of small particles (<100 nm) has been reported to be clathrin- and/or caveolin-mediated [72], whereas
micropinocytosis and phagocytosis are the main mechanisms via which sub-micron particles (~200 nm)
and micron-sized particles (>1000 nm) are taken up [73]. In addition to particle size, surface charge
is an important parameter that influences the efficiency of particle uptake by cells. Prior to their
internalization, particles need to attach on the cell surfaces that are decorated with negatively-charged
proteoglycans [63]. Consequently, the uptake of positively-charged particles can be more efficient
due to electrostatic interactions between the particles and cell surface. In our work, all particles had
negative ζ potential values, which was highest for >1000 nm particles. Therefore, the poorer uptake
efficiency observed for micron-size particles can be due to less-favorable surface charge in addition to
larger particle size.
All the cell types used in our work are important regulators of immune response. BMDCs
and CD103+ are antigen presenting cells that can prime T cells to induce antigen-specific immune
responses [74]. On the other hand, MDSCs play an important role in immune suppression in cancer as
well as in tumor angiogenesis, drug resistance, and promotion of tumor metastases [75], representing
an attractive potential therapeutic target, for things such as cancer immunotherapy. Among the studied
PLGA formulations, ~100 nm particles with almost neutral surface charge would be the most efficient
vehicle to deliver such things as antigens to dendritic cells (DCs) and immunomodulatory drugs to
MDSCs for cancer immunotherapy.
5.4. In Vivo Clearance of Particles
Rapid clearance of particles from the bloodstream through the mononuclear phagocyte system
(MPS) and reticuloendothelial system (RES) represents a major limitation to achieve preferential
accumulation of particles in the target organs [76]. Tuning the size and surface properties of particles
has proven useful in preventing their rapid removal from the bloodstream [77,78]. In order to evaluate
particle clearance in vivo, we administered PLGA particles labeled with a near-infrared (NIR)-emitting
dye (VivoTag-S 750) intravenously (i.v.) to mice. The acceptable particle size range for the i.v.
injections have been reported as 10–1000 nm to prevent possible accumulation of larger particles in
the lung capillaries [61,79,80]. Therefore, we used only sub-micron size particles for in vivo studies.
The colloidal properties of ~100 nm and ~200 nm particles encapsulating the NIR-emitting dye were
similar to those labeled with the green fluorescent dye (Figure S2). Whole-body and ex-vivo organ
imaging were performed at different time points up to 48 h after i.v. administration of sub-micron
PLGA particles (Figure 4).
Whole-body imaging revealed the presence of both particle types mainly in the liver and bladder
already after 30 min following the injection (Figure 4A). The liver signal decreased gradually at later
time points and was still above background levels at 48 h for both ~100 nm and ~200 nm particles.
The presence of a high fluorescence signal in the bladder at 0.5 h was an interesting observation, which
could be related to the excretion of free dye molecules that were burst-released. In fact, intact particles
cannot pass through the renal filtration barrier since it has an effective size cut-off of ~10 nm [81].
The higher percentage of burst release displayed by ~100 nm particles in situ aligned well with the
in vivo observations, in which the bladder signal resulting from the excretion of the free dye molecules
was relatively lower for ~200 nm particles. Overall, the bladder signal did not provide a reliable
measure of the systemic clearance of the particles due to the interference of the burst-released dye.
Thus, we monitored the clearance of particles from the liver as representative of their systemic clearance.
The influence of burst-released dye can be avoided via covalent attachment of the fluorescent dye.
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Figure 4. (A) Fluorescent whole-body images of mice obtained at different time points up to 48 h after
intravenous (i.v.) administration of ~200 nm and ~100 nm PLGA particles. The liver and bladder are
encircled. (B) Variations of liver fluorescence in whole-body images. The fluorescence intensities are
normalized at maximum values observed at 3 h after administration of ~100 nm (blue) and ~200 nm
(green) PLGA particles. (C) Variations of liver fluorescence intensities of ~100 nm (blue) and ~200 nm
(green) PLGA particles obtained on an isolated liver at 24 h and 48 h after particle administration. Data
obtained for untreated mice (negative control) are shown in black.
The variation of liver signal was monitored using the whole-body images obtained at different
time points (Figure 4B). For a better comparison, the values were normalized to maximum intensities
measured at 3 h. From this point on, the decay of liver signal was almost linear for ~100 nm particles
with a slope of −0.014 (R2 = 0.9926) (Figure 4B, blue curve), whereas the decay of ~200 nm particles
better suited an exponential function (Figure 4B, green curve). Since the number of fit points was
not sufficient for an accurate exponential fit, we used a linear fit for ~200 nm particles as well. These
particles displayed a relatively faster decay with a slope of −0.018 (R2 = 0.9537). Ex-vivo imaging
of an isolated liver also showed similar variations in signal intensities, such that ~200 nm particles
(Figure 4C, green curve) displayed a more pronounced decrease at 48 h compared to ~100 nm particles
(Figure 4C, blue curve). Faster clearance of larger particles was also shown in other studies. When
administered intravenously, particles larger than 200 nm activate human complement systems, are
rapidly eliminated from the bloodstream, and gather mainly in the liver and spleen where the rate of
accumulation is proportional to the size of the particles [30]. While particles with a diameter greater
than 200 nm were most likely cleared by Kupffer cells, smaller particles displayed a decreased rate
of clearance and an extended circulation time [82]. Of note, we did not observe a signal originating
from the spleen in whole-body imaging. However, ex-vivo imaging of isolated spleen at 24 h and
48 h revealed signal intensities that were only slightly above the background noise, indicating that the
spleen was not the preferential accumulation site for sub-micron PLGA particles (Figure S3). Indeed, it
has been reported that the spleen receives barely 15% of the i.v. injected dose of nanomedicines [83].
Therefore, additional surface modification strategies may be needed for applications that require
splenic accumulation of PLGA particles.
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6. Conclusions
In this study, we demonstrated how PLGA particle size can be specifically tuned using a
microfluidics system via modulating the formulation and process parameters. Through a series of
optimization experiments, we obtained PEGylated PLGA particles in different sizes, which remarkably
affected the characteristics of the particles in vitro and in vivo confirming the direct relation between
the size and the pharmacokinetics behavior. This work can be considered as a further step towards the
establishment of a production process that is able to generate tailor-made medicine for each individual
clinical need.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4923/11/11/590/s1,
Figure S1: Flow cytometry histograms of the uptake experiments, Figure S2: Size distribution and ζ potential values
of PLGA particles encapsulating a NIR-emitting fluorescent dye, Figure S3: Variations of spleen fluorescence
intensities of ~100 nm and ~200 nm PLGA particles obtained on an isolated spleen at 24 h and 48 h after
particle administration.
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Abstract: Biodegradable poly lactic-co-glycolic acid (PLGA) microspheres can be used to encapsulate
peptide and offer a promising drug-delivery vehicle. In this work we investigate the dynamics of PLGA
microspheres prepared by freeze-drying and the molecular mobility at lower temperatures leading to the
glass transition temperature, using temperature-variable terahertz time-domain spectroscopy (THz-TDS)
experiments. The microspheres were prepared using a water-in-oil-in-water (w/o/w) double-emulsion
technique and subsequent freeze-drying of the samples. Physical characterization was performed by
morphology measurements, scanning electron microscopy, and helium pycnometry. The THz-TDS data
show two distinct transition processes, Tg,β in the range of 167–219 K, associated with local motions, and
Tg,α in the range of 313–330 K, associated with large-scale motions, for the microspheres examined. Using
Fourier transform infrared spectroscopy measurements in the mid-infrared, we were able to characterize
the interactions between a model polypeptide, exendin-4, and the PLGA copolymer. We observe a
relationship between the experimentally determined Tg,β and Tg,α and free volume and microsphere
dynamics.
Keywords: terahertz spectroscopy; microspheres; drug delivery; formulation development; PLGA;
molecular mobility
1. Introduction
Microencapsulation has been explored as a promising method for controlled drug release [1–3].
Polymeric microspheres, for example polylactic acid (PLA), polyglycolic acid (PGA), and
poly(D,L-lactide-co-glycolide) (PLGA), can be used as effective drug-delivery systems protecting the
encapsulated active agent and controlling the release rate over periods of hours to months [1,4].
By applying the correct methodology when preparing microspheres, challenges such as targeting the drug
to a specific organ or tissue, and precisely controlling the rate of drug delivery to the target site can be
addressed [3,5]. The technique of double water-in-oil-in-water (w/o/w) emulsion has been widely used
for the encapsulation of hydrophilic drugs as this preparative method minimizes the loss of drug activity
via contact with the organic solvent [2,6]. The basis of this methodology is to emulsify an aqueous solution
of the active compound in an organic solution of the hydrophobic coating polymer. Then, this primary
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water-in-oil (w/o) emulsion is dispersed in a second aqueous phase, forming a double water-in-oil-in-water
(w/o/w) emulsion. The solid microsphere is produced as the organic solvent evaporates. In this
work, we prepared blank PLGA microspheres (containing no polypeptide) of grades 50:50 and 75:25
(lactide:glycolide ratio), using the double-emulsion process [2]. Using the same technique, we also loaded
PLGA microspheres at low and high concentrations of exendin-4, a glucose-dependent insulinotropic
polypeptide used to treat type 2 diabetes [7]. The microspheres were subsequently freeze-dried. The
objective of this work was to prepare, characterize, and understand the structural dynamics of these
peptide-loaded biodegradable polymeric microspheres.
To optimize the formulation of microspheres and achieve release delivery of the active drug,
the microsphere product ought to be stable [1,8]. When determining the chemical stability of a material,
molecular mobility is a key factor [9–11] and it has been shown that an increase in molecular mobility
is directly linked to an increase in the chemical degradation of a material [9] and aggregation [12],
and therefore its storage stability. Thus, it is critical to understand the molecular mobility behavior of
a material and its dependence on temperature, and specifically the molecular dynamics of the material
leading up to the glass transition temperature (Tg). It has been shown that a great number of polymers
and amorphous pharmaceuticals, ranging from small molecules to high molecular weight peptides and
proteins exhibit at least two dielectric relaxation processes: the primary, or α-relaxation process and a
secondary, or β-relaxation process [13–15]. The former can be observed at temperatures above Tg and can
be designated as Tg,α, and the latter occurs at temperatures below Tg and is associated with a secondary
glass transition process, which can be indicated as Tg,β [16–20].
In previous work we investigated these processes in neat PLGA 50:50 and 75:25 of low, medium,
and high molecular weights [21]. For all the copolymer PLGA film samples we observed three regions of
relaxation behavior with distinct Tg,β and Tg,α transition temperatures. We showed that with an increase in
temperature, the copolymer chains can transition through different conformational environments, each
constrained by its characteristic potential energy landscape, and that the movement of each PLGA chain
is restricted by adjacent entangled chains. At Tg,β, the system has sufficient thermal energy and free
volume to overcome the energy barrier arising from chain entanglement, allowing for local mobility to
occur. Furthermore, we show that there is a relationship between free volume and the value of Tg,β for the
different film samples.
Fourier transform infrared spectroscopy (FTIR) is a vibrational spectroscopy used to gain structural
information about a sample. The advantage of FTIR for structural analysis is it is a non-contact technique;
only a small quantity of sample is needed (∼1 mg mL−1); the sample can be probed in different physical
environments such as the solid state, liquid state, and when adsorbed to a surface; the sample preparation
is minimal and a spectrum can be obtained in a few minutes [22]. For systems with multiple components
such as polymer-peptide microspheres, FTIR can be used to identify the individual components, and
interactions between the components which shift the peaks [23].
Terahertz time-domain spectroscopy (THz-TDS) is a valuable technique which can be used to detect
Tg,α and Tg,β, associated with the α- and β-relaxation processes respectively [10,13]. It is a relatively
recent technique which is used to investigate the molecular dynamics of relaxation processes at high
frequencies [24]. The advantage of this technique is that it is a non-contact technique and can measure
molecular mobility of a material over a broad temperature range over the spectral region of 0.1–3 THz.
It can be used to investigate the microscopic mechanisms of amorphous polymer dynamics [25]. In
the present study we examine samples of freeze-dried microspheres with different concentrations of
encapsulated peptide. We investigate the molecular mobility of these materials and the behavior and
trends these exhibit with respect to the temperature dependence using THz-TDS (Table 1), and physically
characterise each system (Tables 2 and 3). Thus, the purpose of this work is to provide a comprehensive
understanding of the relationship between the relaxation dynamics and the molecular structure of PLGA
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microspheres with varying exendin-4 peptide concentrations, and to rationalize the behavior of these
materials in relation to Tgα and Tgβ.
2. Materials and Methods
2.1. Materials
Throughout this work the polymers are referred to by their monomer ratio used. For instance,
PLGA 75:25 refers to a copolymer consisting of 75% lactic acid and 25% glycolic acid. Medium-MW
(10–25 kDa) PLGA 50:50 and medium-MW (20–30 kDa) PLGA 75:25 were purchased from Evonik
Corporation (Birmingham, AL, USA). The exendin-4 peptide (4.2 kDa) was provided by MedImmune
Limited (Cambridge, UK).
2.2. Microencapsulation Preparation
Blank PLGA microspheres, were prepared for the study using the water-in-oil-in-water (w/o/w)
double-emulsion technique: First, 500 mL of a 0.5% aqueous solution of polyvinyl alcohol (PVA) (87–90%
hydrolyzed, 13–23 kDa) were emulsified in 12.5 mL of a 5% (w/v) PLGA dissolved in dichloromethane
(DCM) by stirring at a rotation speed of 22,000 pm for 15 seconds using an ultra-turrax (IKA T-25,
Cole-Parmer, UK). This primary emulsion was emulsified into 0.5% aqueous PVA under stirring at 200 rpm,
on a stirring plate, for four hours. For the preparation of the peptide-loaded microspheres, exendin-4 was
dissolved into a buffer consisting of citrate, citric acid, (pH = 4.5) and 0.5% PVA. This peptide solution
was emulsified into the 5% (w/v) dispersion of PLGA in DCM, which was stirred at rotation speed 22,000
rpm for 15 s using the ultra-turrax. Different peptide loadings in the microspheres were achieved using
exendin-4 concentrations of 1% and 10% (w/v) in the primary emulsion. Conceptually, the same method
was followed to produce the peptide-loaded microspheres, as that for the blank microspheres. The solid
microspheres were collected by centrifugation at 4000 g for 5 min, then washed with distilled water three
times, and centrifuged once more at 4000 g for 5 min. Finally, after removal of the aqueous supernatant
and dispersion, the microspheres were freeze-dried using a lyophilizer. First, prior to lyophilization,
an annealing step was performed by cooling the shelf to 233 K for 240 min, raising the temperatures
to 257 K for 200 min and cooling the shelf again to 233 K for 170 min at a pressure of 160 mbar. Then,
lyophilization was performed using the following steps: primary drying was completed at 233 K for 30
min, and then the temperature was raised to 253 K for 2440 min at a pressure of 133 mbar; secondary
drying was subsequently performed at 313 K for 960 min, also at 133 mbar. The vials were closed under a
pressure of 266 mbar at 298 K using a rubber stopper, removed from the lyophilizer, and crimped with
aluminum seals. Vials were stored at 278 K until all further measurements and analysis. Exendin-4
concentration was determined using the bicinchoninic acid protein assay kit (MilliporeSigma, St. Louis,
MO, USA) following the manufacturer’s instructions, with bovine serum albumin (BSA) used as the
standard. The exendin-4 concentration was analyzed using a UV-VIS spectrophotometer (Agilent Cary 60
UV-Vis spectrophotometer, Agilent Technologies, Santa Clara, CA, USA) at 562 nm. The encapsulation
efficiency-based BCA assay values were determined on the liquid samples. Based on these measurements,
we calculated the encapsulation efficiency to be: 15.4% and 37.12% for the low and high peptide loading
of PLGA 75:25 microspheres, respectively, and 42.88% and 36.72% for the low and high peptide loading
of PLGA 50:50 microspheres, respectively. This experiment was completed one time. The water content
for each lyophilized microsphere was determined using Karl Fischer (Mettler Toledo, Leicester, UK)
coulometric titration.
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2.3. Helium Pycnometry Measurement
The lyophilized microsphere samples were analyzed as powders using a helium pycnometer
(Micromeritics Accupyc II 1340, Norcross, GA, USA) to determine the density and specific volume
of the microparticles. Approximately 20 mg of each sample were placed in the instrument compartment
and measurements were performed with helium gas at 298 K at a pressure of 10 mbar. No pretreatment
conditions were required. The measurements were repeated for each sample five times. The average
volume of the five repeat measurements was used to determine the density of each material.
For comparison, polymer films of PLGA 50:50 and PLGA 75:25 were prepared using the vacuum
compression molding (VCM) tool (MeltPrep, Graz, Austria), and these were also analyzed using helium
pycnometry.
2.4. Morphology Measurement
The particle size and shape of the microsphere particles were characterized, for unlyophilized liquid
samples and for lyophilized powder samples, using a Morphologi G3 instrument (Malvern Panalytical
Ltd., Malvern, UK). Each unlyophilized liquid sample was dispersed in 1 mL of 5% aqueous PVA solution
to allow for spatial separation of the particles and reduction of agglomerates. The lyophilized powder
samples were prepared for measurement using a dry powder disperser. The instrument captured images
of the individual particles and the morphological properties for each particle were determined from the
images by image analysis using the Morphologi G3 software (Malvern Panalytical Ltd., Malvern, UK).
2.5. Scanning Electron Microscopy
The range of morphologies of the microspheres were characterized using scanning electron
microscopy (SEM), with a Zeiss CrossBeam 540 instrument, equipped with a Gemini 2 column (Carl Zeiss
Microscopy GmbH, Jena, Germany). To qualitatively analyze the shape and surface of the samples, the
lyophilized microspheres were sputter coated with gold using an Emitech 550 (Emitech Ltd., Ashford,
UK). The samples were then examined under vacuum at an acceleration voltage of 1 kV, and imaged using
secondary electrons via an Everhart-Thornley detector (Carl Zeiss SMT GmbH, Oberkochen, Germany).
2.6. Differential Scanning Calorimetry (DSC)
A Q2000 Differential Scanning Calorimeter (TA Instruments, New Castle, DE, USA) was used to
determine the calorimetric glass transition temperature (Tg,DSC, defined by the onset temperature) for each
material. 2–3 mg of sample material were placed in hermetically sealed aluminum pans under a constant
flow of nitrogen atmosphere (flow rate of 50 mL min−1) and heated at a rate of 10 K min−1 to 358 K, and
subsequently cooled down to 293 K at 40 K min−1. Finally, the samples were heated from 293 K through Tg
to 358 K again at a rate of 10 K min−1. The temperature and heat flow of the instrument were calibrated
using indium (Tm = 430 K, ΔHfus = 29 J g−1).
2.7. Fourier Transform Infrared Spectroscopy
FTIR was used to examine the change in the secondary structure of the PLGA 75:25 microspheres at
278 K. For FTIR analysis, each microsphere material (300μg) was mixed with 100 mg potassium bromide
(KBr) using an agate mortar and pressed into 7 mm self-supporting disks using a load of 10 Tons. FTIR
spectra were acquired using a Cary 680 FTIR spectrometer (Agilent Technologies, Santa Clara, CA, USA)
with 60 scans and a resolution of 1 cm−1. At least four spectra were measured for each material. The
recorded spectra were normalized based on the total area under the curve [26].
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2.8. Terahertz Time-Domain Spectroscopy (THz-TDS)
2.8.1. Sample Preparation and Experimental Methodology
For each sample 70 mg were weighed in under atmospheric protection in a glove bag (AtmosBag,
Merck UK, Gillingham, Dorset, UK) which was purged with dry nitrogen gas (relative humidity < 1%)
to avoid moisture sorption from atmospheric water vapor during preparation. The lyophilized powder
samples were pressed into 13 mm diameter disks using a load of 1.5 tons. The tablets were between
300–650 μm in thickness each, and were placed between two z-cut quartz windows of 2.05 mm thickness.
This sandwich structure was sealed in the sample holder, and used immediately following preparation
for THz-TDS measurements.
The THz-TDS spectra were acquired using a commercial TeraPulse 4000 instrument across the spectral
range of 0.2–2.2 THz (TeraView, Cambridge, UK). The sample temperature (90–360 K) was controlled
using a continuous flow cryostat with liquid nitrogen as the cryogen (Janis ST-100, Wilmington, MA, USA)
as outlined previously [27]. The cryostat cold finger accommodated both the reference (two z-cut quartz
windows) as well as the sample (quartz/sample/quartz sandwich structure as described above). The
two z-cut quartz windows that were used for the reference (same thickness and diameter dimensions as
sample) were directly pressed to one another without any spacer in between the two windows to avoid
internal reflections in the time-domain signal. The cryostat cold finger was moved vertically using a
motorized linear stage to switch between sample and reference at each measurement temperature. For
each temperature, the sample and the reference were measured at the center position, with 1000 waveforms
co-averaged for each acquisition, resulting in a measurement time of approximately 1 min for each sample.
The temperature of the sample was measured using a silicon diode mounted to the copper cold finger
of the cryostat. The temperature controller used was a Lake Shore model 331 (Westerville, OH, USA).
For each series of measurements, a sample and a reference were loaded into the cryostat, the cryostat
chamber was evacuated to 10 mbar and the cold finger was cooled to a temperature of 90 K. The cryostat
was allowed to equilibrate for 10–15 min at 90 K and the first set of sample and reference measurements
was acquired. Subsequently the cold finger was heated using temperature intervals of 10 K (at a rate of
2 K min−1). At each desired temperature point the system was allowed to equilibrate for 3 min before a set
of sample and reference measurements were acquired.
2.8.2. Data Analysis
To calculate the absorption coefficient and the refractive index of the sample a modified method
for extracting the optical constants from terahertz measurements based on the concept introduced by
Duvillaret et al. was used [27,28]. The changes in dynamics of the polymer sample were analyzed by
investigating the change in the absorption coefficient at a frequency of 1 THz as a function of temperature
using the methodology introduced in [21].
3. Results
3.1. Differential Scanning Calorimetry Data
The calorimetric Tg,DSC was determined for each sample and the resulting values are listed in Table 1.
We observed no significant difference in Tg between samples. Additionally, we observed one Tg for each
material, indicating that no phase separation occurred for these samples.
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Table 1. Gradient, m, of the linear fit (y = mx + c) for the respective temperature regions as outlined in
Section 2.8.2 as well as the respective glass transition temperatures determined based on the terahertz
analysis and by DSC.
Material
Peptide Loading in Aqueous Phase Region 1 Region 2 Region 3 Tgβ Tgα Tg,DSC
(% m/v) (cm−1 K−1) (cm−1 K−1) (cm−1 K−1) (K) (K) (K)
PLGA 50:50 0 (blank) 0.0026 ± 0.0040 0.0237 ± 0.0010 0.070 ± 0.018 167 318 318
PLGA 50:50 1 (low) 0.0010 ± 0.0012 0.021 ± 0.00062 0.074 ± 0.0044 168 320 316
PLGA 50:50 10 (high) 0.014 ± 0.0013 0.023 ± 0.0012 0.095 ± 0.0052 219 330 317
PLGA 75:25 0 (blank) 0.0087 ± 0.0022 0.026 ± 0.00095 0.043 ± 0.0043 179 313 317
PLGA 75:25 1 (low) 0.0060 ± 0.0016 0.022 ± 0.0014 0.057 ± 0.0024 192 320 320
PLGA 75:25 10 (high) 0.0078 ± 0.0015 0.022 ± 0.0013 0.067 ± 0.0021 215 327 322
3.2. Morphology Measurement Analysis
For each material we report the number of particles counted and the circular equivalent (CE) diameter
D[n, 0.1], D[n, 0.5] and D[n, 0.9] percentiles. As shown from Table 2, preparing the microspheres using
an oil-in-water emulsification yields products with a relatively broad size distribution for both the blank
microspheres and the exendin-4 loaded microspheres before lyophilization. Following lyophilization, the
particle size distribution is significantly narrower than before. This could be due to the removal water
and moisture [5,9]. The Karl Fischer measurements we conducted revealed that the residual moisture for
each vial was less than 1%. Notably, upon lyophilization, as water molecules are removed peptides and
copolymers, for example, exendin-4, and PLGA microspheres, can form an extensive hydrogen bonding
network [11,29,30] leaving few sites for bonding with water molecules. Additionally, the system is exposed
to various stresses of temperature and pressure, and these could cause two or more adjacent pores to
merge, as common pore walls rupture, and adjacent particles can combine. Thus, the removal of water
in the drying step of lyophilization would affect the size distribution of the dry particles produced, and
we can obtain a more narrow particle size distribution compared to a sample in solution [31]. It is worth
noting that exendin-4 is inherently flexible and thus, chemical stability is of primary concern; however,
given that exendin-4 is a peptide, it lacks a defined protein domain with a characteristic architecture that
can undergo unfolding upon exposure to acute freezing and dehydration stresses of lyophilization [32,33].
Finally, when comparing the CE values of the lyophilized samples, the blank PLGA 50:50 samples have a
higher CE compared to the 50:50 loaded samples, while the blank 75:25 samples have a lower CE compared
to the 75:25 loaded samples. This can be explained by considering emulsion stability which dictates
microsphere size. For example, exendin-4 would change the emulsion stability through surfactant-like
activity, and the viscosity of the emulsion can increase with higher polymer concentration, polymer MW,
and hydrophobicity [34]. Specifically, as the polymer is more hydrophobic, as is the case for PLGA 75:25
due to its a higher lactide fraction, more energy would be required to generate smaller droplets; while for
PLGA 50:50 it is expected that smaller droplets could be generated with less energy input; however these
parameters were not optimized for and beyond the scope of this work [33,34].
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Table 2. Morphology data for unlyophilized samples and lyophilized samples. CE is the circular equivalent
diameter: the diameter of a circle with the same area as the 2D projection image of the particle.
Ratio Lyophilized
Peptide Loading in Aqueous Phase Particles Counted CE D[n, 0.1] CE D[n, 0.5] CE D[n, 0.9]
(% m/v) (Number) (μm) (μm) (μm)
50:50 No 0 3218 77 119 176
50:50 No 1 1108 45 76 110
50:50 No 10 1108 45 76 110
50:50 Yes 0 763 73 100 136
50:50 Yes 1 2321 75 116 159
50:50 Yes 10 3839 68 110 156
75:25 No 0 1909 55 106 167
75:25 No 1 2479 68 114 170
75:25 No 10 361 111 178 242
75:25 Yes 0 8465 63 112 163
75:25 Yes 1 903 94 154 197
75:25 Yes 10 1477 82 147 186
3.3. Helium Pycnometry Analysis
The pycnometry data shows that increasing exendin-4 loading increases the density of the material
(Table 3). Our helium pycnometry measurements agree with values reported in the literature [4].
Table 3. Helium pycnometry data for lyophilized microsphere samples and PLGA 50:50 and 75:25
copolymer films.
Material
Peptide Loading in Aqueous Phase Density
(% m/v) (g/cm3)
PLGA 50:50 Film 0 1.39
Microsphere PLGA 50:50 blank 0 0.97
Microsphere PLGA 50:50 1 1.66
Microsphere PLGA 50:50 10 2.09
PLGA 75:25 Film 0 1.36
Microsphere PLGA 75:25 blank 0 1.41
PLGA 75:25 1 1.56
PLGA 75:25 10 1.62
3.4. Scanning Electron Microscopy (SEM) Characterization
Using SEM, qualitative analysis of a representative set of images indicated that the microspheres
examined are predominantly spherical in shape and exhibit a smooth and porous surface (Figure 1,
see Supplementary Materials). The internal structure of fractured spheres revealed a porous interior. The
qualitative analysis of the data showed that for the blank PLGA microspheres, there is no significant
difference visually in the porosity of the blank 50:50 and 75:25 systems, respectively. In contrast, for
both the 50:50 and 75:25 systems, the microspheres with high loading of peptide appeared more porous
compared to the microspheres which contained a low loading of peptide. See Supplementary Materials for
SEM data for blank PLGA 50:50 and 75:25 microspheres, and low polypeptide loaded PLGA 50:50 and
75:25 microspheres.
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d) e) f)
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100 μm100 μm 20 μm
Figure 1. Representative SEM micrographs for low exendin-4 loaded PLGA 75:25 microspheres shown in
(a–c), and high exendin-4 loaded PLGA 75:25 microspheres shown in (d–f).
3.5. Fourier Transform Infrared Spectroscopy
FTIR was performed for the PLGA 75:25 microsphere samples (Figure 2). The absorbance of the peaks
at around 3300 cm−1 and 2950 cm−1 increased in intensity with an increase in polypeptide loading. The
peak at 3300 cm−1 originates from the -OH stretch in exendin-4, and the peak at 2950 cm−1 is assigned to
the C-H stretching modes in exendin-4 [26,35]. The amide I band at 1600–1700 cm−1 can be attributed to
the –C=O stretch, with contributions from the out-of-phase –CN stretch, –CCN deformation, and –NH
in-plane bend and is sensitive to the structure of the protein backbone. Additionally, there is an increase
in absorption in the amide I region around 1600–1700 cm−1, and a shift in the frequency of the mode for
the sample with a high polypeptide loading, which is indicative of changes in the hydrogen bonding
network [22]. Thus, the FTIR spectra confirm the increase in exendin-4 loading between the blank, low
and high polypeptide formulations, and, with this, a change in the hydrogen bonding network. Notably, it
was not possible to investigate an only exendin-4 control, as a stable product could not be freeze-dried.
Figure 2. FTIR spectra of blank microspheres (solid black line), low polypeptide loaded (solid red line) and
high polypeptide loaded (solid blue line) PLGA 75:25 microspheres. (a) shows the wavenumber range of
1300 − 1700 cm−1 and (b) shows the wavenumber range of 2500–4000 cm−1.
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3.6. Analysis of THz-TDS Data
The terahertz spectra of all the microspheres showed an increase in absorption with frequency
and temperature over the entire investigated range in line with previous measurements of amorphous
molecular solids (Figure 3). As expected for non-crystalline materials, no discrete spectral features were
present and the spectra were dominated by the monotonous increase with frequency that is characteristic
for the rising flank of the peak due to the vibrational density of states (VDOS) [24]. In contrast, the
refractive index subtly decreases with increasing frequency. To further investigate the relationship between
the increase of absorption coefficient and temperature we examined the temperature-dependent changes
in absorption losses at a frequency 1 THz in more detail. Given the lack of distinct spectral features we
chose the frequency of 1 THz. The rationale for this choice is based on the fact that the signal-to-noise
ratio of the measurement at this frequency is high and that we know from our previous work that at a
frequency of 1 THz the minimum in losses in the spectral response is exceeded for all samples studied and
hence the absorption is clearly dominated by the VDOS [27].





























Figure 3. Absorption coefficient spectra of high MW PLGA 75:25 in the temperature range of
100–350 K, with 10 K temperature increments between spectra. Solid black line indicates the maximum
absorption coefficient.
The changes in absorption at a frequency of 1 THz with temperature for the microsphere samples
of PLGA 50:50 and PLGA 75:25, are plotted in Figures 4 and 5 respectively. For all the materials the
absorption coefficient was found to increase in a linear fashion with increasing temperature and several
distinct temperature regions can be identified for each material. Tg,β was defined as the intersection point
of the two best-fit linear fits at low temperatures for all cases, and Tg,α was defined as the intersection point
of the two best-fit linear lines at high temperatures, as outlined in [21].
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Figure 4. Mean terahertz absorption coefficient as a function of temperature at 1 THz for PLGA 50:50
microspheres. Error bars represent the standard deviation for n samples. (a) blank (n = 3), (b) low (n = 4),
and (c) high peptide loading (n = 3). Lines show the different linear fits of the respective regions.
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Figure 5. Mean terahertz absorption coefficient as a function of temperature at 1 THz for PLGA 75:25
microspheres. Error bars represent the standard deviation for n samples (a) blank (n = 3), (b) low (n = 3),
and (c) high peptide loading (n = 3). Lines show the different linear fits for the different regions.
For all of the microsphere samples the change in absorption with temperature can be observed to
take place over three distinct regions and two transition temperatures, Tgβ and Tgα, as determined using
the methodology outlined above (see Figure 4 and 5 and Table 1). In this work we attempt to explain the
origin of the transition temperatures by proposing a physical picture of the change in the microsphere
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dynamics with temperature and relate this to the free volume approach, and to peptide and polymer
interactions. It is worth noting that the values of Tg,α, as determined from the THz-TDS experiments, are
in good agreement with our own calorimetric measurements, Tg,DSC, as well as the values reported in the
literature for these materials [36].
4. Discussion
4.1. Understanding Peptide and Copolymer Interactions
It has been shown that the α-relaxation process is associated with large-scale mobility, whereas the
secondary or β-relaxation process is thought to be associated with local mobility, or small-scale mobility [24,
37]. To date, there remains a discussion in the literature as to the origin and molecular mechanisms
associated with the α- and β-relaxation processes. One secondary relaxation, the Johari-Goldstein (JG)
β-relaxation, also referred to as the slow β-relaxation, is considered a universal feature of all amorphous
materials [38,39]. This process is observed at higher frequencies than the α-relaxation, and has been
associated predominantly with the intermolecular degrees of freedom of a material [16,38,40]. Notably,
recent experimental and theoretical work clearly highlights that the potential energy surface (PES) model
proposed by Goldstein almost half a century ago is the most intuitive and comprehensive model to
understand the molecular dynamics in amorphous systems and that intra- and intermolecular processes
are always fundamentally coupled by means of the PES [41,42]. Goldstein explained that as a liquid flows
it can move on the PES from one minimum to another minimum, and each minimum is associated with an
energy barrier, yet as the liquid moves the volume nor energy of the liquid changes. When the liquid is
cooled down to a glass, the liquid structure is trapped in a deep minimum, with some level of mobility
remaining as a distribution of relaxation times [42]. Thus, the work of Goldstein provides an intuitive
illustration that a liquid can exist in numerous transient structures and it is the potential energy barriers
which determine the molecular motions of the viscous liquid which forms a glass: a picture which can be
applied to bulk amorphous systems.
The different molecular motions of a copolymer chain can be tracked with changes in temperature.
At low temperatures, the copolymer chains are completely disordered and are densely packed, and
the motions of the copolymer are restricted. Upon heating to Tg,β, the activation energy and free
volume is sufficient for the copolymer to undergo local motion, giving rise to the β-relaxation
processes [40]. Previously, we have shown that the Tg,β is fundamentally linked to the onset of motions in
an organic molecule that results in changes of the dihedral angle of one or multiple bonds in the system.
Specifically, for PLGA, this could involve local motions of small segments of the copolymer backbone
and side chain groups [37,43]. With a further increase in temperature, the copolymer chains are more
loosely packed and the activation energy and free volume of the system increases further, allowing for
intermolecular large-scale copolymer motions to occur at the temperature indicated by Tg,α associated
with the α-relaxation process.
Exendin-4 is a polypeptide composed of 39 amino acids, and its structure is thought to resemble a
random coil chain [7,44]. The short-range local interactions of a polypeptide influence the conformational
preferences of its amino acid chain [45–47]. In general terms, it is well established that the partial double
bond character of a peptide bond gives rise to its planar structure, and free rotation is restricted about this
bond [47]. We hypothesize that with sufficient thermal energy and free volume present in the system, two
local motions could take place for exendin-4, which would give rise to the β-relaxation process: (1) local
side chain rotations, and (2) local rotation about two single bonds [45,48]. Given that the amino acids of the
exendin-4 polypeptide chain are linked by peptide bonds, rotational freedom arises from the single bonds
between an amino group and the α-carbon atom and the carbonyl group of the peptide backbone [47].
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However, the rotation of these bonds is limited by steric hindrance [47,48]. Based on the chemical
structure of the exendin-4 this polypeptide can act as a hydrogen bond acceptor via its carbonyl groups
(–C=O) or as a hydrogen bond donor via its amine group (–NH), and its hydroxyl groups (–OH) can act as
both the hydrogen bond donor or acceptor. The linear PLGA—[C3H4O2]x[C2H2O2]y—chains include the
methyl side groups of poly(lactic acid) (PLA) and oxygen atoms at every third position of the copolymer
backbone, and C=O bonds which introduce significant structural rigidity to the copolymer backbone.
Specifically, hydrogen bonds can form: (1) between the carbonyl groups of PLGA and the amine groups of
exendin-4, (2) between the amine groups of exendin-4 and the hydroxyl group of PLGA, and (3) between
the hydroxyl groups and the carbonyl groups of exendin-4 and PLGA. Additionally, van der Waals as well
as dipole-dipole interactions between the peptide groups and the hydroxyl groups can serve to stabilize
the system [49]. These strong interactions, the dynamics of which are infrared active, can reduce molecular
mobility and improve the physical stability of these systems [3,29,30]. Notably, it is conceivable that with
additional free volume and thermal energy input large-scale rotational motions of the backbone dihedral
angles in the polypeptide chain could occur, which could lead to large-scale changes in chain conformation,
contributing to the α-relaxation.
4.2. Tracking the Dynamics of Microspheres Using THz-TDS
We observe three regions with two distinct transition points, Tg,β and Tg,α for both the PLGA 50:50
and PLGA 75:25 microspheres (Figure 4). For the PLGA 50:50 formulation, the high exendin-4 loaded
microspheres have a significantly higher Tg,β = 219 K, than the blank and low polypeptide loaded
microspheres (Tg,β = 167 K, and Tg,β = 168 K, respectively). In the polymer dispersion, exendin-4 can
form hydrogen bonds with PLGA. Intuitively, an increase in exendin-4 loading would correspondingly
increase the hydrogen bonding interactions between the polypeptide and PLGA [48], reduce the molecular
mobility of the system, which would raise the value of Tg,β [9,50]. Indeed, we observe a significant
increase in Tg,β for the high polypeptide loaded microspheres, compared to the Tg,β value observed for
the blank and low polypeptide loaded microspheres. Notably, for the blank and low exendin-4 loaded
50:50 microspheres, the onset for local mobility occurs at approximately the same value of Tg,β. This
could suggest that the low polypeptide loaded microsphere behave similarly to the blank microspheres,
due to the limited interaction between peptide and polymer [46,51]. For the blank microspheres and low
exendin-4 loaded microspheres, the onset for local mobility occurs at approximately the same value of Tg,β,
(Tg,β = 167 K). For the high exendin-4 loaded microspheres, Tg,β increases significantly (Tg,β = 219 K). As
more polypeptide is added to the PLGA matrix it forms an extensive hydrogen bonding network, which
in turn reduces the configurational entropy of the system [44,45,51]. The resultant interactions between
exendin-4 and PLGA appear to be stronger compared with the interactions between adjacent PLGA chains.
For the samples of the PLGA 75:25 microspheres, we observe a similar trend to the PLGA 50:50
microspheres. The value of Tg,β increases from 179 K for the blank microspheres, increases further to
192 K for the low exendin-4 loaded microspheres, and rises to Tg,β = 215 K, for the high exendin-4
loaded microspheres (Figure 5). Notably, we have previously shown that the methyl side group of PLGA
75:25 inhibits polymer mobility and introduces steric hinderance [43]. Thus, for PLGA 75:25, the steric
hinderance caused by the lactide monomer can restrict the intermolecular interactions between exendin-4
and PLGA, limiting the sites that are able to participate in hydrogen bonding, most likely making the
carbonyl group of PLGA more favorable for hydrogen bonding. With limited sites for hydrogen bonding,
less hydrogen bonds can form between exendin-4 and PLGA, resulting in PLGA chain entanglement,
lower mobility, and reduced free volume. Our measurement that the PLGA 75:25 microspheres exhibit
higher Tg,β values compared to the 50:50 microspheres could therefore be explained by steric effects.
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Finally, we observe that for both PLGA 50:50 and PLGA 75:25 the value of Tg,α increases in the order
of blank < low polypeptide loaded < high polypeptide loaded microspheres (Figure 5). This suggests that
at high temperature, sufficient activation energy and free volume must be available to facilitate mobility
of the polymer and polypeptide. Thus, with increase in exendin-4 loading, due to steric hinderance the
threshold for mobility increases, as reflected in the raised value of Tg,α (Figure 6). Ideally if it were possible
to produce a stable freeze-dried exendin-4 product, it may be feasible to determine whether the exendin
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Figure 6. Behavior of the different materials with increasing steric hinderance and free volume. Blue lines
represent the PLGA copolymer (20–30 kDa MW), and solid red circles represent the exendin-4 molecules
(4.2 kDa MW). Low loading and high loading refers to 1 mg/mL and 10 mg/mL of polypeptide loaded in
PLGA microspheres, respectively. With an increase in free volume and decrease in steric hinderance, the
values of Tg,β is decreased.
5. Conclusions
We have produced and characterized lyophilized blank PLGA microspheres and lyophilized PLGA
microspheres containing two different loadings of the polypeptide exendin-4. We studied the dynamics
and relaxations and the glass transition behavior of these PLGA microspheres by performing variable
temperature THz-TDS measurements. A monotonous increase of absorption coefficient with temperature
was observed for all the materials examined, and all of the microspheres exhibit three temperature regimes,
with a distinct Tg,β and Tg,α. We explain our experimental results using the concepts of free volume and
discuss the interactions of the polypeptide and copolymer matrix and steric effects. We define Tg,β as
the point at which the material has sufficient amount of activation energy and free volume to allow for
local motions to occur, and Tg,α as the point at which large-scale movement can take place, and relate the
onset of the transition temperatures to the interaction strength between the polymer and the peptide. Our
work provides a physical explanation for the behavior of these microspheres leading to Tg, and agrees
with the PES concept outlined by Goldstein [42]. This work provides a framework for understanding the
dynamics of complex systems, such as lyophilized microspheres, and considers the parameter of Tg,β
as a valuable criterion for preparing stable formulations. Finally, this work demonstrates that THz-TDS
is an effective method to measure the molecular dynamics and temperature-dependent behavior of a
polymer-polypeptide microsphere system.
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s1: Figure S1: Representative SEM micrographs for blank PLGA 50:50 microspheres shown in (a–c) and blank PLGA
75:25 microspheres shown in (d–f), Figure S2: Representative SEM micrographs for low exendin-4 loaded PLGA
50:50 microspheres shown in (a–c) and high exendin-4 loaded PLGA 50:50 microspheres shown in (d–f), Figure S3:
FTIR spectra of blank microspheres (solid black line), low polypeptide loaded (solid red line) and high polypeptide
loaded (solid blue line) PLGA 75:25 microspheres, Figure S4: MDSC thermogram of PLGA 50:50 blank microsphere,
Figure S5: MDSC thermogram of PLGA 50:50 low peptide loading microsphere, Figure S6: MDSC thermogram of
PLGA 50:50 high peptide loading microsphere, Figure S7: MDSC thermogram of PLGA 75:25 blank microsphere,
Figure S8: MDSC thermogram of PLGA 75:25 low peptide loading microsphere, Figure S9: MDSC thermogram
of PLGA 75:25 high peptide loading microsphere, Figure S10: Terahertz absorption spectra of a blank PLGA 75:25
microsphere sample over 0.3–2.8 THz in the temperature range of 100–360 K, Figure S11: Refractive index spectra
of a blank PLGA 75:25 microsphere sample over 0.1–2.8 THz in the temperature range of 100–360 K, Figure S12:
Terahertz absorption spectra of a blank PLGA 50:50 microsphere sample over 0.3–2.8 THz in the temperature range
of 100–350 K, Figure S13: Refractive index spectra of a blank PLGA 50:50 microsphere sample over 0.1–2.8 THz in
the temperature range of 100–350 K, Figure S14: Terahertz absorption spectra of a low polypeptide loaded PLGA
75:25 microsphere sample over 0.3–2.8 THz in the temperature range of 100–350 K, Figure S15: Refractive index
spectra of a low polypeptide loaded PLGA 75:25 microsphere sample over 0.1–2.8 THz in the temperature range of
100–350 K, Figure S16: Terahertz absorption spectra of a low polypeptide loaded PLGA 50:50 microsphere sample
over 0.3–2.8 THz in the temperature range of 100–370 K, Figure S17: Refractive index spectra of a low polypeptide
loaded PLGA 50:50 microsphere sample over 0.1–2.8 THz in the temperature range of 100–350 K, Figure S18: Terahertz
absorption spectra of a low polypeptide loaded PLGA 75:25 microsphere sample over 0.3–370 THz in the temperature
range of 100–350 K, Figure S19: Refractive index spectra of a low polypeptide loaded PLGA 75:25 microsphere sample
over 0.1–3 THz in the temperature range of 100–370 K, Figure S20: Terahertz absorption spectra of a high polypeptide
loaded PLGA 50:50 microsphere sample over 0.3–2.8 THz in the temperature range of 100–370 K, Figure S21: Refractive
index spectra of a high polypeptide loaded PLGA 50:50 microsphere sample over 0.1–2.8 THz in the temperature
range of 100–370 K, Figure S22: Terahertz absorption spectra of a medium MW PLGA 50:50 over 0.3–2.2 THz in the
temperature range of 90–360 K, Figure S23: Refractive index spectra of a medium MW PLGA 50:50 over 0.3–2.2 THz in
the temperature range of 90–360 K, Figure S24: Terahertz absorption spectra of a medium MW PLGA 75:25 sample
over 0.3–1.9 THz in the temperature range of 90–350 K, Figure S25: Refractive index spectra of a medium MW PLGA
75:25 sample over 0.3–1.9 THz in the temperature range of 90–350 K. All raw data are available for download at
https://doi.org/10.17863/CAM.40737.
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Abbreviations
The following abbreviations are used in this manuscript:
CE Circular equivalent
DCM Dichloromethane
DSC Differential scanning calorimetry
FTIR Fourier transform infrared spectroscopy
JG β-relaxation Johari-Goldstein secondary relaxation
PES potential energy surface
PGA Polyglycolic acid
PLA Polylactic acid
PLGA Poly(D,L-lactic-co-glycolic acid), Poly(lactide-co-glycolide)
SEM Scanning electron microscopy
THz-TDS Terahertz time-domain spectroscopy
VDOS Vibrational density of states
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